


DESIGN, SYNTHESIS AND ESTROGEN RECEPTOR BINDING STUDY OF FLAVONE AND INDANONE BASED LIGANDS

Ph.D. THESIS

by

GULAB KHUSHALRAO PATHE



DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY ROORKEE
ROORKEE – 247667, INDIA
JULY, 2015

**DESIGN, SYNTHESIS AND ESTROGEN RECEPTOR BINDING
STUDY OF FLAVONE AND INDANONE BASED LIGANDS**

A THESIS

*Submitted in partial fulfilment of the
requirements for the award of the degree*

of


DOCTOR OF PHILOSOPHY

in

CHEMISTRY

by

GULAB KHUSHALRAO PATHE



**DEPARTMENT OF CHEMISTRY
INDIAN INSTITUTE OF TECHNOLOGY ROORKEE
ROORKEE – 247667, INDIA
JULY, 2015**

©INDIAN INSTITUTE OF TECHNOLOGY ROORKEE, ROORKEE- 2015
ALL RIGHTS RESERVED



INDIAN INSTITUTE OF TECHNOLOGY ROORKEE ROORKEE

CANDIDATE'S DECLARATION

I hereby certify that the work which is being presented in the thesis entitled, “**DESIGN, SYNTHESIS AND ESTROGEN RECEPTOR BINDING STUDY OF FLAVONE AND INDANONE BASED LIGANDS**” in partial fulfilment of the requirements for the award of the Degree of Doctor of Philosophy and submitted in the Department of Chemistry of the Indian Institute of Technology Roorkee, Roorkee is an authentic record of my own work carried out during a period from Jan, 2013 to July, 2015 under the supervision of Dr. Naseem Ahmed, Associate Professor, Department of Chemistry, Indian Institute of Technology Roorkee, Roorkee.

The matter presented in this thesis has not been submitted by me for the award of any other degree of this or any other institute.

(GULAB KHUSHALRAO PATHE)

This is to certify that the above statement made by the candidate is correct to the best of my knowledge.

Dated:

(Naseem Ahmed)
Supervisor

ABSTRACT

The thesis entitle “**Design Synthesis and Estrogen Receptor Binding Study of Flavone and Indanone Based Ligands**” is divided into five chapters.

The present work is aimed to synthesize the novel flavone and indanone based ligands and their anti-proliferative evaluation against breast and cervical cancers. The novel methods are developed in the deprotection of hydroxyl groups for alcohols and phenols. Also, novel reagents are explored for the McMurray coupling reaction using different metal catalysts. All synthesized compounds are characterized using standard analytical techniques like IR, ¹H-NMR, ¹³C-NMR, GC-MS, HRMS, etc. The thesis has been divided into five chapters for further transparency and clarity and elaborated as follows:

CHAPTER-1

Introduction

The **first chapter** describes the introduction of flavones, indanone and their biological applications, deprotection methods of hydroxyl groups for alcohols and phenols and reagents in the McMurray coupling reaction. Flavone, a sub-class of flavonoid compounds (polyphenolic phytochemicals), is a secondary metabolite of plants which plays important role in various biological processes. Various natural, semi-synthetic and synthetic derivatives of flavones have been synthesized and evaluated for several therapeutic activities like anti-inflammatory, anti-estrogenic, anti-microbial anti-allergic, anti-oxidant, anti-tumour and anti cytotoxic activities. Indanone, indenone and indane skeletons are important moiety present in different natural products and biologically active compounds. For example, indenone (3-(2,3-dihydrobenzofuran-6-yl)-5,6-dimethoxy-2-methyl-2,3-dihydro-1H-inden-1-one) was isolated from the fruits of virola sebifera, indanone (pterosin C) is a cytotoxic and antibacterial natural products, donepezil, a potent acetylcholinesterase inhibitor prescribed for the treatment of Alzheimer’s disease, is a marketed drug (AriceptTM), and indenone (5-(4-chlorophenyl)-3-(methylsulfonyl)-2H-indeno[5,6-d]oxazole-2,7(3H)-dione) is a structural analogue of the selective COX-2 inhibitor nimesulide (**Fig.1**)





Fig. 1: Bioactive compounds containing indanone and indenone core.

CHAPTER-2

Part-A: Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn (IV) Cl₄ catalyst

Naseem Ahmed*^a, Gulab Khushalrao Pathe ^a and B. Venkata Babu ^a *Tetrahedron Letters* **2014**, 55, 3683 – 3687.

In this chapter, we have developed a novel, rapid and efficient deprotection method for the phenolic THP and MOM ethers and sequel intramolecular Friedel-Crafts alkylation reaction of THP and MOM protected chalcone epoxides to indanone by SnCl₄ catalyst under mild conditions. The reaction took place in 2-3 min to gave the products **1a-1s** in excellent yield (90-98%) at 0 °C without affecting the other functional groups (**Scheme 1**). These products were fully characterized on the basis of their spectral analysis ¹H-, ¹³C-NMR and GC-MS.




Scheme 1: Detetrahydropyranylation and demethoxymethylation of phenol and sequel cyclization reaction.

Part-B: SnCl₄ or TiCl₄: Highly efficient catalysts for detetrahydropyranylation and demethoxymethylation of phenolic ethers and sequel one-pot asymmetric synthesis of 3-aryl-2-hydroxy-2,3-dihydroindan-1-ones from chalcone epoxides

Naseem Ahmed*^a, Gulab Khushalrao Pathe^a *RSC Advances* **2015**, Accepted.

In this section, we have described the role of novel SnCl₄ or TiCl₄ catalysts for the deprotection of phenolic THP and MOM ethers and sequel one-pot regioselective synthesis of trans-3-aryl-2-hydroxy-1-indanones (R/S) by intramolecular Friedel-Crafts alkylation of chalcone epoxides with enantiomeric excess up to 99.9% under same conditions. Epoxide ring opening followed

by intramolecular Friedel-Crafts alkylation was performed in the presence of TiCl_4 to obtain the diastereoisomerically pure *trans* (2*R*, 3*S*) indanone derivatives **6a-e** (Scheme 2).




Scheme 2: Synthesis of enantioselective 3-aryl-2-hydroxyindan-1-ones.

CHAPTER- 3

Part-A: Zn-SnCl₄: A novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins

Gulab Khushalrao Pathe and Naseem Ahmed*, *Tetrahedron Letters* **2015**, 56, 1555-1561.

In this part, SnCl_4 -Zn complex provided a novel reductive system in the deoxygenative cross-coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins in high yield (55-86%) at reflux temperature in THF. The advantage of this reagent is inexpensive, short reaction time and high yield compare to the reagents used in the McMurry cross-coupling reaction. These products were fully characterized on the basis of their spectral analysis ^1H -, ^{13}C -NMR, HRMS and GC-MS.




Scheme 3: SnCl_4 -Zn mediated deoxygenative cross-coupling reaction.

Part-B: Design, Synthesis of McMurry cross-coupled indanophen, analogs of Tamoxifen by novel SnCl_4 -Zn reagent and Anti-Proliferative Evaluation of Flavone-Estradiol adduct and Indanone based Ligands against Breast Cancer Cell Line

Gulab Khushalrao Pathe, Naveen Konduru, Iram Parveen and Naseem Ahmed*, *European Journal of Medicinal Chemistry* **2015**, Under Review.

In this section, we described the synthesis of McMurry cross-coupled indanophen, analog of tamoxifen using novel SnCl₄-Zn reagent and anti-proliferative evaluation of indanone based ligands and flavone-estradiol adduct, against human cervical cancer cell line (HeLa) and human breast cancer cell lines (MCF-7& MDA-MB-231). The compounds **3ac**, **3ad**, **3ae**, **3ao** displayed the best activity having IC₅₀ = 2.13 - 3.81 μM and rest of the compounds also showed comparable activity to the standard drug doxorubicin having IC₅₀ = <28 μM. The flavones-estradiol adduct **6ab**, **6ad** showed excellent activity than the standard drug having IC₅₀ values in μM 2.85 ± 0.165 & 2.42 ± 0.226 and 3.64 ± 0.276, 2.93 ± 0.137 against MCF-7& MDA-MB-231 and 2.17 ± 0.183, 2.56 ± 0.322 against HeLa respectively. The structure of all the compounds was confirmed by ¹H-, ¹³C-NMR, HRMS, ESI/MS and IR analysis.




Scheme 4: Synthesis of Tamoxifen Analogs.

CHAPTER-4

SeO₂ in water: A mild and efficient promoter for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of carbonyl carbons

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, *RSC Advances* **2015**, *5*, 59114-59119.

In this chapter, we have reported SeO₂-water system provided an efficient and one-pot green deprotection of acetyl, THP and MOM ethers in alcohols and phenols and sequel oxidation of alpha carbonyl carbons to dicarbonyl functional groups at 80 °C in 30-60 min. Using substrate: SeO₂ in 1:3 ratio, the reaction gave excellent yield (85-95%) for acetyl and THP deprotections and a moderate yield (30-40%) for MOM deprotection without affecting other functional groups. However, substrate: SeO₂ in 1:1 ratio in 1ml H₂O, got only deprotection product in 85-95% yields for Ac and THP and demethoxymethylation gave moderate yields (30-40%) at 80 °C in 30-60 min (**Scheme 6**). The products were characterized on the basis of their spectral analysis ¹H- and ¹³C-NMR, GC-MS.




Scheme 6: Deprotection of acetyl, MOM and tetrahydropyranyl ethers and sequel oxidation of active methylene in SeO_2 -water promoter.

CHAPTER-5

Part-A: Mild and efficient reductive deoxygenation of epoxides to olefins with SnCl_2/NaI as a novel reagent

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, *Synthesis* **2015**, Ahead of print.

In this chapter, we have developed a novel, highly efficient protocol for deoxygenation of aliphatic and aromatic epoxides, chalcone epoxide, nitro styrene epoxide and nitrochromene epoxide to corresponding olefins using SnCl_2/NaI in ethanol as a novel reagent, for this conversion with up to 96% yield. This methodology has more importance than the earlier methods such as inexpensive reagents, high yield, short reaction time, environment friendly (**Scheme 7**). These compounds were further characterised by NMR, IR and GC-MS.




Scheme 7: Deoxygenation of aliphatic and aromatic epoxide by SnCl_2/NaI .

Part-B: Efficient and green protocol for the eliminative deoxygenation of aliphatic and aromatic epoxides to olefin with polyphosphoric acid as a novel catalyst

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, *Helvetica Chimica Acta* **2015**, Under Review.

In this part, we have developed a highly efficient and green catalytic deoxygenation of aliphatic and aromatic epoxides, chalcone epoxide, nitro styrene epoxide and nitrochromene epoxide to olefin using 30 mol% of polyphosphoric acid up to 96 % yields. This methodology have more importance than the earlier methods such as inexpensive reagents, high yield, short reaction time, environment friendly and solvent free. These compounds were further characterised by NMR, IR and GC-MS.



Scheme 8: Deoxygenation of nitrostyrene epoxide by polyphosphoric acid catalyst.

ACKNOWLEDGEMENT

I would like to express my sincere gratitude to my Supervisor Dr. Naseem Ahmed, Department of Chemistry, IIT Roorkee who was always available for discussion, guardian and as a friend. He has contributed a great deal to my understanding in research through valuable discussions, ideas and useful comments, which were a great source of my inspiration.

I take the opportunity to express the gratitude to my Student Research Committee (SRC) members Prof. M. R. Maurya and Dr. Anuj Sharma, Department of Chemistry, and Dr. Prasenjeet Mondol, Department of Chemical Engineering, IIT Roorkee for extending me all possible helps and valuable suggestions during the course work.

I am thankful to Prof. Anil Kumar (Head), Department of Chemistry, for providing me with necessary facilities and support to carry out my work. I am thankful to Mr. S. P. Singh, Mr. Abdul Haque, Mr. Madan Pal, Mr. Tiwari and other staffs, Department of Chemistry, for giving a helping hand to me on all occasions.

I also thank the Coordinator NMR central facility Prof. Ritu Barthwal, Department of Biotechnology for giving me the time to carry out the experiments related to my study whenever required.

I wish to put on record my gratitude to the Editors & Reviewers for their comments/suggestions during publishing manuscripts and conference proceedings.

I would like to take this opportunity to thank Department of Science and Technology (DST), New Delhi for providing me financial assistance during my course of research.

I would like thank my seniors and colleagues Dr. B. Venkata Babu, Dr. Naveen Konduru, Shaily, Nishant, Sumit, Iram, Waheed, Manu, Pushpendra, Ila, Anjali, Varun, Sheela, Pankaj, Balakrishna and Anand for their unflinching helps throughout.

My family deserves special mention for their unflagging love and support in my life. This work simply be impossible without them. I am indebted to my father Khushalrao Pathe and mother Shobha Pathe for their everlasting care and love to me. I also thank to my sister Jayashree and brother Mahesh for their love and encouragement.

Finally, I am thankful to almighty GOD, for his mercy and grace bestowed upon me during my education.

(GULAB KHUSHALRAO PATHE)

LIST OF CONTENTS

	Page no.
Candidate's declaration	
Acknowledgement	
Abbreviation	i
Appendix -1 (List of Schemes)	iii
Appendix -2 (List of Figures)	vi
Appendix -3 (List of Tables)	vii
Appendix -4 (List of Spectra's)	x
<u>CHAPTER 1: Introduction</u>	
1.1 General introduction of flavonoids	1
1.1.1 Biosynthetic pathway for Flavonoids	3
1.2 Chalcone	4
1.2.1 Bioactivity of chalcone	4
1.2.2 Methods of synthesis of chalcone	5
1.2.2.1 Chalcone Synthesis	5
1.2.2.2 Biosynthesis method of chalcone	6
1.3 Flavone	7
1.3.1 Bioactivity of Flavone	7
1.3.2 Methods of synthesis of Flavone	8
1.3.2.1 Synthesis of Flavon	8
1.3.2.2 Biosynthesis of Flavone	9
1.3.2.3 Flavonoids based ligands	10
1.4 Deprotection of hydroxyl protecting groups	11
1.4.1 THP deprotection	11
1.4.2 MOM-Cl deprotection	12
1.4.3 Deprotection of acetate groups	12
1.4.4 EXAMPLES (deprotection of MOMCl, THP and Acetate)	13
1.5 McMurray coupling	14
1.5.1 Introduction	15
1.5.2 Mechanism and Stereochemistry	15

1.5.2.1 Prevailing Mechanism	16
1.5.2.2 Stereochemistry	16
1.5.3 Comparison to Other Methods	17
1.5.4 Scope and Limitations	18
1.6 Indanone	21
1.6.1 Methods of synthesis of Indanone	23
1.6.2 Reactivity of indanone	23
1.7 References	25
<u>CHAPTER 2: Part A: Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn (IV) Cl₄ cataly</u>	
2.1 Introduction	40
2.2 Objective	41
2.3 Results and Discussion	41
2.3.1 Optimization reaction conditions by using different catalyst	41
2.3.2 Solvent effect	42
2.3.3 Examples of the THP and MOM ethers deprotection and sequel cyclization reaction	43
2.3.4 Synthesis of diastereoisomerically pure trans-3-(4-bromophenyl)-2-hydroxy-2,3-dihydroindan-1-one.	45
2.4 Mechanism	46
2.5 Conclusion	47
2.6 Experimental Details	47
2.6.1 General procedure	48
2.6.2 Spectroscopic data	48
2.7 References	50
<u>CHAPTER 2: Part B: SnCl₄ or TiCl₄: Highly efficient catalysts for detetrahydropyranylation and demethoxymethylation of phenolic ethers and sequel one-pot asymmetric synthesis of 3-aryl-2-hydroxy-2, 3-dihydroindan-1-ones from chalcone epoxides</u>	
3.1 Introduction	54
3.2 Objective	56
3.3 Results and Discussion	56
3.3.1 Optimization reaction conditions by using different catalyst	56

3.3.2 Solvent effect by catalyst SnCl ₄ or TiCl ₄	58
3.3.3 Examples of the THP and MOM ethers deprotection and sequel cyclization reaction by catalyst SnCl ₄ or TiCl ₄	59
3.3.4 Asymmetric synthesis	61
3.3.5 Synthesis of enantioselective 3-aryl-2-hydroxyindan-1-ones	63
3.4 Mechanism	66
3.5 Conclusion	67
3.6 Experimental Details	67
3.6.1 General procedure	67
3.6.2 Spectroscopic data	68
3.7 References	79

CHAPTER 3: Part A: SnCl₄ - Zn: a novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins

4.1 Introduction	87
4.2 Objective	88
4.3 Results and Discussion	88
4.3.1 Optimized reaction condition	88
4.3.2 Deoxygenative cross-coupling of aromatic ketone and aldehyde with acetone	90
4.3.3 Deoxygenative cross-coupling of chalcone epoxides with propiophenone	92
4.3.4 Synthesis of Tamoxifen analogs	94
4.3.5 Determination of E and Z-Tamoxifen analogs	96
4.4 Conclusion	97
4.5 Experimental Details	97
4.5.1 General procedure	97
4.5.2 Spectroscopic data	98
4.6 References	106

CHAPTER 3: Part-B: Design, Synthesis of McMurry cross-coupled indanophen, analogs of Tamoxifen by novel SnCl₄-Zn reagent and Anti-Proliferative Evaluation of Flavone-Estradiol adduct and Indanone based Ligands against Breast Cancer Cell Line

5.1 Introduction	110
5.2 Objective	112
5.3 Results and Discussion	113

5.3.1 Synthesis of Tamoxifen Analogs by Cross -McMurry coupling reaction between indanone derivatives and propiophenone derivatives	115
5.3.2 Synthesis of E and Z Tamoxifen analogs of indanone	118
5.3.3 Synthesis of Flavone-Estradiols adducts	120
5.3.4 Pharmacology	121
5.4 Conclusion	125
5.5 Experimental Details	126
5.5.1 General procedure	126
5.5.2 Spectroscopic data	126
5.6 References	139

CHAPTER 4: SeO₂ in water: A mild and efficient promoter for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of alpha carbonyl carbons

6.1 Introduction	145
6.2 Objective	146
6.3 Results and Discussion	146
6.3.1 Optimization reaction conditions by using different oxidizing agents	146
6.3.2 Solvent effect	147
6.3.3 Examples of the deprotection of acetyl, THP and MOM ethers	148
6.3.4 Examples of the deprotection of acetyl, THP and MOM ethers and sequel oxidation of alpha carbonyl carbon	151
6.4 Mechanism	154
6.5 Conclusion	155
6.6 Experimental Details	155
6.6.1 General procedure	155
6.6.2 Spectroscopic data	156
6.7 References	162

CHAPTER 5: Part A: Mild and efficient reductive deoxygenation of epoxides to olefins with SnCl₂/NaI as a novel reagent

7.1 Introduction	167
7.2 Objective	167
7.3 Results and Discussion	168

7.3.1 Optimization reaction conditions for deoxygenation of styrene epoxide by SnCl ₂ /NaI	168
7.3.2 Comparison of the SnCl ₂ /NaI reagent and recent reported methods of deoxygenation of epoxides to corresponding olefins	168
7.3.3 Examples of the deoxygenation of aliphatic and aromatic epoxides by SnCl ₂ /NaI	169
7.3.4 Examples of the deoxygenation of chalcone epoxides by SnCl ₂ /NaI	171
7.3.5 Examples of the deoxygenation of nitro styrene epoxides by SnCl ₂ /NaI	172
7.3.6 Examples of the deoxygenation of nitro chromene epoxides by SnCl ₂ /NaI	172
7.4 Mechanism	173
7.5 Conclusion	173
7.6 Experimental Details	169
7.6.1 General procedure	174
7.7 References	175
CHAPTER 5: <u>Part-B: Efficient and green protocol for the eliminative deoxygenation of aliphatic and aromatic epoxides to olefin with polyphosphoric acid as a novel catalyst</u>	
8.1 Introduction	178
8.2 Objective	178
8.3 Results and Discussion	179
8.3.1 Optimization reaction conditions for deoxygenation of styrene epoxide by PPA	179
8.3.2 Comparison of polyphosphoric acid system with earlier methods	179
8.3.3 Examples of the deoxygenation of aliphatic and aromatic epoxides by PPA	180
8.3.4 Examples of the deoxygenation of chalcone epoxides by PPA	182
8.3.5 Examples of the deoxygenation of nitro styrene epoxides by PPA	183
8.3.6 Examples of the deoxygenation of nitro chromene epoxides by PPA	183
8.4 Mechanism	184
8.5 Conclusion	184
8.6 Experimental Details	184
8.6.1 General procedure	185
8.6.2 Spectroscopic data	185
8.7 References	195
NMR Spectra of Selected Compounds	198
List of Publications	349

LIST OF ABBREVIATION

ACN	Acetonitrile
AChE	Acetylcholinesterase
CHI	Chalcone isomerase
CHS	Chalcone synthase
CrO ₃	Chromium trioxide
CoA	Coenzyme-A
DCM	Dichloromethane
DHP	Dihydropyran
DDQ	2,3-Dichloro-5,6-dicyano-1,4-benzoquinon
DMF	N,N-Dimethyl Formamide
DMSO	Dimethyl Sulphoxide
ee	Enantiomeric excess
ER	Estrogen Receptors
FT-IR	Fourier transform infrared spectroscopy
FLS	Flavonol synthase
GC-MS	Gas chromatography mass spectrometry
gm.	Gram
HRMS	High resolution mass spectrometry
HeLa	Human cervical cancer cell line
InCl ₃	Indium(III)chloride
IPA	Isopropanol
MS	Mass spectrometry
MnO ₂	Manganese dioxide
MP	Melting point
MOM	Methoxymethyl

MCF-7	Michigan cancer foundation-7
mg	Milligram
ml	Milliliter
MIC	Minimum inhibitory concentration
NMR	Nuclear magnetic resonance
NaI	Sodium iodide
OsO ₄	Osmium tetroxide
Pd	Palladium
PPA	Polyphosphoric acid
Py	Pyridine
PCC	Pyridinium chlorochromate
RT	Room temperature
SeO ₂	Selenium dioxide
SnCl ₂	Tin(II)chloride
SnCl ₄	Tin Tetrachloride
TBDMSCl	tert-butyl dimethylsilylchloride
THP	Tetrahydropyranyl
THF	Tetrahydrofuran
TMS	Tetra methyl silane
TLC	Thin layer chromatography
TiCl ₄	Titanium(IV)chloride
TFA	Trifluoro acetic acid
Zn	Zinc metal

APPENDIX-I

Page no.

LIST OF SCHEMES

CHAPTER 1

Scheme 1: Flavonoids biosynthetic pathway	4
Scheme 2: Synthesis of chalcone by Claisen-Schmidt reaction	6
Scheme 3: Synthesis of chalcone by Cross-Aldol Condensation reaction	6
Scheme 4: Synthesis of chalcone by Suzuki reaction	6
Scheme 5: Biosynthesis of chalcone	7
Scheme 6: Synthesis of flavones by via beta diketone intermediate	8
Scheme 7: Synthesis of flavone by Claisen-Schmid condensation reaction	9
Scheme 8: Palladium catalysed synthesis is carried out in basic environment by Hua & Yang	9
Scheme 9: Flavones via micro-assisted, one-pot Sonagashira “Carbonylation” Annulations reaction used by E. Awuah & A. Capretta	9
Scheme 10: Biosynthetic pathway of flavones	10
Scheme 11: Selective deprotection of MOM ethers	12
Scheme 12: Demethoxymethylation with ZnBr ₂ as a catalyst	13
Scheme 13: Detetrahydropyranylation with expansive graphite as a catalyst	14
Scheme 14: Detetrahydropyranylation with bismuth triflate as a catalyst	14
Scheme 15: Detetrahydropyranylation with expansive zeolite as a catalyst	14
Scheme 16: Reductive coupling of carbonyl compounds to afford alkenes by low-valent Ti	15
Scheme 17: Plausible mechanism for alkene formation	16
Scheme 18: Formation of mixtures of (<i>E</i>) - and (<i>Z</i>)-isomers by McMurry couplings	16
Scheme 19: Exception to the McMurry couplings gave (<i>Z</i>)-isomers as a major product	17
Scheme 20: Comparison of the McMurry coupling with Wittig reaction	17
Scheme 21: Alternative to the McMurry coupling (Tebbe's reagent)	17
Scheme 22: Alternative to the McMurry coupling	18

Scheme 23: Effect of additives on McMurry couplings	19
Scheme 24: Intramolecular McMurry couplings by low valent Ti	19
Scheme 25: Selectivity in McMurry couplings	20
Scheme 26: Application of McMurry couplings in synthesis of bicyclic products	20
Scheme 27: Effect of amount of substrate on formation of mix- coupled products	20
Scheme 28: Drawbacks of the McMurry coupling	20
Scheme 29: $[\text{Rh}(\text{C}_2\text{H}_4)\text{Cl}]_2$ -catalysed Asymmetric intramolecular 1,4-addition	23
Scheme 30: Synthesis of indanone 29 via a Heck-Matsuda (HM) reaction	23
Scheme 31: Synthesis of BINA	23
Scheme 32: Industrial manufacture of donepezil via a pyridine derivative	24
Scheme 33: Stereoselective synthesis of dimer of 2-(E)-benzylidene-1-indanone	24
Scheme 34: Synthesis of complex spiropolycyclic compounds	24
Scheme 35: Synthesis of methyl indanone	25
Scheme 36: Synthesis of 1-indanone oxime tosylate and their Beckmann rearrangement	25

CHAPTER -2

Part-A:

Scheme 1: Synthesis of diastereoisomerically pure trans-3-(4-bromophenyl)-2-hydroxy-2, 3-dihydroindan-1-one	46
Scheme 2: A propose mechanism for the deprotection of MOM ethers followed by cyclization with SnCl_4	47

Part-B:

Scheme 1: Synthesis of indanone derivative in one-pot deprotection and cyclization	57
Scheme 2: Synthesis of enantioselective 3-aryl-2-hydroxyindan-1-ones	64
Scheme 3: Proposed mechanism for the deprotection of THP ethers followed by cyclization with TiCl_4	67

CHAPTER 3

Part-A:

- Scheme 1:** Under optimized conditions, SnCl₄-Zn mediated deoxygenative cross-coupling of aromatic ketone and aldehyde with acetone 91
- Scheme 2:** Deoxygenation of simple carbonyl compound to olefin by using SnCl₄-Zn 91
- Scheme 3:** Under optimized conditions, SnCl₄-Zn mediated deoxygenative cross-coupling of aromatic ketone with propiophenone 91

Part-B:

- Scheme 1:** Synthesis of Flavone-Estradiols adduct by coupling at alpha to the carbonyl 120
- Scheme 2:** Synthesis of Flavone-Estradiols adduct by coupling at benzene ring 120

CHAPTER 4

- Scheme 1:** Propose mechanism for the deprotection of THP ethers followed by oxidation of active methylene to dicarbonyl by SeO₂-Water 154

CHAPTER 5

- Part-A: Scheme 1:** Deoxygenation of chalcone epoxide by SnCl₂/NaI 171
- Scheme 2:** Deoxygenation of nitro styrene epoxide by SnCl₂/NaI 172
- Scheme 3:** Deoxygenation of nitrochromene epoxide by SnCl₂/NaI 172
- Scheme 4:** Proposed mechanism for the deoxygenation of epoxide to olefin by SnCl₂/NaI 173
- Part-B: Scheme 1:** Deoxygenation of chalcone epoxide by polyphosphoric acid 182
- Scheme 2:** Deoxygenation of nitro styrene epoxide by polyphosphoric acid 183
- Scheme 3:** Deoxygenation of nitrochromene epoxide by polyphosphoric acid 183
- Scheme 4:** Plausible mechanism for the deoxygenation of epoxides to alkenes by polyphosphoric acid 184

APPENDIX-II

Page no.

LIST OF FIGURES

CHAPTER-1

Fig. 1: Structure of the structural backbones of the main flavonoid groups (flavan, isoflavan and neoflavan) and of relevant flavonoids classes and classification	1
Fig. 2: Structure of flavonoids and their naturally occurring compounds	2
Fig. 3: General structure of chalcone (C ₆ -C ₃ -C ₆)	4
Fig. 4: Naturally occurring bioactive chalcone	5
Fig. 5: General structure of flavones	7
Fig. 6: Some examples of natural and synthetic flavones	8
Fig. 7: Natural and synthetic biologically active flavonoids conjugates	11
Fig. 8: Bioactive compounds containing indanone and indenone core	22

CHAPTER-2

Part-A:	-
Part-B: Fig. 1: Bioactive indan-1-one derivatives	55
Figure 2. Comparison of InCl ₃ and TiCl ₄ catalysts loading only for cyclization reaction	58

CHAPTER 3

Part-A:	-
Part-B: Fig. 1: In vitro anti- cancer activity of a compounds 3ab-3au against Human cervical cancer cell line and Human Breast cancer cell lines	124
Fig. 2: In vitro anti- cancer activity of a compound 6ab-6ag against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines	125

CHAPTER 4 & CHAPTER 5

-

APPENDIX-III

	Page no.
<u>LIST OF TABLES</u>	
CHAPTER-1	-
CHAPTER-2	
Part-A: Table 1: Optimization conditions in deprotection of the THP and MOM ethers and sequel cyclization of phenolic compounds with different catalysts	41
Table 2: Solvent effects on yields in deprotection of the THP and the MOM ethers and sequel cyclization reaction	42
Table 3: Examples of the THP and MOM ethers deprotection and sequel cyclization reaction	43
Part-B: Table 1: Optimization of catalysts for Scheme 1	57
Table 2: Solvent effects on yields in the deprotection of THP and MOM ethers	58
Table 3: Examples of the THP and MOM ethers deprotection and sequel cyclization reaction	59
Table 4: Synthesis of racemic 3-aryl-2-hydroxy-1-indanones from racemic chalcone epoxides	61
Table 5: Synthesis of Enantioselective 3-aryl-2-hydroxy-1-indanones	64
Table 6: HPLC conditions and retention times of racemic and enantiomeric excess of the epoxide derivatives	65
Table 7: HPLC conditions and retention times of racemic and enantiomeric excess of the indanone derivatives	66
CHAPTER 3	
Part-A: Table 1: Optimized condition for cross-coupling reaction by using different equivalent of SnCl ₄ -Zn	89
Table 2: Optimized condition for cross-coupling reaction by varying reaction time	89
Table 3: Comparison of McMurry reagents and solvents in McMurry cross-coupling of chalcone epoxide and propiophenone	90

Table 4: SnCl ₄ -Zn mediated deoxygenative cross-coupling of chalcone epoxides with propiophenone	92
Table 5: Synthesis of Tamoxifen analogs (E isomers) of indanone using novel SnCl ₄ -Zn reagent	94
Table 6: Determination of E and Z Tamoxifen analogs by using novel SnCl ₄ -Zn reagent	96
Part-B: Table 1: Optimized condition for cross-coupling reaction by using different equivalent of SnCl ₄ -Zn	114
Table 2: Optimized condition for cross-coupling reaction by varying reaction time	114
Table 3: Comparison of McMurry reagents and solvents in McMurry cross- coupling of Indanone and propiophenone	115
Table 4: Synthesis of Tamoxifen Analogs by Cross -McMurry coupling reaction between indanone derivatives and propiophenone derivatives	117
Table 5: Synthesis of E and Z Tamoxifen analogs of indanone	118
Table 6: Showing anti-proliferative data (IC ₅₀ Values in μM) of all the synthesized tamoxifen analog drugs and standard drug against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines	122
Table 7: Showing anti-proliferative data (IC ₅₀ Values in μM) of all the synthesized Flavone-Estradiol adduct and standard drug against Human Breast cancer celllines (MCF-7& MDA-MB-231) and Human Cervical cancer cell line (HeLa)	125
CHAPTER 4	
Table 1. Optimization of deprotection conditions for Ac, THP and MOM groups and sequel oxidation of alpha carbons	147
Table 2. Solvents effects in deprotection of Ac, THP and MOM groups and sequel oxidation of alpha carbons	147
Table 3. Examples of deprotection of Ac, THP and MOM groups in alcohols and phenols	148
Table 4. Deprotection of Ac, THP and MOM groups and sequel oxidation of alpha carbonyl carbon	152

CHAPTER 5

Part-A: Table 1: Optimized condition for the deoxygenation of styrene oxide by stannous chloride and sodium iodide (SnCl ₂ /NaI)	168
Table 2. Comparison of the SnCl ₂ /NaI reagent and recent reported methods of deoxygenation of epoxides to corresponding olefins	169
Table 3: Deoxygenation of aliphatic and aromatic epoxide by SnCl ₂ /NaI	169
Part-B: Table 1: Optimized condition for the Deoxygenation of styrene oxide by polyphosphoric acid	179
Table 2. Comparison of the green PPA system with formerly reported systems for deoxygenation of epoxides to alkenes	179
Table 3: Deoxygenation of aliphatic and aromatic epoxide by polyphosphoric acid	180

APPENDIX-IV

	Page no.
<u>LIST OF NMR SPECTRA</u>	
Figure S-1: ^1H NMR Spectrum of compound 1n	198
Figure S-2: ^{13}C NMR Spectrum of compound 1n	199
Figure S-3: ^1H NMR Spectrum of compound 1o	200
Figure S-4: ^{13}C NMR Spectrum of compound 1o	201
Figure S-5: ^1H NMR Spectrum of compound 1p	202
Figure S-6: ^{13}C NMR Spectrum of compound 1p	203
Figure S-7: ^1H NMR Spectrum of compound 1q	204
Figure S-8: ^{13}C NMR Spectrum of compound 1q	205
Figure S-9: ^1H NMR Spectrum of compound 1r	206
Figure S-10: ^{13}C NMR Spectrum of compound 1r	207
Figure S-11: ^1H NMR Spectrum of compound 1s	208
Figure S-12: ^{13}C NMR Spectrum of compound 1s	209
Figure S-13: ^1H NMR Spectrum of compound 3c	210
Figure S-14: ^{13}C NMR Spectrum of compound 3c	211
Figure S-15: ^1H NMR Spectrum of compound 4c	212
Figure S-16: ^{13}C NMR Spectrum of compound 4c	213
Figure S-17: ^1H NMR Spectrum of compound 4e	214
Figure S-18: ^{13}C NMR Spectrum of compound 4e	215
Figure S-19: ^1H NMR Spectrum of compound 4p	216
Figure S-20: ^{13}C NMR Spectrum of compound 4p	217
Figure S-21: ^1H NMR Spectrum of compound 4q	218
Figure S-22: ^{13}C NMR Spectrum of compound 4q	219
Figure S-23: ^1H NMR Spectrum of compound 4s	220

Figure S-24: ^{13}C NMR Spectrum of compound 4s	221
Figure S-25: ^1H NMR Spectrum of compound 4t	222
Figure S-26: ^{13}C NMR Spectrum of compound 4t	223
Figure S-27: ^1H NMR Spectrum of compound 4v	224
Figure S-28: ^{13}C NMR Spectrum of compound 4v	225
Figure S-29: ^1H NMR Spectrum of compound 6a	226
Figure S-30: ^1H NMR Spectrum of compound 6a	227
Figure S-31: ^1H NMR Spectrum of compound 6c	228
Figure S-32: ^1H NMR Spectrum of compound 6c	229
Figure S-33: ^{13}C NMR Spectrum of compound 2ad	230
Figure S-34: ^1H NMR Spectrum of compound 2ad	231
Figure S-35: ^{13}C NMR Spectrum of compound 9c	232
Figure S-36: ^1H NMR Spectrum of compound 9c	233
Figure S-37: ^{13}C NMR Spectrum of compound 11ab	234
Figure S-38: ^1H NMR Spectrum of compound 12ab	235
Figure S-39: ^{13}C NMR Spectrum of compound 12ab	236
Figure S-40: ^1H NMR Spectrum of compound 12ac	237
Figure S-41: ^{13}C NMR Spectrum of compound 12ac	238
Figure S-42: ^1H NMR Spectrum of compound 12ad	239
Figure S-43: ^{13}C NMR Spectrum of compound 12ad	240
Figure S-44: ^1H NMR Spectrum of compound 12ae	241
Figure S-45: ^{13}C NMR Spectrum of compound 12ae	242
Figure S-46: ^1H NMR Spectrum of compound 12af	243
Figure S-47: ^{13}C NMR Spectrum of compound 12af	244
Figure S-48: ^1H NMR Spectrum of compound 12ag	245
Figure S-49: ^{13}C NMR Spectrum of compound 12ag	246

Figure S-50: ^1H NMR Spectrum of compound 12ah	247
Figure S-51: ^{13}C NMR Spectrum of compound 12ah	248
Figure S-52: ^1H NMR Spectrum of compound 12ai	249
Figure S-53: ^{13}C NMR Spectrum of compound 12ai	250
Figure S-54: ^1H NMR Spectrum of compound 3ab	251
Figure S-55: ^{13}C NMR Spectrum of compound 3ab	252
Figure S-56: ^1H NMR Spectrum of compound 3ac	253
Figure S-57: ^{13}C NMR Spectrum of compound 3ac	254
Figure S-58: ^1H NMR Spectrum of compound 3ad	255
Figure S-59: ^{13}C NMR Spectrum of compound 3ad	256
Figure S-60: ^1H NMR Spectrum of compound 3ag	257
Figure S-61: ^{13}C NMR Spectrum of compound 3ag	258
Figure S-62: ^1H NMR Spectrum of compound 3ah	259
Figure S-63: ^{13}C NMR Spectrum of compound 3ah	260
Figure S-64: ^1H NMR Spectrum of compound 3ai	261
Figure S-65: ^{13}C NMR Spectrum of compound 3ai	262
Figure S-66: ^1H NMR Spectrum of compound 3an	263
Figure S-67: ^{13}C NMR Spectrum of compound 3an	264
Figure S-68: ^1H NMR Spectrum of compound 3as	265
Figure S-69: ^{13}C NMR Spectrum of compound 3as	266
Figure S-70: ^1H NMR Spectrum of compound 4ab	267
Figure S-71: ^{13}C NMR Spectrum of compound 4ab	268
Figure S-72: ^1H NMR Spectrum of compound 4ac	269
Figure S-73: ^{13}C NMR Spectrum of compound 4ac	270
Figure S-74: ^1H NMR Spectrum of compound 4ae	271
Figure S-75: ^{13}C NMR Spectrum of compound 4ae	272

Figure S-76: ^1H NMR Spectrum of compound 4af	273
Figure S-77: ^{13}C NMR Spectrum of compound 4af	274
Figure S-78: ^1H NMR Spectrum of compound 4ag	275
Figure S-79: ^{13}C NMR Spectrum of compound 4ag	276
Figure S-80: ^1H NMR Spectrum of compound 5ab	277
Figure S-81: ^{13}C NMR Spectrum of compound 5ab	278
Figure S-82: ^1H NMR Spectrum of compound 5ac	279
Figure S-83: ^{13}C NMR Spectrum of compound 5ac	280
Figure S-84: ^1H NMR Spectrum of compound 5ad	281
Figure S-85: ^{13}C NMR Spectrum of compound 5ad	282
Figure S-86: ^1H NMR Spectrum of compound 5ae	283
Figure S-87: ^{13}C NMR Spectrum of compound 5ae	284
Figure S-88: ^1H NMR Spectrum of compound 5af	285
Figure S-89: ^{13}C NMR Spectrum of compound 5af	286
Figure S-90: ^1H NMR Spectrum of compound 5ag	287
Figure S-91: ^{13}C NMR Spectrum of compound 5ag	288
Figure S-92: ^1H NMR Spectrum of compound 16e	289
Figure S-93: ^{13}C NMR Spectrum of compound 16e	290
Figure S-94: ^1H NMR Spectrum of compound 16f	291
Figure S-95: ^{13}C NMR Spectrum of compound 16f	292
Figure S-96: ^1H NMR Spectrum of compound 16g	293
Figure S-97: ^{13}C NMR Spectrum of compound 16g	294
Figure S-98: ^1H NMR Spectrum of compound 16h	295
Figure S-99: ^{13}C NMR Spectrum of compound 16h	296
Figure S-100: ^1H NMR Spectrum of compound 16i	297
Figure S-101: ^{13}C NMR Spectrum of compound 16i	298

Figure S-102: ^1H NMR Spectrum of compound 16j	299
Figure S-103: ^{13}C NMR Spectrum of compound 16j	300
Figure S-104: ^1H NMR Spectrum of compound 23a	301
Figure S-105: ^{13}C NMR Spectrum of compound 23a	302
Figure S-106: ^1H NMR Spectrum of compound 23b	303
Figure S-107: ^{13}C NMR Spectrum of compound 23b	304
Figure S-108: ^1H NMR Spectrum of compound 23c	305
Figure S-109: ^{13}C NMR Spectrum of compound 23c	306
Figure S-110: ^1H NMR Spectrum of compound 23d	307
Figure S-111: ^{13}C NMR Spectrum of compound 23d	308
Figure S-112: ^1H NMR Spectrum of compound 23e	309
Figure S-113: ^{13}C NMR Spectrum of compound 23e	310
Figure S-114: ^1H NMR Spectrum of compound 23f	311
Figure S-115: ^{13}C NMR Spectrum of compound 23f	312
Figure S-116: ^1H NMR Spectrum of compound 23g	313
Figure S-117: ^{13}C NMR Spectrum of compound 23g	314
Figure S-118: ^1H NMR Spectrum of compound 23h	315
Figure S-119: ^{13}C NMR Spectrum of compound 23h	316
Figure S-120: ^1H NMR Spectrum of compound 23i	317
Figure S-121: ^{13}C NMR Spectrum of compound 23i	318
Figure S-122: ^1H NMR Spectrum of compound 23j	319
Figure S-123: ^{13}C NMR Spectrum of compound 23j	320
Figure S-124: ^1H NMR Spectrum of compound 24a	321
Figure S-125: ^{13}C NMR Spectrum of compound 24a	322
Figure S-126: ^1H NMR Spectrum of compound 24b	323
Figure S-127: ^{13}C NMR Spectrum of compound 24b	324

Figure S-128: ^1H NMR Spectrum of compound 24c	325
Figure S-129: ^{13}C NMR Spectrum of compound 24c	326
Figure S-130: ^1H NMR Spectrum of compound 24d	327
Figure S-131: ^{13}C NMR Spectrum of compound 24d	328
Figure S-132: ^1H NMR Spectrum of compound 24e	329
Figure S-133: ^{13}C NMR Spectrum of compound 24e	330
Figure S-134: ^1H NMR Spectrum of compound 24f	331
Figure S-135: ^{13}C NMR Spectrum of compound 24f	332
Figure S-136: ^1H NMR Spectrum of compound 24g	333
Figure S-137: ^{13}C NMR Spectrum of compound 24g	334
Figure S-138: ^1H NMR Spectrum of compound 24h	335
Figure S-139: ^{13}C NMR Spectrum of compound 24h	336
Figure S-140: ^1H NMR Spectrum of compound 24i	337
Figure S-141: ^{13}C NMR Spectrum of compound 24i	338
Figure S-142: ^1H NMR Spectrum of compound 24j	339
Figure S-143: ^{13}C NMR Spectrum of compound 24j	340
Figure S-144: HPLC Chromatogram of 5a (racemic)	341
Figure S-145: HPLC Chromatogram of 5a (asymmetric)	342
Figure S-146: HPLC Chromatogram of 6a (racemic)	343
Figure S-147: HPLC Chromatogram of 6a (asymmetric)	344
Figure S-148: HPLC Chromatogram of 5b (racemic)	345
Figure S-149: HPLC Chromatogram of 5b (asymmetric)	346
Figure S-150: HPLC Chromatogram of 6b (racemic)	347
Figure S-151: HPLC Chromatogram of 6b (asymmetric)	348



CHAPTER- 1

INTRODUCTION

Introduction

1.1 GENERAL INTRODUCTION OF FLAVONOIDS

First time in 1936 flavonoids are reported by Hungarian scientist Rusznyak and Sent-Gyorgyi, as polyphenolic compounds of plant origin that are the most important compounds in human diet due to their widespread distribution in foods and beverages. In the late 1980s and throughout the 1990s flavonoids were intensely studied concerning their actions as a mutagenic agents, antioxidants and pro-oxidants as their likely roles in biological systems. They can occur both in the free form (aglycones) and as glycosides and differ in their substituent's (types, number and position) and in their in saturation. The most common sub-classes are flavones, flavonols, flavonones, catechins, isoflavones and anthocyanidines, which account for around 80 % of flavonoids (**Figure 1**).

All flavonoids share a basic C₆-C₃-C₆ phenyl-benzopyran backbone. The position of the phenyl ring relative to the benzopyran moiety allows a broad separation of these compounds into flavonoids (2-phenyl-benzopyrans) (**Figure 1**).




Figure 1: Structure of the structural backbones of the main flavonoid groups (flavan, isoflavan and neoflavan) and of relevant flavonoids classes and classification

Flavonoids and bioflavonoids are widely distributed in plant kingdom, modulating the human metabolism for prevention of chronic and degenerative diseases. The Hungarian scientist termed flavonoids as citrin or vitamin P to explain the synergy between pure vitamin




















C and as yet unidentified co-factors from the peels of lemons.[1] Till now, more than 4000 such molecules have been identified from fruits, vegetables and beverages. They are produced in plants via the flavonoids branch of the phenylpropanoid and acetate-malonate metabolic pathway. These phenolic compounds comprising a general structure of flavan nucleus phenyl benzopyrone skeleton (C-3-C-6-C-3) in all molecules and having a chromene type skeleton having phenyl substituent in C2-C3 position. They have the general structure of a 15-carbon skeleton, which consists of two phenyl rings (A and B) and heterocyclic ring (C). The three cycle or heterocycles in the flavonoid backbone are generally called ring A, B and C. Ring A usually shows a phloroglucinol substitution pattern.[2] The ring A synthesized in polyacetate pathway whereas, B and C rings in shikimic pathway. The different classes of flavonoids have been categorized based on the oxidation status of central ring C. Anthocyanidins are produced by oxidation and reduction gives rise to flavon-3-ols and flavan-3, 4-diols. Intermediate compounds such as flavanones, flavonols and flavones produces based on the presence or absence of the double bond between C2-C3 of the molecule.

There are three major classes of flavonoids viz. flavones, isoflavonoids, neoflavonoids. Flavones are derived from 2-phenyl-1,4-benzopyrene derivatives such as quercetin and rutin. Isoflavanoids are derivatives of 3-phenyl-1,4-benzopyrene where being derived from neoflavonoids 4-phenyl-1,4-benzopyrene. Alternative to chemical or synthetic antimicrobials and antioxidants to control the food borne diseases, inhibiting lipid oxidation and thus extending the shelf-life and quality of food products is an increasing trend in food industry.[3]

The common flavonoids obtained from plants in various classes are shown in Figure 2. All classes of flavonoids exhibit variety of biological activities, but among them, the flavones have been considerably explored. Various natural, semi-synthetic and synthetic derivatives of flavones have been synthesized and evaluated for several therapeutic activities like anti-inflammatory, anti-oestrogenic, anti-microbial, anti-allergic, anti-oxidant, anti-tumor and anti-cytotoxic activities (**Figure 2**).

Figure 2: Structure of flavonoids and their naturally occurring compounds


Group of flavonoids	Structure backbones	Examples
---------------------	---------------------	----------

Flavone		 Lutiolin	 Apigenin	 Chrycin
Flavonol		 quercetin	 kaempferol	 galangin
Flavanones		 hesperitin	 naringenin	--
Flavanonols		 taxifolin	--	--
Isoflavones		 genistein	 daidzein	--
Flavan-3-ols		 catechin	 epicatechin	--

1.1.1 Biosynthetic pathway for Flavonoids

Flavonoids are synthesized by the phenylpropanoid metabolic pathway in which the amino acid phenylalanine is used to produce 4-coumaroyl-CoA [3]. This can be combined with malonyl-CoA to give the true backbone of flavonoids, a group of compounds called hydroxychalcones. The metabolic pathway continues through a series of enzymatic modifications to yield flavanones → dihydroflavonols → anthocyanins. Along this pathway,

many products can be formed, including the flavonols, flavan-3-ols, proanthocyanidins (tannins) and a host of other various polyphenolics (**Scheme 1**).



Scheme 1: Flavonoids biosynthetic pathway

1.2 Chalcone

Chalcone is an aromatic ketone and an enone that forms the central core for a variety of important biological compounds, which are known collectively as chalcones or chalconoids. Benzylidene acetophenone is the parent member of the chalcone series. The alternative name given to chalcone is phenyl styryl ketone, benzalacetophenone, β -phenylacrylophenone and α -phenyl- β -benzoyl ethylene (**Figure 3**).




Figure 3: General structure of chalcone ($C_6-C_3-C_6$)

1.2.1 BIOACTIVITY OF CHALCONES

Chalcone are valuable chemicals because of their well known diverse pharmacological activity. A number of chalcone have demonstrated cytotoxic properties which is an implication of anticancer activity. Dimnock et. al. [4] have studied cytotoxic property of a number of chalcone and their related Mannich base towards murine P388 and L1210 leukemia cell lines, as well as human tumor cell line and are found that compound **1** exhibited the highest activity towards L1210 and human tumor cells. Compounds **2** and **3** are other compound of interest due to its huge differential in cytotoxicity between P388 and L1210 cells, where compound **5** exhibited a high therapeutic index by comparison of the toxicity of P388 cells toward Molt 4/C8 T-lymphocytes. The study showed that in general the Mannich bases were more toxic than the corresponding chalcones.

Attempting to determine the influence of relative direction of the two phenyl rings towards cytotoxic effect, Dimnock et. al. [5] studied the cytotoxic properties of 2-arylideneindanone **4**, 2-arylideneindanones **5** and 2-arylideneindanones **6** derivatives against murine P388, L1210, and Molt 4/C8 cancer cell lines and found out that in general the order of cytotoxicity was **6** > **5** > **4**.

Exploration of the mechanism of action as anticancer agent bring us to a better understanding of cancer and can lead us to design better anticancer drug. Licochalcones A (**7**) and Licochalcones E (**8**) are retrochalcone isolated from the root of glycyrrhiza inflata exhibited the DNA topoisomerase inhibitory activity in dose dependent manners and this property might explain the cytotoxic activity of these compounds against some human cancer cell line. (**Figure 4**) [6]





Figure 4: Naturally occurring bioactive chalcone

1.2.2 Methods of Synthesis of chalcone


1.2.2.1 Chalcone synthesis

Chalcone and its derivatives are primarily synthesized in the laboratory using Claisen-Schmidt reaction, in which acetophenone and its derivative reacted with benzaldehyde or its derivative using strong base, such as NaOH, KOH, or NaH in polar solvent.[7] Other catalyst is also used, such as sodium phosphate doped sodium nitrite[8] and aluminium-magnesium hydroxide hydrate.[9]




Scheme 2: Synthesis of chalcone by Claisen-Schmidt reaction

Microwave irradiation induced reaction in the chalcone synthesis is another alternative procedure to synthesize chalcone. This reaction method can shorten the reaction time and simplify the purification procedure. Cross aldol condensation by using microwave was used for the synthesis of chalcone analog **9** namely 2, 6-bis (benzyliden)-cyclohexanone employing BMPTO (bis-(4-methoxyphenyl)-telluroxide) as catalyst. [10]



Scheme 3: Synthesis of chalcone by Cross-Aldol Condensation reaction

Chalcone **10** could be synthesized using Suzuki reaction, employing cinnamoyl-chloride and phenyl boronic acids as reagents and Pd-catalyst in base reaction condition. More exotic synthetic protocols have also been developed to pursue high reaction yield and to minimize the side reaction. [11]




Scheme 4: Synthesis of chalcone by Suzuki reaction

1.2.2.2 Biosynthesis method of chalcone

In biosynthetic pathway, chalcones are synthesized their carbon skeleton from two basic compounds, malonyl-CoA and L-phenylalanine. L-alanine synthesized through the shikimate pathway which is deaminated by phenylalanine deaminase to give trans-cinnamate, and then in the presence of trans-cinnamate 4-monooxygenase generates 4-coumarate which reacts with

coenzyme A to produce 4-coumaroyl-CoA. It reacts with malonyl-CoA in the presence of naringenin chalcone synthase by losing coenzyme A produce naringenin chalcone. (Scheme 5) [12, 13]



Scheme 5: Biosynthesis of chalcone

1.3 FLAVONE

Flavones (flavus = yellow), are a class of flavonoids based on the backbone of 2-phenylchromene-4-one apart from flavonoids are isoflavonoids, derived from 3-phenylchromene-4-one structure and neoflavonoids, derived from 4-phenylcoumarine structure. The three flavonoids classes are all ketone-containing compounds, and as such, are anthoxanthins (flavones and flavonols). Flavones are well known for their various biological activities such as anticancer, anti-inflammatory, anti-osteoporotic and anti-diabetic (**Figure 5**).




Figure 5: General structure of flavones

1.3.1 BIOACTIVITY OF FLAVONES

The major natural flavones are apigenin (4, 5, 7-trihydroxyflavone), chrysin (5, 7-dihydroxyflavone), 6-hydroxyflavone, baicalein (5, 6, 7-trihydroxyflavone), and wogonin (5, 7-dihydroxy-8-methoxyflavone). They are mainly found in cereals and herbs. Synthetic flavones are diosmin, hindrosmin and flavoxate (**Figure 6**). Flavones intake in the form of dietary supplements and plant extracts has been steadily increasing. Natural dietary flavones, found in parsley, celery and citrus peels. The estimated daily intake of flavones is in the flavones, found in parsley, celery and citrus peels. The estimated daily intake of flavones is in the range 20-50 mg/day. In recent years, scientific and public interest in flavone has grown enormously due to

wide spectrum of biological activities and their putative beneficial effects against atherosclerosis, osteoporosis, diabetes mellitus and certain cancers. Flavones are used to treat urinary bladder spasms, treatment of various disease, neurodegenerative diseases such as Alzheimer's disease, anti-inflammatory and anti-apoptotic activity has been demonstrated in neuronal cells, in vitro. [14]





Figure 6: Some examples of natural and synthetic flavones

1.3.2 Methods of Synthesis of flavone


1.3.2.1. Synthesis of flavones

Flavones can be synthesized by various synthetic schemes like Claisen-Schmidt condensation, [15] Baker-Venkataraman-rearrangement, [16] Ionic liquid promoted synthesis, [17] Allan-Robinson, [18] Vilsmeier-Haack reaction, [19] Wittig reaction, Fries rearrangement, [20] and modified Schotten- Baumann reaction. [21] Now a day's most of the flavones are synthesized based on the Baker-Venkataraman method. It involves the conversion of o-hydroxyacetophenone into phenolic esters, which undergoes an intramolecular Claisen condensation in the presence of a base to form beta- diketones, which is cyclized to flavones by an acid catalysed cyclodehydration (**Schemes 6 & 7**).




Scheme 6: Synthesis of flavones by via beta diketone intermediate

Aldehyde and ketone using base form a chalcone followed by Claisen-Schmidt condensation at 110-130 °C to give compound **12**.




Scheme 7: Synthesis of flavone by Claisen-Schmid condensation reaction

Ferrer, J. L. et. al. synthesized the flavone **13** in excellent yield by reaction of iodo-phenoxy acetate through Sonagashira coupling using palladium catalyst and base. [22]



Scheme 8: Palladium catalyzed synthesis is carried out in basic environment by Hua & Yang


Choi, R. C. Y. et. al. discovered the one-pot micro-assisted synthesis of compound **14** through Sonagashira “carbonylation” annulations in 30 min. using Pd_2dba_3 - catalyst and DBU base. [23]



Scheme 9: Flavones via micro-assisted, one-pot Sonagashira “Carbonylation” Annulations reaction used by E. Awuah & A. Capretta

1.3.2.2 Biosynthesis of flavones

Flavones biosynthesis starts with the condensation of one molecule of 4-coumaroyl-CoA and three molecules of malonyl-CoA yielding neringenin chalcone, carried out by the enzyme chalcone synthase (CHS). The two immediate precursors of the chalcone originate from two different pathways of primary metabolism. Coumaroyl-CoA is synthesized from the amino acid phenylalanine by three enzymatic steps, collectively called the general phenyl propanoid pathway, Malonyl-CoA IS synthesized by carboxylation of acetyl-CoA, a central intermediate in the Krebs tricarboxylic acid cycle. The chalcone is consequently isomerized by the enzyme chalcone flavonone isomerase (CHI) to yield a flavonone. From this central intermediate the pathway diverges into several different classes of flavonoids. [24] (**Scheme 10**)



Scheme 10: Biosynthetic pathway of flavones

1.3.2.3 Flavonoids based ligands

Flavonoids based natural or synthetic compounds have been widely reported to exhibit various biological activities, when incorporate new functional groups (hydroxyl, methoxy, amino, carboxyl, sulphone, prenyl, geranyl, glucose) or biologically active moieties (tetrahydropyran, indole, pyrrole, quinolone, triazole, and admantyl) improves its activity. For example, hydroxyl groups containing chalcone derivative butein extracted from *Rhus verniciflua* which shows good antioxidant activity Flavokawain B found in kava plant it demonstrated To possess potent apoptotic abilities, Xanthohumol is, a *prenylated-chalconoid* from hops and beer. Xanthohumol is a free radical scavenger it, has anticancer properties and prevents platelet build-up. Cycloaltilisin extracted from the bud cover of *Artocarpus altilis* showed activity in a cathepsin K inhibition assay and showed IC₅₀ value 840 Nm, Flavone-triazole-tetrahydropyran conjugates shows a excellent antiproliferative activity against human cancer cell line. [25] Tetrahydropyran containing flavone derivative calyxin G and epicalyxin G are extracted from the seeds of *A. blepharocalyx* showed significant hepatoprotective activity

against CCl_4 induced hepatotoxicity in rats. Triazole moiety attached isoflavone found inhibitor of estrogen receptor alpha-positive breast cancer.




Figure 7: Natural and synthetic biologically active flavonoids conjugates

Based on the literature, we have synthesized novel flavone based ligands as flavone-estradiol adducts and are reported in chapter 2. They were exhibited excellent anti-proliferative activity against human breast cancer cells (MCF-7 and MDA-MB-231) and cervical cancer cells (HeLa). Some derivatives were shown better than the standard drug Doxorubicin.

1.4 DEPROTECTION OF HYDROXYL PROTECTING GROUPS


1.4.1 THP deprotection

Tetrahydropyranyl ethers are usually transformed into their parent alcohols or phenols under acid-catalysed conditions. [26] A wide variety of catalysts have been already used for this conversion, including the use of protic acids [27] (acetic acid, toluene-p-sulphonic acids, boric acid), lewis acids [28] (magnesium bromide in diethyl ether, dimethyl aluminium chloride), electrogenerated acids, [29] pyridinium toluene-p-sulphonate, [30] ion-exchange resins, [31] (Amberlyst H-15, Dowex 50W X8, Nafion-117), Bis-(trimethylsilyl)sulphate, [32] distannoxane, [33] organotin phosphate condensates [34] and triphenyl phosphine dibromide (PPh_3Br_2), [35] more recently, 2, 3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), [36] mesoporous H-MCM-41 molecular sieve, [37] and heteropolyacid, [38] have been applied to this reaction.

1.4.2 MOM-Cl-deprotection

Protection of functional groups in multistep organic synthesis is one of the key factors in the success of the synthesis. The protecting group should selectively react in good yield to give a protected substrate and should be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the regenerated functional group. [39] one of the most abundant functional groups is the hydroxyl group, which is present in a number of compounds of biological and synthetic interest, including nucleosides, carbohydrates, steroids, macrolides, polyethers, and the side chain of some amino acids or in large number of intermediates in total synthesis of complex natural products. [40] diverse protecting groups have been developed for hydroxyl groups, but it is hard to find an appropriate protecting group for each hydroxyl in the many cases where multiple hydroxyl groups are present in the molecule. [41]

The methoxymethyl (MOM) group is widely used as a hydroxyl-protecting group because MOM ethers can be easily prepared and are stable under the removal conditions of protecting groups such as silyl, alkoxyacyl, or benzyl derivative, as well as in strongly basic and weakly acidic conditions. [42a] many methods have been developed to cleave MOM ethers using Bronstead acids. [42b] Lewis acids, [42c] but synthetic application of these methods has been limited, largely due to the high reactivity combined with long reaction time and low selectivity for MOM in the presence of other protecting groups.



Scheme 11: Selective deprotection of MOM ethers

1.4.3 Deprotection of acetate groups


Nucleosides and their analogues have been extensively investigated due to their potential activity as antibiotics, enzyme inhibitors, anticancer and antiviral agents. [43] Consequently, improved and abbreviated synthesis of modified nucleosides from readily available precursors is of considerable interest. [44] However, nucleosides are challenging synthetic substrates as they contain several functionalized groups that must be chemically differentiated for successful transformations. Therefore, multi-step synthesis frequently requires the introduction of protective groups and their subsequent removal. [45-46] Typical methods for the removal of

acetate groups in acetylated nucleosides rely on the use of methanolic ammonia, [47] metal alkoxides, [48] and hydrolytic enzymes, [49] often in good yields. Although all of the above procedures offer certain benefits, they also suffer from drawbacks such as long reaction times, high costs, the use of unstable or noxious reagents, harmful conditions, and the need for special safety precautions, which represent major disadvantages due to environmental concerns. Also, the generation of non-volatile by-products such as acetamide or alkaline salts from the corresponding ammonolysis or alcoholysis of acetates requires additional separation steps for complete product purification. Therefore, the development of a simple catalytic process for the fast and efficient cleavage of acetate groups in acetylated nucleosides, including facilitated workup and purification steps, is highly desirable.

Phenolic hydroxyl groups are frequently observed in various bioactive natural products. The modifications and synthesis of these compounds generally require the protection of this hydroxyl groups. [50] This protection is usually carried out by making the acetates of the compounds as the acetates as the acetate can easily be prepared and again be converted into the parent hydroxyl compounds. [51] However, these deprotection methods may affect several sensitive functional groups present in the molecules. Different methods are also now known for the deprotection of aromatic acetates but the number of process for the selective deprotection of this conversion is limited. Several manipulations can be carried out on the regenerated phenolic hydroxyl groups of a molecule in the presence of alkyl acetate groups and other sensitive functionalities and this method can be utilized in multistep organic transformation and synthesis.


1.4.4 EXAMPLES (deprotection of MOMCl, THP and Acetate)

Hocek, M. & co-workers developed the methodology for the deprotection of mom ethers to alcohol **16** using zinc dibromide as a novel catalyst in DCM at 0°C. [52]




Scheme 12: Demethoxymethylation with ZnBr₂ as a catalyst

Sá, M. M. et. al. used expansive graphite as a catalyst for the detetrahydropyranylation of hydroxyl group in methanol at 40-50 °C to afford corresponding alcohol **17**. [53]




Scheme 13: Detetrahydropyranylation with expansive graphite as a catalyst

Witczak, Z. J. et. al. developed novel methods for the deprotection of THP ethers using bismuth triflate as a novel catalyst in 1 mol% loading to give alcohol **18**. [54]



Scheme 14: Detetrahydropyranylation with bismuth triflate as a catalyst

Ahmed, N. et. al. used expansive zeolite for the detetrahydropyranylation of hydroxyl group in methanol at reflux temperature to afford corresponding alcohol **19**. [55]



Scheme 15: Detetrahydropyranylation with expansive zeolite as a catalyst

Deprotection of THP, MOM and acetate used in total synthesis of Tonkinecin, [56] Solamin, [57] Jimenezin, [58-59] Muricatacin. [60]

We have developed a novel, efficient and green methodology for the deprotection of THP, MOM and acetate groups of alcohol and phenol by using novel catalysts SnCl_4 , TiCl_4 and SeO_2 in water and are reported in chapters 2 and 4. These methods have more advantage than the earlier reported methods like short reaction time, high yields, green reaction condition and easy experimental procedures.


1.5 McMURRY COUPLING

The reaction is discovered by John E. McMurry for the ketones and aldehydes eliminative deoxygenation reaction to alkene using titanium (III) and titanium (IV) as a reductant. [61] The original reaction involved the use of a mixture TiCl_3 and LiAlH_4 , which produces the active reagent(s). Related species have been developed involving the combination of TiCl_3 or TiCl_4 with various other reducing agents, including potassium, zinc, and magnesium. [62, 63] The coupling is related to the Pinacol coupling reaction which also proceeds by the reductive coupling of carbonyl compounds to diol. This eliminative deoxygenation can be viewed as involving two steps. First is the formation of a pinacolate (1, 2-diolate) complex, a step which is equivalent to the Pinacol coupling reaction. The second step is

the deoxygenation of the pinacolate which yields the alkene. The second step exploits the oxophilicity of titanium.

1.5.1 Introduction

The McMurry coupling is the reaction of two carbonyl functional groups to establish a new double bond between the carbons of the carbonyl groups. The reaction is mediated by low-valent titanium reagents, which may be generated through the combination of titanium chlorides with any of a number of reducing agents. The McMurry coupling is useful for the construction of sterically hindered alkenes, but has limited scope due to a lack of stereochemical control and statistical mixtures of products in mixed-coupling reactions. [64] The formation of alkenes as minor products in Pinacol couplings of aromatic carbonyl compounds with aluminum amalgam was first reported in 1970. [65] Since then, the reductive coupling of carbonyl compounds to afford alkenes has been developed into a useful synthetic method, most notably by McMurry and colleagues. The modern McMurry coupling employs low-valent titanium generated from a titanium source and a reducing agent (**Scheme 16**), and the scope of the reaction has benefited from the development of several titanium-reductant combinations. Aldehydes and ketones may be coupled in an intra- or intermolecular fashion to afford alkenes that may be difficult to access using other methods. Carboxylic acid derivatives such as esters, amides, and thioesters are amenable to coupling in some cases.




Scheme 16: Reductive coupling of carbonyl compounds to afford alkenes by low-valent Ti

In general, the McMurry coupling has four possibility for the formation of products, homo- and hetero-coupled products and *E/Z*-isomers, the (*E*)-isomer of product is favored over the (*Z*)-isomer, that depends on the substituent on carbonyl groups. One- and two-electron transfer mechanisms have been postulated for the McMurry coupling and the details of its mechanism remain unknown. When the steric environments and reduction potentials of the carbonyl groups involved are similar, achieving selective mixed coupling (rather than a statistical mixture of homo-coupling and mixed-coupling products) is often difficult. Methods that circumvent this issue have relied on the use of carbonyl equivalents such as thioacetals and geminal dihalides.

1.5.2 Mechanism and Stereochemistry

1.5.2.1 Prevailing Mechanism

The mechanism of the McMurry coupling is unclear at present, and isolated observations have pointed to both one-electron and two-electron mechanisms. One-electron reduction may afford two titanium ketyl radicals **20**, which could subsequently couple with one another to yield titanium pinacolate **21**. Elimination of two titanium oxo molecules would then occur to afford the product olefin. This mechanism has been supported by electron paramagnetic resonance spectroscopy. [66] More readily reducible aromatic carbonyl compounds undergo two-electron reduction to produce titanium ketyl anion **22**, which leads to the same pinacolate **21** after addition to a second molecule of the carbonyl compound (**Scheme 17**). [67]




Scheme 17: Plausible mechanism for alkene formation

Several mechanisms have been discussed for this reaction, [68] the nature of low-valent titanium species formed is varied as the products formed by reduction of the precursor titanium halide complex will naturally depend upon both the solvent (most commonly THF or DME) and the reducing agent employed typically, lithium aluminum hydride, zinc-copper couple, zinc dust, magnesium-mercury amalgam, magnesium, or alkali metals. [69]

1.5.2.2 Stereochemistry


McMurry couplings generally produce mixtures of (*E*)- and (*Z*)-isomers, with the (*E*)-isomer predominating. Increasing the size difference between the substituent's increases the selectivity for the less sterically hindered (*E*)-isomer. [70]



Scheme 18: Formation of mixtures of (*E*)- and (*Z*)-isomers by McMurry couplings

Coupling reactions between monoaryl ketones are an interesting and important exception to this rule. The tendency of these reactions to yield the (*Z*)-isomer as the major product when R

is small has been attributed to coordination of the aryl groups to the titanium center. (**Scheme 19**) [71]




R	Yield (%)	(E)/(Z)
Me	81	26:74
Et	59	27:73
Pr	55	11:89
i-Pr	25	88:12

Scheme 19: Exception to the McMurry couplings gave (*Z*)-isomers as a major product


1. 5. 3. Comparison to Other Methods

The McMurry coupling is limited by the formation of *E/Z* mixtures and by formation of statistical mixtures of products in many mixed-coupling reactions. A number of alternative olefination methods exist, and these tend to dominate the McMurry coupling in organic synthesis. The Wittig reaction (**Scheme 20**) employs a carbonyl compound in combination with a phosphonium ylide (the latter, in a sense, serving as a carbonyl equivalent). [72]




Scheme 20: Comparison of the McMurry coupling with Wittig reaction

Carbonyl olefinating reagents involving pre-formed or intermediate metal carbenes offer another alternative to the McMurry coupling (**Scheme 21**). Schrock carbenes associated with high-valent metals such as niobium and tantalum react with carbonyl compounds to afford the corresponding alkenes. [92] Tebbe's reagent, a titanium methylene complex, is used for the formation of terminal olefins from aldehydes and ketones. [73]



Scheme 21: Alternative to the McMurry coupling (Tebbe's reagent)

The original publication by Mukaiyama demonstrated reductive coupling of ketones using reduced titanium reagents. McMurry and Fleming coupled retinal to give carotene using a mixture of titanium trichloride and lithium aluminium hydride. Other symmetrical alkenes were prepared similarly, e.g. civetone from adamantanone and tetraphenylethylene from benzophenone. [74]





Scheme 22: Alternative to the McMurry coupling

1.5.4 Scope and Limitations

The McMurry coupling employing titanium requires a low-valent species, which is typically generated ‘in situ’ via treatment of a titanium halide with a reducing agent. A variety of titanium-reductant combinations have been employed for the reaction. Reductants include zinc metal, Zn/Cu, LiAlH₄, alkali and alkali earth metals, lithium arenes, and butyllithium. TiCl₄ and TiCl₃ are the most common titanium sources employed. In general, aliphatic ketones are more difficult to couple than aromatic ketones. For example, aliphatic ketones exclusively form pinacols in the presence of the low-valent titanium reagent generated from TiCl₄ and Zn, and are poor substrates for titanium powder. Other metals employed in McMurry couplings include zirconium, vanadium, [75] niobium, [76] molybdenum, [77] tungsten, [78] aluminum, [79] and zinc. [80] The practical utility of some of these metals is limited by their cost and availability, but the scope of the reaction certainly benefits from the large number of metallic reagents that may be used.


In many cases, additives can have a beneficial effect on McMurry couplings suffering from reduced yields due to pinacol formation and rearrangement. For example, amines suppress the formation of pinacols and rearrangement in the homo-coupling of β-ionone. (**Scheme 23**) [81] Sub-stoichiometric amounts of iodine facilitate the coupling of aliphatic carbonyl compounds by TiCl₃-Li at low temperatures and short reaction times. [82]



Tert-amine	68(%)	69 (%)	70 (%)
none	44	8	25
Bu ₃ N	91	0	0
Py	82	0	0
Et ₃ N	82	0	0
	94	0	0
DABCO	72	0	0


Scheme 23: Effect of additives on McMurry coupling

Amides are relatively versatile substrates, and both inter- and intramolecular homo-coupling reactions of amides have been reported. [83] The intramolecular coupling of amides with ketones has been employed for the synthesis of indole derivatives **26**. (Scheme 24) [84]




Scheme 24: Intramolecular McMurry coupling with low valent Ti -metal


Homo-coupling reactions are the most straightforward transformations that can be accomplished under the conditions of the McMurry coupling. Aliphatic and aromatic ketones can be converted into the corresponding symmetric alkenes in high yield and stereoselectivity. In reactions that could form diastereomers, selectivity for the (*E*)-isomer is typical. (Scheme 25)

**Scheme 25:** Selectivity in McMurry coupling


Mixed-coupling reactions between carbonyl substrates with different substitution patterns often afford a statistical mixture of products unless an excess of one of the coupling partners is employed. (**Scheme 26**) The success of a mixed-coupling also depends on the structures of the substrates; in some cases, an excess of one of the coupling partners does not minimize homo-coupling.

**Scheme 26:** Application of McMurry coupling in the synthesis of bicyclic products

When the reduction potentials of the two substrates employed are sufficiently different, selective mixed-couplings can be accomplished using equimolar amounts of the two coupling partners. For example, monoaryl and diaryl ketones readily couple with one another in high yield in the presence of $\text{TiCl}_3\text{-Zn}$. (**Scheme 27**) [85]

**Scheme 27:** Effect of amount of substrate on formation of mix-coupled products

The McMurry coupling is severely limited by the drawback that mixed coupling between ketones and aldehydes is difficult to achieve. Reactions employing carbonyl equivalents such as *gem*-dihalides and thioacetals are amenable to mixed coupling and nicely complement the traditional McMurry coupling. Essentially, these reactions are an extension of the strategy of using coupling partners with very different reduction potentials. Esters, amides, and thioesters are useful substrates and afford electron-rich olefins. (**Scheme 28**) [86]

**Scheme 28:** Drawbacks of the McMurry coupling

In chapter 3, we have developed a novel methodology for the deoxygenation of carbonyl compounds to olefin using the novel reagent, $\text{SnCl}_4\text{-Zn}$ (1:1.5) in THF which gave the major cross-coupled products over the homo-coupled products within 1h at 66 °C and this methodology extended for the synthesis of E & Z- isomers of Tamoxifen analogs.

1.6 INDANONE

Indanone, indenone and indane skeletons are important moieties present in a variety of natural products and biologically active compounds. For example, indenone (3-(2,3-dihydrobenzofuran-6-yl)-5,6-dimethoxy-2-methyl-2,3-dihydro-1H-inden-1-one) was isolated from the fruits of *Viola sebifera*, [87] indanone (pterosin C) is a cytotoxic and antibacterial natural products, [88] donepezil, a potent acetylcholinesterase inhibitor prescribed for the treatment of Alzheimer's disease, [89] is a marketed drug (AriceptTM), and indenone (5-(4-chlorophenyl)-3-(methylsulfonyl)-2H-indeno[5,6-d]oxazole-2,7(3H)-dione) is a structural analogue of the selective COX-2 inhibitor nimesulide. [90] Indan-1-one and indan-2-one derivatives are important moieties in the core structures of many natural products, agrochemicals and medicines [91-94] including Indacrinone, [95 a-c] indanoyl isoleucine conjugates, [95d] indanocines, [95e] quadranglularin A, [95 f, g] parthenocissin A, [95 h, i] (+)-pauciflorol F, [96] norditerpene taiwaniaquinol B, [97] sulindac, NSAID, [98a-c] NMDA receptor antagonists, [98d] benzodiazepines, [98e] melatonin precursor, [98f] and neoflavonoids [99,100] (Figure 11). They are also reported from higher plants such as *Uvaria afzelii* roots, [101] *Pteridium aquilinum* [102a-c] and *Equisetum arvense* [102d] and screened for various biological activities including cancer and Alzheimer's diseases. 2-(Alkoxy carbonyl) and 2-acetyl-1-indanones are present in cytotoxic natural compound pterosines, a potent and selective COX-2 inhibitor flosulide, and the acetyl cholinesterase inhibitor donepezil hydrochloride. They are approved by US-FDA for the treatment of mild to moderate Alzheimer's disease. Similarly, the enantiomerically pure derivative, 1-amino-2-indanol is a key precursor of the chiral ligand and the chiral auxiliary for asymmetric synthesis of indinavir, a potent inhibitor of the protease of human immunodeficiency virus (HIV) [103] and Detrol LA (tolterodine tartrate), a muscarine receptor antagonist used for the treatment of urinary bladder disorder. [104a] The Indan-1-one bearing carboxylate scaffold is also used a peroxisome proliferator activated receptor γ (PPAR γ) agonist in the treatment of type-2 diabetes. [104b]





Figure 8: Bioactive compounds containing indanone and indenone cores

Various methods have reported in the literature to access indanones and indenones. Substituted indanones were obtained by using the intramolecular Friedal-Crafts reaction, [105] photochemical reactions, [106] Nazarov cyclization [107] and organometallic-catalysed reactions.[108] Friedel-Crafts alkylation, [109] Nazarov cyclization, [110,111] Tandem Knoevenagel Condensation-cycloalkylation, [112] Heck & Negishi coupling, [113] Larock annulations. [114] Similarly, enantioselective indanones synthesis required multi-step reaction and high catalyst loading for the 3-substituted indanone derivatives. [115] Indanone frameworks are commonly found in a wealth of natural products and biologically active compounds. [116] Among them, 1-indanone bearing a stereogenic center at the 3-position are not only particularly important structural components of many pharmaceutical agents but also versatile intermediates in organic synthesis and medicinal chemistry. [117] As a result, methods that enable convenient access to optically active 3-substituted 1-indanones are of great importance. Surprisingly however, only a limited number of methods for the stereoselective formation of 3-substituted 1-indanones have been developed. [118]


1.6.1 Methods of synthesis of Indanone

Ho, T. et. al. synthesized the indanone **27** by using Rh-catalyst and (R)-Monophos ligand in toluene at 80 °C in a good yield. [119]




Scheme 29: [Rh(C₂H₄)Cl]₂-catalysed asymmetric intramolecular 1,4-addition

Brunner, et. al. investigated that the target compound could be prepared via a process involving a one pot Pd-catalysed Heck-Matsuda (HM) reaction [120] procedure followed by hydrolysis of the ester **28** to afford the corresponding carboxylic acid. Finally, as the last step, an acid catalyzed cyclization reaction was employed to provide compound **29**. (Scheme 30)



Scheme 30: Synthesis of indanone **29** via a Heck-Matsuda (HM) reaction


Galici, R. & co-workers prepared BINA in nine steps from 3-bromotoluene, 2, 3-dimethyl anisole, ethyl 4-iodobenzoate, and cyclopentylacetic acid in 16% overall yield. BINA constitutes a highly selective positive allosteric modulator of mGluR2 with a long duration of action and robust efficacy in several preclinical models used to predict anxiolytic and antipsychotic-like activity. [121]



Scheme 31: Synthesis of BINA


1.6.2 Reactivity of indanone

Vidyadhar, et. al. industrially manufactured the indanone derivative donepezil **31**, which is used for the treatment of mild to moderate Alzheimer's disease, in three steps via aldol condensation of indanone and pyridine aldehyde. [122]




Scheme 32: Industrial manufacture of donepezil via a pyridine derivative

It has been observed that 2-(E)-benzylidene-1-indanone **32** undergoes dimerization under basic conditions. The reaction is highly stereoselective and provides almost exclusively dimer **33** using $\text{NaHCO}_3/\text{DMF}$, guanidine carbonate/DMF, or $\text{Cs}_2\text{CO}_3/\text{CH}_3\text{CN}$. [123]




Scheme 33: Stereoselective synthesis of dimer of 2-(E)-benzylidene-1-indanone

Treatment of 1-indanone with aromatic aldehydes and NaOEt in THF afforded complex spirocyclic compounds **34** through a four-component reaction in which two molecules of each starting compounds are combined with formation of four new carbon-carbon bonds, leading to the elaboration of a new five-membered ring that bears five contiguous stereogenic centers with a well defined relative configuration. The reaction seems to take place by cross-aldol condensation, dehydration and dimerization of enones. [124]




Scheme 34: Synthesis of complex spirocyclic compound

2, 2-methyl benzylbromide was reacted with diethyl malonate in alcoholic sodium ethoxide to give diethyl (2-methylbenzyl)malonate in 75% yield followed by saponification and intramolecular ring formation in PPA to gave compound **35** in 90% yields. [125]



Scheme 35: Synthesis of methyl indanone

Indanone on reaction with hydroxyl amine hydrochloride at -10°C followed by tosylation to give a 1-indanone oxime tosylate. Then undergo Beckmann rearrangement in presence of aluminium chloride to obtained isomers **36** & **37**. [126]



Scheme 36: Synthesis of 1-indanone oxime tosylate and their Beckmann rearrangement

We have also synthesized indanone based ligands as tamoxifen analogs via McMurry reaction. A major cross-coupled product was obtained within 1h at 66°C . Tamoxifen analogs were exhibited excellent anti-proliferative activity against human breast cancer cells (MCF-7 and MDA-MB-231) and cervical cancer cells (HeLa) are reported in chapter 3, part B.

1.7 References

- [1] Sandhar, H. K.; Kumar, B.; Tiwari, P.; Salhan, M.; Sharma, P.; *A review of phytochemistry and pharmacology of flavonoids*, International Pharmaceutica Scientia 2011, 1, 25.
- [2] Cushnie, T. P. T.; Lamb, A. J.; *Antimicrobial activity of flavonoids*, Int. J. Antimicrobial Agents 2005, 26, 343.
- [3] Perumalla, A. V.; Navam, S.; Hettiarachchy, S.; *Green tea and grape seed extracts- Potentials applications in food safety and quality*, Food Res. Int. 2011, 44, 827.

- [4] Richard, J. L.; Cambien, F.; Ducimetiere, P.; *Epidemiologic characteristics of coronary disease in France*, *Nouv. Med.* 1981, 10, 1111.
- [5] Nijveldt, R. J.; Nood, E. V.; Hoorn, D.; Boelens, P. G.; Norren, K.; Leeuwen, P.; *Flavonoids: A review of probable mechanism of action and potential applications*, *Am. J. Clin. Nutr.* 2001, 74, 418.
- [6] Cushnie, T. P. T.; Lamb, A. J.; *Antimicrobial activity of flavonoids*, *Int. J. Antimicrob. Agents* 2005, 26, 343.
- [7] Havsteen, B.; *Flavonoids, a class of natural products of high pharmacological potency*, *Biochem. Pharmacol.* 1983, 32, 1141.
- [8] Middleton, E.; Chithan, K.; *The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer*, In: J. B. Harborne (ed.), *The Flavonoids: Advances in research since 1986*, pp 145.
- [9] Tapas, A. R.; Sakarkar, D. M.; Kakde, R. B. *Flavonoids as a neutraceuticals: A review*, *Tropical J. Pharma Res* 2008, 3, 1089.
- [10] Aron, P. M.; Kenedly, J. A.; *Mol. Flavan-3-ol: nature, occurrence and biological activity*, *Nutr. Food. Res.* 2008, 52, 79.
- [11] Mitrasinovic, P. M. *Electronic processes at organic/metal interfaces: recent progress and pitfalls*, *Current. Org. Chem.* 2010, 14, 198.
- [12] Januel, C.; Fay, L. B.; Ruggiero, D.; Lagarde, M.; Vericel, E. *Covalent coupling of reduced glutathione with ribose: loss of co-substrate ability to glutathione peroxidises*, *Biochem. Biophys. Acta* 2003, 1, 125.
- [13] Filippou, V.; Emmanouil, T.; Carl, D.; Guenter, V.; Georg, K.; Nickolas P.; *"Biotechnology of flavonoids and other phenylpropanoid-derived natural products. Part I: Chemical diversity, impacts on plant biology and human health"*, *Biotechnology Journal* 2007, 2, 1214.
- [14] Dimnock, J. R.; Kandepu, N. M.; Hetherington, M.; Quail, J. W.; Pugazhenth, U.; Sudom, A. M.; Chamankhah, M.; Rose, P.; Pass, E.; Allen, T. M.; Halleran, S.; Szydlowski, J.; Mutus, B.; Tannous, M.; Manavathu, E. K.; Myers, T.; De Clerck, E. *Cytotoxic Activities of Mannich Bases of Chalcones and Related Compounds*, *J. Med. Chem.* 1998, 41, 1014.
- [15] Dimnock, J. R.; Kandepu, N. M.; Nazarali, A. J.; Kowalchuk, T. P.; Motaganahalli, N.; Quail, J. W.; Mykytyuk, P. A.; Audette, G. F.; Prasad, L.; Allen, T. M.; Balzarini, J.;

- Conformational and Quantitative Structure-Activity Relationship Study of Cytotoxic 2-Arylidenebenzocycloalkanones*, J. Med. Chem. 1999, 42, 1358.
- [16] Yoon, G.; Kang, B. Y.; Cheon, S. H.; *Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza inflata*, Pharm. Res. 2007, 30, 313.
- [17] Sebti, S.; Solhi, A.; Tahir, R.; Boulaajaj, S.; Mayoral, J. A.; Fraile, J. M.; Kossir, A.; Oumimoun, H. *Calcined sodium nitrate/natural phosphate: an extremely active catalyst for the easy synthesis of chalcones in heterogeneous media*, Tetrahedron Lett. 2001, 42, 7953.
- [18] Zakaria, Z. A.; Sani, M. H.; Mohammat, M. F.; Mansor, N. S.; Shaameri, Z.; Kek, T. L.; Salleh, M. Z.; Hamzah, A. S. *Antinociceptive activity of a synthetic oxopyrrolidine-based compound, ASH21374, and determination of its possible mechanisms*, Canadian Journal of Physiology and Pharmacology 2013, 91, 1143.
- [19] Zeng, M.; Wang, L.; Shao, J.; Zhong, Q.; *A facile synthesis of α,α' -bis(substituted benzylidene)cycloalkanones catalyzed by bis(p-ethoxyphenyl) telluroxide (BMPTO) under microwave irradiation*, Synth. Commun. 1997, 27, 351.
- [20] Eddarir, S.; Cotelle, N.; Bakkour, Y.; Rolando, C. *An efficient synthesis of chalcones based on the Suzuki reaction*, Tetrahedron Lett. 2003, 44, 5359.
- [21] Reddy, M. V. B.; Tsai, W. J.; Qian, K.; Lee, K. H.; Wu, T. S. '*Structure-activity relationships of chalcone analogs as potential inhibitors of ADP-and collagen-induced platelet aggregation*' Bioorg. Med. Chem. 2011, 19, 7711.
- [22] (a) Ferrer, J. L.; Jez, J. M.; Bowman, M. E.; Dixon, R. A.; Noel, J. P. '*Structure of chalcone synthase and the molecular basis of plant polyketide biosynthesis*', Nat. Struct. Biol. 1999, 9, 6775; (b) Jada, S. R.; Subur, G. S.; Matthews, C.; Hamzah, A. S.; Lajis, N. H.; Saad, M. S.; Stevens, M. F. G.; Stanslas, J. *Semi synthesis and in vitro anticancer activities of andrographolide analogues*, Phytochemistry 2007, 68, 904; (c) Shadid, K. A.; Shaari, K.; Abas, F.; Israf, D. A.; Hamzah, A. S.; Syakroni, N.; Saha, K.; Lajis, N. H.; *Cytotoxic caged-polyprenylated xanthonoids and a xanthone from Garcinia cantleyana*, Phytochemistry 2007, 68, 2537.
- [23] Choi, R. C. Y.; Zhu, J. T. T.; Yung, A. W. Y.; Lee, P. S. C.; Xu, S. L.; Guo, A. J. Y.; Zhu, K. Y.; Dong, T. T. X.; Tsim, K. W. K. '*Synergistic action of flavonoids, baicalein, and daidzein in estrogenic and Neuroprotective effects: A development of potentials health*

- products and therapeutic drugs against alzheimer's disease*, Evid. Based Complement. Alternat. Med. 2013, Article ID 635694, <http://dx.doi.org/10.1155/2013/635694>.
- [24] Sashidhara, K. V.; Avula, S. R.; Palnati, G. R.; Singh, S. V.; Srivastava, K.; Puri, S. K.; Saxena, J. K.; *Synthesis and in vitro evaluation of new chloroquine-chalcone hybrids against chloroquine-resistant strain of Plasmodium falciparum*, Bioorg. Med. Chem. Lett. 2012, 22, 5455.
- [25] (a) Ahmed, N.; Konduru, N. K.; Ahmad, S.; Owais, M. *Design, synthesis and antiproliferative activity of functionalized flavone-triazole-tetrahydropyranconjugates against human cancer cell line.*, Eur. J. Med. Chem. 2014, 82, 552; (b) Mahal, H. S.; Venkataraman, K.; *Synthesis experiments in the hormone group. Part xiv. The action of sodamide on 1-acyloxy-2-acetonaphthones*, J. Chem. Soc. 1934, 10, 1767.
- [26] Baker, W.; *Molecular rearrangement of some o-acyloxyacetophenones and the mechanism of the production of 3-acylchromones*, J. Chem. Soc. 1933, 10, 1381.
- [27] Sarda, S. R.; Pathan, M. Y.; Paikhe, V. V.; Pachmase, P. R.; Jadhav, W. N.; Pawar, R. P.; *A facile synthesis of flavones using recyclable ionic liquid under microwave irradiation*, Arkivok 2006, 16, 43.
- [28] Allan, J.; Robinson, R. *An accessible derivative of chromonol*, J. Chem. Soc. 1924, 15, 2192.
- [29] Mitrasinovic, P. M. *Theoretical insights into dispersion and hydrogen-bonding interactions in biomolecular systems*, Current. Org. Chem. 2010, 14, 129.
- [30] Sashidhara, K. V.; Kumar, M.; Kumar, A. *A novel route to synthesis of flavones from salicylaldehyde and acetophenone derivative*, Tetrahedron Lett. 2012, 53, 2355.
- [31] Koes, R. E.; Quattrocchio, F.; *The flavonoids biosynthetic pathway in plants: function and evolution*, J. Mol. Bioassays 1994, 16, 123.
- [32] (a) Ahmed, N.; Konduru, N. K.; *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177; (b) Hua, M.; Zhen Y.; *Regiospecific Carbonylative Annulation of Iodophenol Acetates and Acetylenes To Construct the Flavones by a New Catalyst of Palladium-Thiourea-dppp Complex*, Org. Lett. 2000, 2, 1765.

- [33] Emelia, A.; Alfredo, C. *Access to Flavones via a Microwave-Assisted, One-Pot Sonagashira-Carbonylation-Annulation Reaction*, *Org. Lett.* 2009, 11, 3210.
- [34] Reddy, M. V. B.; Tsai, W. J.; Qian, K.; Lee, K. H.; Wu, T. S. 'Structure-activity relationships of chalcone analogs as potential inhibitors of ADP-and collagen-induced platelet aggregation' *Bioorg. Med. Chem.* 2011, 19, 7711.
- [35] (a) Farhoosh, R. 'Antioxidant activity and mechanism of action of butein linoleic acid', *Food Chem.* 2005, 93, 633; (b) Kuo, Y. F.; Su, Y. Z. Tseng, Y. H.; Wang, H. M.; Chueh, P. J. 'Flavokawain B, a novel chalcone from *Alpinia priceihayata* with potent apoptotic activity: Involvement of ROS and GADD153 upstream of mitochondria-dependent apoptosis in HCT116', *Free Radical Biol. Med.* 2010, 49, 214;(c) Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lera, A. R. 'Inhibition of I κ B kinase- β and anticancer activities of novel chalcone admantyl arotinoids', *J. Med. Chem.* 2008, 51, 5431.
- [36] (a) Green T. W.; Wuts, P. G. M. *Protectiv Groups in Organic Synthesis*, Wiley, New York, 2nd edn. 1991, p. 31; (b) Kocienski, P. J.; *Protective Groups*, Georg Thieme Verlag, Stuttgart 1994, p. 83.
- [37] Corey, E. J.; Danheiser, R. L. Chandrasekaran, S.; Siret, P.; Kelk, G.; Cras, E. J. L.; *Stereospecific total synthesis of gibberellic acid. A key tricyclic intermediate*, *J. Am. Chem. Soc.* 1978, 100, 8031.
- [38] Kim, S.; Park, H. *Selective removal of tetrahydropyranyl ethers in the presence of tert-butyltrimethylsilyl ethers with magnesium bromide in ether*, *Tetrahedron Lett.* 1987, 28, 439.
- [39] Torii, S.; Inokuchi, T.; Kondo, K.; Ito, H. *Methods of deprotection of hydroxyl group by novel catalyst*, *Bull. Chem. Soc. Jpn.* 1985, 58, 1947.
- [40] Miyasita, N.; Yoshikoshi, A.; Grieco, P. A. *Pyridinium p-toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranlation of alcohols*, *J. Org. Chem.* 1977, 42, 3772.
- [41] Olah, G. A.; Husain, A.; Singh, B. P. *Catalysis by solid superacids; 19. Simplified and improved polymeric perfluorinated resin sulfonic acid (Nafion-H) catalyzed protection-deprotection reactions*, *Synthesis* 1983, 29, 892.
- [42] (a) Meyers, A. I.; Durandetta, J. L.; Munavu, R. *J. Org. Chem.* 1975, 40, 2025; (b) Ireland, R. E.; Varneey, M. D. *J. Approach to the total synthesis of chlorothricolide: synthesis of (\pm)-19,20-dihydro-24-O-methylchlorothricolide methyl ester ethyl carbonate*, *Org. Chem.*,

- 1986, 51, 635; (c) Mander, L. N.; Thomson, R. J.; *Total Synthesis of Sordaricin*, J. Org. Chem. 2005, 70, 1654.
- [43] Dienstag, J.; Easley, C.; Kirkpatrick, P.; *Telbivudine*, Nat. Rev. Drug Discovery 2007, 6, 267.
- [44] Matthews, S. J.; *Entecavir for the treatment of chronic hepatitis B virus infection*, Clin. Ther. 2006, 28, 184.
- [45] De Clercq, E.; Field, H. J.; *Antiviral prodrugs - the development of successful prodrug strategies for antiviral chemotherapy*, J. Pharmacol. 2006, 147, 1.
- [46] Kaminskis, E.; Farrell, A.; Abraham, S.; Baird, A.; Hsieh, L.-S.; Lee, S.-L.; Leighton, J. K.; Patel, H.; Rahman, A.; Sridhara, R.; Wang, Y.-C.; Pazdur, R.; *Approval Summary: Azacitidine for Treatment of Myelodysplastic Syndrome Subtypes*, Clin. Cancer Res. 2005, 11, 3604.
- [47] Qu, G.; Zhang, Z.; Guo, H.; Geng, M.; Xia, R.; *Microwave-assisted rapid and regioselective synthesis of N-(alkoxycarbonylmethyl) nucleobases in water*, J. Braz. Chem. Soc. 2007, 18, 1061.
- [48] Nowak, I.; Robins, M. J. *Protection of the Amino Group of Adenosine and Guanosine Derivatives by Elaboration into a 2,5-Dimethylpyrrole Moiety*, Org. Lett. 2003, 5, 3345.
- [49] Jagtap, P. G.; Chen, Z.; Szabó, C.; Klotz, K.-N. *2-(N-Acyl) and 2-N-acyl-N6-substituted analogues of adenosine and their affinity at the human adenosine receptors*, Bioorg. Med. Chem. Lett. 2004, 14, 1495.
- [50] Gupta, M.; Nair, V. *Facile, chemoenzymatic synthesis of the potent antiviral compound, 2-acetonylinosine*, Tetrahedron Lett. 2005, 46, 1165.
- [51] Lin, X.; Robins, M. J. *Mild and Efficient Functionalization at C6 of Purine 2'-Deoxynucleosides and Ribonucleosides*, Org. Lett. 2000, 2, 3497.
- [52] Hocek, M.; Holy, A.; Votruba, I.; Dvorakova, H. *Synthesis and Cytostatic Activity of Substituted 6-Phenylpurine Bases and Nucleosides: Application of the Suzuki-Miyaura Cross-Coupling Reactions of 6-Chloropurine Derivatives with Phenylboronic Acids*, J. Med. Chem. 2000, 43, 1817.
- [53] Sá, M. M.; Meier, L. *Pyridine-free and solvent-free acetylation of nucleosides promoted by molecular sieves*, Synlett 2006, 14, 3474.

- [54] Witczak, Z. J.; Lorchak, D.; Nguyen, N. *A click chemistry approach to glycomimetics: Michael addition of 2,3,4,6-tetra-O-acetyl-1-thio-β-D-glucopyranose to 4-deoxy-1,2-O-isopropylidene-L-glycero-pent-4-enopyranos-3-ulose - a convenient route to novel 4-deoxy-(1→5)-5-C-thiodisaccharides*, Carbohydr. Res. 2007, 342, 1929.
- [55] (a) Ahmed, N.; Pathe, G. K.; Venkata, B. B. *Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn(IV)Cl₄ catalyst*, Tetrahedron Lett. 2014, 55, 3683; (b) Pathe, G. K.; Ahmed, N.; *SeO₂ in water: a mild and efficient promoter for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of methyl/methylene carbons of alpha carbonyl carbon*, RSC Advance 2015, Ahead of print.
- [56] Zweifel, G. S.; Nantz, M. H. *Modern Organic Synthesis; An introduction*; W. H. Freeman: New York, NY, 2007, pp 58.
- [57] M. Narender, M. S. Reddy, K. R. Rao, *A mild and efficient oxidative deprotection of THP ethers with NBS in the presence of β-cyclodextrin in water*, Synthesis 2004, 25, 1741.
- [58] Liu, J.; Wong, C.-H. *An efficient method for the cleavage of p-methoxybenzylidene (PMP), tetrahydropyranyl (THP) and 1,3-dithiane protecting groups by Selectfluor*, Tetrahedron Lett. 2002, 43, 4037.
- [59] Stephens, J. R.; Butler, P. L.; Clow, C. H.; Oswald, M. C.; Smith, R. C.; Mohan, R. S. *Bismuth triflate: An efficient catalyst for the formation and deprotection of tetrahydropyranyl ethers*, Eur. J. Org. Chem. 2003, 23, 3827.
- [60] Choi, J.-E.; Ko, K.-Y. *Zeolite H-beta: an efficient and recyclable catalyst for the tetrahydropyranlation of alcohols and phenols, and the deprotection of tetrahydropyranyl ethers*, Bull. Korean. Chem. Soc. 2001, 55, 1177.
- [61] Chen, Y.; Yu, D. Q. *Tonkinecin, a novel bioactive annonaceous acetogenin from Uvaria tonkinesis*, J. Nat. Prod. 1996, 59, 507.
- [62] (a) Pathe, G. K.; Ahmed, N. *SnCl₄ - Zn: A novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins*, Tetrahedron Lett. 2015, 56, 1555; (b) Myint, S. H.; Cortes, D.; Laurens, A.; Hocquemiller, R.; Leboeuf, M.; Cave, A.; Cotte, J.; Quero, A. M.; *Acetogenins from Annonaceae. Part II. Solamin, α-cytotoxic mono-tetrahydrofuranic γ-lactone acetogenin from Annona muricata seeds*, Phytochemistry 1991, 30, 3335.

- [63] Chavez, D.; Acevedo, L. A.; Mata, R. *Jimenezin, a novel annonaceous acetogenin from the seeds of Rollinia mucosa containing adjacent tetrahydrofuran-tetrahydropyran ring systems*, J. Nat. Prod. 1998, 61, 419.
- [64] Meyer, B. N.; Ferrigni, N. R.; Putnam, J.E.; Jacobsen, L. B.; Nichols, D. E.; McLaughlin, J. L. *Brine shrimp: a convenient general bioassay for active plant constituents*, Planta Med. 1982, 45, 31.
- [65] Yoshimitsu, T.; Makino, T.; Nagaoka, H. *Synthesis of (-)-Muricatacin via α - and α' -C-H Bond Functionalization of Tetrahydrofuran*, J. Org. Chem. 2003, 68, 7548.
- [66] McMurry, J. E.; Fleming, M. P. *"New method for the reductive coupling of carbonyls to olefins. Synthesis of β -carotene"*. J. Am. Chem. Soc. 1974, 96, 4708.
- [67] Richards I. C. *"Titanium (IV) Chloride–Zinc"* in *Encyclopedia of Reagents for Organic Synthesis*, John Wiley, London, 2001.
- [68] Banwell, M. G. *"Titanium (III) Chloride–Lithium Aluminum Hydride"* in *Encyclopedia of Reagents for Organic Synthesis* John Wiley, London, 2001.
- [69] (a) Ahmed, N.; Van Lier, J. E. *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 5407; (b) Ahmed, N.; Van Lier, J. E. *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 2725.
- [70] Mukaiyama, T.; Sato, T. *"Reductive Coupling of Carbonyl Compounds to Pinacols and Olefins by Using TiCl₄ and Zn"*, J. Chem. Lett. 1973, 15, 1041.
- [71] Ephritikhine, M.; *A new look at the McMurry reaction*, Chem. Commun. 1998, 29, 2549.
- [72] Fürstner, A.; Jumbam, D. N. *Titanium reagent in heterocyclic chemistry*, Tetrahedron 1992, 48, 5991.
- [73] Coe, P. L.; Scriven, C. E.; *Z-Olefin suitable for radiolabeling with iodine-124*, J. Chem. Soc., Perkin Trans. 1986, 23, 475..
- [74] Okazoe, T.; Takai, K.; Oshima, K.; Utimoto, K. *Alkylidenation of ester carbonyl groups by means of a reagent derived from RCHBr₂, Zn, TiCl₄, and TMEDA. Stereoselective preparation of (Z)-alkenyl ethers*, J. Org. Chem. 1987, 52, 4410.

- [75] Villiers, C.; Ephritikhine, M. *New insights into the mechanism of the McMurry reaction*, *Angew. Chem., Int. Ed. Engl.* 1997, 36, 2380.
- [76] Furstner, B. A.; Bogdanovic, B. *"New developments in the chemistry of low-valent titanium"*. *Angew. Chem. Int. Ed.* 1996, 35, 2442.
- [77] Senge, M. O.; Gerzevske, K. R.; Vicente, M. G. H.; Forsyth, T. P.; Smith, K. M. *Formyl porphyrine and their derivative in the chemistry*, *Angew. Chem., Int. Ed. Engl.* 1993, 32, 750.
- [78] Eisch, J. J.; Fregene, P. O. *Organic Chemistry of Subvalent Transition Metal Complexes. Part 44. Vanadium(I) chloride and lithium vanadium(I) dihydride as selective epimetallating reagents for π - and σ -bonded organic substrates*, *Eur. J. Org. Chem.* 2008, 18, 4482.
- [79] Kauffmann, T.; Kallweit, H. *Deoxygenation of carbonyl to olefin by low valent metal complex*, *Chem. Ber. Recl.* 1992, 125, 149.
- [80] Fujiwara, Y.; Ishikawa, R.; Akiyama, F.; Teranishi, S. *Reductive coupling of carbonyl compounds to olefins by tungsten hexachloride-lithium aluminum hydride and some tungsten and molybdenum carbonyls*, *J. Org. Chem.* 1978, 43, 2477.
- [81] Howarth, J.; Finnegan, J. *Synthesis of 9,10-dimethyl[7]helicene and 8,11-diaza[7]helicene*, *Synth. Commun.* 1997, 27, 3663.
- [82] Dutta, D. K.; Konwar, D. *A new method for reductive coupling of carbonyl compounds to olefins*, *Tetrahedron Lett.* 2000, 41, 6227.
- [83] Schmidt, A.; Beckert, R.; Weib, D. *Simple procedure for reductive coupling of steroids with a cross conjugated dienone system*, *Tetrahedron Lett.* 1992, 33, 4299.
- [84] Ishida, A.; Mukaiyama, T. *A convenient method for the preparation of symmetrical polyolefins. Synthesis of β -carotene*, *Chem. Lett.* 1976, 10, 1127.
- [85] Talukdar, S.; Nayak, S. K.; Banerji, A. *Activation of Low-Valent Titanium Reagents with Iodine: Facile Low-Temperature McMurry Reaction and N/O-Debenzylation/Deallylation*, *J. Org. Chem.* 1998, 63, 4925.
- [86] Ogawa, A.; Takami, N.; Sekiguchi, M.; Ryu, I.; Kambe, N.; Sonoda, N. *The first deoxygenative coupling of amides by an unprecedented samarium/samarium diiodide system*, *J. Am. Chem. Soc.* 1992, 114, 8729.
- [87] Maercker, A. *The Wittig reaction*, *Org. React.* 1965, 14, 270.

- [88] Schrock, R. R. *Multiple metal-carbon bonds. The reaction of niobium and tantalum neopentylidene complexes with the carbonyl function*, J. Am. Chem. Soc. 1976, 98, 5399.
- [89] Meier, H.; Rose, B.; Schollmeyer, D. *Band-shaped structures by repetitive cycloaddition reactions of benzo [1,2-b:4,5-b']bisthiete*, Liebigs Ann./Recl. 1997, 6, 1173.
- [90] Bogdanovic, B. Bolte, A. "A comparative study of the McMurryreaction utilizing $[HTiCl(THF)_{0.5}]_x$, $TiCl_3(DME)_{1.5}-Zn(Cu)$ and $TiCl_2*LiCl$ as coupling reagents". J. Organomet. Chem. 1995, 502, 109.
- [91] Wessig, P.; Teubner, J. *Total synthesis of pterosines B and C via a photochemical key step*, Synlett 2006, 22, 1543.
- [92] Sugimoto, H.; Iimura, Y.; Yamanishi, Y.; Yamatsu, K. *Synthesis and Structure-Activity Relationships of Acetyl cholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds*, J. Med. Chem. 1995, 38, 4821.
- [93] Park, C. H.; Siomboing, S.; Yous, S.; Gressier, B. Luyckx, M.; Chavatte, P. *Synthesis and Structure-Activity Relationships of Acetyl cholinesterase Inhibitors: 1-Benzyl-4-[(5,6-dimethoxy-1-oxoindan-2-yl)methyl]piperidine Hydrochloride and Related Compounds*, J. Med. Chem. 1995, 38, 4821.
- [94] Riveira, M. J.; Mischne, M. P.; J. *An Interrupted Vinylogous Iso-Nazarov Reaction: Cycloisomerization of Conjugated Trienones to Cyclopenta[b]furan Derivatives*, Org. Chem. 2014, 79, 8244.
- [95] (a) Hanna, G. M.; Lau-cam, C. A. *Determination of the optical purity of indacrinone by proton nuclear magnetic resonance spectroscopy using chiral lanthanide chelates*, J. Pharm. Biomed. Anal. 1989, 7, 919; (b) Field, M. J.; Fowler, N.; Giebisch, G. H.; *Effects of enantiomers of indacrinone (MK-196) on cation transport by the loop of Henle and distal tubule studied by microperfusion in vivo*, J. Pharmacol. Exp. Ther. 1984, 62; (c) Ioav, C. Z.; Shirley, K.; Miriam, K. *Anion transport inhibitors as suppressors of Plasmodium falciparum growth in in vitro cultures*, G. Mol. Pharmacol. 1983, 23, 92; (d) Mithofer, A.; Maitrejean, M.; Boland, M. *Role of abscisic acid in seed dormancy*, J. Plant Growth Regul. 2005, 24, 170; (e) Leoni, L. M.; Hamel, E.; Genini, D.; Carrera, C. J.; Cottam, H. B.; Dennis, A.; Carson, D. A. *Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells*, J. Natl. Cancer Inst. 2000, 22, 217;

- (f) Adesanya, S. A.; Nia, R.; Martin, M. T.; Boukamcha, N.; Montagnac, A.; Pais, M.; *Stilbene derivatives from Cissus quadrangularis*, J. Nat. Prod. 1999, 28, 1694; (g) Li, W.; Li, H.; Li, Y.; Hou, Z. *Total synthesis of (±)-quadrangularin A*, Angew. Chem., Int. Ed. 2006, 25, 7609; (h) Tanaka, T.; Iinuma, M.; Murata, H. *Formation of polyhydroxylated isoflavones from the isoflavones genistein and biochanin A by bacteria isolated from tempe*, Phytochemistry 1998, 18, 1045; (i) Kim, H. J.; Saleem, M.; Seo, S. H.; Jin, C.; Lee, Y. S. *Two new antioxidant stilbene dimers, parthenostilbenins A and B from Parthenocissus tricuspidata*, Planta Med. 2005, 17, 973.
- [96] Rao, R. J. R.; Rao, A. K. S. B.; Murthy, Y. L. N. *Efficient and Industrially Viable Synthesis of Donepezil*, Synth. Commun. 2007, 5, 2847.
- [97] (a) Silver, S.; Leppanen, A. S.; Sjöholm, R.; Penninkangas, A.; Leino, R. *Towards benign synthesis of indenenes from indanones: zinc-mediated allylation of ketones in aqueous media as a source of substituted indenyl ligand precursors*, Eur. J. Org. Chem. 2005, 14, 1058; (b) Izmer, V. V.; Lebedev, A. Y.; Nikulin, M. V.; Ryabov, A. N.; Asachenko, A. F.; Lygin, A. V.; Sorokin, D. A.; Voskoboynikov, A. Z. *Palladium-Catalyzed Pathways to Aryl-Substituted Indenes: Efficient Synthesis of Ligands and the Respective ansa-Zirconocenes*, Organometallics 2006, 33, 1217.
- [98] (a) Maguire, A. R.; Papot, S.; Ford, A.; Touhey, S.; O'Connor, R.; Clynes, M. *Enantioselective synthesis of Sulindac*, Synlett 2001, 41, 432; (b) Birman, V. B.; Zhao, Z.; Guo, L. *Benzo[b]fluorenes via Indanone Dianion Annulation. A Short Synthesis of Prekinamycin*, Org. Lett. 2007, 23, 1223; (c) Fukatsu, K.; Uchikawa, O.; Kawada, M.; Yamano, T.; Yamashita, M.; Kato, K.; Miyamoto, M.; Ohkawa, S. *Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists*, J. Med. Chem. 2002, 45, 4212; (d) Bonnefous, C.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; Daggett, L. P.; Kamenecka, T. M. *Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor*, Bioorg. Med. Chem. Lett. 2005, 15, 4354; (e) Kielsztejn, L. M.; Bruno, A. M.; Renou, S. G.; Iglesias, G. Y. M. *Design, synthesis, and biological evaluation of alcyopterosin A and illudalane derivatives as anticancer agents*, Bioorg. Med. Chem. 2006, 14, 1863; (f) Yin, W.; Ma, Y.; Xu, J.; Zhao, Y. *Microwave-assisted one-pot synthesis of 1-indanones from arenes and α,β -unsaturated acyl chlorides*, J. Org. Chem. 2006, 71, 4312.

- [99] (a) Donnelly, D. M. X.; Boland, G. M. *Isoflavonoids and neoflavonoids: naturally occurring o-heterocycles*, Nat. Prod. Rep. 1995, 12, 321; (b) Gaviia, F.; Costero, A. M.; Gonzllez, A. M. *Reactive annulenones: a comparative study*, J. Org. Chem. 1990, 55, 2060.
- [100] (a) Neugebauer, R. C.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M. *Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode*, J. Med. Chem. 2008, 51, 1203; (b) Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A. *Inhibitors of Sir2: Evaluation of Splitomicin Analogues*, J. Med. Chem. 2004, 47, 2635.
- [101] Shintani, R.; Takatsu, K.; Hayashi, T. *Rhodium-catalyzed asymmetric synthesis of 3,3-disubstituted 1-indanones*, Angew. Chem., Int. Ed. 2007, 3735.
- [102] (a) Prakash, G. K. S.; Paknia, F.; Vaghoo, H.; Rasul, G.; Mathew, T.; Olah, G. A.; *Preparation of Trifluoromethylated Dihydrocoumarins, Indanones, and Arylpropanoic Acids by Tandem Superacidic Activation of 2-(Trifluoromethyl)acrylic Acid with Arenes*, J. Org. Chem. 2010, 75, 2219; (b) Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Kato, K.; Hirai, K.; Miyamoto, M.; Ohkawa, S. *Synthesis of a Novel Series of Tricyclic Indan Derivatives as Melatonin Receptor Agonists*, J. Med. Chem. 2002, 45, 4222. (c) Hikino, H.; Takahashi, T.; Arihara, S.; Takemoto, T. *Structure of pteroside B, glycoside of Pteridium aquilinum var latiusculum*, Chem. Pharm. Bull. 1970, 18, 1488. (d) Syrchina, A. I.; Gorenysheva, O. N.; Biyushkin, V. N.; Malinovskii, T. I. *Isolation of indanone from Equisetum arvense and its crystal and molecular structure*, Khim. Prir. Soedin. 1978, 44, 508.
- [103] Cui, D. M.; Zhang, C.; Kawamura, M.; Shimada, S. *Synthesis of 1-indanones by intramolecular Friedel-Crafts reaction of 3-arylpropionic acids catalyzed by Tb(OTf)₃*, Tetrahedron Lett. 2004, 45, 1741.
- [104] (a) Wenk, H. H.; Schwab, W.; *Biocatalytic Production of Dihydrocoumarin from Coumarin by Saccharomyces cerevisiae*, J. Agric. Food Chem. 2006, 21, 6236; (b) Ahn, J. H.; Shin, M. S.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Jung, W. H.; Yang, S. D.; Kim, S. J.; Woo, J. R.; Lee, J. H.; Cheon, H. G.; Kim, S. S. *Indenone Derivatives: A Novel Template for Peroxisome Proliferator-Activated Receptor γ (PPAR γ) Agonists*, J. Med. Chem. 2006, 22, 4781.

- [105] Wessig, P.; Glombitza, C.; Moller, G.; Teubner, J. *Photochemical Preparation of Highly Functionalized 1-Indanones*, *J. Org. Chem.* 2004, 69, 7582.
- [106] Lawrence, N. J.; Armitage, E. M.S.; Greedy, B.; Cook, D.; Ducki, S.; McGown, A. T.; *The synthesis of indanones related to combretastatin A-4 via microwave-assisted Nazarov cyclization of chalcones*, *Tetrahedron Lett.* 2006, 47, 1637.
- [107] Shintani, R.; Hayashi, T. *Rhodium-catalyzed addition of arylzinc reagents to aryl alkynyl ketones: Synthesis of β,β -disubstituted indanones*, *Org. Lett.*, 2005, 7, 2071.
- [108] Cui, D. M.; Zhang, C.; Kawamura, M.; Shimada, S. *Synthesis of 1-indanones by intramolecular Friedel-Crafts reaction of 3-arylpropionic acids catalyzed by $Tb(OTf)_3$* , *Tetrahedron Lett.* 2004, 25, 1741.
- [109] (a) Pellissier, H. *Recent developments in the Nazarov process*, *Tetrahedron* 2005, 61, 6479; (b) Frontier, A.; Collison, C. *The Nazarov cyclization in organic synthesis. Recent advances*, *Tetrahedron* 2005, 61, 7577; (c) Clive, D. L. J.; Sannigrahi, M.; Hisaindee, S. *Synthesis of (\pm)-Puraquinonic Acid: An Inducer of Cell Differentiation*, *J. Org. Chem.* 2001, 66, 954.
- [110] Ma, J. A.; Cahard, D. *Mild Electrophilic Trifluoromethylation of β -Ketoesters and Silyl Enol Ethers with 5-Trifluoromethyldibenzothiophenium Tetrafluoroborate*, *J. Org. Chem.* 2003, 68, 8726.
- [111] Sartori, G.; Maggi, R.; Bigi, F.; Porta, C.; Tao, X.; Ianelli, S.; Nardelli, M. *Selective synthesis of 1-indanones via tandem Knoevenagel condensation-cycloalkylation of β -dicarbonyl compounds and aldehydes*, *Tetrahedron* 1995, 51, 12179.
- [112] Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Lawrence, N. J. *Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivasular activity*, *Bioorg. Med. Chem.* 2009, 17, 7698.
- [113] Lee, B. H.; Choi, Y. L.; Shin, S.; Heo, J. -N. *Stereoselective Palladium-Catalyzed α -Arylation of 3-Aryl-1-Indanones: An Asymmetric Synthesis of (+)-Pauciflorol F*, *J. Org. Chem.* 2011, 76, 6611.
- [114] Floyd, M. B.; Allen, G. A. *Efficient synthesis of selected indanones*, *J. Org. Chem.* 1970, 35, 2647.
- [115] (a) Kiasat, A. R.; Badri, R.; Zargar, B.; Sayyahi, S. *Polyethylene glycol Grafted onto Dowex Resin: An Efficient, Recyclable, and Mild Polymer-Supported Phase Transfer*

- Catalyst for the Regioselective Azidolysis of Epoxides in Water*, J. Org. Chem. 2008, 73, 8382; (b) Kim, H. Y.; Talukdar, A.; Cushman, M. *Regioselective Synthesis of N- β -Hydroxyethylaziridines by the Ring-Opening Reaction of Epoxides with Aziridine Generated in Situ*, Org. Lett. 2006, 8, 1085; (c) McCluskey, A.; Leitch, S. K.; Garner, J.; Caden, C. E.; Stewart, S. G. *BiCl₃-mediated opening of epoxides, a facile route to chlorohydrins or amino alcohols: one reagent, two paths*, Tetrahedron Lett. 2005, 46, 8229; (d) Wang, Z.; Cui, Y. T.; Xu, Z-B.; Qu, J. *Hot Water-Promoted Ring-Opening of Epoxides and Aziridines by Water and Other Nucleophiles*, J. Org. Chem. 2008, 73, 2270; (e) Singh, M. C.; Peddinti, R. K. *Antimony(III) chloride-catalyzed ring opening of epoxides with anilines*, Tetrahedron Lett. 2007, 48, 7354; (f) Kalow, J. A.; Doyle, A. G. *Enantioselective ring opening of epoxides by fluoride anion promoted by a cooperative dual-catalyst system*, J. Am. Chem. Soc. 2010, 132, 3268.
- [116] Lattanzi, A. *Enantioselective Epoxidation of α , β -Enones Promoted by α,α -Diphenyl-L-prolinol as Bifunctional Organocatalyst*, Org. Lett. 2005, 7, 2579.
- [117] Feng, C.-G.; Wang, Z. Q.; Shao, C.; Xu, M. H.; Lin, G. Q. *Highly Practical Catalytic Asymmetric 1,4-Addition of Arylboronic Acids in Water Using New Hydrophilic Chiral Bicyclo[3.3.0] Diene Ligands*, Org. Lett. 2008, 10, 4101.
- [118] Hayashi, T.; Yamasaki, K. *Rhodium-Catalyzed Asymmetric 1,4-Addition and Its Related Asymmetric Reactions*, Chem. Rev. 2003, 103, 2829.
- [119] Ho, T. -L.; Lee, K. Y.; Chen, C. K. *Structural Amendment and Stereoselective Synthesis of Mutisianthol*, J. Org. Chem. 1997, 62, 3365.
- [120] Brunner, H.; Cousturier, Le.; de Courcy, N.; Genet, J.-P. *Heck reactions using aryldiazonium salts to give phosphonic acid derivatives*, Synlett 2000, 18, 201.
- [121] Galici, R.; Carrie, K.; Hemstapat, J. K.; Nong, Y.; Nicholas, G.; Echemendia, Lily C.; Tomas, W.; Jeffrey, P. *Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic and anxiolytic-like effect in mice*. J. Pharma. And Expt. Therap. 2006, 318, 173.
- [122] Vidyadhar, J. S.; Venkataraman, N. A.; Pandurang, S. R. *Synthesis of indanone analogs*, US Patent 6, 649, 765.
- [123] Berthelette, C.; McCooye, C.; Leblanc, Y.; Trimble, L. A. *Studies on the dimerization 2-benzyledene-1-indanone*, J. Org. Chem. 1997, 62, 4339.

- [124] Camps, P.; Domingo, L. R.; Formosa, X.; Galdeano, C.; Gonzalez, D.; Munoz-Torrero, D.; Segales, S.; Solan, X. *Highly diastereoselective one-pot synthesis of spiro{cyclopenta[a]indene-2,2'-indene}diones from 1-indanones and aromatic aldehydes*, J. Org. Chem. 2006, 71, 3464.
- [125] Dethé, D. H.; Murhade, G. *FeCl₃ Catalyzed Prins-Type Cyclization for the Synthesis of Highly Substituted Indenes: Application to the Total Synthesis of (±)-Jungianol and epi-Jungianol*, Org. Lett. 2013, 15, 429.
- [126] Lee, B. S.; Chu, S.; Lee, I. Y.; Song, C. E.; Chi, D. Y. *Beckmann rearrangement of 1-indanone oxime derivative using aluminium chloride*, Bull. Korean Chem. Soc. 2000, 21, 860.

CHAPTER- 2

Part-A: Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn (IV) Cl₄ catalyst

Naseem Ahmed*^a, Gulab Khushalrao Pathe^a and B. Venkata Babu^a
Tetrahedron Letters **2014**, 55, 3683 – 3687.

Part-B: SnCl₄ or TiCl₄: Highly efficient catalysts for detetrahydropyranylation and demethoxymethylation of phenolic ethers and sequel one-pot asymmetric synthesis of 3-aryl-2-hydroxy-2,3-dihydroindan-1-ones from chalcone epoxides

Naseem Ahmed*^a, Gulab Khushalrao Pathe^a RSC Advances **2015**,
Accepted.

Part A: Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn (IV) Cl₄ catalyst

2.1 INTRODUCTION

Protection-deprotection of the functional groups is the most frequent used strategies in the multi-steps organic syntheses. In particular, the protection and the deprotection of hydroxyl group is extremely important because of its enormous demand for the synthesis of a number of compounds of biological and synthetic interest such as carbohydrates, macrolides, peptides, steroids, nucleotides and polyethers.[1] The protection of hydroxyl groups with 3,4-dihydro-2H-pyran is the most frequent used method due to stability of the resulting 2-tetrahydropyranyl ethers (THPEs) in the presence of strong bases or nucleophiles such as Grignard reagents, organolithium compounds, metal hydrides, catalytic hydrogenation, alkylating and acylating agents.[2] Similarly, methoxymethyl chloride (MOMCl) is an another important reagent for the hydroxyl group protection.[3]

The deprotection of THP and MOM ethers therefore required efficient methods to avoid the decomposition of the products and/or loss of other functional groups in the products under harsh reaction conditions. Therefore, several catalysts have been explored for the detetrahydropyranlation of alcohols and phenols that include protic acids,[4] Lewis acids like BF₃-etherate,[5] LiBr,[6] LiBF₄,[7] LiOTf,[8] LiClO₄,[9] Sc(OTf)₃,[10] In(OTf)₃,[11] I₂,[12] InCl₃,[13] ZrCl₄,[14] CuCl₂,[15] and NH₄Cl,[16] expansive graphite,[17] clay materials,[18] silica-supported sulfuric acid,[19] and other miscellaneous catalysts.[20-25] Similarly, many catalysts have been used for the demethoxymethylation of alcohols and phenols such as HCl, BBr₃, pyridinium *p*-toluene sulphonate under strong acidic condition, mild Lewis acids ZnBr₂, and TiCl₄ in aprotic conditions and BBr₃ derivatives Me₂BBr, and (i-PrS)₂BBr.[26] Most of these methods have different drawbacks such as longer reaction time, low yields, refluxing at high temperature and the tedious workup procedures. Hence, there is still a scope to develop mild and efficient methods in the deprotection of tetrahydropyranyl and methoxymethyl ethers. In continuation of our interest to develop new methods for the synthesis and the acid catalysis reactions, [27] herein, we report an efficient deprotection method of the THP and the MOM ethers and sequel Friedel-Crafts alkylation reaction of the protected THP and MOM chalcone epoxides using SnCl₄ catalyst under mild reaction conditions.

2.2 OBJECTIVE


Protection and deprotection of hydroxyl group is very important development, frequently used in organic synthesis of molecule like, carbohydrates, macrolides, peptides, steroids, nucleotides and polyethers. Hence, our intention to developed a highly efficient protocol for the deprotection of hydroxyl group by using metal catalyst, and we used different metal catalyst and found that SnCl₄ catalyst provided a rapid and efficient deprotection method for the phenolic THP and MOM ethers and sequel intramolecular Friedel-Crafts alkylation reaction of THP and MOM protected chalcone epoxides under mild conditions. The reaction took 2-3 min to give the products in excellent yield (90-98%) at 0 °C without affecting the other functional groups.

2.3 Results and Discussion

2.3.1. Optimization reaction conditions by using different catalyst

The catalytic efficiency of different metal halides was screened (Table 1). The metal halides (Table 1, entries 1-5) were shown poor to moderate catalytic activity. InCl₃ (Table 1, entry 6) was found to be a better catalyst at 10 mol% catalyst loading, which gave 90% yield of the cyclized products without deprotecting the THP or the MOM ethers. However, the reaction was completed in 4-5 hours. SnCl₄ (Table 1, entries 7, 8) at less than 10 mol% catalyst loading gave lower yields in a longer reaction time. SnCl₄ (Table 1, entry 9) at 10 mol% catalyst loading was found to be the most efficient catalyst, which gave the optimal yield (98%) with deprotecting the THP and the MOM ethers within 2-3 min. Further, increase in the catalyst loading of SnCl₄ (Table 1, entry 10) gave the side-product as 3-(4-chlorophenyl)-2-chloro-2,3-dihydro indan-1-one along with the desider product. We also applied SnI₄ and SnBr₄ in 5, 10, and 20 mol% catalysts loading during the deprotection of THP and MOM ethers. However, it gave the desired products only 5-10% yields after stirring for 2-6 h at 0 °C.

Table 1. Optimization conditions in deprotection of the THP and the MOM ethers and sequel cyclization of phenolic compounds with different catalysts



Entry	Catalyst	Mol %	Time	Yield (%)
-------	----------	-------	------	-----------


1	SbCl ₃	10	20-24 h	28 ^a
2	SnI ₄	10	6 h	7 ^b
3	SbCl ₅	10	20-24 h	20 ^a
4	MgCl ₂	10	18-24 h	18 ^a
5	SnBr ₄	10	6 h	10 ^b
6	InCl₃	10	4-5 h	90^a
7	SnCl ₄	1	3 min	75 ^b
8	SnCl ₄	5	2 min	90 ^b
9	SnCl₄	10	3 min	98^b
10	SnCl ₄	20	3 min	70+20 ^c

^a Gave only cyclization. ^b Gave both THP and MOM ethers deprotection and sequel cyclization. ^c Other product as 3-(4-chlorophenyl)-2-chloro-2,3-dihydro indan-1-one (20%).

2.3.2. Solvents effect

We observed the solvent effects using different solvents like CH₃COCH₃, CHCl₃, CH₂Cl₂ and THF. CHCl₃ and CH₂Cl₂ were found to be the desired solvents (Table 2, entries 4, 6).


Table 2. Solvent effects on yields in deprotection of the THP and the MOM ethers and sequel cyclization reaction

























Entry	Mol%	Solvents	Yield (%)
1	1	Acetone	40 ^a
2	5	Acetone	45 ^a
3	2	DCM	80 ^b
4	10	DCM	98^b
5	2	CHCl ₃	85 ^c
6	10	CHCl₃	96^c
7	5	THF	52 ^d
8	10	THF	60 ^d











Reaction time: ^a 2h, ^{b,c} 3 min, ^d 3 h.**2.3.3. Examples of the THP and MOM ethers deprotection and sequel cyclization reaction**

Under optimized reaction conditions, the deprotection of THP and MOM ethers in phenols, chalcone and chalcone epoxides were achieved using 10 mol% of SnCl₄ in excellent yields (90-98%) within 2-3 min at 0 °C in the presence of other functional groups. However, in the case of alcoholic THP and MOM ethers, even 20 mol% of catalyst loading gave less yield 10 and 25% respectively (Table 3, entry 1). In case of chalcone **1f-1m**, only THP and MOM removal was observed without intramolecular Friedel-Crafts alkylation. These products were characterized by comparing their physical and spectral data with the literature values.[22, 28] Interestingly, the THP and MOM removal followed by the Friedel-Crafts alkylation was observed for the chalcone epoxides which gave the corresponding indanones **1n-1s** in excellent yield (90-98%) within 2-3 min at 0 °C (Table 3). The stereochemistry and the distereomeric excess ratio of the products **1n-1s** were determined by the chiral column separation and determined as 2R, 3S-configuration. These products were fully characterized on the basis of their spectral analysis ¹H-, ¹³C-NMR, GC-MS, Chiral HPLC (Supporting information).

Table 3. Examples of the THP and MOM ethers deprotection and sequel cyclization reaction

Entry	ROTHP/MOM	ROH	Time (min)	Yield (%) ^a	Yield (%) ^b
1			2	10	25
2			2	95	92
3			2	96	95

4			2	92	95
5			2	90	92
6			3	98	94
7			3	96	98
8			2	97	94
9			2	96	93
10			3	95	92
11			3	96	95
12			2	90	92
13			3	95	95
14			3	96	93

15			2	98	98
16			2	95	94
17			3	96	93
18			3	95	92
19			2	92	92

^a yield (1-19) from R-OTHP and ^b yield (1-19) from R-OMOM ethers deprotection.


2.3.4. Synthesis of diastereoisomerically pure *Trans*-3-(4-bromophenyl)-2-hydroxy-2, 3-dihydroindan-1-one.

The stereochemistry and the diastereomeric excess ratio of the indanone derivatives **1n-1s** were determined by the chiral column separation of racemic mixture of diastereomers. For example, in the synthesis of racemic indanone 3-(4-bromophenyl)-2-hydroxy-2, 3-dihydroindan-1-one (Scheme 1), the chiral HPLC purification gave peaks at 40.14 (51%) and 56.43 (49%) min. for the diastereomers (See Supporting Information). Then, we synthesized enantiomerically excess (ee) *trans*-chalcone epoxide of 2R, 3S-configuration from chalcone with α, α' -diphenyl-L-prolinol and TBHP in hexane which gave a good yield (58%) with

77.6% ee (scheme 1). Asymmetric epoxides were characterized by comparing with the literature value of $^1\text{H NMR}$ and enantiomeric excess was determined by chiral HPLC column and optical rotation in chloroform. [24]

It was observed that during the ring opening of epoxides, the C-2 configuration remained same while the C-3 configuration changed due to $\text{S}_{\text{N}}1$ -like mechanism therefore it gave the regio- and stereoselective intramolecular Friedel-Crafts alkylation. The protons at C-2 and C-3 positions are in *trans*-orientation which is confirmed by the coupling constant ($J = 2.0$ Hz) in $^1\text{H NMR}$ spectrum. [24] The absolute configurations at C-2 and C-3 are confirmed as 2*R* and 3*S* respectively. The stereoselectivity and high yields for 1-indanones under acidic condition (SnCl_4) might be due to the variable oxidation state and availability of relatively low energy 5d-orbitals on tin. On ligation with epoxide oxygen, the tetrahedron structure of SnCl_4 was converted to a trigonal bipyramide/octahedron structure. This geometrical change enhanced the steric hindrance which results in a faster epoxide ring opening from β -carbon due to considerable electron deficient character at benzylic carbon. Therefore, the nucleophile attacked at β -carbon of carbonyl group.

Scheme 1. Synthesis of diastereoisomerically pure *trans*-3-(4-bromophenyl)-2-hydroxy-2,3-dihydroindan-1-one.




2.4. MECHANISM

A proposed reaction mechanism is shown in the scheme 1 for the MOM ether deprotection and the sequel intramolecular Friedel-Crafts alkylation, where ligation of SnCl_4 with MOM oxygen resulted in the removal of the methyl (methylene) oxonium group followed by its reaction with Cl^- generated the MOMCl. [23] Same time, the epoxide oxygen ligation with SnCl_4 might change the tetrahedron structure of SnCl_4 into trigonal bipyramide/octahedron structure. The geometry changes enhanced the steric hindrance which results in faster epoxide ring opening from β -carbon due to considerable electron deficient character at benzylic position not on α -carbon due to a 4-membered cyclobutanone (unstable intermediate). Therefore, the nucleophilic attack took place at β -carbon of carbonyl which gave a resonance stabilized

benzyl intermediate. Finally, a base hydrolysis regenerated SnCl_4 catalyst which is used in the next catalytic-cycle.

Scheme 2. A propose mechanism for the deprotection of MOM ethers followed by cyclization with SnCl_4



2.5. CONCLUSION

In conclusion, we have illustrated an optimized reaction conditions for the rapid and efficient deprotection of the phenolic THP and MOM ethers and sequel intramolecular Friedel-Crafts alkylation reaction of chalcone epoxides. All reactions were completed within 2-3 min and gave excellent yield (90-98%) at 0°C for both the THP and the MOM ethers and sequel cyclization reactions without affecting the other functional groups.

2.6. EXPERIMENTAL DETAILS


Organic solvents were dried by standard methods, the reagents (chemicals) were purchased from commercial sources, and used without further purification. All reactions were monitored by TLC using precoated silica gel aluminum plates. Visualization of TLC plates was accomplished with an UV lamp. Column chromatography was performed using silica gel 60–120 mesh size (RANKEM Limited) with EtOAc–hexanes as eluent. Melting points were recorded on Perfit apparatus and are uncorrected. All products were characterized by NMR, IR and MS spectra. ^1H and ^{13}C NMR spectra were recorded in deuterated chloroform (CDCl_3) on a 500 MHz and 125 MHz spectrometer (Bruker), respectively. Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br).

2.6.1. General Procedure for Deprotection of Tetrahydropyranyl and Methoxymethyl Ethers of Alcohols and Phenols:


SnCl_4 (10 mol %) was added to a stirred solution of THP and MOM ethers (1 mmol) in CH_2Cl_2 (5 mL) at 0°C . TLC monitoring, the reaction mixture was poured into 10% aqueous Na_2CO_3 solution and extracted with CH_2Cl_2 . The organic layer washed with brine solution, dried with anhyd. Na_2SO_4 , and concentrated in *vacuo* to give corresponding alcohol or phenol, which was purified by silica gel column chromatography with hexane-ethyl acetate when required to obtain the products **1** to **19** with excellent yield (90-98%).

2.6.2. Characterization data for selected synthesized compounds


(a) Selected spectral data of THP and MOM deprotected products:



(E)-3-(4-fluorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (1f): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 8.5$ Hz, 2H), 7.77 (d, $J = 15.5$ Hz, 1H), 7.62 (dd, $J = 6, 13.5$ Hz, 2H), 7.46 (d, $J = 15.5$ Hz, 1H), 7.10 (t, $J = 8$ Hz, 2H), 6.95 (d, $J = 8.5$ Hz, 2H), 6.24 (s, 1H, br, D_2O exchangeable); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 187.50, 164.68, 162.67, 141.94, 132.02, 131.52, 131.45, 129.53, 122.46, 116.42, 116.25. IR ν_{max} (KBr , cm^{-1}) 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; GC-MS (m/z) 242 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_2$].




(E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (1g): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 8.5$ Hz, 2H), 7.76 (d, $J = 15.5$ Hz, 1H), 7.63-7.61 (m, 2H), 7.45 (d, $J = 16$ Hz, 1H), 7.10 (t, $J = 8.5$ Hz, 2H), 6.94 (d, $J = 8.5$ Hz, 2H), 6.2 (s, 1H, br, D_2O exchangeable); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 187.20, 162.37, 141.64, 131.72, 131.22, 131.15, 129.23, 122.16, 116.12, 115.95; IR ν_{max} (KBr , cm^{-1}) 3408 (OH str), 2928, 2876 (aromatic C-H str), 1684 (C=O str), 1598 (aromatic, C=C str), 1268, 1085, 864, 735; GC-MS (m/z) 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_2$].




(E)-3-(4-bromophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (1h): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 8$ Hz, 2H), 7.77 (d, $J = 15.5$ Hz, 1H), 7.63 (t, $J = 8$ Hz, 2H), 7.46 (d, $J = 15.5$ Hz, 1H), 7.10 (t, $J = 8.5$ Hz, 2H), 6.95 (d, $J = 8$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 186.88, 162.05, 141.32, 131.41, 130.90, 130.83, 128.92, 121.85, 115.81, 115.21; IR ν_{max} (KBr , cm^{-1})


3410 (OH str), 2926, 2875 (aromatic C-H str), 1686 (C=O str), 1599 (aromatic, C=C str), 1265, 1078, 862, 730; **GC-MS (m/z)** 302 [M^+ , $C_{15}H_{11}BrO_2$], 304 [$M+2$].




3-(4-fluorophenyl)-2,5-dihydroxy-2,3-dihydroindan-1-one (1n): 1H NMR ($CDCl_3$, 500 MHz) δ ppm 7.87 (d, $J = 8.5$ Hz, 2H), 7.54 (dd, $J = 8.5, 14$ Hz, 2H), 7.06 (d, $J = 9$ Hz, 2H), 6.95 (d, $J = 9$ Hz, 1H), 6.4 (s, 1H), 5.29 (t, $J = 7$ Hz, 1H), 5.22 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR ($CDCl_3$, 125 MHz) δ ppm 195.55, 161.83, 137.36, 131.82, 131.42, 129.79, 125.99, 123.01, 116.23, 75.01, 63.53; **IR ν_{max} (KBr, cm^{-1})** 3405 (OH str), 2922, 2875 (aromatic C-H str), 1688 (C=O str), 1595 (aromatic, C=C str), 1266, 1089, 858, 731; **GC-MS (m/z)** 258 [M^+ , $C_{15}H_{11}FO_3$].




3-(4-chlorophenyl)-2,5-dihydroxy-2,3-dihydroindan-1-one (1o): 1H NMR ($CDCl_3$, 500 MHz) δ ppm 7.88 (d, $J = 8.5$ Hz, 2H), 7.56-7.53 (m, 1H), 7.07 (t, $J = 7$ Hz, 2H), 6.96 (d, $J = 9$ Hz, 2H), 6.45 (s, 1H), 5.30 (t, $J = 7$ Hz, 1H), 5.23 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR ($CDCl_3$, 125 MHz) δ ppm 195.72, 162.00, 137.53, 131.99, 131.59, 129.96, 126.16, 123.18, 116.40, 76.23, 63.70; **IR ν_{max} (KBr, cm^{-1})** 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **GC-MS (m/z)** 274 [M^+ , $C_{15}H_{11}ClO_3$].




3-(4-bromophenyl)-2,5-dihydroxy-2,3-dihydroindan-1-one (1p): 1H NMR ($CDCl_3$, 500 MHz) δ ppm 7.86 (d, $J = 8.5$ Hz, 2H), 7.54-7.52 (m, 1H), 7.05 (t, $J = 7$ Hz, 2H), 6.95 (d, $J = 9$ Hz, 2H), 6.42 (s, 1H), 5.29 (t, $J = 7$ Hz, 1H), 5.22 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR ($CDCl_3$, 125 MHz) δ ppm 195.57, 161.85, 137.38, 131.84, 131.45, 129.81, 126.01, 123.04, 116.25, 75.40, 63.55; **IR ν_{max} (KBr, cm^{-1})** 3425 (OH str), 2935, 2877 (aromatic C-H str), 1687 (C=O str), 1585 (aromatic, C=C str), 1266, 1088, 862, 733; **GC-MS (m/z)** 318 [M^+ , $C_{15}H_{11}BrO_3$], 320 [$M+2$].



5-fluoro-2-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydroindan-1-one (1q): 1H NMR ($CDCl_3$, 500 MHz) δ ppm 7.86 (d, $J = 8.5$ Hz, 2H), 7.53 (dd, $J = 8.5, 14$ Hz, 2H), 7.06 (t, $J = 7$ Hz, 2H), 6.95 (d, $J = 9$ Hz, 1H), 6.44 (s, 1H, br, D_2O exchangeable), 5.30 (t, $J = 7$ Hz, 1H), 5.22 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR ($CDCl_3$, 125 MHz) δ ppm 195.53, 161.81, 137.34, 131.79, 131.40, 129.76, 125.96, 122.99, 116.21, 75.36, 63.51; **IR ν_{max} (KBr, cm^{-1})** 3428 (OH str), 2933, 2877 (aromatic C-H str), 1687 (C=O str), 1599 (aromatic, C=C str), 1265, 1088, 858, 725; **GC-MS (m/z)** 258 [M^+ , $C_{15}H_{11}FO_3$].



5-chloro-2-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydroinden-1-one (1r): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.87 (d, $J = 8.5$ Hz, 2H), 7.54-7.52 (m, 1H), 7.06 (t, $J = 7$ Hz, 2H), 6.95 (d, $J = 9$ Hz, 2H), 6.45 (s, 1H, br, D_2O exchangeable), 5.30 (t, $J = 7$ Hz, 1H), 5.22 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 195.82, 162.10, 137.63, 132.09, 131.69, 130.06, 126.26, 123.28, 116.50, 75.65, 63.80; IR ν_{max} (KBr , cm^{-1}) 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; GC-MS (m/z) 274 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_3$].



5-bromo-2-hydroxy-3-(4-hydroxyphenyl)-2,3-dihydroinden-1-one (1s): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.86 (d, $J = 8.5$ Hz, 2H), 7.54-7.52 (m, 1H), 7.06 (t, $J = 7$ Hz, 2H), 6.95 (d, $J = 9$ Hz, 2H), 6.44 (s, 1H, br, D_2O exchangeable), 5.30 (t, $J = 7$ Hz, 1H), 5.22 (d, $J = 1.5$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 195.54, 161.82, 137.35, 131.80, 131.41, 129.78, 125.97, 123.00, 116.22, 75.37, 63.52; IR ν_{max} (KBr , cm^{-1}) 3427 (OH str), 2937, 2875 (aromatic C-H str), 1685 (C=O str), 1593 (aromatic, C=C str), 1266, 1083, 864, 727; GC-MS (m/z) 318 [M^+ , $\text{C}_{15}\text{H}_{11}\text{BrO}_3$], 320 [$\text{M}+2$].

2.7. REFERENCES

- [1] (a) Amaranth, V.; Broom, A. D.; *Chemical synthesis of oligonucleotides*, Chem. Rev. 1977, 77, 183.
- [2] Hajipour, A. R.; Kargosha, M.; Ruoho, A. E.; *Tetrahydropyranylation of alcohols under solvent-free conditions*, Synth. Commun. 2009, 39, 1084.
- [3] (a) Green, T. W.; Wuts, P. G. M.; *Organic Synthesis*, 3rd ed.; John Wiley: New York, 1999; 306; (b) Caine, D.; Deutsch, H. J.; *Stereospecific total synthesis of gibberellic acid. A key tricyclic intermediate*, J. Am. Chem. Soc. 1978, 100, 8031
- [4] Tamami, B.; Parvanak, K.; *Chemoselective tetrahydropyranylation of alcohols and phenols using polystyrene supported aluminum chloride as a catalyst*, Tetrahedron Lett. 2004, 45, 715

- [5] Kumara, B.; Mushtaq A. A.; Mukherjee, D.; Chinnib, S. S.; Taneja, S. C.; Kumar, B.; *Allyl tetrahydropyranyl ether: a versatile alcohol/thiol protecting reagent*, Tetrahedron Lett. 2009, 50, 6236.
- [6] Diaz, R. R.; Melgarejo, C. R.; Plaza, M. T.; Cubero, I. I.; *A Novel, Mild, and Practical Regeneration of Alcohols from their Allylic Ethers by NBS/H₂O*, J. Org. Chem. 1994, 59, 7928.
- [7] Babu, B. S.; Balasubramanian, K.; *Mild and efficient tetrahydropyranlation of alcohols - catalysis by lithium perchlorate in diethyl ether*, Tetrahedron Lett. 1998, 39, 9287;
- [8] Reddy, P. N.; Sunil, B. K.; Kumar, P. S.; Srinivasulu, N. Y.; Reddy, T.; Rajitha, B.; *Origins of the journal Khimiya Geterotsiklicheskikh soedinenii*, Chemistry of Heterocyclic Compounds 2005, 41, 11.
- [9] (a) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron Lett. 2005, 61, 5209; (b) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron Lett. 2006, 47, 261; (c) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron 2007, 9, 966.
- [10] Karimi, B.; Maleski, J.; *Lithium triflate (LiOTf) catalyzed efficient and chemoselective tetrahydropyranlation of alcohols and phenols under mild and neutral reaction conditions*, Tetrahedron Lett. 2002, 43, 5353.
- [11] Khan, F. A.; Regina, C.; Ulrich, R. H. *A Novel Pd(0)-Catalyzed One-Pot Transformation of Substituted Siloxycyclopropanes to Indane Derivatives*, Synlett 1996, 8, 533.
- [12] (a) Ahmed, N.; Ali, H.; van Lier, J. E. *Silica gel supported InBr₃ and InCl₃: new catalysts for the facile and rapid oxidation of 2'-hydroxychalcones and flavanones to their corresponding flavones under solvent free conditions*, Tetrahedron Lett. 2005, 46, 253; (b) Ahmed, N.; Ali, H.; van Lier, J. E. *The Reaction of Porphyrins with α,β -acetylenic Ketone/ester (Morita-Baylis-Hillman) Promoted by MgI₂ and Subsequent Sonogashira Coupling Reactions*, J. Porphyrins Phthalocyanines 2006, 10, 1172; (c) Ranu, B. C.; Saha, M.; *A Simple, Efficient, and Selective Method for Tetrahydropyranlation of Alcohols on a Solid Phase of Alumina Impregnated with Zinc Chloride*, J. Org. Chem. 1994, 59, 8269.
- [13] Haraldsson, G. G.; Baldwin, J. E.; *A selective cleavage of aromatic benzyl ethers located ortho to a carbonyl group by magnesium bromide*, Tetrahedron 1997, 53, 215.

- [14] Tanemura, K.; Haraguchi, T.; Suzuki, A.; *2,3-Dichloro-5,6-dicyano-p-benzoquinone as a mild and efficient catalyst for the tetrahydropyranylation of alcohols*, Bull. Chem. Soc. Jpn. 1992, 65, 304.
- [15] Khan, F. A.; Sahu, N. *Highly Efficient and Recyclable Ruthenium-based Supported Catalysts*. J. Catal. 2005, 230, 438.
- [16] Yadav, J. S.; Srinivas, D.; Reddy, G. S.; *A mild and versatile method for the tetrahydropyranylation of alcohols and their detetrahydropyranylation*, Synth. Commun. 1998, 28, 1399
- [17] Molnarand, A. T. B.; *Mild and efficient tetrahydropyranylation and deprotection of alcohols catalyzed by heteropoly acids*, Tetrahedron Lett. 1996, 37, 8597.
- [18] Namboodiri, V. V.; Varma, R. S. *Solvent-free tetrahydropyranylation (THP) of alcohols and phenols and their regeneration by catalytic aluminum chloride hexahydrate*, Tetrahedron Lett. 2002, 43, 1143;
- [19] Srikrishna, A. R.; Sattigeri, J. A.; Vijaykumar, D.; *A new, convenient reductive procedure for the deprotection of 4-methoxybenzyl (MPM) ethers to alcohols*, J. Org. Chem. 1995, 60, 5961.
- [20] Isobe, M.; Iio, H.; Kawai, T.; Goto, T.; *Total synthesis of (S)-12-hydroxy-5,8,14-cis,-10-trans-eicosatetraenoic acid (Samuelsson's HETE)*, J. Am. Chem. Soc. 1978, 100, 1942.
- [21] Akai, S.; Tanaka, R.; Hoshi, H.; Sato, K. I.; *Selective Deprotection Method of N-Phenylcarbamoyl Group*, J. Org. Chem. 2013, 78, 8802.
- [22] Robertson, D. N.; *Adducts of tert-alcohols containing an ethynyl group with dihydropyran. Potentially useful intermediates*, J. Org. Chem. 1960, 25, 931.
- [23] Sabhita, G.; Yadav, J. S.; Rajkumar, M.; Babu, R.; *A Highly Efficient, Mild, and Selective Cleavage of β -Methoxyethoxymethyl (MEM) Ethers by Cerium(III) Chloride in Acetonitrile*, Org. Lett. 2001, 3, 1149.
- [24] Rigby, J. H.; Wilson, J. Z.; *Removal of methoxyethoxymethyl ethers with trimethylsilyl chloride-sodium iodide*, Tetrahedron Lett. 1984, 25, 1429.

- [25] William, D. R.; Sakdarat, S.; *Opportunities for selective removal of methoxyethoxymethyl (MEM) ethers*, Tetrahedron Lett. 1983, 24, 3965.
- [26] Han, J. H.; Kwon, Y. E.; Sohn, J. H.; Ryu, D. H.; *A facile method for the rapid and selective deprotection of methoxymethyl (MOM) ethers*, Tetrahedron 2010, 66, 1673.
- [27] (a) Ahmed, N.; Van Lier, J. E.; *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 5407; (b) Ahmed, N.; Van Lier, J. E.; *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 2725; (c) Ahmed, N.; Konduru, N. K.; *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177; (d) Konduru, N. K.; Ahmed, N.; *Regioselective opening of chalcone epoxides with nitrogen heterocycles using indium(III) chloride as an efficient catalyst*, Synth. Commun. 2013, 43, 2008; (e) A. T. Khan, A. Choudhury, S. Ali, Md. M. Khan, *Regioselective Monobromination of (E)-1-(2'-hydroxy-4',6'-dimethoxyphenyl)-3-aryl-2-propen-1-ones using Bromodimethyl-sulfonium Bromide and Synthesis of 8-Bromoflavones and 7-Bromoaurones*, Tetrahedron Lett. 2012, 53, 4852.

Part B: SnCl_4 or TiCl_4 : Highly efficient catalysts for detetrahydropyranylation and demethoxymethylation of phenolic ethers and sequel one-pot asymmetric synthesis of 3-aryl-2-hydroxy-2, 3-dihydroindan-1-ones from chalcone epoxides

3.1. INTRODUCTION

Protection and deprotection of functional groups are the most frequently used strategies in the multi-step organic syntheses. In particular, the protection and deprotection of the hydroxyl group is extremely important because of its enormous demand for the synthesis of a number of compounds of biological and synthetic interest such as carbohydrates, macrolides, peptides, steroids, nucleotides and polyethers.[1] Protection of the hydroxyl group with 3,4-dihydro-2H-pyran (DHP) and methoxymethyl chloride (MOMCl) is the most frequently used method due to the stability of the resulting 2-tetrahydropyranyl ethers (THPEs) and the methoxymethyl ethers (MOMEs) respectively in the presence of strong bases or nucleophiles such as Grignard reagents, organolithium compounds, metal hydrides, catalytic hydrogenation, alkylating and acylating agents.[2,3]

Conversely, the deprotection of THP and MOM ethers required efficient methods to avoid decomposition and/or loss of other functional groups in the product under harsh reaction conditions. Therefore, many catalysts are explored for the detetrahydropyranylation of alcohols and phenols include protic acids,[4] Lewis acids such as BF_3 -etherate,[5] LiBr , [6] LiBF_4 , [7] LiOTf , [8] LiClO_4 , [9] $\text{Sc}(\text{OTf})_3$, [10] $\text{In}(\text{OTf})_3$, [11] I_2 , [12] InCl_3 , [13] ZrCl_4 , [14] CuCl_2 , [15] and salt NH_4Cl , [16] expansive graphite, [17] clay materials, [18] silica-supported sulfuric acid, [19] and other miscellaneous catalysts. [20-26] Similarly, many catalysts are used for the demethoxymethylation of alcohols and phenols; these catalysts include HCl , BBr_3 , pyridinium *p*-toluene sulphonate under strong acidic condition, mild Lewis acids ZnBr_2 , and TiCl_4 in aprotic conditions and BBr_3 derivatives like Me_2BBr , and $(i\text{-PrS})_2\text{BBr}$. [27] Most of these methods have different drawbacks such as long reaction time, low yields, reflux at high temperature and tedious workup procedures. Hence, there is still scope to develop more straightforward and efficient methods in the deprotection of tetrahydropyranyl and methoxymethyl ethers.

Indan-1-one and indan-2-one derivatives are important moieties in the core structures of many natural products, agrochemicals and medicines [28] including indacrinone, [28a-c]

indanoyl isoleucine conjugates,[28d] indanocines,[28e] quadrangularin A,[28 f,g] parthenocissin A,[28 h,i] (+)-pauciflorol F,[29] norditerpene taiwaniaquinol B,[30] sulindac, NSAID,[31a-c] NMDA receptor antagonists,[31d] benzodiazepines,[31e] melatonin precursor,[31f] and neoflavonoids[32,33] (Figure 1). They are also reported from higher plants such as *Uvaria afzelii* roots,[34] *Pteridium aquilinum* [34c] and *Equisetum arvense* [34d] and screened for various biological activities including cancer and Alzheimer's diseases. 2-(Alkoxy carbonyl)- and 2-acetyl-1-indanones are present in cytotoxic natural compound pterosines,[28,29] a potent and selective COX-2 inhibitor flosulide,[30,32] and the acetylcholinesterase inhibitor donepezil hydrochloride.[30] They are approved by US-FDA for the treatment of mild to moderate Alzheimer's disease.[29] Similarly, the enantiomerically pure derivative, 1-amino-2-indanol is a key precursor of the chiral ligand and the chiral auxiliary for asymmetric synthesis of indinavir, a potent inhibitor of the protease of human immunodeficiency virus (HIV)[35] and Detrol LA (tolterodine tartrate), a muscarine receptor antagonist used for the treatment of urinary bladder disorder.[36a] The Indan-1-one bearing carboxylate scaffold is also used a peroxisome proliferator activated receptor γ (PPAR γ) agonist in the treatment of type-2 diabetes.[36b]




Figure 1. Bioactive indan-1-one derivatives.

Therefore, a number of synthetic methods have been reported that include intramolecular Friedel-Crafts alkylation, [37] Nazarov cyclization, [38,39] tandem Knoevenagel

condensation-cycloalkylation,[40] Heck & Negishi coupling,[41] Larock annulations [42] and ring-closing metathesis[43] reactions under different Lewis acids such as SbF_5 ,[44a] AlCl_3 ,[44b] and TiCl_4 . [45-51] The Friedel-Crafts reactions were carried out at high temperature and in strong acidic conditions. Similarly, enantioselective indanones synthesis required multi-step reaction and high catalyst loading for the 3-substituted indanone derivatives.[32] In continuation of our interest in Lewis acid catalysis[52] and metal halides were used as inexpensive, easily available and stable catalysts during epoxide ring opening.[53] Herein, we report an efficient deprotection method of THP and MOM ethers and sequel Friedel-Crafts alkylation reaction in the stereoselective synthesis of functionalized 3-aryl 2-hydroxy-1-indanone derivatives catalyzed by a highly efficient TiCl_4 catalyst at 0°C (Scheme 1, Table 1). In comparison with other methods, our protocol gave high yields (76-98%) with excellent regioselective products (up to 99.9% ee) in short reaction time (2-3 min).

3.2. OBJECTIVE

Metal catalysed organic transformation are the very important tool for inter and intramolecular reaction in Stereoselective synthesis under mild condition. Now a day's people are trying to synthesize the cheap, inexpensive, commercial favorable methods for the one pot conversion in organic synthesis. Hence, our goal is to synthesize the commercially favorable methodology by using catalyst and we used different metal catalyst and SnCl_4 or TiCl_4 was found to be the versatile catalyst for the opening of chalcone epoxide and deprotection of hydroxyl group in a single step. Stereoselective syntheses of 3-aryl-2-hydroxy-1-indanones were also reported using TiCl_4 as a catalyst. Our protocol gave regio-selective products in excellent yield (76-98%) and enantiomeric excess up to 99.9% under same conditions.

3.3. RESULTS AND DISCUSSION

3.3.1. Optimization reaction conditions by using different catalyst

The catalytic efficiency of different metal halides was screened (Table 1). Metal halides (Table 1, entries 1-6) exhibited poor to moderate catalytic activity. InCl_3 (Table 1, entry 7) was found to be a better catalyst at 10 mol% catalyst loading, which gave 90% yield of cyclized product without deprotecting of THP or MOM ethers. However, TiCl_4 (Table 1, entry 10,12) was found to be the most efficient catalyst at 10 mol% catalyst loading, which gave the optimal yield (98%) with deprotecting of THP and MOM ethers. We also used SnI_4 and SnBr_4 in 5, 10, and 20 mol% during the deprotection of THP and MOM ethers which gave the desired product

in a 5-10% yield after stirring for 2-6 h at 0 °C temperature. However, TiCl₄ gave excellent yield of 90-98% within 2-3 min. under the same conditions (Table 1, entry 10, 12).

To optimize the catalysts (InCl₃ and TiCl₄) loading, the reactions were carried out in 2, 5, 10 and 20 mol% (Table 1, entries 8-12) in dichloromethane and the efficiency of the catalyst loading was determined from the amount of time needed for the complete conversion of epoxides (Figure 2). TiCl₄ at 2 & 5 mol% loading, proceeded the reaction slowly, whereas at 20 mol% the loading reaction gave the side product as 3-(4-Chlorophenyl)-2-chloro-2,3-dihydroindan-1-one (20%), which was isolated and characterized by GC-MS.

Scheme 1. Synthesis of indanone derivative in one-pot deprotection and cyclization.





Table 1. Optimization of catalysts for Scheme 1


Entry	Catalyst	Loading (mol%)	Rxn.Time	Yield (%)
1	SbCl ₃	10	20-24 h	28 ^a
2	SbCl ₅	10	20-24 h	20 ^a
3	MgCl ₂	10	18-24 h	18 ^a
4	ZrCl ₄	10	10-15 h	10 ^a
5	SnBr ₄	10	6 h	10 ^b
6	SnI ₄	10	6 h	7 ^b
7	InCl ₃	10	4-5 h	90 ^a
8	SnCl ₄	2	30 min	45 ^b
9	SnCl ₄	5	15 min	65 ^b
10	SnCl ₄	10	2 min	98 ^b
11	InCl ₃ /SnCl ₄	20	1 min	70+20 ^c
12	TiCl ₄	10	2 min	98 ^d

^aGave only cyclization. ^{b,d}Gave both THP and MOM ethers deprotection and sequel cyclization other product as 3-(4-chlorophenyl)-2-chloro-2,3-dihydro indan-1-one(20%).

Figure 2. Comparison of InCl_3 and TiCl_4 catalysts loading only for cyclization reaction

3.3.2. Solvent effect by catalyst SnCl_4 or TiCl_4

We also observed the solvent effects using acetone, chloroform, dichloromethane and tetrahydrofuran where chloroform and dichloromethane were found to be desired solvents (Table 2, entries 4, 6).


Table 2. Solvent effects on yields in the deprotection of THP and MOM ethers

Entry	Mol%	Solvents	Yield (%)
1	2	Acetone	40 ^a
2	5	Acetone	45 ^a
3	5	DCM	80 ^b
4	10	DCM	98 ^b
5	5	CHCl_3	85 ^c
6	10	CHCl_3	96 ^c
7	5	THF	52 ^d
8	10	THF	60 ^d





















3.3.3. Examples of the THP and MOM ethers deprotection and sequel cyclization reaction by catalyst SnCl_4 or TiCl_4











Under optimized reaction conditions, the deprotection of THP and MOM ethers in phenols, chalcone and chalcone epoxides were achieved using 10 mol% of SnCl_4 or TiCl_4 in excellent yields (90-98%) within 2-3 min at 0°C in the presence of other functional groups. However, in the case of alcoholic THP and MOM ethers, even 20 mol% of catalyst loading gave less yield 10 and 25% respectively (Table 3, entry 1). In case of chalcone **2f-2m**, only THP and MOM removal was observed without intramolecular Friedel-Crafts alkylation. These products were characterized by comparing their physical and spectral data with the literature values.[22,28] Interestingly, the THP and MOM removal followed by the Friedel-Crafts alkylation was observed for the chalcone epoxides which gave the corresponding indanones **2n-2s** in excellent yield (90-98%) within 2-3 min at 0°C (Table 3). The stereochemistry and the diastereomeric excess ratio of the products **2n-2s** were determined by the chiral column separation and determined as 2R, 3S-configuration. These products were fully characterized on the basis of their spectral analysis ^1H -, ^{13}C -NMR, GC-MS, Chiral HPLC

Table 3. Examples of the THP and MOM ethers deprotection and sequel cyclization reaction



Entry	ROTHP/MOM	ROH	Time (min)	Yield (%) ^a	Yield (%) ^b
1			2	10	25
2			2	95	92
3			2	96	95
4			2	92	95

5		 2e	2	90	92
6		 2f	3	98	94
7		 2g	3	96	98
8		 2h	2	97	94
9		 2i	2	96	93
10		 2j	3	95	92
11		 2k	3	96	95
12		 2l	2	90	92
13		 2m	3	95	95
14		 2n	3	96	93

15			2	98	98
16			2	95	94
17			3	96	93
18			3	95	92
19			2	92	92



^a yield (**1-19**) from R-OTHP and ^b yield (**1-19**) from R-OMOM ethers deprotection.

3.3.4. Asymmetric synthesis

In asymmetric synthesis, following a simple experimental procedure (given in the experimental section), chalcone epoxides **3a-3w** was dissolved in dichloromethane by stirring, SnCl₄ or TiCl₄ was added in proportion and stirred at 0 °C temperature for 2-3 min. After the usual work up, the 3-aryl-2-hydroxy-2, 3-dihydroindan-1-ones **4a-4w** were obtained in 76-98% yields (Table 4).

Table 4. Synthesis of racemic 3-aryl-2-hydroxy-1-indanones from racemic chalcone epoxides^a,

^{b, c}



^aEpoxides and 2-hydroxyindan-1-ones are racemic compounds and are shown as a single enantiomeric derivative (*trans*-configuration). ^bReaction of **4e**, **4j**, **4r**, **4w** were carried out at $-20\text{ }^\circ\text{C}$ and others are at $0\text{ }^\circ\text{C}$ using 10 mol % of SnCl_4 . ^cIsolated yield of racemic 2-hydroxy indan-1-ones.


For example, in the synthesis of racemic indanone **4b** (table 4) HPLC purification gave peaks at 26.9 (50%) and 35.4 (50%) min. for enantiomers (see experimental section). The assigned structures of chalcone epoxides **3a-3w** and products **4a-4w** were confirmed on the basis of their spectral analysis (IR, ^1H and ^{13}C -NMR, and GC-MS/EI MS) and also when compared with reported data in the literature.[32] The *trans*-stereochemistry of epoxides **3a-3w** was confirmed by the coupling constants of the α - & β -protons. For example, (*4-chlorophenyl*)-

3-(4-bromophenyl) oxiran-2-yl-methanone (**3i**), the ^1H NMR (500 MHz) δ (ppm): 4.07 (d, $J = 2.0$ Hz, $\beta\text{-H}$, 1H), 4.21 (d, $J = 2.0$ Hz, $\alpha\text{-H}$, 1H), in which the J -values (2.0 Hz) indicate a *trans*-substituted epoxide. Similarly, the *trans*-configuration of 2-hydroxy-2,3-dihydro indan-1-ones **4a-4w** was confirmed by the coupling constants of the α - & β -protons. For example, *trans* 3-(4-bromophenyl)-5-chloro-2-hydroxy-2,3-dihydroindan-1-one (**4i**), the ^1H NMR (500 MHz) δ (ppm) at 5.15 (d, $J = 2.0$ Hz, $\beta\text{-H}$, 1H), 5.31 (d, $J = 2.0$ Hz, $\alpha\text{-H}$, 1H), in which the J -values (2.0 Hz) indicate a *trans*-configuration.[42] The stereoselectivity and high yields for 1-indanones under acidic condition (SnCl_4) might be due to the variable oxidation state and availability of relatively low energy 5d-orbitals on tin. On ligation with epoxide oxygen, the tetrahedron structure of SnCl_4 was converted to a trigonal bipyramide/octahedron structure. This geometrical change enhanced the steric hindrance which results in a faster epoxide ring opening from β -carbon due to considerable electron deficient character at benzylic position therefore, nucleophile attack takes place at β -carbon of carbonyl. In the case of electron donating (Table 4, entry **4j**) and electron withdrawing groups on ring- Ar_2 (Table 4, entries **4e**, **4r**, **4w**) the reaction at 0 $^\circ\text{C}$ temperature gave decomposed products. Therefore, reactions were carried out by lowering the temperature (-20 $^\circ\text{C}$) to obtain the desired product.

3.3.5. Synthesis of enantioselective 3-aryl-2-hydroxyindan-1-ones.

During enantioselective synthesis of indanones, first we synthesized diastereoisomerically pure *trans*-(2*R*, 3*S*)-chalcone epoxides (**5a-e**) from corresponding chalcones with α , α' -diphenyl-L-prolinol and TBHP in hexane which gave a good yield (58%) with 64-99.9% enantiomeric excess. Epoxides were characterized by comparing with literature values and enantiomeric excess was determined by chiral HPLC column and optical rotation in chloroform (see in experimental section).[54] Epoxide ring opening followed by intramolecular Friedel-Crafts alkylation was performed in the presence of SnCl_4 to obtain the diastereoisomerically pure *trans* (2*R*,3*S*) indanone derivatives **6a-e** (Scheme 2). The enantiomeric excess of indanones was again determined by chiral HPLC column and optical rotation in chloroform (see in experimental section). In general, indanones were obtained in 90-98% yields and 64-99.9% ee (table 6). It was observed that with the ring opening of epoxide in the presence of metal halides, the configuration at C-2 position is retained while C-3 position is changed due to $\text{S}_{\text{N}}1$ -like mechanism to obtain regio- and stereoselective intramolecular Friedel-Crafts alkylation. Therefore, protons at C-2 and C-3 positions are in *trans*-oriented which was

confirmed by the coupling constant ($J = 2.0$ Hz) in ^1H NMR spectrum.[42] Therefore, the absolute configurations at C-2 and C-3 were confirmed as $2R$, and $3S$ respectively.











Scheme 2. Synthesis of enantioselective 3-aryl-2-hydroxyindan-1-ones.

The assigned structures of diastereoisomerically pure *trans* chalcone epoxides **5a-5e** and products **6a-6e** were confirmed on the basis of their spectral analysis (^1H - & ^{13}C -NMR and chiral HPLC) and also when compared with those reported data.[32] For example, *trans*-3-(4-chlorophenyl)-2-hydroxy-2,3-dihydroindan-1-one (**6a**), the ^1H NMR (500 MHz) δ (ppm) at 5.36 (d, $J = 2.0$ Hz, 1H, $-\text{CO}-\underline{\text{C}}\text{H}-$), and 5.21 (d, $J = 2.0$ Hz, $-\underline{\text{C}}\text{H}-\text{Ar}$, 1H), in which the J -values indicate a *trans*-configuration.[15] The ^{13}C NMR spectrum gave peaks at δ 197.49 ppm for the characteristic carbonyl carbon, 62.95 ppm for $\text{Ar}-\underline{\text{C}}\text{H}-\text{CH}$, and 75.89 ppm for $\text{Ar}-\text{CH}-\underline{\text{C}}\text{H}-\text{CO}$ of indanone ring carbon. Since enantioselective epoxide **5a** gave peaks at 54.7 min (13%) and 58.7 min (87%), the major peak correlated with retention time of reported literature.⁵⁴ Therefore, the configuration is confirmed as $2R$ and $3S$. We also took enantioselective indanone **6a** (table 5) which gave peaks at 27.9 min (13.9%) and 36.9 min (86.1%) (See HPLC chromatogram in supporting information). These retention time match those of racemic indanone (**4b**). Similarly, all other compounds **6b** to **6e** were confirmed on the basis of analytical data.

Table 5. Synthesis of Enantioselective 3-aryl-2-hydroxy-1-indanones. ^{a,b,c}

Entry	Epoxide	Indanone	Yield (%) ^b	ee(%) ^a Configuration
1	<p>5a 74% ee; ($2R,3S$)</p>	<p>6a</p>	98	72.2% ($2R,3S$)

2	 <p>5b</p> <p>77.6% ee; (2R,3S)</p>	 <p>6b</p>	90	75% (2R,3S)
3	 <p>5c</p> <p>64.8% ee; (2R,3S)</p>	 <p>6c</p>	92	64.8% (2R,3S)
4	 <p>5d</p> <p>>99.9% ee; (2R,3S)</p>	 <p>6d</p>	95	>99.9% (2R,3S)
5	 <p>5e</p> <p>66.8% ee; (2R,3S)</p>	 <p>6e</p>	93	66.8% (2R,3S)

^aEnantiomeric excess was determined by chiral HPLC column and found to be equivalent to literature data, ^bisolated yields. ^call reactions are carried out at 0 °C for 2-3 min. HPLC conditions and retention times of racemic and enantiomeric excess of the epoxide and indanone derivatives given in Tables 6 and 7.

Table 6. HPLC conditions and retention times of racemic and enantiomeric excess of the epoxide derivatives.^a

S.No	Indanone ^a	Chiral Column	Eluent (hexane:Isopropanol)	Flow rate (ml/min)	Retention time (min) & Area (%)	ee (config) ^a
1	5a	Chiralcel-OD-H	55/1	0.5	54.7(13) 58.7 (87)	74% (2R,3S)
2	5b	Chiralcel-OD-H	95/5	0.8	22.4(11.2) 22.4(88.8)	77.6% (2R,3S)
3	5c	Chiralpak-AD-H	95/5	1	20.8(17.6) 23.5(82.4)	64.8% (2R,3S)
4	5d	Chiralpak-AD-H	95/5	0.5	54.0(>99.9)	>99.9% (2R,3S)
5	5e	Chiralcel-AD-H	95/5	0.8	20.5 16.6) 22.9(83.4)	66.8% (2R,3S)

^aDetection at 254 nm. Configuration determined based on HPLC data analysis.


Table 7. HPLC conditions and retention times of racemic and enantiomeric excess of the indanone derivatives.^a

S. No	Indanone ^a	Chiral Column	Eluent (hexane:Isopropanol)	Flow rate (ml/min)	Retention time (min) & Area (%)	ee ^a (config) ^a
1	6a	Chiralcel-OD-H	97.5/2.5	0.5	26.9(13.9) 36.9(86.1)	72.2% (2R,3S)
2	6b	Chiralcel-OD-H	92.5/7.5	0.8	38.8(12.5) 53.1(87.5)	75% (2R,3S)
3	6c	Chiralpak-AD-H	92.5/7.5	1	28.6 82.4) 32.5(17.6)	64.8% (2R,3S)
4	6d	Chiralpak-AD-H	92.5/7.5	1	5.3(>99.9)	>99.9% (2R,3S)
5	6e	Chiralcel-AD-H	92.5/7.5	0.5	28.8(16.5) 42.5(83.5)	66.8% (2R,3S)

^aDetection at 254 nm. Configuration determined based on HPLC data analysis.

3.4. MECHANISM

Proposed mechanism is shown in Scheme 3, where ligation of TiCl₄ with MOM oxygen resulted in the removal of the methyl(methylene)oxonium group followed by its reaction with Cl⁻ generated the MOMCl.[24] Similarly, epoxide oxygen ligation might change the tetrahedron structure of TiCl₄ into trigonal bipyramide/octahedron structure. The geometry changes enhanced the steric hindrance which results in faster epoxide ring opening from β -carbon due to considerable electron deficient character at benzylic position. Therefore, the nucleophilic attack takes place at β -carbon of carbonyl. Finally, base hydrolysis produces TiCl₄ which is used as a Lewis acid in the next catalytic-cycle.



Scheme 3: Propose mechanism for the deprotection of MOM ethers followed by cyclization with TiCl_4

3.5. CONCLUSION

In conclusion, we have developed a novel and highly efficient catalytic protocol for the deprotection of phenolic THP and MOM ethers and stereoselective synthesis of 2-hydroxy-3-aryl-1-indanone derivatives by sequential ring opening of chalcone epoxides and intramolecular Friedel-Crafts alkylation in the presence of SnCl_4 or TiCl_4 . This method has advantages such as (i) mild protocol (ii) excellent yield (up to 98%) with high regio and enantioselectivity (up to 99.9% ee) (iii) short reaction time (2-3 min) and (iv) easy work-up procedure. To the best of our knowledge, SnCl_4 and TiCl_4 has not been studied in this capacity before and therefore represents a novel subject for investigation.

3.6. EXPERIMENTAL DETAILS

3.6.1. GENERAL PROCEDURES


Synthesis of chalcones epoxides: Aqueous NaOH (5M, 10 ml) was added drop wise to a stirred solution of chalcones (18 mmol) in aq. THF (30 ml, H_2O : THF, 1:2 ratio) and further stirred for 10 min. Then, H_2O_2 (15 ml, 30% wt.%) was added drop wise and further stirred for 6-7 h at room temperature. TLC monitoring, the reaction mixture was poured in water. The resulting precipitate was filtered, washed with water and dried under reduced pressure. The product was recrystallized in EtOH or silica gel column chromatography in petroleum ether: CH_2Cl_2 (8:2) as eluent gave 80-90% yields.

Synthesis of 3-aryl-2-hydroxy-2, 3-dihydroindan-1-one (6a-6e): Chlalone epoxides (1.0 mmol) were dissolved in dichloromethane (5 mL) by stirring, SnCl₄ or TiCl₄ (10 mol%) was added drop wise and stirred for 2-3 min. at 0 °C. The reaction mixture was extracted with CH₂Cl₂ by adding water. The organic layer was dried (anhyd. Na₂SO₄), filtered and evaporated under reduced pressure to obtain the pure product or purified by flash column chromatography on silica gel using hexane: CH₂Cl₂ (8:2) as eluent to afford the products in 76-98% yields and 64-99.9% enantiomeric excess.


Synthesis of Enantioselective chalcones epoxides: To a solution of (-)(s) α,α'-diphenyl-L-prolinol (23.0 mg, 0.090 mmol) and trans-chalcone (77.5 mg, 0.30 mmol) in distilled hexane (3.0 mL) (hexane of HPLC grade furnished comparable results) was added TBHP (5-6 M decane solution, 75 μL, 0.40 mmol) at room temperature and stirring was maintained for the indicated time. The crude reaction mixture was then purified by flash chromatography on silica gel (petroleum ether/ diethyl ether 99/1) to provide the epoxy ketone.

3.6.2. Spectral data of deprotected chalcone, 2-hydroxy- indanone, epoxy chalcones and 2-hydroxy-indanone derivatives

a) Spectral data of chalcone epoxides derivatives




3-(4-Chlorophenyl)oxiran-2-yl-phenyl methanone (3b): White crystalline solid, Yield: 88%, m.p. = 120-123 °C; ¹H-NMR (CDCl₃, 500 MHz): δ ppm: 8.00 (dd, J₁=7.5Hz, J₂=1.5Hz, Ar-H, 2H), 7.63-7.48 (m, Ar-H, 5H), 7.40-7.30 (m, Ar-H, 4H), 4.25 (d, J=1.5 Hz, -CO-CH- 1H), 4.06 (d, J= 2.0 Hz, -CH-Ar- 1H); ¹³C-NMR (CDCl₃, 125MHz): δ ppm 192.8, 135.4, 134.9, 134.2, 129.7, 129.3, 129.0, 128.7, 128.4, 127.2, 60.9, 58.7; IR ν_{max} (KBr, cm⁻¹): CO ν_{stretch} 1685.55, 1592.37, 1438.03, 1391.67, 1232.43, 1089.53, 1010.26, 888.63, 808, 700.79, 527.01; MS (EI, 70eV): m/z (%) 258 [M⁺, C₁₅H₁₁O₂Cl], 242, 207, 165, 125, 105(100), 91, 77, 65.




Phenyl-3-(3-nitrophenyl) oxiran-2-yl-methanone (3e): Yellow solid; yield: 86%; m.p = 125–129 °C; IR ν_{max} (KBr, cm⁻¹): 1689 (C=O str), 1589 (arom C=C str), 1525 (N–O str), 1405, 1344 (N–O bending), 1232, 1081, 1009, 891, 812, 691, 601; ¹H-NMR (500 MHz, CDCl₃): 8.25–8.24 (m, 2 H, H_{Ar}), 8.03–8.01 (m, 2 H, H_{Ar}), 7.73 (d, J = 6.5 Hz, 1 H, H_{Ar}), 7.67–7.59 (m, 2 H, H_{Ar}), 7.53–7.50 (dd, J = 8.0, 1.5 Hz, 2 H, H_{Ar}), 4.31 (d, J = 2.0 Hz, 1 H, C(O)CH], 4.22 (d, J = 1.5 Hz, 1 H, Ar-CH(-O)CH); ¹³C-NMR (CDCl₃, 125 MHz): δ (ppm) 192.2 (C=O), 148.6, 137.9, 135.2, 134.7, 133.4,

131.9, 129.9, 129.4, 128.7, 128.4, 123.9, 120.8, 60.9 (C(O)-CH), 58.7 (Ar-CH-O); **MS (EI, 70 eV):** m/z (%) 269 (24) [M⁺, C₁₅H₁₁NO₄], 253 (23), 105 (100), 91 (68).




(4-Chlorophenyl)-3-(4-chlorophenyl)oxiran-2-yl-methanone (3g):

White crystalline solid; Yield = 85%; m.p = 121-123 °C; **IR v_{max} (KBr, cm⁻¹):** 3095, 3043 (aromatic C-H str), 1675 (C=O str), 1587 (aromatic, C=C str), 1485, 1399, 1235, 1177, 1090, 817 (C-Cl, str); **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm): 7.97 (dd, *J* = 9.0 Hz, 2.0 Hz, 2 H, H_{Ar}), 7.48 (dd, *J* = 9.0 Hz, 2.0 Hz, 2 H, H_{Ar}), 7.39 (d, *J* = 8.5 Hz, 2 H, H_{Ar}), 7.31 (m, 2 H, H_{Ar}), 4.20 (d, *J* = 1.5 Hz, 1 H, C(O)CH), 4.07 (d, *J* = 1.5 Hz, 1 H, Ar-CH(-O-)CH); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 191.7 (C=O), 60.9 (C(O)CH), 58.6 (Ar-CH-O-), 140.7, 135.1, 133.7, 130.0, 129.7, 129.3, 129.1, 127.1; **MS (EI, 70 eV):** m/z (%) 292 [M⁺, C₁₅H₁₀Cl₂O₂]: 292, 139 (100).



(4-Chlorophenyl)-3-(4-bromophenyl)oxiran-2-yl-methanone (3i):


White crystalline solid; Yield = 89%; m.p = 127-129 °C; **IR v_{max} (KBr, cm⁻¹):** 3039 (aromatic C-H str), 1675 (C=O str), 1587 (aromatic, C=C str), 1430, 1400, 1236, 1177, 1092, 1011, 735 (C-Cl, str); **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm) 7.99 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 7.54 (m, 4 H, H_{Ar}), 7.27 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 4.21 (d, *J* = 2.0 Hz, 1 H, C(O)CH), 4.07 (d, *J* = 2.0 Hz, 1 H, Ar-CH(-O-)CH); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 191.7 (C=O), 60.9 (C(O)CH), 58.7 (Ar-CH-O-), 140.7, 134.4, 133.6, 132.0, 129.8, 129.3, 127.4, 123.2; **MS (EI, 70 eV):** m/z (%) = 336 [M⁺, C₁₅H₁₀ClBrO₂]: 336, 139 (100).




Naphthalen-2-yl-3-phenyloxiran-2-ylmethanone (3s): White crystalline

solid; Yield = 88%; m.p = 90-92 °C; **IR v_{max} (KBr, cm⁻¹):** 2928, 2891 (aromatic C-H str), 1695 (C=O str), 1595 (aromatic, C=C str), 1460, 1396, 1230, 1127, 1011, 820 (C-Cl, str); **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm) 8.54 (s, 1 H, H_{Ar}), 8.03 (dd, *J* = 8.5, 1.5 Hz, H_{Ar}), 7.93-7.85 (m, 3 H, H_{Ar}), 7.61 (t, *J* = 8.0 Hz, 1H, H_{Ar}), 7.54 (t, *J* = 8.0 Hz, 1H, H_{Ar}), 7.43-7.38 (m, 5 H, H_{Ar}), 4.43 (d, *J* = 1.5 Hz, 1 H, C(O)CH), 4.14 (d, *J* = 1.5 Hz, 1 H, Ar-CH(-O-)CH); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 193.0 (C=O), 61.1 (C(O)CH), 59.6 (Ar-CH-O-), 135.9, 135.6, 132.8, 132.4, 130.5, 130.2, 129.7, 129.1, 129.1, 128.9, 128.8, 128.4, 127.1, 125.9, 123.7; **MS (EI, 70 eV):** m/z (%) = 274 [M⁺, C₁₉H₁₄O₂]: 257 (12), 155 (100), 91 (25).


(c) Spectral data of indanone derivatives



3-Phenyl-2-hydroxy-2,3-dihydroindan-1-one (4a): Light yellow solid; m.p = 178-180 °C; Yield = 98%; **IR** ν_{\max} (KBr, cm^{-1}): 3452 (OH str), 2963 (aromatic C-H str), 1686 (C=O str), 1599 (aromatic, C=C str), 1451, 1419, 1262, 1021, 933, 868, 799 and 704; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz): δ (ppm) 7.89 (m, 2 H, H_{Ar}), 7.66 (m, 1 H, H_{Ar}), 7.54 (m, 3 H, H_{Ar}), 7.37-7.30 (m, 3 H, H_{Ar}), 5.39 (d, $J = 2.0$ Hz, 1 H, H2), 5.24 (d, $J = 2.0$ Hz, 1 H, H3), 4.05 (s, br, D_2O exchangeable, 1 H); **$^{13}\text{C-NMR}$** (CDCl_3 , 125 MHz): δ (ppm) 197.8 (C=O), 138.1, 134.3, 133.6, 129.2, 128.8, 128.6, 127.9, 76.1 (C2), 63.8 (C3); **MS (EI, 70eV):** m/z (%) 224(35) [M^+ , $\text{C}_{15}\text{H}_{12}\text{O}_2$], 207(25), 195(29), 178(37), 165(40), 152(33), 121(64), 105(100), 91(62), 77(74) and 51(69).




3-(4-Chlorophenyl)-2-hydroxy-2,3-dihydroindan-1-one (4b): Light yellow solid; m.p = 188-190 °C; Yield = 98%; **IR** ν_{\max} (KBr, cm^{-1}): 3408 (OH str), 2917 (aromatic C-H str), 1689 (C=O str), 1589 (aromatic, C=C str), 1489, 1415, 1288, 1177, 1091, 1014, 929 and 701; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz): δ (ppm) 7.83 (d, $J = 7.5$ Hz, 2 H, H_{Ar}), 7.59 (t, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.48-7.45 (m, 2 H, H_{Ar}), 7.40 (dd, $J = 6.0, 2.0$ Hz, 2 H, H_{Ar}), 7.25 (m, 1 H, H_{Ar}), 5.27 (d, $J = 2.0$ Hz, 1 H, H2), 5.12 (d, $J = 2.0$ Hz, 1 H, H3), 4.02 (s, br, D_2O exchangeable, 1 H); **$^{13}\text{C-NMR}$** (CDCl_3 , 125 MHz): δ (ppm) 197.4 (C=O), 136.6, 134.8, 134.4, 133.5, 129.4, 129.2, 128.7, 128.5, 75.9 (C2), 62.9 (C3); **MS (EI, 70eV):** m/z (%) 258(17) [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_2$], 242(28), 207(36), 179(43), 165(32), 135(57), 130(61), 105(100), 89(49), 77(61), 75(55) and 51(62).



2-Hydroxy-3-p-tolyl-2,3-dihydroindan-1-one (4c): Light yellow solid; m.p = 144-146 °C; Yield = 91%; **IR** ν_{\max} (KBr, cm^{-1}): 3391 (OH str), 2951 (aromatic C-H str), 1693 (C=O str), 1577 (aromatic, C=C str), 1468, 1401, 1271, 1152, 1084, 1002, 910 and 725; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz): δ (ppm) 7.81 (d, $J = 5.5$ Hz, 2 H, H_{Ar}), 7.55 (m, 1 H, H_{Ar}), 7.44 (m, 1 H, H_{Ar}), 7.34 (d, $J = 6.0$ Hz, 2 H, H_{Ar}), 7.07 (d, $J = 5.0$ Hz, 2 H, H_{Ar}), 5.28 (d, $J = 2.0$ Hz, 1 H, H2), 5.14 (d, $J = 2.0$ Hz, 1 H, H3), 4.05 (s, br, D_2O exchangeable, 1 H), 2.24 (s, 3 H); **$^{13}\text{C-NMR}$** (CDCl_3 , 125 MHz): δ (ppm) 197.9 (C=O), 138.7, 135.2, 134.3, 133.7, 129.2, 129.2, 128.6, 127.9, 76.2 (C2), 63.8 (C3), 21.2; **MS (EI, 70eV):** m/z (%) 238(21) [M^+ , $\text{C}_{16}\text{H}_{14}\text{O}_2$], 212(28), 203(16), 159(43), 145(32), 125(57), 105(100), 79(49), and 55(42).

3-(4-Bromophenyl)-2-hydroxy-2,3-dihydroindan-1-one (4d): Light yellow solid; m.p = 183-185 °C; Yield = 90%; **IR** ν_{\max} (KBr, cm^{-1}): 3434 (OH str), 2924 (aromatic C-H str), 1670 (C=O


str), 1588 (aromatic, C=C str), 1485, 1413, 1288, 1177, 1071, 930, 703 and 545; **¹H-NMR**



(CDCl₃, 500 MHz): δ (ppm) 7.82 (d, *J* = 7.5 Hz, 2 H, H_{Ar}), 7.57 (t, *J* = 7.0 Hz, 1 H, H_{Ar}), 7.46-7.43 (m, 2 H, H_{Ar}), 7.38 (dd, *J* = 6.0, 2.0 Hz, 2 H, H_{Ar}), 7.24 (m, 1 H, H_{Ar}), 5.30 (d, *J* = 2.0 Hz, 1 H, H₂), 5.21 (d, *J* = 2.0 Hz, 1 H, H₃), 4.11 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR** (CDCl₃, 125 MHz):


δ(ppm) 197.3 (C=O), 136.6, 134.6, 134.2, 133.4, 129.3, 129.3, 128.6, 128.4, 76.0 (C₂), 62.5 (C₃); **MS (EI, 70eV):** *m/z* (%) 302(16) [M⁺, C₁₅H₁₁BrO₂], 196(55), 169(45), 139(73), 105(100), 89(47), 77(54), 63(49) and 51(66).

3-(3-Nitrophenyl)-2-hydroxy-2,3-dihydroindan-1-one (4e): Light yellow solid; m.p = 196-




198 °C; Yield = 82%; **IR v_{max} (KBr, cm⁻¹):** 3369 (OH str), 2923 (aromatic C-H str), 1680 (C=O str), 1613 (aromatic, C=C str), 1528 (N—O str), 1393, 1348 (N—O bending), 1259, 1094, 986, 911, 840, 728, 687; **¹H-NMR**

(CDCl₃, 500 MHz): δ (ppm): 8.14 (d, *J* = 7.5 Hz, 1 H, H_{Ar}), 7.99 (m, 1 H, H_{Ar}), 7.86 (m, 2 H, H_{Ar}), 7.70 (t, *J* = 7.5 Hz, 1 H, H_{Ar}), 7.61-7.58 (m, 2 H, H_{Ar}), 7.45 (m, 1 H, H_{Ar}), 5.57 (d, *J* = 2.0 Hz, 1 H, H₂), 5.32 (d, *J* = 2.0 Hz, 1 H, H₃), 3.82 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR** (CDCl₃, 125 MHz): δ (ppm) 197.4 (C=O), 147.8, 137.7, 134.9, 134.2, 129.4, 129.2, 128.7, 123.8, 123.2, 76.5 (C₂), 61.75 (C₃); **MS (EI, 70eV):** *m/z* (%) 269(13) [M⁺, C₁₅H₁₁NO₄], 241(21), 196(61), 176(32), 165(48), 136(43), 105(100), 89(64), 77(44), 63(39) and 51(60).




3-Phenyl-5-chloro-2-hydroxy-2,3-dihydroindan-1-one (4f): Light yellow solid; m.p = 180-182 °C; Yield = 97%; **IR v_{max} (KBr, cm⁻¹):** 3449 (OH str), 2950 (aromatic C-H str), 1682 (C=O str), 1582 (aromatic, C=C str), 1389, 1275, 1059, 854, 723 (C-Cl, str); **¹H-NMR** (CDCl₃, 500 MHz): δ (ppm)

7.92 (d, *J* = 8.5 Hz, 2 H, H_{Ar}), 7.78 (d, *J* = 8.5 Hz, 2 H, H_{Ar}), 7.45 (m, 2 H, H_{Ar}), 7.17 (m, 2 H, H_{Ar}), 5.23 (d, *J* = 4.0 Hz, 1 H, H₂), 5.10 (d, *J* = 4.0 Hz, 1 H, H₃), 3.92 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR** (CDCl₃, 125 MHz): δ (ppm) 196.7 (C=O), 140.8, 137.7, 132.0, 130.0, 129.5, 128.9, 128.6, 127.9, 76.1 (C₂), 63.7 (C₃); **MS (EI, 70eV):** *m/z* (%) 258(35) [M⁺, C₁₅H₁₁ClO₂], 139 (100).




3-(4-Chlorophenyl)-5-chloro-2-hydroxy-2,3-dihydroindan-1-one (4g): Light yellow solid; m.p = 202-204 °C; Yield = 98%; **IR v_{max} (KBr, cm⁻¹):** 3438 (OH str), 2922 (aromatic C-H str), 1674 (C=O str), 1591 (aromatic, C=C str), 1396, 1282, 1173, 1091, 756 (C-Cl, str); **¹H-NMR** (CDCl₃, 500

MHz): δ (ppm) 8.06 (d, $J = 8.5$ Hz, 1 H, H_{Ar}), 7.89 (m, 1 H, H_{Ar}), 7.53 (d, $J = 8.5$ Hz, 1 H, H_{Ar}), 7.47 (d, $J = 8.5$ Hz, 1 H, H_{Ar}), 7.28 (m, 2 H, H_{Ar}), 7.16 (d, $J = 8.5$ Hz, 1 H, H_{Ar}), 5.48 (d, $J = 3.5$ Hz, 1 H, H2), 5.21 (d, $J = 3.5$ Hz, 1 H, H3), 3.72 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR (CDCl₃, 125MHz):** δ (ppm) 196.4 (C=O), 141.0, 136.3, 134.3, 131.8, 131.6, 129.9, 129.6, 129.4, 128.9, 128.8, 75.9 (C2), 62.8 (C3); **MS (EI, 70eV):** m/z (%) 292(10) [M^+ , C₁₅H₁₀Cl₂O₂], 245(25), 139(100).



5-Chloro-2-hydroxy-3-p-tolyl-2,3-dihydroindan-1-one (4h): Light yellow solid; m.p = 182-184 °C; Yield = 91%; **IR ν_{max} (KBr, cm⁻¹):** 3439 (OH str), 2922 (aromatic C-H str), 1670 (C=O str), 1594 (aromatic, C=C str), 1491, 1399, 1296, 1095, 760 (C-Cl, str); **¹H-NMR (CDCl₃, 500**


MHz): δ (ppm) 8.01 (dd, $J = 8.0, 2.0$ Hz, 2 H, H_{Ar}), 7.74 (m, 1 H, H_{Ar}), 7.54 (m, 2 H, H_{Ar}), 7.21 (m, 2 H, H_{Ar}), 5.02 (d, $J = 3.0$ Hz, 1 H, H2), 4.95 (d, $J = 3.0$ Hz, 1 H, H3), 3.68 (s, br, D₂O exchangeable, 1 H), 2.49 (s, 3H); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 193.4 (C=O), 146.5, 141.5, 131.4, 131.2, 130.3, 130.1, 129.8, 129.4, 128.9, 76.2 (C2), 62.3 (C3), 22.3; **MS (EI, 70eV):** m/z (%) 272(25) [M^+ , C₁₆H₁₃ClO₂], 160(55), 141(72), 139(100), 111(62), 105(73).



3-(4-Bromophenyl)-5-chloro-2-hydroxy-2,3-dihydroindan-1-one (4i): Light yellow solid; m.p = 210-212 °C; Yield = 95%; **IR ν_{max} (KBr, cm⁻¹):** 3426 (OH str), 2923 (aromatic C-H str), 1678 (C=O str), 1591 (aromatic, C=C str), 1417, 1395, 1282, 1170, 1092, 757 (C-Cl, str); **¹H-**

NMR (CDCl₃, 500 MHz): δ (ppm) 7.88 (m, 2 H, H_{Ar}), 7.55-7.49 (m, 3 H, H_{Ar}), 7.40 (m, 2 H, H_{Ar}), 5.31 (d, $J = 2.5$ Hz, 1 H, H2), 5.15 (d, $J = 2.5$ Hz, 1 H, H3), 4.05 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 196.3 (C=O), 141.1, 136.8, 131.8, 131.8, 129.9, 129.6, 129.6, 123.1 75.8 (C2), 62.8 (C3); **MS (EI, 70eV):** m/z (%) = 336(18) [M^+ , C₁₅H₁₀ClBrO₂], 139 (100), 111(53).


3-(3, 4, 5-Trimethoxyphenyl)-5-chloro-2-hydroxy-2,3-dihydroindan-1-one (4j): Light



yellow solid; m.p = 220-222 °C; Yield = 80%; **IR ν_{max} (KBr, cm⁻¹):** 3440 (OH str), 2920 (aromatic C-H str), 1666 (C=O str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1125(C-O-C, str), 1091, 771 (C-Cl, str); **¹H-**


NMR (CDCl₃, 500 MHz): δ (ppm) 7.84 (d, $J = 6.5$ Hz, 2 H, H_{Ar}), 7.51 (d, $J = 7.0$ Hz, 1 H, H_{Ar}), 6.74 (s, 2 H, H_{Ar}), 5.35 (d, $J = 2.5$ Hz, 1 H, H2), 5.10 (d, $J = 2.5$ Hz, 1 H, H3), 4.10 (s, br, D₂O exchangeable, 1 H), 3.87 (s, OMe, 9H) ; **¹³C-NMR (CDCl₃, 125 MHz)**

δ (ppm): 191.2 (C=O), 153.6, 132.3, 131.6, 131.5, 129.8, 129.3, 128.9, 127.6, 107.4, 75.2(C2), 61.0(C3), 60.8, 56.3; **MS (EI, 70eV):** m/z (%) 348(29) [M^+ , $C_{18}H_{17}ClO_5$], 181(69), 139 (100), 111(59).




3-Phenyl-5-bromo-2-hydroxy-2,3-dihydroindan-1-one (4k): Light yellow solid; m.p = 192-194 °C; Yield = 98%; **IR ν_{max} (KBr, cm^{-1}):** 3466 (OH str), 2920 (aromatic C-H str), 1678 (C=O str), 1593 (aromatic, C=C str), 1398, 1281, 1095, 843, 713 (C-Br, str); **1H -NMR (CDCl₃, 500 MHz):**

δ (ppm) 7.99 (dd, $J = 8.5$ Hz, 1.5 Hz, 1 H, H_{Ar}), 7.87 (dd, $J = 8.5$ Hz, 1.5 Hz, 2 H, H_{Ar}), 7.69 (m, 3 H, H_{Ar}), 7.54 (m, 2 H, H_{Ar}), 5.48 (d, $J = 2.5$ Hz, 1 H, H2), 5.15 (d, $J = 2.5$ Hz, 1 H, H3), 3.51 (s, br, D₂O exchangeable, 1 H); **^{13}C -NMR (CDCl₃, 125 MHz):** δ (ppm) 196.9 (C=O), 137.7, 132.5, 132.4, 131.7, 130.6, 130.4, 129.6, 128.9, 128.6, 128.6, 127.9, 76.1 (C2), 63.7 (C3); **MS (EI, 70eV):** m/z (%) 302(18) [M^+ , $C_{15}H_{11}BrO_2$], 185(69), 183(53), 91(100).




3-(4-Chlorophenyl)-5-bromo-2-hydroxy-2,3-dihydroindan-1-one (4l): Light yellow solid; m.p = 205-207 °C; Yield = 95%; **IR ν_{max} (KBr, cm^{-1}):** 3422 (OH str), 3087 (aromatic C-H str), 1678 (C=O str), 1583

(aromatic, C=C str), 1404, 1278, 1169, 1091, 830, 752 (C-Br, str); **1H -NMR (CDCl₃, 500 MHz) δ (ppm):** 7.78 (m, 1 H, H_{Ar}), 7.70 (m, 2 H, H_{Ar}), 7.47 (m, 2 H, H_{Ar}), 7.35 (m, 2 H, H_{Ar}), 5.30 (d, $J = 2.0$ Hz, 1 H, H2), 5.16 (d, $J = 2.0$ Hz, 1 H, H3), 3.62 (s, br, D₂O exchangeable, 1 H); **^{13}C -NMR (CDCl₃, 125 MHz) δ (ppm):** 196.6 (C=O), 136.3, 134.9, 132.6, 132.3, 129.8, 129.4, 128.8, 75.9 (C2), 62.8 (C3); **MS (EI, 70eV):** m/z (%) 336(30) [M^+ , $C_{15}H_{10}ClBrO_2$], 185(79), 183 (100), 125(49).




3-(4-Bromophenyl)-5-bromo-2-hydroxy-2,3-dihydroindan-1-one (4m): Light yellow solid; m.p = 198-200 °C; Yield = 96%; **IR ν_{max} (KBr, cm^{-1}):** 3441 (OH str), 2921, 2853 (aromatic C-H str), 1676 (C=O str), 1588 (aromatic, C=C str), 1276, 1066, 820, 746 (C-Br, str); **1H -NMR**


(CDCl₃, 500MHz): δ (ppm) 7.79 (d, $J = 8.5$ Hz, 1 H, H_{Ar}), 7.71 (d, $J = 7.0$ Hz, 2 H, H_{Ar}), 7.50 (d, $J = 7.0$ Hz, 2 H, H_{Ar}), 7.40 (m, 2 H, H_{Ar}), 5.30 (d, $J = 4.5$ Hz, 1 H, H2), 5.15 (d, $J = 4.5$ Hz, 1 H, H3), 4.05 (s, br, D₂O exchangeable, 1 H); **^{13}C -NMR (CDCl₃, 125 MHz):** δ (ppm) 196.5 (C=O), 136.8, 132.6, 132.2, 131.8, 130.0, 129.8, 129.6, 123.1, 75.9 (C2), 62.8 (C3); **MS (EI, 70eV):** m/z (%) 380(32) [M^+ , $C_{15}H_{10}Br_2O_2$], 185(75), 183 (100).



3-p-Tolyl-5-bromo-2-hydroxy-2,3-dihydroindan-1-one (4n): Light yellow solid; m.p = 181-183 °C; Yield = 89%; IR ν_{\max} (KBr, cm^{-1}): 3464 (OH str), 2917, 2849 (aromatic C-H str), 1685 (C=O str), 1586 (aromatic, C=C str), 1279, 1071, 815, 757 (C-Br, str); $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.69 (m, 2 H, H_{Ar}), 7.69 (m, 1 H, H_{Ar}), 7.32 (d, $J = 8.0$ Hz, 2 H, H_{Ar}), 7.10 (m, 2 H, H_{Ar}), 5.23 (d, $J = 2.5$ Hz, 1 H, H2), 5.10 (d, $J = 2.5$ Hz, 1 H, H3), 3.98 (s, br, D_2O exchangeable, 1 H), 2.26 (s, 3 H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz): δ (ppm) 195.99 (C=O), 137.84, 133.76, 131.41, 129.00, 128.24, 126.79, 75.23 (C2), 62.68 (C3), 20.12; MS (EI, 70eV): m/z (%) 316(14) [M^+ , $\text{C}_{16}\text{H}_{13}\text{BrO}_2$], 219(59), 185 (100), 183(82).




2-Hydroxy-5,6-dimethyl-3-phenyl-2,3-dihydroinden-1-one (4o): Light yellow solid; m.p = 112-114 °C; Yield = 92%; IR ν_{\max} (KBr, cm^{-1}): 3420 (OH str), 2959, 2869 (aromatic C-H str), 1688 (C=O str), 1583 (aromatic, C=C str), 1253, 1063, 835; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.71 (m, 1 H, H_{Ar}), 7.63 (dd, $J = 7.0, 1.5$ Hz, 1 H, H_{Ar}), 7.54 (d, $J = 7.5$ Hz, 2 H, H_{Ar}), 7.36 (t, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.32 (d, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.27 (d, $J = 8.0$ Hz, 1 H, H_{Ar}), 5.35 (d, $J = 2.5$ Hz, 1 H, H2), 5.25 (d, $J = 2.5$ Hz, 1 H, H3), 3.95 (s, br, D_2O exchangeable, 1 H), 2.34 (s, 3 H), 2.33 (s, 3 H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz): δ (ppm) 197.4 (C=O), 144.2, 138.4, 137.8, 131.3, 130.3, 129.8, 128.7, 128.5, 127.9, 126.2, 75.8 (C2), 64.1 (C3), 20.2, 19.8; MS (EI, 70eV): m/z (%) = 252(07) [M^+ , $\text{C}_{17}\text{H}_{16}\text{O}_2$], 234(15), 105 (25), 88(100).



3-(4-Chlorophenyl)-2-hydroxy-5,6-dimethyl-2,3-dihydro inden-1-one (4p): Light yellow solid; m.p = 116-118 °C; Yield = 93%; IR ν_{\max} (KBr, cm^{-1}): 3412 (OH str), 2952, 2847 (aromatic C-H str), 1675 (C=O str), 1609 (aromatic, C=C str), 1225, 1091, 842, 762; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.70 (m, 1 H, H_{Ar}), 7.62 (d, $J = 7.5$ Hz, 1 H, H_{Ar}), 7.49 (m, 2 H, H_{Ar}), 7.34 (m, 1 H, H_{Ar}), 7.29 (d, $J = 7.5$ Hz, 1 H, H_{Ar}), 5.32 (d, $J = 2.5$ Hz, 1 H, H2), 5.21 (d, $J = 2.5$ Hz, 1 H, H3), 4.12 (s, br, D_2O exchangeable, 1 H), 2.36(s, 3H), 2.35 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz): δ (ppm) 197.1 (C=O), 144.4, 137.9, 136.9, 134.6, 131.1, 130.3, 129.7, 129.4, 128.7, 126.1, 75.6 (C2), 63.2 (C3), 20.2, 19.9; MS (EI, 70eV): m/z (%) = 286(10) [M^+ , $\text{C}_{17}\text{H}_{15}\text{ClO}_2$], 268 (20), 122 (100).


2-Hydroxy-5,6-dimethyl-3-(3-nitrophenyl)-2,3-dihydro inden-1-one (4r): Light yellow solid; m.p = 142-144 °C; Yield = 79%; IR ν_{\max} (KBr, cm^{-1}): 3381 (OH str), 2943 (aromatic C-H str), 1674 (C=O str), 1620 (aromatic, C=C str), 1504 (N—O str), 1371, 1353 (N—O bending),

1241, 1061, 916, 832, 783, 675; **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm) 8.14 (m, 1 H, H_{Ar}),



7.94 (m, 1 H, H_{Ar}), 7.59 (m, 2 H, H_{Ar}), 7.44 (d, *J* = 8.0 Hz, 1 H, H_{Ar}),
7.29 (d, *J* = 8.0 Hz, 1 H, H_{Ar}), 5.54 (d, *J* = 4.0 Hz, 1 H, H₂), 5.34 (d, *J* =
4.0 Hz, 1 H, H₃), 3.82 (s, br, D₂O exchangeable, 1 H), 2.35 (s, 3 H), 2.30


(s, 3 H); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 196.9 (C=O), 147.7, 145.1, 138.1, 137.7,
134.3, 131.7, 130.5, 129.6, 129.1, 126.4, 123.7, 123.2, 76.5 (C₂), 62.0 (C₃), 20.2, 19.8; **MS**
(EI, 70eV): *m/z* (%) = 297 (14) [M⁺, C₁₇H₁₅NO₄], 280 (10), 133 (100).



2-Hydroxy-3-phenyl-2,3-dihydrocyclopenta[b]naphthalen-1-one (4s):

Light yellow solid; m.p = 114-116 °C; Yield = 92%; **IR** *v*_{max} (KBr, cm⁻¹):


3395 (OH str), 2951, 2848 (aromatic C-H str), 1677 (C=O str), 1580
(aromatic, C=C str), 1247, 1092, 842; **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm) 8.41 (m, 1H,
H_{Ar}), 7.95 (m, 2 H, H_{Ar}), 7.85 (m, 1 H, H_{Ar}), 7.63 (t, *J* = 7.0 Hz, 1 H, H_{Ar}), 7.58 (m, 3H, H_{Ar}),
7.38-7.30 (m, 3 H, H_{Ar}), 5.53 (d, *J* = 2.0 Hz, 1H, H₂), 5.31 (d, *J* = 2.0 Hz, 1H, H₃), 4.21 (s, br,
D₂O exchangeable, 1 H); **¹³C-NMR (CDCl₃, 125 MHz):** δ (ppm) 197.7 (C=O), 138.2,
136.0, 132.4, 130.9, 130.5, 129.7, 129.3, 129.2, 128.8, 128.6, 128.0, 127.9, 127.3, 123.9, 76.2
(C₂), 64.1 (C₃); **MS (EI, 70eV):** *m/z* (%) = 274 (12) [M⁺, C₁₉H₁₄O₂], 256 (15), 110 (100).



3-(4-Chlorophenyl)-2-hydroxy-2,3-dihydrocyclopenta[b] naphthalen-

1-one (4t): Light yellow solid; m.p = 108-110 °C; Yield = 91%; **IR** *v*_{max}

(KBr, cm⁻¹): 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O
str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **¹H-NMR (CDCl₃, 500 MHz):** δ (ppm)
8.41 (m, 1H, H_{Ar}), 7.97 (t, *J* = 8.0 Hz, 2 H, H_{Ar}), 7.92 (t, *J* = 8.0 Hz, 2 H, H_{Ar}), 7.62 (dd, *J* =
2.0, 7.5 Hz, 2 H, H_{Ar}), 7.50 (d, *J* = 7.0 Hz, 2 H, H_{Ar}), 7.33 (d, *J* = 7.5 Hz, 1H, H_{Ar}), 5.49 (d, *J* =
2.0 Hz, 1H, H₂), 5.27 (d, *J* = 2.0 Hz, 1H, H₃), 4.15 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR**
(CDCl₃, 125 MHz): δ (ppm) 197.4 (C=O), 136.7, 136.0, 134.8, 132.4, 130.8, 130.5, 129.7,
129.4, 129.3, 129.3, 128.8, 128.0, 127.4, 123.8, 75.9 (C₂), 63.1 (C₃); **MS (EI, 70eV):** *m/z* (%)
308 (11) [M⁺, C₁₉H₁₃ClO₂], 290 (23), 144 (100), 65 (45).




3-(4-Bromophenyl)-2-hydroxy-2,3-dihydrocyclopenta[b]

naphthalen-1-one (4u): Light yellow solid; m.p = 112-114 °C; Yield =


92%; **IR** *v*_{max} (KBr, cm⁻¹): 3409 (OH str), 2925, 2870 (aromatic C-H
str), 1685 (C=O str), 1590 (aromatic, C=C str), 1258, 1080, 865, 730;
¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 8.42 (m, 1 H, H_{Ar}), 7.98 (t, *J* = 8.0 Hz, 2 H, H_{Ar}), 7.93

(t, $J = 8.0$ Hz, 2 H, H_{Ar}), 7.65 (dd, $J = 2.0, 7.5$ Hz, 2 H, H_{Ar}), 7.50 (d, $J = 7.0$ Hz, 2 H, H_{Ar}), 7.43 (d, $J = 7.5$ Hz, 1 H, H_{Ar}), 5.50 (d, $J = 2.0$ Hz, 1 H, H2), 5.27 (d, $J = 2.0$ Hz, 1 H, H3), 4.20 (s, br, D₂O exchangeable, 1 H); ¹³C-NMR (CDCl₃, 125 MHz): δ (ppm) 197.3 (C=O), 137.2, 136.0, 132.4, 131.7, 130.8, 130.5, 129.7, 129.7, 129.3, 129.3, 128.0, 127.4, 123.7, 123.0, 75.9 (C2), 63.2 (C3); MS (EI, 70eV): m/z (%) = 352 (09), 354 (09) [M^+ , C₁₉H₁₃BrO₂], 155 (100).




2-Hydroxy-3-p-tolyl-2,3-dihydrocyclopenta[b]naphthalen-1-one

(4v): Light yellow solid; m.p = 125-127 °C; Yield = 86%; IR ν_{max} (KBr, cm⁻¹): 3429 (OH str), 2951, 2880 (aromatic C-H str), 1692 (C=O str), 1607 (aromatic, C=C str), 1271, 1107, 843, 729; ¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 8.41 (m, 1 H, H_{Ar}), 7.98-7.87 (m, 3 H, H_{Ar}), 7.63 (m, 2 H, H_{Ar}), 7.45 (d, $J = 8.0$ Hz, 2 H, H_{Ar}), 7.17 (d, $J = 8.0$ Hz, 2 H, H_{Ar}), 5.52 (d, $J = 2.0$ Hz, 1 H, H2), 5.29 (d, $J = 2.0$ Hz, 1 H, H3), 4.09 (s, br, D₂O exchangeable, 1 H), 2.32 (s, 3H); ¹³C-NMR (CDCl₃, 125 MHz): δ (ppm) 197.8 (C=O), 138.8, 136.0, 135.3, 132.4, 130.9, 130.5, 129.7, 129.3, 129.2, 128.6, 128.3, 127.9, 127.3, 123.9, 76.3 (C2), 64.0 (C3), 21.2; MS (EI, 70eV): m/z (%) 288 (08) [M^+ , C₂₀H₁₆O₂], 270 (28), 133 (100).




2-Hydroxy-3-(3-nitrophenyl)-2,3-dihydrocyclopenta[b]naphthalen-1-one

(4w): Light yellow solid; m.p = 138-140 °C; Yield = 76%; IR ν_{max} (KBr, cm⁻¹): 3382 (OH str), 2992, 2886 (aromatic C-H str), 1695 (C=O str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; ¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 8.54 (m, 1 H, H_{Ar}), 8.14 (m, 1 H, H_{Ar}), 7.97-7.87 (m, 3 H, H_{Ar}), 7.70 (m, 1 H, H_{Ar}), 7.62 (m, 1 H, H_{Ar}), 7.59 (m, 1 H, H_{Ar}), 7.43 (m, 1 H, H_{Ar}), 7.25 (m, 1 H, H_{Ar}), 5.72 (d, $J = 2.0$ Hz, 1 H, H2), 5.40 (d, $J = 2.0$ Hz, 1 H, H3), 3.84 (s, br, D₂O exchangeable, 1 H); ¹³C-NMR (CDCl₃, 125 MHz): δ (ppm) 197.2 (C=O), 137.8, 136.2, 134.2, 132.3, 131.2, 130.9, 129.8, 129.7, 129.5, 129.2, 128.0, 127.6, 123.8, 123.6, 123.2, 76.6 (C2), 61.9 (C3); MS (EI, 70eV): m/z (%) 319 (09) [M^+ , C₁₉H₁₃NO₄], 302 (12), 189 (20), 155 (100), 127 (50).




trans-(2R,3S)-3-(4-Chlorophenyl)oxiran-2-yl(phenyl)methanone (5a):


¹H-NMR (CDCl₃, 500 MHz): δ ppm 8.00 (dd, $J_1=7.5$ Hz, $J_2=1.5$ Hz, Ar-H, 2H), 7.63-7.48 (m, Ar-H, 5H), 7.40-7.30 (m, Ar-H, 4H), 4.25 (d, $J=2.0$ Hz, -CO-CH- 1H), 4.06 (d, $J=2.0$ Hz, -CH-Ar- 1H). The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -171.9$ (c 0.53, CHCl₃) and chiral HPLC using Chiralcel OD-H columns and compared with the literature data.

***trans*-(2*R*,3*S*)-3-(4-Bromophenyl)oxiran-2-yl(phenyl)methanone (5b):**


¹H-NMR (CDCl₃, 500MHz): δ ppm 8.02-7.98 (m, Ar-H, 2H), 7.63-7.59 (m, Ar-H, 1H), 7.56-7.48 (m, Ar-H, 4H), 7.26-7.24 (m, Ar-H, 1H), 4.25 (d, *J*=2.0 Hz, -CH-Ar, 1H), 4.05 (d, *J*= 1.5 Hz, -CO-CH-, 1H). The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -118.4$ (c 0.27, CHCl₃) [lit. for (2*R*,3*S*)-epoxy-3-phenyl-1-(4-bromophenyl)-propan-1-one: $[\alpha]_D^{25} = -162.1$ (c 0.46, CHCl₃) for 74% ee and chiral HPLC using Chiralcel OD-H column and compared with the literature data.

***trans*-(2*R*,3*S*)-Naphthalen-2-yl(3-phenyloxiran-2-yl)methanone (5c):**


¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 8.54 (s, 1 H, H_{Ar}), 8.03 (dd, *J* = 8.5, 1.5 Hz, H_{Ar}), 7.93-7.85 (m, 3 H, H_{Ar}), 7.61 (t, *J* = 8.0 Hz, 1H, H_{Ar}), 7.54 (t, *J* = 8.0 Hz, 1H, H_{Ar}), 7.43-7.38 (m, 5 H, H_{Ar}), 4.43 (d, *J* = 1.5 Hz, 1 H, C(O)CH), 4.14 (d, *J* = 1.5 Hz, 1 H, Ar-CH(-O)-CH). The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -89.7$ (c 1.0, CHCl₃) [lit.²⁸ for (2*R*,3*S*)-epoxy-3-phenyl-1-(2-naphthyl)-propan-1-one: $[\alpha]_D^{25} = -90.1$ (c 1.0, CH₂Cl₂) for 64% ee] and chiral HPLC using Chiralpak AD-H column and compared with the literature data.

***trans*-(2*R*,3*S*)-(4-Bromophenyl)(3-(4-chlorophenyl)oxiran-2-yl)methanone (5d):**


¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 7.98 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 7.53 (m, 4 H, H_{Ar}), 7.28 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 4.22 (d, *J* = 2.0 Hz, 1 H, C(O)CH), 4.08 [d, *J* = 2.0 Hz, 1 H, Ar-CH(-O)-CH]. The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -108.5$ (c 0.31, CHCl₃) and chiral HPLC using Chiralpak AD-H column.

***trans*-(2*R*,3*S*)-(3-(4-Chlorophenyl)oxiran-2-yl)(3,4-dimethylphenyl)methanone (5e):**


¹H-NMR (CDCl₃, 500 MHz): δ (ppm) 7.85 (m, 1H, H_{Ar}), 7.72 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 7.61 (m, 2 H, H_{Ar}), 7.30 (dd, *J* = 7.0, 2.0 Hz, 2 H, H_{Ar}), 4.27 [d, *J* = 2.0 Hz, 1 H, C(O)CH], 4.05 [d, *J* = 2.0 Hz, 1 H, Ar-CH(-O)-CH], 2.36 (s, 3H), 2.35 (s, 3H). The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -134.3$ (c 0.28, CHCl₃) and chiral HPLC using Chiralpak AD-H column.




trans-(2R,3S)-3-(4-Chlorophenyl)-2-hydroxy-2,3-dihydroindan-1-one (6a): $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.92 (d, $J = 7.5$ Hz, 2 H, H_{Ar}), 7.69 (d, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.56 (t, $J = 7.0$ Hz, 2 H, H_{Ar}), 7.49 (d, $J = 7.5$ Hz, 2 H, H_{Ar}), 7.35 (d, $J = 7.0$ Hz, 1 H, H_{Ar}), 5.36 (d, $J = 2.0$ Hz, 1 H, H2), 5.21 (d, $J = 2.0$ Hz, 1 H, H3), 4.13 (s, br, D_2O exchangeable, 1 H); The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_{\text{D}}^{25} = -16.4$ (c 1.0, CHCl_3) and chiral HPLC using Chiralcel OD-H column.




trans-(2R,3S)-3-(4-Bromophenyl)-2-hydroxy-2,3-dihydroindan-1-one (6b): $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.91 (d, $J = 7.5$ Hz, 2 H, H_{Ar}), 7.57 (t, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.50 (d, $J = 7.0$ Hz, 2 H, H_{Ar}), 7.43 (d, $J = 7.0$, 2.0 Hz, 2 H, H_{Ar}), 7.24 (m, 1 H, H_{Ar}), 5.35 (d, $J = 2.0$ Hz, 1 H, H2), 5.19 (d, $J = 2.0$ Hz, 1 H, H3), 4.13 (s, br, D_2O exchangeable, 1 H); The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_{\text{D}}^{25} = -8.8$ (c 1.2, CHCl_3) and chiral HPLC using Chiralcel OD-H column.



trans-(2R,3S)-2-Hydroxy-3-phenyl-2,3-dihydrocyclopenta[b]naphthalen-1-one (6c): $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 8.45 (m, 1 H, H_{Ar}), 7.99 (m, 2 H, H_{Ar}), 7.85 (m, 1 H, H_{Ar}), 7.65 (t, $J = 7.0$ Hz, 1 H, H_{Ar}), 7.60 (m, 3 H, H_{Ar}), 7.39-7.34 (m, 3 H, H_{Ar}), 5.57 (d, $J = 2.0$ Hz, 1 H, H2), 5.32 (d, $J = 2.0$ Hz, 1 H, H3), 4.19 (s, br, D_2O Exchange-able, 1H); The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_{\text{D}}^{25} = -3.5$ (c 0.12, CHCl_3) and chiral HPLC using Chiralcel AD-H column.



trans-(2R,3S)-3-(4-Chlorophenyl)-5-bromo-2-hydroxy-2,3-dihydroindan-1-one (6d): $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.89 (m, 2 H, H_{Ar}), 7.56-7.50 (m, 3 H, H_{Ar}), 7.41 (m, 2 H, H_{Ar}), 5.31 (d, $J = 2.0$ Hz, 1 H, H2), 5.16 (d, $J = 2.0$ Hz, 1 H, H3), 4.04 (s, br, D_2O exchangeable, 1 H). The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_{\text{D}}^{25} = -10.1$ (c 0.26, CHCl_3) & chiral HPLC using Chiralcel AD-H column.



trans-(2R,3S)-3-(4-Chlorophenyl)-2-hydroxy-5,6-dimethyl-2,3-dihydroindan-1-one (6e): $^1\text{H-NMR}$ (CDCl_3 , 500 MHz): δ (ppm) 7.71 (m, 1 H, H_{Ar}), 7.61 (d, $J = 7.5$ Hz, 1 H, H_{Ar}), 7.50 (m, 2 H, H_{Ar}), 7.33 (m, 1 H, H_{Ar}), 7.28 (d, $J = 7.5$ Hz, 1 H, H_{Ar}), 5.25 (d, $J = 2.0$ Hz, 1 H, H2), 5.14 (d, $J = 2.0$ Hz, 1 H,

H3), 4.10 (s, br, D₂O exchangeable, 1 H), 2.36(s, 3H), 2.35 (s, 3H); The absolute configuration was determined by comparison with the optical rotation reported in the $[\alpha]_D^{25} = -9.5$ (c 0.57, CHCl₃) and chiral HPLC using Chiralcel AD-H column.

3.7. REFERENCES

- [1] (a) Amaranth, V.; Broom, A. D.; *Chemical synthesis of oligonucleotides*, Chem. Rev. 1977, 77, 183.
- [2] Rao, M. L. N.; "Triphenylbismuthane", *Encyclopedia of Reagents for Organic Synthesis*, John & Wiley 2012.
- [3] Green, T. W.; Wuts, P. G. M.; *Organic Synthesis*, 3rd ed.; John Wiley: New York, 1999; 306; (b) Caine, D.; Deutsch, H. J.; *Stereospecific total synthesis of gibberellic acid. A key tricyclic intermediate*, J. Am. Chem. Soc. 1978, 100, 8031
- [4] Tamami, B.; Parvanak, K.; *Chemoselective tetrahydropyranylation of alcohols and phenols using polystyrene supported aluminum chloride as a catalyst*, Tetrahedron Lett. 2004, 45, 715
- [5] Kumara, B.; Mushtaq A. A.; Mukherjee, D.; Chinnib, S. S.; Taneja, S. C.; Kumar, B.; *Allyl tetrahydropyranyl ether: a versatile alcohol/thiol protecting reagent*, Tetrahedron Lett. 2009, 50, 6236.
- [6] Diaz, R. R.; Melgarejo, C. R.; Plaza, M. T.; Cubero, I. I.; *A Novel, Mild, and Practical Regeneration of Alcohols from their Allylic Ethers by NBS/H₂O*, J. Org. Chem. 1994, 59, 7928.
- [7] Babu, B. S.; Balasubramanian, K.; *Mild and efficient tetrahydropyranylation of alcohols - catalysis by lithium perchlorate in diethyl ether*, Tetrahedron Lett. 1998, 39, 9287.
- [8] Reddy, P. N.; Sunil, B. K.; Kumar, P. S.; Srinivasulu, N. Y.; Reddy, T.; Rajitha, B.; *Origins of the journal Khimiya Geterotsiklicheskikh soedinenii*, Chemistry of Heterocyclic Compounds 2005, 41, 11.
- [9] (a) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron Lett. 2005, 61, 5209; (b) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron Lett. 2006, 47, 261; (c) Wiles, C.; Watts, P.; Haswell, S. J.; Tetrahedron 2007, 9, 966.

- [10] (a) Kishali, N. H.; Dogan, D.; Şahin, E.; Gunel, A.; Kara, Y.; Balci, M. *Stereoselective Synthesis of Deoxycarbaheptopyranose Derivatives: 5a-carba-6-deoxy- α -DL-galacto-heptopyranose and 5a-carba-6-deoxy- α -DL-gulo-heptopyranose*, *Tetrahedron* 2011, 67, 1193; (b) Karimi, B.; Maleski, J.; *Lithium triflate (LiOTf) catalyzed efficient and chemoselective tetrahydropyranylation of alcohols and phenols under mild and neutral reaction conditions*, *Tetrahedron Lett.* 2002, 43, 5353.
- [11] Mineno, T.; *A fast and practical approach to tetrahydropyranylation and depyranylation of alcohols using indium triflate*, *Tetrahedron Lett.* 2002, 43, 7975.
- [12] Ranu, B. C.; Saha, M.; *A Simple, Efficient, and Selective Method for Tetrahydropyranylation of Alcohols on a Solid Phase of Alumina Impregnated with Zinc Chloride*, *J. Org. Chem.* 1994, 59, 8269.
- [13] Haraldsson, G. G.; Baldwin, J. E.; *A selective cleavage of aromatic benzyl ethers located ortho to a carbonyl group by magnesium bromide*, *Tetrahedron* 1997, 53, 215.
- [14] Tanemura, K.; Haraguchi, T.; Suzuki, A.; *2,3-Dichloro-5,6-dicyano-p-benzoquinone as a mild and efficient catalyst for the tetrahydropyranylation of alcohols*, *Bull. Chem. Soc. Jpn.* 1992, 65, 304.
- [15] Kumar, H. M. S.; Reddy, B. V. S.; Reddy, E. J.; Yadav, J. S.; *Microwave assisted organic synthesis*, *Chem. Lett.* 1999, 28, 857.
- [16] Yadav, J. S.; Srinivas, D.; Reddy, G. S.; *A mild and versatile method for the tetrahydropyranylation of alcohols and their detetrahydropyranylation*, *Synth. Commun.* 1998, 28, 1399
- [17] Molnarand, A. T. B.; *Mild and efficient tetrahydropyranylation and deprotection of alcohols catalyzed by heteropoly acids*, *Tetrahedron Lett.* 1996, 37, 8597.
- [18] Namboodiri, V. V.; Varma, R. S. *Solvent-free tetrahydropyranylation (THP) of alcohols and phenols and their regeneration by catalytic aluminum chloride hexahydrate*, *Tetrahedron Lett.* 2002, 43, 1143;
- [19] Srikrishna, A. R.; Sattigeri, J. A.; Vijaykumar, D.; *A new, convenient reductive procedure for the deprotection of 4-methoxybenzyl (MPM) ethers to alcohols*, *J. Org. Chem.* 1995, 60, 5961.

- [20] Isobe, M.; Iio, H.; Kawai, T.; Goto, T.; *Total synthesis of (S)-12-hydroxy-5,8,14-cis,-10-trans-eicosatetraenoic acid (Samuelsson's HETE)*, J. Am. Chem. Soc. 1978, 100, 1942.
- [21] Akai, S.; Tanaka, R.; Hoshi, H.; Sato, K. I.; *Selective Deprotection Method of N-Phenylcarbamoyl Group*, J. Org. Chem. 2013, 78, 8802.
- [22] Koza, G.; Karahan, E.; Balci, M. *Regioselective Synthesis of the 5,6-dihydro-4H-furo[2,3-c]pyrrol-4-one Skeleton: a New Class of Compound*, Helvetika Chemica Acta 2010, 93, 1698.
- [23] Sabhita, G.; Yadav, J. S.; Rajkumar, M.; Babu, R.; *A Highly Efficient, Mild, and Selective Cleavage of β -Methoxyethoxymethyl (MEM) Ethers by Cerium (III) Chloride in Acetonitrile*, Org. Lett. 2001, 3, 1149.
- [24] Rigby, J. H.; Wilson, J. Z.; *Removal of methoxyethoxymethyl ethers with trimethylsilyl chloride-sodium iodide*, Tetrahedron Lett. 1984, 25, 1429.
- [25] William, D. R.; Sakdarat, S.; *Opportunities for selective removal of methoxyethoxymethyl (MEM) ethers*, Tetrahedron Lett. 1983, 24, 3965.
- [26] Han, J. H.; Kwon, Y. E.; Sohn, J. H.; Ryu, D. H.; *A facile method for the rapid and selective deprotection of methoxymethyl (MOM) ethers*, Tetrahedron 2010, 66, 1673.
- [27] Ahmed, N.; van Lier, J. E. *Alumina supported-CeCl₃·7H₂O-NaI: an efficient catalyst for the cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent free conditions*, Tetrahedron Lett. 2007, 48, 13.
- [28] (a) Hanna, G. M.; Lau-cam, C. A.; J. Pharm. Biomed. Anal. 1989, 919; (b) Field, M. J.; Fowler, N.; Giebisch, G. H.; J. Pharmacol. Exp. Ther. 1984, 62, 522; (c) Ioav, C. Z.; Shirley, K.; Miriam, K.; Hagai, *Anion transport inhibitors as suppressors of Plasmodium falciparum growth in vitro cultures*, G. Mol. Pharmacol. 1983, 23, 92; (d) Mithofer, A.; Maitrejean, M.; Boland, M. J. Plant Growth Regul. 2005, 22, 170; (e) Leoni, L. M.; Hamel, E.; Genini, D.; Carrera, C. J.; Cottam, H. B.; Dennis, A.; Carson, D. A.; *Indanocine, a microtubule-binding indanone and a selective inducer of apoptosis in multidrug-resistant cancer cells*, J. Natl. Cancer Inst. 2000, 19, 217; (f) Adesanya, S. A.; Nia, R.; Martin, M. T.; Boukamcha, N.; Montagnac, A.; Pais, M.; *Stilbene derivatives from Cissus quadrangularis*, J. Nat. Prod. 1999, 14, 1694; (g) Li, W.; Li, H.; Li, Y.; Hou, Z.; *Total synthesis of (\pm)-quadrangularin A*, Angew. Chem., Int. Ed. 2006, 7609; (h) Tanaka, T.;

- Linuma, M.; Murata, H.; *Formation of polyhydroxylated isoflavones from the isoflavones genistein and biochanin A by bacteria isolated from tempe*, *Phytochemistry* 1998, 25, 1045;
- (i) Kim, H. J.; Saleem, M.; Seo, S. H.; Jin, C.; Lee, Y. S.; *Two new antioxidant stilbene dimers, parthenostilbenins A and B from Parthenocissus tricuspidata*, *Planta Med.* 2005, 15, 973.
- [29] Rao, R. J. R.; Rao, A. K. S. B.; Murthy, Y. L. N.; *Efficient and Industrially Viable Synthesis of Donepezil*, *Synth. Commun.* 2007, 11, 2847.
- [30] (a) Silver, S.; Leppanen, A. S.; Sjöholm, R.; Penninkangas, A.; Leino, R.; *Towards benign synthesis of indenenes from indanones: zinc-mediated allylation of ketones in aqueous media as a source of substituted indenyl ligand precursors*, *Eur. J. Org. Chem.* 2005, 14, 1058; (b) Izmer, V. V.; Lebedev, A. Y.; Nikulin, M. V.; Ryabov, A. N.; Asachenko, A. F.; Lygin, A. V.; Sorokin, D. A.; Voskoboynikov, A. Z.; *Palladium-Catalyzed Pathways to Aryl-Substituted Indenes: Efficient Synthesis of Ligands and the Respective ansa-Zirconocenes*, *Organometallics* 2006, 25, 1217.
- [31] (a) Maguire, A. R.; Papot, S.; Ford, A.; Touhey, S.; O'Connor, R.; Clynes, M.; *Enantioselective synthesis of Sulindac*, *Synlett* 2001, 41, 120; (b) Birman, V. B.; Zhao, Z.; Guo, L.; *Benzo[b]fluorenes via Indanone Dianion Annulation. A Short Synthesis of Prekinamycin*, *Org. Lett.* 2007, 25, 1223; (c) Fukatsu, K.; Uchikawa, O.; Kawada, M.; Yamano, T.; Yamashita, M.; Kato, K.; Miyamoto, M.; Ohkawa, S.; *Synthesis of a Novel Series of Benzocycloalkene Derivatives as Melatonin Receptor Agonists*, *J. Med. Chem.* 2002, 45, 4212; (d) Bonnefous, C.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; Daggett, L. P.; Kamenecka, T. M.; *Biphenyl-indanones: Allosteric potentiators of the metabotropic glutamate subtype 2 receptor*, *Bioorg. Med. Chem. Lett.* 2005, 15, 4354; (e) Kielsztein, L. M.; Bruno, A. M.; Renou, S. G.; Iglesias, G. Y. M.; *Design, synthesis, and biological evaluation of alcyopterosin A and illudalane derivatives as anticancer agents*, *Bioorg. Med. Chem.* 2006, 14, 1863; (f) Yin, W.; Ma, Y.; Xu, J.; Zhao, Y.; *Microwave-assisted one-pot synthesis of 1-indanones from arenes and α,β -unsaturated acyl chlorides*, *J. Org. Chem.* 2006, 71, 4312.
- [32] (a) Donnelly, D. M. X.; Boland, G. M.; *Isoflavonoids and neoflavonoids: naturally occurring o-heterocycles*, *Nat. Prod. Rep.* 1995, 12, 321; (b) Gaviiia, F.; Costero, A. M.;

- Gonzllez, A. M.; *Reactive annulenones: a comparative study*, J. Org. Chem. 1990, 55, 2060.
- [33] (a) Neugebauer, R. C.; Meier, R.; Hruby, H.; Valkov, V.; Verdin, E.; Sippl, W.; Jung, M.; *Structure-activity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode*, J. Med. Chem. 2008, 51, 1203; (b) Posakony, J.; Hirao, M.; Stevens, S.; Simon, J. A.; Bedalov, A.; *Evaluation of Splitomicin Analogues*, J. Med. Chem. 2004, 47, 2635.
- [34] (a) Prakash, G. K. S.; Paknia, F.; Vaghoo, H.; Rasul, G.; Mathew, T.; Olah, G. A.; *Preparation of Trifluoromethylated Dihydrocoumarins, Indanones, and Arylpropanoic Acids by Tandem Superacidic Activation of 2-(Trifluoromethyl)acrylic Acid with Arenes*, J. Org. Chem. 2010, 75, 2219; (b) Uchikawa, O.; Fukatsu, K.; Tokunoh, R.; Kawada, M.; Matsumoto, K.; Kato, K.; Hirai, K.; Miyamoto, M.; Ohkawa, S.; *Synthesis of a Novel Series of Tricyclic Indan Derivatives as Melatonin Receptor Agonists*, J. Med. Chem. 2002, 45, 4222. (c) Hikino, H.; Takahashi, T.; Arihara, S.; Takemoto, T.; *Structure of pteroside B, glycoside of Pteridium aquilinum var latiusculum*, Chem. Pharm. Bull. 1970, 18, 1488. (d) Syrchina, A. I.; Gorenysheva, O. N.; Biyushkin, V. N.; Malinovskii, T. I.; *Isolation of indanone from Equisetum arvense and its crystal and molecular structure*, Khim. Prir. Soedin. 1978, 21, 508.
- [35] (a) Shintani, R.; Takatsu, K.; Hayashi, T.; *Rhodium-catalyzed asymmetric synthesis of 3,3-disubstituted 1-indanones*, Angew. Chem. Int. Ed. 2007, 3735.
- [36] (a) Wenk, H. H.; Schwab, W.; *Biocatalytic production of dihydrocoumarin from coumarin by saccharomyces cerevisiae*, J. Agric. Food Chem. 2006, 32, 6236; (b) Ahn, J. H.; Shin, M. S.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Jung, W. H.; Yang, S. D.; Kim, S. J.; Woo, J. R.; Lee, J. H.; Cheon, H. G.; Kim, S. S.; *Indenone derivatives: A novel template for peroxisome proliferator-activated receptor γ (PPAR γ) Agonists*, J. Med. Chem. 2006, 21, 4781.
- [37] Cui, D. M.; Zhang, C.; Kawamura, M.; Shimada, S.; *Synthesis of 1-indanones by intramolecular Friedel-Crafts reaction of 3-arylpropionic acids catalyzed by Tb(OTf)₃*, Tetrahedron Lett. 2004, 26, 1741.
- [38] (a) Pellissier, H.; *Recent developments in the Nazarov process*, Tetrahedron 2005, 61, 6479; (b) Frontier, A.; Collison, C.; *The Nazarov cyclization in organic synthesis. Recent*

- advances*, Tetrahedron 2005, 61, 7577; (c) Clive, D. L. J.; Sannigrahi, M.; Hisaindee, S.; *Synthesis of (±)-Puraquinonic Acid: An Inducer of Cell Differentiation*, J. Org. Chem. 2001, 66, 954.
- [39] (a) Ma, J. A.; Cahard, D.; Mild Electrophilic Trifluoromethylation of β -Ketoesters and Silyl Enol Ethers with 5-Trifluoromethyldibenzothiophenium Tetrafluoroborate, J. Org. Chem. 2003, 68, 8726; (b) Umemoto, T.; Adachi, K.; *New Method for Trifluoromethylation of Enolate Anions and Applications to Regio-, Diastereo- and Enantioselective Trifluoromethylation*, J. Org. Chem. 1994, 59, 5692.
- [40] Sartori, G.; Maggi, R.; Bigi, F.; Porta, C.; Tao, X.; Ianelli, S.; Nardelli, M.; *Selective synthesis of 1-indanones via tandem Knoevenagel condensation-cycloalkylation of β -dicarbonyl compounds and aldehydes*, Tetrahedron 1995, 51, 12179.
- [41] (a) Ducki, S.; Rennison, D.; Woo, M.; Kendall, A.; Lawrence, N. J.; *Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivasular activity*, Bioorg. Med. Chem. 2009, 17, 7698; (b) Brekan, J. A.; Reynolds, T. E.; Scheidt, K. A.; *Enantioselective synthesis of substituted indanones from silyloxyallenes*, J. Am. Chem. Soc. 2010, 132, 1472.
- [42] (a) Lee, B. H.; Choi, Y. L.; Shin, S.; Heo, J. -N.; *Stereoselective palladium-catalyzed α -arylation of 3-Aryl-1-indanones: An asymmetric synthesis of (+)-Pauciflorol F*, J. Org. Chem. 2011, 76, 6611.
- [43] Coyanis, E. M.; Panayides, J. L.; Fernandes, M. A.; van Otterlo, W. A. L.; *Ring-closing metathesis for the synthesis of substituted indenols, indenones, indanones and indenes: tandem RCM-dehydrogenative oxidation and RCM-formal redox isomerization*, J. Organomet. Chem. 2006, 691, 5222.
- [44] (a) Saito, A.; Umakoshi, M.; Yagyu, N.; Hanzawa, Y.; *Novel One-Pot Approach to Synthesis of Indanones through Sb(V)-Catalyzed Reaction of Phenylalkynes with Aldehydes*, Org. Lett. 2008, 10, 1783; (b) Gold, A.; Schultz, J.; Eisenstadt, E.; Tetrahedron Lett. 1978, 19, 4491; (c) Zhang, W.; Cao, X.; Zi, H.; Pei, J.; *Single-molecule nanosized polycyclic aromatics with alternant five- and six-membered rings: Synthesis and optical properties*, Org. Lett. 2005, 7, 959.

- [45] (a) Satchell, D. P. N.; *Acylation. II. H. Friedel-Crafts acylation, with stannic chloride as catalyst, in solvents of low dielectric constant*, J. Chem. Soc. 1961, 23, 5404; (b) Melvyn, G.; *An efficient Friedel-Crafts synthesis of 2-acylbenzofurans*, Tetrahedron 1984, 40, 621.
- [46] (a) Popp, F. D.; McEwen, W. E.; *Polyphosphoric acid as a reagent in organic chemistry*, Chem. Rev. 1958, 58, 321; (b) Guy, A.; Guette, J.; *Utilization of polyphosphoric acid in the presence of a cosolvent*, Synthesis 1980, 18, 222; (c) Braun, M.; *A regioselective synthesis of daunomycinone and related anthracyclines*, Tetrahedron 1984, 40, 4585.
- [47] Premasagar, V.; Palaniswamy, V. A.; Eisenbraun, E. J.; *Methanesulfonic acid catalyzed cyclization of 3-arylpropanoic and 4-arylbutanoic acids to 1-indanones and 1-tetralones*, J. Org. Chem. 1981, 46, 2974.
- [48] Posner, G. H.; Chapdelaine, M. J.; Lentz, C. M.; *Short, simple, stereocontrolled, steroid synthesis: (\pm)-11-oxoequilenin methyl ether and a new 9,11-seco-13-ethyl steroid*, J. Org. Chem. 1979, 44, 3661.
- [49] Johnson, W. S.; Glenn, H. J.; *Intramolecular acylation. II. The inverse Friedel-Crafts method*, J. Am. Chem. Soc. 1949, 71, 1092.
- [50] Ragan, J. A.; Murry, J. A.; Castaldi, M. J.; Conrad, A. K.; Jones, B. P.; McDermott, R.; Sitter, B. J.; White, T. D.; Young, G. R.; *Investigation of methods for seven-membered ring synthesis: A practical synthesis of 4-Oxo-5,6,7,8-tetrahydro-4H-cyclohepta[b]furan-3-carboxylic acid*, Org. Process Res. Dev. 2001, 5, 498.
- [51] (a) Yamato, T.; Hideshima, C.; Prakash, G. K.; Olah, G. A.; *Organic reactions catalyzed by solid superacids. 5. Perfluorinated sulfonic acid resin (Nafion-H) catalyzed intramolecular Friedel-Crafts acylation*, J. Org. Chem. 1991, 56, 3955; (b) Olah, G. A.; Mathew, T.; Prakash, G. K.; *Catalysis by solid superacids. Part 33. Nafion-H catalyzed intramolecular Friedel-Crafts acylation. Formation of cyclic ketones and related heterocycles*, Synlett 1999, 21, 1067.
- [52] (a) Ahmed, N.; van Lier, J. E. *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 13; (b) Ahmed, N.; van Lier, J. E. *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 5345 (c) Ahmed, N.; Konduru, N. K. *Efficient, highly diastereoselective MS 4 Å-promoted*

one-pot, three-component synthesis of 2, 6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization, *Beilstein J. Org. Chem.* 2012, 8, 177.

- [53] (a) Kiasat, A. R.; Badri, R.; Zargar, B.; Sayyahi, S.; *Poly(ethylene glycol) Grafted onto Dowex Resin: An efficient, recyclable, and mild polymer-supported phase transfer catalyst for the regioselective azidolysis of epoxides in Water*, *J. Org. Chem.* 2008, 73, 8382; (b) Kim, H. Y.; Talukdar, A.; Cushman, M.; *Regioselective synthesis of N- β -hydroxyethylaziridines by the ring-opening reaction of epoxides with Aziridines generated in Situ*, *Org. Lett.* 2006, 8, 1085; (c) McCluskey, A.; Leitch, S. K.; Garner, J.; Caden, C. E.; Stewart, S. G.; *BiCl₃-mediated opening of epoxides, a facile route to chlorohydrins or amino alcohols: one reagent, two paths*, *Tetrahedron Lett.* 2005, 46, 8229; (d) Wang, Z.; Cui, Y. T.; Xu, Z-B.; Qu, J.; *Hot Water-Promoted Ring-Opening of Epoxides and Aziridines by Water and Other Nucleophiles*, *J. Org. Chem.* 2008, 73, 2270; (e) Singh, M. C.; Peddinti, R. K.; *Antimony(III) chloride-catalyzed ring opening of epoxides with anilines*, *Tetrahedron Lett.* 2007, 48, 7354; (f) Kalow, J. A.; Doyle, A. G.; *Enantioselective ring opening of epoxides by fluoride anion promoted by a cooperative dual-catalyst system*, *J. Am. Chem. Soc.* 2010, 132, 3268.
- [54] Lattanzi, A.; *Enantioselective Epoxidation of α,β -Enones Promoted by α,α -Diphenyl-L-prolinol as Bifunctional Organocatalyst*, *Org. Lett.* 2005, 7, 2579.

CHAPTER- 3

Part-A: Zn-SnCl₄: A novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins

Gulab Khushalrao Pathe and Naseem Ahmed*, *Tetrahedron Letters* **2015**, *56*, 1555-1561.

Part-B: Design, Synthesis of McMurry cross-coupled indanophen, analogs of Tamoxifen by novel SnCl₄-Zn reagent and Anti-Proliferative Evaluation of Flavone-Estradiol adduct and Indanone based Ligands against Breast Cancer Cell Line

Gulab Khushalrao Pathe, Naveen Konduru, Iram Parveen and Naseem Ahmed*, *European Journal of Medicinal Chemistry* **2015**, Under Review.

Part A: SnCl₄ - Zn: A novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins

4.1. INTRODUCTION

In the carbon-carbon bond formation, the McMurry reaction plays an important role to obtain homo and cross-coupled alkenes from aliphatic and aromatic aldehydes and ketones in the presence of *in situ* generated low valent titanium (LVT) reagents at reflux temperature.[1] However, the reaction gave a moderate yield due to homo and cross-coupled products formation. To enhance the yield of cross-coupled products under mild reaction conditions, different reagents are explored for the McMurry reaction. For example, magnesium-mercury couple, NbCl₅/NaAlH₄,[2] zinc-copper couple,[3] LiAlH₄,[4] dicyclopentadienyl titaniumdichloride,[5] trimethyl aluminium.[6] Although, these procedures have drawbacks like costly reagents, low yield, longer reaction time and/or less functional group tolerance. In recent years, tin tetrahalides (SnX₄, X=Cl, Br) have been widely used as Lewis acids in numerous organic syntheses.[7] In many cases, these metal halides have been reported as efficient catalysts and easy to handle as compare to other metal halides such as TiX₄, AlX₃, ZnX₂ and ZrX₄. [8]

Generally, metal alloy is used as reductive deoxygenating agent in the organic synthesis for coupling reactions. For example, zinc alloy is prepared by mixing of zinc and SnCl₄ in 2:1 ratio following the Rieck method.[9] Where metals like Zn involves reduction of an oxidized metal species by enhancing the reactivity of zinc at the surface of the alloy. The reductive deoxygenating reagents may also be generated *in situ* by reaction of two equivalent of zinc dust with one equivalent metal chloride under refluxing temperature in ether or hydrocarbon solvents. In the case of McMurry reaction reagent Ti (IV) reduced to Ti (II) with reducing agent Zn in THF, which generate a complex TiCl₄ -Zn-(THF)₂ *in situ*. [10, 11] which is responsible for the coupling of aldehyde or ketone to pinacolate, followed by removal of TiO₂ gave olefins. [12] Likewise, it might be taking place in SnCl₄-Zn and THF to form a complex SnCl₄-Zn-(THF)₂ for the coupling of aldehydes or ketones. Initially Sn(IV) converted into Sn(II) by reduction of tin halide with Zn, Sn(II) converted carbonyl oxygen to pinacolate, followed by removal of SnO₂ gave olefins.

Therefore, in continuation of our interest to develop new methods in the organic synthesis and the acid catalysis reactions.[13] Herein, we report a novel and efficient reagent, SnCl₄-Zn

system for the McMurry cross-coupling reaction in the conversion of aliphatic and aromatic ketones, aldehydes, chalcone epoxides and indanones into olefins and also useful in the synthesis of molecules like tamoxifen analogs in good yield within 4-4.5 h at reflux temperature.

4.2. OBJECTIVE

The McMurry reaction plays an important role in the carbon- carbon bonds formation, in which aliphatic and aromatic aldehydes and ketones undergo eliminative deoxygenation to gave homo and cross-coupled alkenes by using low valent titanium (LVT) reagents at reflux temperature. Several reagents explored for the McMurry reaction to enhance the cross-coupled products formation over the homo-coupled. Therefore, in continuation of our interest to develop new methods in the organic synthesis and the acid catalysis reactions. Hence, our aim is to find a novel and efficient reagent for McMurry reaction, we observed that SnCl₄-Zn system for the McMurry cross-coupling reaction in the conversion of aliphatic and aromatic ketones, aldehydes, chalcone epoxides and indanones into olefins and also useful in the synthesis of molecules like tamoxifen analogs in good yield within 4-4.5 h at reflux temperature.

4.3. RESULTS AND DISCUSSION


4.3.1. Optimized reaction condition

Initially, we optimized the cross-coupling reaction conditions in the reaction of chalcone epoxide **1** and propiophenone **2** used in 1:1.5 ratio and varying the equivalents of SnCl₄-Zn (prepared in 1:2 ratio). We obtained the cross-coupled product in 50% and 55% yields in 4h using 1 and 2 equivalent of SnCl₄-Zn respectively (Table1, entries 1 & 2). When SnCl₄-Zn was used in 3 equivalents, the yield was serendipitously improved up to 75% in 4h (Table1, entry 3). Further, increase in SnCl₄-Zn equivalent decreased the yields of the cross-coupled product and increased the homo-coupled products (Table 1, entries 4 & 5).

We optimized the reaction time, by using optimized condition of table 1, we checked the progress of reaction from 1h-3h to get only 20 to 60% of conversion at reflux temperature (Table 2, entries 1-3).Further increasing time from 3h to 4h gave a very good yield up to 75% (Table 2, entry 4). And further increase in time from 4 to 5h decreased in product yield to 35% (Table 2, entry 5). After separating the homo-coupled products, we also determined the formation of E and Z isomers in the cross-coupled product where E-isomer and Z- isomer were

found as major and minor products respectively. Due to the closed R_f -values of *Z*- isomers with byproducts, we were unable to separate the *Z*- isomers by the column chromatography. However, the yields of *Z*- isomers were confirmed by GC analysis which is ranging between 2-5%.


Table 1. Optimized condition for cross-coupling reaction by using different equivalent of $\text{SnCl}_4\text{-Zn}$



Entry	$\text{SnCl}_4\text{-Zn}$	Time (h)	Yield (%) ^a
1	$\text{SnCl}_4\text{-Zn}$ (1 equiv.)	4	50
2	$\text{SnCl}_4\text{-Zn}$ (2 equiv.)	4	55
3	$\text{SnCl}_4\text{-Zn}$ (3 equiv.)	4	75
4	$\text{SnCl}_4\text{-Zn}$ (3.5 equiv.)	4	60
5	$\text{SnCl}_4\text{-Zn}$ (4 equiv.)	4	35

^aIsolated yield of cross-product

Table 2. Optimized condition for cross-coupling reaction by varying reaction time




Entry	$\text{SnCl}_4\text{-Zn}$	Time (h)	Yield (%) ^a
1	$\text{SnCl}_4\text{-Zn}$ (3equiv.)	1	20
2	$\text{SnCl}_4\text{-Zn}$ (3 equiv.)	2	35
3	$\text{SnCl}_4\text{-Zn}$ (3 equiv.)	3	60
4	$\text{SnCl}_4\text{-Zn}$ (3 equiv.)	4	75
5	$\text{SnCl}_4\text{-Zn}$ (3 equiv.)	5	65

^aIsolated yield of cross-product

Under optimal reaction conditions, the efficiency of different McMurry reagents was compared (Table 3). Aluminium and Indium complexes gave poor products yield (20%) at

reflux in 14 h (Table 3, entries 1, 2). However, the titanium complex (TiCl₄-Zn-THF) gave the yield (40%) at reflux temperature in 6 h (Table 3, entry 3), while the tin complex (SnCl₄-Zn-THF) gave the optimal yield (75%) at reflux temperature within 4 h (Table 3, entry 4). Other reagents gave poor yield (traces to 20-25 %) in acetonitrile solvent (Table 3, entries 5, 6, 7 & 8).

Table 3. Comparison of McMurry reagents and solvents in McMurry cross-coupling of chalcone epoxide and propiophenone



Entry	McMurry reagents	Time (h)	Yield (%) ^a
1 ^b	AlCl ₃ -Zn (3 equiv.)	14	20
2 ^b	InCl ₃ -Zn (3 equiv.)	14	20
3 ^b	TiCl ₄ -Zn (3 equiv.)	6	60
4 ^b	SnCl ₄ -Zn (3 equiv.)	4	75
5 ^c	AlCl ₃ -Zn (3 equiv.)	14	trace
6 ^c	InCl ₃ -Zn (3 equiv.)	14	trace
7 ^c	TiCl ₄ -Zn (3 equiv.)	14	20
8 ^c	SnCl ₄ -Zn (3 equiv.)	14	25


^a Isolated yield of cross-product at 64-66 °C.

^b reaction performed in THF

^c reaction performed in Acetonitrile

4.3.2. Deoxygenative cross-coupling of aromatic ketone and aldehyde with acetone

In the case of aromatic aldehydes or aromatic ketones **7a-7c** with acetone (1:1.5 ratio) and SnCl₄-Zn (1:2 ratio) gave the corresponding cross-coupled olefin **2ab-2ad** in excellent yield 80-85% along with minor homo-coupled product **3aa-3cc** and **4aa** in yield 8-10% at reflux temperature within 1 h (Scheme 1). The reaction of aromatic aldehydes or aromatic ketones **8a-8g** with SnCl₄-Zn (1:2 ratio) gave the homo-coupled olefins **8a-8g** in excellent yield 70-86% at reflux temperature within 1 hour. Products **9a-9g** was characterized on the basis of their spectral data IR, ¹H NMR and melting point and comparing it with those of authentic samples.




Entry	R ¹	R ²	Time (h)	Yield (%) ^a
1	PH	H	2	80(11ab)
2	PH	CH ₃	2	77(11ac)
3	PH	PH	2	70(11ad)

^aIsolated product yield.

4.3.3. Deoxygenative cross-coupling of chalcone epoxides with propiophenone

The tin reagent (SnCl₄-Zn) was further applied as an alternate reagent in the McMurry reaction for the synthesis of various classes of carbonyl compounds. For example, the cross-coupled products **12ab-12ak** was obtained in good yield (55-75%) from different chalcone epoxides **11a-11j** and propiophenone **11** under optimized reaction conditions (table 4). Along with major cross-coupled product some minor homo-coupled products **13aa-13jj** and **14bb** were obtained in 8-10% yields. These homo-coupled products were isolated and the yields of product were written as isolated yields. The products were characterized on the basis of their spectral data. In ¹H NMR spectra, the characteristic doublet signal appeared for **12ab-12ak** in the range of δ 3.85-3.20 ppm, whereas for the compounds **11a-11j** was obtained in the range of δ 4.30-4.20 ppm, the characteristic quartet and triplet signal of -CH₂CH₃ appeared in between δ 0.80-2.5 ppm, indicates the cross-coupling reactions (Experimental section).

Table 4. SnCl₄-Zn mediated deoxygenative cross-coupling of chalcone epoxides with propiophenone



Entry	11a-11j	11	Cross-coupled products (12ab-12ak)	Homo-coupled products		Time (h)	Yield (%) ^a
				13aa-13jj	14bb		
1				8	10	4	66
2				9	8	4	60
3				10	9	4	64
4				8	8	4.5	58
5				10	10	4.5	55
6				9	8	4	75

7				10	9	4	72
8				9	9	4	70
9				10	10	4.5	68
10				10	9	4.5	67

^a Isolated yield of cross-product at 64-66 °C.

4.3.4. Synthesis of Tamoxifen analogs


The tin reagent ($\text{SnCl}_4\text{-Zn}$) was also successfully used in the synthesis of tamoxifen and tamoxifen analogs (Table 5). Products **12al-12ao** were synthesized in good yield 58- 72% at reflux temperature in 4-5 h using $\text{SnCl}_4\text{: Zn}$ (1:2 equiv.) and the products were confirmed on the basis of their spectral data (supporting information). For example, product **12al**, the ^1H NMR spectra showed the characteristic double doublet peaks at δ 4.70- 4.60 ppm for CH-CH which shifted from δ 5.30- 5.23 ppm in the indanone molecule and the characteristic quartet and triplet peaks of $-\text{CH}_2\text{CH}_3$ protons appeared at δ 0.90- 2.30 ppm, indicated the cross-coupling product.[14] The structures of all other compounds were further confirmed by IR and HRMS.

Table 5. Synthesis of Tamoxifen analogs (E isomers) of indanone using novel $\text{SnCl}_4\text{-Zn}$ reagent


4.3.5. Determination of E and Z-Tamoxifen analogs

Compounds **4ab-4ac** and **5ab-5ac** were synthesized as a mixture of E and Z isomers which can be separated by using column chromatography and by comparing their spectral values in the literature. We observed that the E isomer is the major isomer with 52-55% yields and Z isomer is the minor product with 8-10% yields in 5 h, using SnCl₄: Zn (1:2 equiv.) in indanone and propiophenone (1: 1.5 equiv.). The ¹HNMR chemical shift (δ) 1.0-1.3 ppm for -CH₃ and 2.0-2.3 ppm for -CH₂ indicated the E isomer of products **13ab-13ac** and δ 0.6-0.7 ppm for -CH₃ and 1.6-1.9 ppm for -CH₂ gave the Z isomer for products **14ab-14ac**. Similarly, ¹³CNMR chemical shift (δ) 13-15 ppm for -CH₃ and 27-28 ppm for -CH₂ indicated the E isomer for products **13ab-13ac** and δ 10-12 ppm for -CH₃ and 23-25 ppm for -CH₂ gave the Z isomer in **14ab-14ac**.^[15] Similarly, products **12ab-12ao** was characterized as E-isomer. The NMR chemical shift (δ) values of -CH₂CH₃ in products **12ab-12ao** is matches with the **13ab-13ac** (E-isomer) and not with **14ab-14ac** (Z-isomer). We were unable to isolate the Z-isomer due to close R_f values with other byproducts. However, the yields of Z-isomers were confirmed by GC analysis which is ranging between 2-5%.

Table 6. Determination of E and Z-Tamoxifen analogs by using novel SnCl₄-Zn reagent



Entry	Indanone	E-Analog ^a	Z-Analog ^a	Time (h)
1		 13ab yield- 55%	 14ab yield-8%	5



^aIsolated yield of E and Z isomers.

4.4. CONCLUSION

In conclusion, we have reported a novel, efficient and economical tin-reagent for the reductive cross-coupling reaction of carbonyl compounds, known as McMurry coupling with aliphatic and aromatic ketones, aldehydes, chalcone epoxides and indanones in high yield with minor homo-coupling products. To our knowledge, no studies exploiting this reagent for such conversion have previously been reported.

4.5. EXPERIMENTAL DETAILS


Materials and methods. All the required chemicals were purchased from Merck and Aldrich Chemical Company. Pre-coated aluminium sheets (silica gel 60 F₂₅₄, Merck) were used for thin-layer chromatography (TLC) and spots were visualized under UV light. IR spectra were recorded with KBr on Thermo Nicolet FT-IR spectrophotometer. ¹H NMR and ¹³C NMR spectra were recorded respectively on Bruker Spectrospin DPX 500 MHz and Bruker Spectrospin DPX 125 MHz spectrometer using CDCl₃ as a solvent and trimethylsilane (TMS) as an internal standard. Splitting patterns are designated as follows; s, singlet; d, doublet; m, multiplet. Chemical shift values are given in ppm.

4.5.1. General procedure for the synthesis compounds 2ab-2ad/9a-9g/11ab-11ad/12ab-12ao/13ab-13ac & 14ab-14ac:


Under N₂ atmosphere, a three neck flask equipped with magnetic stirrer was charged with Zn-powder (1.5gm, 12 mmol) and 50 mL THF solvent. The mixture was cooled at 0 °C and SnCl₄ (2.3mL, 6 mmol) was added drop wise at 0 °C. The suspension was warmed to room temperature and stirred for 15 min and then heated at 64-66 °C for 1.5 h. The solution of aromatic aldehyde or ketone **10a-10c** /chalcone epoxide **11a-11j**/ indanone and propiophenone derivatives (1:1.5 molar ratio, 2 mmol) dissolved in THF (30 mL) was added slowly at same temperature. TLC monitoring, the reaction mixture was stirred at same temperature until the carbonyl compound was consumed in the reaction. Then, the reaction mixture was cooled and

quenched with 10% aqueous NaHCO₃ solution and extracted in EtOAc. The organic layer was washed with brine solution, dried with anhydrous Na₂SO₄ and concentrated in *vacuo*. The crude material was purified by column chromatography to give the desired products **2ab-2ad/9a-9g/11ab-11ad/12ab-12ao/13ab-13ac & 14ab-14ac** in 55-86 % yields.


4.5.2. SPECTRAL DATA OF SYNTHESIZED COMPOUNDS




(2-methylprop-1-en-1-yl)benzene (2ab): White solid; Yield: (111 mg, 85%); **IR** ν_{\max} (**KBr**, cm^{-1}): 3083 (aliphatic, =C-H str), 2946 (aromatic C-H str), 1655 (aliphatic, C=C str), 1582 (aromatic, C=C str), 1391, 1280, 1062, 864; **¹H-NMR** (**CDCl₃**, 500 MHz) δ (**ppm**): 7.91 (t, $J = 7.0$ Hz, 2H), 7.52 (dd, $J = 1.5, 8.0$ Hz, 2H), 7.41 (dd, $J = 1.5, 8.0$ Hz, 2H), 1.91 (s, 3H); **¹³C-NMR** (**CDCl₃**, 125 MHz) δ (**ppm**): 138.82, 135.76, 129.03, 128.97, 128.68, 127.65, 25.66, 19.65; **HRMS (ES-TOF)** calcd for C₁₀H₁₂ 132.0939, found 132.0941.




(3-methylbut-2-en-2-yl)benzene (2ac): White solid; Yield: (119 mg, 82%); **IR** ν_{\max} (**KBr**, cm^{-1}): 2975 (aromatic C-H str), 1680 (aliphatic, C=C str), 1578 (aromatic, C=C str), 1392, 1270, 1072, 845; **¹H-NMR** (**CDCl₃**, 500 MHz) δ (**ppm**): 7.31 (t, $J = 7.0$ Hz, 1H), 7.12 (t, $J = 6.5$ Hz, 2H), 6.81 (dd, $J = 1.5, 8.0$ Hz, 2H), 2.56 (s, 3H), 1.95 (s, 6H); **¹³C-NMR** (**CDCl₃**, 125 MHz) δ (**ppm**): 145.54, 139.76, 129.65, 128.97, 128.68, 127.03, 22.90, 12.77; **HRMS (ES-TOF)** calcd for C₁₁H₁₄ 146.1096, found 146.1098.




(2-methylprop-1-ene-1,1-diyl)dibenzene (2ad): White solid;; Yield: (165 mg, 80%); **IR** ν_{\max} (**KBr**, cm^{-1}): 2962 (aromatic C-H str), 1667 (aliphatic, C=C str), 1568 (aromatic, C=C str), 1390, 1284, 1065, 835; **¹H-NMR** (**CDCl₃**, 500 MHz) δ (**ppm**): 7.52 (t, $J = 8.0$ Hz, 4H), 7.31 (t, $J = 7.0$ Hz, 4H), 7.11 (dd, $J = 1.5, 6.5$ Hz, 2H), 1.92 (s, 6H); **¹³C-NMR** (**CDCl₃**, 125 MHz) δ (**ppm**): 141.76, 138.77, 128.97, 128.65, 127.66, 19.65; **HRMS (ES-TOF)** calcd for C₁₆H₁₆ 208.1252, found 208.1250.




1,2-diphenylethene (9c): White solid; Yield: (153 mg, 85%); **IR** ν_{\max} (**KBr**, cm^{-1}): 3083 (aliphatic, =C-H str), 2948 (aromatic C-H str), 1648 (aliphatic, C=C str), 1580 (aromatic, C=C str), 1393, 1280, 1062, 864; **¹H-NMR** (**CDCl₃**, 500 MHz) δ (**ppm**): 7.82 (t, $J = 8.0$ Hz, 4H), 7.62 (dd, $J = 1.0, 7.0$ Hz, 2H), 7.50 (t, $J = 7.5$ Hz, 4H), 7.00 (s, 2H); **¹³C-NMR** (**CDCl₃**, 125 MHz) δ (**ppm**): 162.68, 133.58, 130.68, 127.35, 115.78; **HRMS (ES-TOF)** calcd for C₁₄H₁₂ 180.0939, found 180.0940.




4,4'-(but-2-ene-2,3-diyl)bis(fluorobenzene) (9d): White solid; Yield: (174 mg, 83%); IR ν_{\max} (KBr, cm^{-1}): 2955 (aromatic C-H str), 1674 (aliphatic, C=C str), 1574 (aromatic, C=C str), 1396, 1277, 1074, 855; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.87-7.84 (m, 4H), 7.16 (t, $J = 8.5$ Hz, 4H), 6.94 (s, 2H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 137.65, 129.97, 129.68, 128.66, 127.97; HRMS (ES-TOF) calcd for $\text{C}_{16}\text{H}_{14}\text{F}_2$ 244.1064, found 244.1064.




4,4'-(but-2-ene-2,3-diyl)bis(chlorobenzene) (9e): White solid; Yield: (193 mg, 80%); IR ν_{\max} (KBr, cm^{-1}): 2958 (aromatic C-H str), 1665 (aliphatic, C=C str), 1568 (aromatic, C=C str), 1399, 1288, 1062, 830; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.95 (t, $J = 7.0$ Hz, 4H), 7.56 (dd, $J = 1.0, 7.5$ Hz, 4H), 6.95 (s, 2H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 135.65, 133.58, 129.67, 128.68, 127.77; HRMS (ES-TOF) calcd for $\text{C}_{16}\text{H}_{14}\text{Cl}_2$ 276.0473, found 276.0473.



4,4'-(but-2-ene-2,3-diyl)bis(methylbenzene) (9f): White solid; Yield: (165 mg, 70%); IR ν_{\max} (KBr, cm^{-1}): 2960 (aromatic C-H str), 1665 (aliphatic, C=C str), 1570 (aromatic, C=C str), 1397, 1278, 1072, 852; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.75 (t, $J = 7.0$ Hz, 4H), 7.25 (dd, $J = 1.5, 8.0$ Hz, 4H), 6.96 (s, 2H), 2.39 (s, 6H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 137.65, 135.53, 129.67, 128.68, 127.77, 21.65; HRMS (ES-TOF) calcd for $\text{C}_{18}\text{H}_{20}$ 236.1565, found 236.1566.




4,4'-(but-2-ene-2,3-diyl)bis(methoxybenzene) (9g): White solid; Yield: (231 mg, 86%); IR ν_{\max} (KBr, cm^{-1}): 2957 (aromatic C-H str), 1668 (aliphatic, C=C str), 1568 (aromatic, C=C str), 1395, 1283, 1065, 833; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.55 (t, $J = 7.0$ Hz, 4H), 7.05 (dd, $J = 1.5, 8.0$ Hz, 4H), 6.90 (s, 2H), 3.19 (s, 6H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 162.42, 133.92, 130.66, 127.51, 115.78, 55.78; HRMS (ES-TOF) calcd for $\text{C}_{18}\text{H}_{20}\text{O}_2$ 268.1463, found 268.1463.




but-1-ene-1,2-diyl dibenzene (11ab): Light yellow semi solid; Yield: (155 mg, 80%); IR ν_{\max} (KBr, cm^{-1}): 3080 (aliphatic, =C-H str), 2950 (aromatic C-H str), 1644 (aliphatic, C=C str), 1582 (aromatic, C=C str), 1391, 1278, 1062, 860; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.78 (t, $J = 7.5$ Hz, 2H), 7.49 (dd, $J = 1.5, 7.0$ Hz, 2H), 7.39 (t, $J = 7.0$ Hz, 2H), 7.08 (t, $J = 7.0$ Hz, 2H), 6.96 (t, $J = 7.0$ Hz, 2H), 6.46 (s, 1H), 2.07 (q, J

=2.0, 8.0 Hz, 2H), 1.18 (t, $J = 7.0$ Hz, 3H), ^{13}C -NMR (CDCl_3 , 125 MHz) δ (ppm): 142.32, 138.46, 137.44, 128.95, 127.97, 126.66, 28.35, 12.97; MS (EI, 70eV): m/z (%) = 195 $[\text{M}]^+$, for $\text{C}_{15}\text{H}_{15}$; HRMS (ES-TOF) calcd for $\text{C}_{15}\text{H}_{15}$ 195.1174, found 195.1172.




pent-2-ene-2,3-diyl dibenzene (11ac): Light brown semi solid; Yield: (171 mg, 77%); IR ν_{max} (KBr, cm^{-1}): 2958 (aromatic C-H str), 1678 (aliphatic, C=C str), 1572 (aromatic, C=C str), 1395, 1278, 1072, 850; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 7.49 (dd, $J = 1.5, 7.0$ Hz, 2H), 7.39 (t, $J = 7.5$ Hz, 4H), 6.96 (t, $J = 8.0$ Hz,

4H), 2.44 (s, 3H), 2.12 (q, $J = 2.0, 7.5$ Hz, 2H), 1.17 (t, $J = 7.0$ Hz, 3H), ^{13}C -NMR (CDCl_3 , 125 MHz) δ (ppm): 146.54, 144.47, 142.32, 129.68, 128.66, 127.97, 126.95, 28.35, 14.28, 12.95; MS (EI, 70eV): m/z (%) = 222 $[\text{M}]^+$, for $\text{C}_{17}\text{H}_{18}$; HRMS (ES-TOF) calcd for $\text{C}_{17}\text{H}_{18}$ 222.1409, found 222.1411.



But-1-ene-1,1,2-triyl tribenzene (11ad): Yellow semi solid; Yield: (198 mg, 70%); IR ν_{max} (KBr, cm^{-1}): 2958 (aromatic C-H str), 1665 (aliphatic, C=C str), 1568 (aromatic, C=C str), 1399, 1288, 1062, 830; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 7.88 (dd, $J = 2.5, 7.5$ Hz, 4H), 7.78 (t, $J = 8.5$ Hz, 4H), 7.48 (t, $J = 7.5$ Hz,

2H), 7.34 (t, $J = 8.0$ Hz, 2H), 6.80 (t, $J = 8.0$ Hz, 2H), 2.10 (q, $J = 2.5, 8.0$ Hz, 2H), 0.98 (t, $J = 7.0$ Hz, 3H); ^{13}C -NMR (CDCl_3 , 125 MHz) δ (ppm): 140.51, 139.41, 129.12, 128.68, 128.36, 128.12, 127.85, 127.78, 126.28, 26.66, 13.68; MS (EI, 70eV): m/z (%) = 284 $[\text{M}]^+$, for $\text{C}_{22}\text{H}_{20}$; HRMS (ES-TOF) calcd for $\text{C}_{22}\text{H}_{20}$ 284.1565, found 284.1563.




2-(4-chlorophenyl)-3-(1-(4-chlorophenyl)-2-phenylbut-1-en-1-yl) oxirane (12ab): Light brown semi Solid; Yield: (260 mg, 66 %); IR ν_{max} (KBr, cm^{-1}): 2937, 2878 (aromatic C-H str), 1588 (aromatic, C=C str), 1268, 1090, 868, 735; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 8.18-8.06 (m, 3H), 7.87 (t, $J = 8.0$ Hz, 2H), 7.48 (dd, $J = 1.5, 8.5$ Hz, 2H), 7.39 (d, $J = 8.5$ Hz, 2H), 7.30 (m, 2H),

6.88-6.85 (m, 2H), 3.60 (d, $J = 1.5$ Hz, 1H), 3.47 (d, $J = 1.5$ Hz, 1H), 2.19 (q, $J = 2.5, 8.0$ Hz, 2H), 1.07 (t, $J = 7.0$ Hz, 3H); ^{13}C -NMR (CDCl_3 , 125 MHz) δ (ppm): 144.35, 143.27, 137.95, 132.55, 132.49, 131.65, 130.49, 130.47, 130.05, 129.65, 128.97, 128.77, 128.66, 127.66, 67.72, 61.05, 27.05, 12.95; MS (EI, 70eV): m/z (%) = 394 $[\text{M}]^+$, for $\text{C}_{24}\text{H}_{20}\text{Cl}_2\text{O}$, 396 $[\text{M}+2\text{H}]^+$; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{20}\text{Cl}_2\text{O}$ 394.0891, found 394.0893.


2-(1-(4-chlorophenyl)-2-phenylbut-1-en-1-yl)-3-(3,4,5-trimethoxyphenyl)oxirane (12ac): Light yellow semi solid; Yield: (269 mg, 60 %); IR ν_{max} (KBr, cm^{-1}): 2952 (aromatic C-H str),

1582 (aromatic, C=C str), 1393, 1277, 1060, 856; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 8.00



(d, $J = 8.5$ Hz, 2H), 7.61 (d, $J = 8.5$ Hz, 2H), 7.03 (d, $J = 8.5$ Hz, 1H), 6.98 (d, $J = 8.5$ Hz, 1H), 6.80 (t, $J = 9$ Hz, 1H), 6.76 (d, $J = 7.5$ Hz, 1H), 6.49 (dd, $J = 2, 7$ Hz, 1H), 3.91 (s, 6H), 3.89 (s, 3H), 3.62 (d, $J = 2$ Hz, 1H), 3.46 (d, $J = 2$ Hz, 1H), 2.10 (q, $J = 2, 7.5$ Hz, 2H), 1.17 (t, $J = 7$ Hz, 3H) $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 156.27, 141.54, 137.76, 132.54,


132.47, 131.77, 130.65, 130.49, 130.05, 129.65, 128.97, 128.68, 128.66, 127.03, 100.06, 67.82, 64.13, 60.33, 54.52, 28.95, 14.05; **MS (EI, 70eV)**: m/z (%) = 450 $[\text{M}]^+$, for $\text{C}_{27}\text{H}_{27}\text{ClO}_4$; **HRMS (ES-TOF) calcd** for $\text{C}_{27}\text{H}_{27}\text{ClO}_4$ 450.1598, found 450.1596.



2-(1-(4-bromophenyl)-2-phenylbut-1-en-1-yl)-3-(p-tolyl) oxirane (12ad):

Light yellow semi solid; Yield: (267 mg, 64 %); **IR** ν_{max} (KBr , cm^{-1}): 2922 (aromatic C-H str), 1594 (aromatic, C=C str), 1491, 1399, 1296, 1095; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.92-7.90 (m, 2H), 7.66 (dd, $J = 1.5, 6.5$ Hz, 2H), 7.29-7.23 (m, 4H), 6.91-6.86 (m, 3H), 6.47 (t, $J = 7.5$ Hz, 2H), 3.84

(d, $J = 2$ Hz, 1H), 3.66 (d, $J = 2$ Hz, 1H), 2.41 (s, 3H), 2.09 (q, $J = 2.0, 7.0$ Hz, 2H), 1.19 (t, $J = 6.5$ Hz, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 143.45, 143.05, 134.31, 129.74, 129.52, 128.65, 127.93, 127.69, 127.65, 126.76, 125.75, 125.48, 125.18, 124.07, 68.56, 62.95, 28.01, 21.54, 13.47; **MS (EI, 70eV)**: m/z (%) = 418 $[\text{M}]^+$, for $\text{C}_{25}\text{H}_{23}\text{BrO}$, 420 $[\text{M}+2\text{H}]^+$; **HRMS (ES-TOF) calcd** for $\text{C}_{25}\text{H}_{23}\text{BrO}$ 418.0932, found 418.0929.




2-(1-(4-chlorophenyl)-2-phenylbut-1-en-1-yl)-3-(3,4-

dimethylphenyl)oxirane (12ae): Light yellow semi solid; Yield: (223 mg, 58 %); **IR** ν_{max} (KBr , cm^{-1}): 2925 (aromatic C-H str), 1594 (aromatic, C=C str), 1399, 1289, 1091, 845; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.70-7.62 (m, 3H), 7.50-7.47 (m, 2H), 7.36-7.29 (m, 3H), 6.88-6.75 (m, 3H), 3.65 (d, $J = 3.5$

Hz, 1H), 3.51 (d, $J = 3.5$ Hz, 1H), 2.66 (s, 3H), 2.65 (s, 3H), 2.10 (q, $J = 1.5, 7.5$ Hz, 2H), 0.98 (t, $J = 7$ Hz, 3H); $^{13}\text{C-NMR}$ (CDCl_3 , 125 MHz) δ (ppm): 146.05, 145.79, 144.93, 137.47, 132.74, 132.57, 131.65, 130.93, 130.68, 130.66, 129.79, 128.79, 128.45, 128.16, 127.05, 68.78, 64.05, 27.87, 21.15, 19.35, 14.43; **MS (EI, 70eV)**: m/z (%) = 388 $[\text{M}]^+$, for $\text{C}_{26}\text{H}_{25}\text{ClO}$, 390 $[\text{M}+2\text{H}]^+$; **HRMS (ES-TOF) calcd** for $\text{C}_{26}\text{H}_{25}\text{ClO}$ 388.1594, found 388.1590.

2-(4-bromophenyl)-3-(1-(4-bromophenyl)-2-phenylbut-1-en-1-yl) oxirane (12af): Light brown semi solid; Yield: (263 mg, 55 %); **IR** ν_{max} (KBr , cm^{-1}): 2923 (aromatic C-H str), 1591

(aromatic, C=C str), 1417, 1395, 1282, 1170, 1092, 757 (C-Br, str); **¹H-NMR (CDCl₃, 500**




MHz) δ (ppm): 7.92-7.89 (m, 2H), 7.68-7.66 (m, 2H), 7.58-7.56 (m, 2H), 7.29-7.26 (m, 3H), 6.67-6.55 (m, 4H), 3.78 (d, *J* = 3.5 Hz, 1H), 3.62 (d, *J* = 3.5 Hz, 1H), 2.12 (q, *J* = 2.5, 7.5 Hz, 2H), 0.88 (t, *J* = 7.0 Hz, 3H); **¹³C- NMR (CDCl₃, 125 MHz) δ (ppm):**142.65, 141.32, 138.52, 131.66, 130.97, 130.68,

129.97, 129.58, 128.68, 127.97, 126.68, 121.97, 121.68, 116.66, 115.32, 70.68,

64.08, 26.12, 13.03; **MS (EI, 70eV):** *m/z* = 482[M+2H]⁺, 484[M+4H]⁺, for C₂₄H₂₀Br₂O;

HRMS (ES-TOF) calcd for C₂₄H₂₀Br₂O 481.9881, found 481.9884.



2-(1,2-diphenylbut-1-en-1-yl)-3-phenyloxirane (12ag): Light brown semi solid;

Yield: (243 mg, 75 %); **IR v_{max} (KBr, cm⁻¹):** 2935, 2877 (aromatic C-H str), 1585

(aromatic, C=C str), 1266, 1088, 862, 733; **¹H-NMR (CDCl₃, 500 MHz) δ**

(ppm): 7.91-7.63 (m, 5H), 7.54-7.51 (m, 4H), 7.37-7.33 (m, 3H), 7.32-7.29 (m, 3H), 3.88 (d, *J* = 3.0 Hz, 1H), 3.62 (d, *J* = 3.0 Hz, 1H), 2.32 (q, *J* = 1.5, 8.5 Hz,


2H), 1.18 (t, *J* = 8.0 Hz, 3H); **¹³C- NMR (CDCl₃, 125 MHz) δ (ppm):**142.51, 141.28, 138.58,

131.52, 130.97, 130.68, 129.97, 129.68, 128.68, 127.78, 126.35, 121.97, 121.68, 68.03, 66.51,

26.68, 13.66; **MS (EI, 70eV):** *m/z* (%) = 326[M]⁺, for C₂₄H₂₂O; **HRMS (ES-TOF) calcd** for

C₂₄H₂₂O 326.1671, found 326.1673.

2-(1-(4-fluorophenyl)-2-phenylbut-1-en-1-yl)-3-phenyloxirane (12ah): Light yellow semi



solid; Yield: (247 mg, 72 %); **IR v_{max} (KBr, cm⁻¹):** 2950 (aromatic C-H str),

1582 (aromatic, C=C str), 1389, 1275, 1059, 854; **¹H-NMR (CDCl₃, 500 MHz)**

δ (ppm): 7.88-7.85 (m, 4H), 7.55-7.49 (m, 4H), 7.41-7.39 (m, 3H), 6.88-6.85 (t,


J = 7.5 Hz, 3H), 3.78 (d, *J* = 3.5 Hz, 1H), 2.37 (d, *J* = 3.5 Hz, 1H), 2.37 (q, *J* =

2.5, 7.0 Hz, 2H), 1.38 (t, *J* = 7.5 Hz, 3H); **¹³C- NMR (CDCl₃, 125 MHz) δ (ppm):**160.54,

142.32, 141.58, 138.65, 130.97, 130.68, 129.97, 129.68, 128.66, 127.97, 126.68, 125.65,

116.66, 115.05, 67.65, 64.08, 27.35, 13.12; **MS (EI, 70eV):** *m/z* (%) = 344[M]⁺, for C₂₄H₂₁FO;

HRMS (ES-TOF) calcd for C₂₄H₂₁FO 344.1576, found 344.1574



2-(1,2-diphenylbut-1-en-1-yl)-3-(4-fluorophenyl) oxirane (12ai): Light yellow


semi solid; Yield: (240 mg, 70 %); **IR v_{max} (KBr, cm⁻¹):** 2922 (aromatic C-H str),

1592 (aromatic, C=C str), 1495, 1397, 1298, 1093; **¹H-NMR (CDCl₃, 500 MHz)**


δ (ppm): 7.88-7.86 (m, 4H), 7.56-7.50 (m, 4H), 7.41-7.40 (m, 3H), 6.88 (t, *J* =

7.5 Hz, 3H), 3.92 (d, *J* = 3.0 Hz, 1H), 3.71 (d, *J* = 3.0 Hz, 1H), 2.37 (q, *J* = 2.0,


7.5 Hz, 2H), 1.38 (t, $J = 7.0$ Hz, 3H); ^{13}C - NMR (CDCl_3 , 125 MHz) δ (ppm): 160.55, 142.32, 141.65, 138.58, 130.97, 130.66, 129.97, 129.68, 128.68, 127.97, 126.68, 125.65, 116.66, 115.08, 67.67, 64.15, 27.35, 13.08; MS (EI, 70eV): m/z (%) = 344 $[\text{M}]^+$, for $\text{C}_{24}\text{H}_{21}\text{FO}$; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{FO}$ 344.1576, found 344.1574.



2-(4-fluorophenyl)-3-(1-(4-fluorophenyl)-2-phenylbut-1-en-1-yl) oxirane (12aj): Light yellow semi solid; Yield: (246 mg, 68 %); IR ν_{max} (KBr, cm^{-1}): 2920 (aromatic C-H str), 1597 (aromatic, C=C str), 1399, 1285, 1092, 845; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 8.10-8.06 (m, 2H), 7.94 (d, $J = 8.5$ Hz, 1H), 7.53 (d, $J = 8.5$ Hz, 2H), 7.47 (d, $J = 8.5$ Hz, 1H), 7.28 (d, $J = 8.0$ Hz, 2H), 7.16 (d, $J = 8.5$ Hz, 2H), 6.89 (dd, $J = 2.0, 8.0$ Hz, 2H), 3.85 (d, $J = 4.5$ Hz, 1H), 3.51 (d, $J = 4.5$ Hz, 1H), 2.19 (q, $J = 2, 8$ Hz, 2H), 1.09 (t, $J = 8$ Hz, 3H); ^{13}C - NMR (CDCl_3 , 125 MHz) δ (ppm): 160.58, 160.32, 135.54, 134.47, 130.97, 130.68, 129.97, 129.68, 128.66, 127.97, 126.95, 116.66, 115.05, 68.52, 63.66, 28.35, 14.95; MS (EI, 70eV): m/z (%) = 362 $[\text{M}]^+$, for $\text{C}_{24}\text{H}_{20}\text{F}_2\text{O}$; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{20}\text{F}_2\text{O}$ 362.1482, found 362.1482.




2-(4-chlorophenyl)-3-(1,2-diphenylbut-1-en-1-yl) oxirane (12ak): Light brown semi solid; Yield: (240 mg, 67 %); IR ν_{max} (KBr, cm^{-1}): 2928 (aromatic C-H str), 1591 (aromatic, C=C str), 1419, 1397, 1278, 1172, 1097, 755 (C-Cl, str); ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 7.98 (t, $J = 7.5$ Hz, 2H), 7.79-7.77 (m, 2H), 7.69 (dd, $J = 2.0, 8.0$ Hz, 2H), 7.48-7.45 (m, 2H), 7.36-7.33 (m, 3H), 6.86 (dd, $J = 2.5, 7.5$ Hz, 3H), 3.86 (d, $J = 2.0$ Hz, 1H), 3.73 (d, $J = 2.0$ Hz, 1H), 2.29 (q, $J = 2.0, 7.0$ Hz, 2H), 1.28 (t, $J = 7.0$ Hz, 3H); ^{13}C - NMR (CDCl_3 , 125 MHz) δ (ppm): 142.32, 141.58, 138.65, 131.52, 130.97, 130.68, 129.68, 128.68, 127.78, 126.35, 125.65, 116.66, 115.32, 66.65, 63.12, 26.68, 13.66; MS (EI, 70eV): m/z 360 $[\text{M}]^+$, for $\text{C}_{24}\text{H}_{21}\text{ClO}$, 362 $[\text{M}+2\text{H}]^+$; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{ClO}$ 360.1281, found 360.1283.



1-phenyl-3-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (12al): Light brown semi solid; Yield: (259 mg, 72 %); IR ν_{max} (KBr, cm^{-1}): 3425 (OH str), 2935, 2877 (aromatic C-H str), 1585 (aromatic, C=C str), 1266, 1088, 862, 733; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 7.91-7.66 (m, 4H), 7.6-7.54 (m, 1H), 7.54-7.50 (m, 4H), 7.37-7.34 (m, 2H), 7.33-7.32 (m, 1H), 7.31-7.23 (m, 2H), 4.72 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 2.31 (q, $J = 1.0, 7.5$ Hz, 2H), 1.17 (t, $J = 7.0$ Hz, 3H), 3.30 (s, br, D_2O exchangeable, 1H); ^{13}C - NMR (CDCl_3 , 125 MHz) δ (ppm): 157.60,

142.65, 141.32, 138.58, 131.52, 130.97, 130.68, 129.97, 129.68, 128.68, 127.78, 126.35, 121.97, 121.68, 116.66, 115.32, 71.12, 51.03, 26.66, 13.68; **MS (EI, 70eV):** m/z (%) 326[M]⁺ for C₂₄H₂₂O; **HRMS (ES-TOF) calcd** for C₂₄H₂₂O 326.1671, found 326.1673.



1-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (12am): Light yellow semi solid; Yield: (268 mg, 65 %);


IR ν_{\max} (KBr, cm⁻¹): 3452 (OH str), 2963 (aromatic C-H str), 1599 (aromatic, C=C str), 1451, 1419, 1262, 1021, 933, 868, 799 and 704; **¹H-NMR (CDCl₃, 500**

MHz) δ (ppm): 7.92 (d, $J = 8$ Hz, 2H), 7.83 (d, $J = 7.5$ Hz, 2H), 7.60 (d, $J = 7$

Hz, 1H), 7.49-7.45 (m, 2H), 7.41 (dd, $J = 7.5, 2.5$ Hz, 2H), 7.27-7.25 (m, 2H), 6.92 (d, $J = 7.5$ Hz, 2H) 4.73 (d, $J = 3.5$ Hz, 1H), 4.62 (d, $J = 3.5$ Hz, 1H), 4.15 (t, $J = 1.5$ Hz,

2H), 2.90 (s, 6H), 2.61 (t, $J = 1.5$ Hz, 2H), 2.25 (q, $J = 8.0, 2.0$ Hz, 2H), 1.18 (t, $J = 7$ Hz, 3H), 3.60 (s, br, D₂O exchangeable, 1 H); **¹³C-NMR (CDCl₃, 125 MHz) δ (ppm):** 160.25,

157.05, 137.76, 132.57, 132.42, 131.77, 130.65, 130.49, 130.33, 129.65, 128.97, 128.68, 128.66, 127.05, 116.56, 116.32, 114.65, 71.65, 67.73, 61.35, 52.65, 48.35, 28.27, 14.03; **MS (EI, 70eV):** $m/z = 413$ [M]⁺ for C₂₈H₃₁NO₂; **HRMS (ES-TOF) calcd** for C₂₈H₃₁NO₂ 413.2355, found 413.2354.



2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethanamine (12an): White solid; Yield: (264 mg, 71%); **IR ν_{\max} (KBr, cm⁻¹):** 2920

(aromatic C-H str), 1670 (C=C str for alkene), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1125 (C-O-C, str), 1091; **¹H-NMR (CDCl₃, 500 MHz) δ**

(ppm): 7.89-7.85 (m, 4H), 7.55-7.49 (m, 4H), 7.41-7.39 (m, 2H), 6.86 (t, J

= 7.5 Hz, 2H), 4.15 (t, $J = 2.5$ Hz, 2H), 2.9 (s, 6H), 2.62 (t, $J = 2.5$ Hz, 2H), 2.25 (q, $J = 2.5,$

7.0 Hz, 2H), 1.18 (t, $J = 2.0$ Hz, 3H); **¹³C-NMR (CDCl₃, 125 MHz) δ (ppm):** 158.66, 139.97,

138.77, 131.65, 130.49, 130.47, 130.05, 129.65, 128.97, 128.77, 128.68, 127.66, 114.05, 67.72,

61.05, 47.11, 26.05, 12.95; **MS (EI, 70eV):** m/z (%) = 371[M]⁺ for C₂₆H₂₉NO; **HRMS (ES-**


TOF) calcd for C₂₆H₂₉NO 371.2249, found 371.2251.

1-(4-chlorophenyl)-3-(1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-

inden-2-ol (12ao): Light yellow semi solid; Yield: (281 mg, 58 %); **IR ν_{\max} (KBr, cm⁻¹):** 3440


(OH str), 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1125 (C-O-C, str), 1091, 771 (C-Cl, str); **¹H-NMR (CDCl₃, 500 MHz) δ (ppm):** 7.92 (d, $J = 7.0$ Hz, 2H), 7.83 (d, $J = 7.5$ Hz, 2H), 7.59 (d, $J = 7.0$ Hz, 1H), 7.48-7.45 (m, 1H), 7.41 (dd, $J = 7.0, 2.5$ Hz,

1H), 7.27-7.25 (m, 2H), 6.91 (d, $J = 7.5$ Hz, 1H), 5.27 (d, $J = 2.0$ Hz, 1H), 5.12 (d, $J = 3.0$ Hz,



1H), 4.14 (t, $J = 3.0$ Hz, 2H), 2.94-2.90 (m, 2H), 2.77 (t, $J = 6.0$ Hz, 2H), 2.49-2.47 (m, 4H), 1.59 (q, $J = 7.0, 2.0$ Hz, 2H), 1.44 (t, $J = 6.0$ Hz, 4H), 1.19 (t, $J = 7.0$ Hz, 3H), 3.70 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 157.78, 153.62, 137.74, 132.57, 132.47, 131.79, 130.65, 130.45, 130.05, 129.63, 128.79, 128.68, 128.66, 127.05, 118.96, 117.65, 117.05, 115.66, 76.13, 74.32, 64.73, 58.90, 56.75, 27.95, 26.79, 25.45, 14.35; MS (EI, 70eV): m/z (%) = 487[M]⁺, C₃₁H₃₄ClNO₂, 488[M+H]⁺, for C₃₁H₃₅ClNO₂, 489[M+2H]⁺; HRMS

(ES-TOF) calcd for C₃₁H₃₄ClNO₂ 487.2278, found 487.2276.




(E)-5-bromo-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-

hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (13ab): Light

brown semi solid; Yield: (265mg, 55 %); IR ν_{\max} (KBr, cm⁻¹): 3451 (OH str), 2952 (aromatic C-H str), 1588 (aromatic, C=C str), 1389, 1277, 1060, 854; ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 7.88 (dd, $J = 8.0, 2.5$ Hz, 2H), 7.81 (d, $J = 8.5$ Hz, 1H), 7.69-7.59 (m, 4H), 7.35-7.32 (m, 1H), 6.95 (d, $J =$

9 Hz, 3H), 5.34 (s, 1H), 4.87 (d, $J = 2.0$ Hz, 1H), 4.48 (d, $J = 2.0$ Hz, 1H), 4.26 (t, $J = 2.5$ Hz, 2H), 3.52 (s, 1H), 2.74 (s, 6H), 2.58 (t, $J = 2.5$ Hz, 2H), 2.12 (q, $J = 7.5, 1.5$ Hz, 2H), 1.04 (t, $J = 7.0$ Hz, 3H); ¹³C- NMR (CDCl₃, 125 MHz) δ (ppm): 163.14, 161.127, 159.41, 157.88, 156.62, 140.112, 139.53, 136.28, 133.63, 131.54, 130.78, 129.62, 129.30, 124.37, 123.13, 116.12, 115.11, 73.13, 68.13, 62.15, 52.12, 47.45, 27.45, 14.10; HRMS (ES-TOF) calcd for C₂₈H₃₀BrNO₃ 507.1409, found 507.1407.

(E)-5-bromo-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-




2,3-dihydro-1H-inden-2-ol (13ac): Light yellow semi solid; Yield:

(275mg, 52 %); IR ν_{\max} (KBr, cm⁻¹): 3355 (OH str), 2955 (aromatic C-H str), 1570 (aromatic, C=C str), 1458, 1410, 1277, 1154, 1088, 1012, 915

and 730; ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 8.03 (d, $J = 8.0$ Hz, 3H), 7.82 (d, $J = 7.0$ Hz, 2H), 7.76 (dd, $J = 2.0, 7.0$ Hz, 4H), 7.49 (d, $J = 9.0$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz, 3H), 5.56 (s, 1H), 4.75 (d, $J = 2.0$ Hz, 1H),


4.36 (d, $J = 2.0$ Hz, 1H), 4.14 (t, $J = 2.5$ Hz, 2H), 3.75 (s, 1H), 3.05 (t, $J = 2.5, 2$ Hz), 2.65 (t, $J = 3.0$ Hz, 4H), 2.33 (q, $J = 1.5, 9.0$ Hz, 2H), 1.64-1.61 (m, 2H), 1.51 (t, $J = 2.5$ Hz, 2H), 1.02 (t, $J = 8.0$ Hz, 3H); ¹³C- NMR (CDCl₃, 125 MHz) δ (ppm): 161.13, 157.13, 156.41, 142.62,

140.10, 139.54, 136.27, 133.63, 131.54, 130.78, 129.62, 129.30, 122.37, 122.13, 116.19, 115.19, 73.13, 69.15, 58.10, 57.45, 52.81, 29.17, 25.14, 23.10, 12.56; **HRMS (ES-TOF) calcd** for $C_{31}H_{34}BrNO_3$ 547.1722, found 547.1724.



(Z)-5-bromo-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (14ab): Light brown semi solid; Yield: (45mg, 8 %); **IR** ν_{max} (KBr, cm^{-1}): 3415 (OH str), 2934, 2875 (aromatic C-H str), 1599 (aromatic, C=C str), 1265, 1081, 865, 735; **1H -NMR (CDCl₃, 500 MHz) δ (ppm):** 7.89-7.69 (m, 4H), 7.55-7.48

(m, 2H), 6.97-6.81(m, 5H), 4.69 (d, $J = 2.5$ Hz, 2H), 4.28 (d, $J = 2.5$ Hz, 2H), 4.27 (t, $J = 2.5$ Hz, 2H), 2.93 (s, 6H), 2.87 (t, $J = 2.5$ Hz, 2H), 1.78 (q, $J = 8.0, 2.5$ Hz, 2H), 0.67 (t, $J = 7$ Hz, 3H); **^{13}C - NMR (CDCl₃, 125 MHz) δ (ppm):** 163.14, 161.22, 159.42, 157.87, 156.62, 140.12, 139.53, 136.27, 133.63, 132.54, 130.77, 129.62, 129.30, 124.37, 123.13, 116.12, 115.10, 71.14, 66.13, 60.13, 50.17, 46.45, 25.45, 12.20; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}BrNO_3$ 507.1409, found 507.1407.



(Z)-5-bromo-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (14ac): Light yellow semi solid; Yield: (55mg, 10 %); **IR** ν_{max} (KBr, cm^{-1}): 3444 (OH str), 2922 (aromatic C-H str), 1595 (aromatic, C=C str), 1412, 1333, 1235, 1126(C-O-C, str), 1091; **1HNMR (CDCl₃, 500 MHz):** δ (ppm) 7.91-7.86

(m, 3H), 7.71-7.51 (m, 1H), 7.49-7.26 (t, $J = 8.0$ Hz, 4H), 7.12-6.85 (m, 4H), 5.59(s, 1H), 4.59 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 2.98 (t, $J = 2.5$ Hz, 2H), 2.87(t, $J = 2.5$ Hz, 4H), 4.02 (t, $J = 2.5$ Hz, 2H), 1.87 (q, $J = 1.5, 8.0$ Hz, 2H), 1.34 (t, $J = 2.5$ Hz, 2H), 1.26 (t, $J = 2.5$ Hz, 4H), 0.78 (t, $J = 7.0$ Hz, 3H)); **$^{13}CNMR$ (CDCl₃, 125 MHz) δ (ppm):** 161.124, 157.13, 156.41, 142.63, 140.10, 139.54, 136.27, 133.63, 131.54, 130.77, 129.62, 129.30, 122.36, 122.12, 116.19, 115.19, 73.11, 69.15, 58.48, 57.55, 52.81, 25.25, 23.14, 21.30, 10.77; **HRMS (ES-TOF) calcd** for $C_{31}H_{34}BrNO_3$ 547.1722, found 547.1724.

4.6. REFERENCES

- [1] (a) McMurry, J. E. *Carbonyl-coupling reactions using low-valent titanium*, Chem. Rev.1989, 89, 1513; (b) McMurry, J. E.; Felming, M. P. *New method for the reductive coupling of carbonyls to olefins. Synthesis of β -carotene*, J. Am. Chem.Soc. 1974, 96, 4708; (c) Furstner, A.; Bogdanovic, B. *New developments in the chemistry of low-valent*

- titanium*, *Angew. Chem., Int. Ed. Engl.* 1996, 35, 2443;(d) Yadav, D. K.; Quraishi, M. A. *Electrochemical investigation of Substituted Pyranopyrazoles Adsorption on Mild Steel in Acid Solution*, *Ind. Eng. Chem. Res.* 2012, 51, 8194;(e) Sato, F.; Urabe, H. In *Titanium and Zirconium in Organic Synthesis*; Marek, I., Ed.; Wiley-VCH:Weinheim, Germany, 2002; pp 319.
- [2] Corey, E. J.; Danheiser, C. S. *New reagents for the intermolecular and intramolecular pinacolic coupling of ketones and aldehydes*, *J. Org. Chem.* 1976, 41, 258.
- [3] Ghiringelli, D. *A synthesis of (S,S)-(+)-grahamimycin A1*, *Tetrahedron Lett.* 1983, 24, 287.
- [4] (a) Khan, A. T.; Mohan, L.; Prasanta, R. B.; Basha, S. R.; Parameswaran, S.; Sanjukta, P. *Synthesis of tetra-Substituted Pyrroles, a Potential Phosphodiesterase 4B Inhibitor, Through Nickel(II) chloride Hexahydrate Catalyzed One-Pot Four-component Reaction*, *Tetrahedron Lett.* 2012, 53, 4145; (b) Meegan, M. J.; Hughes, R. B.; Lloyd, D. G.; Williams, D. C.; Zisterer, D. M. *Flexible estrogen receptor modulators: design, synthesis, and antagonistic effects in human MCF-7 breast cancer cells*, *J. Med. Chem.* 2001, 44, 1072.
- [5] (a) Castedo, L.; Saa, J. M.; Suau, R.; Tojo, G. *Stereoselective introduction of chiral centers in acyclic precursors: a probe into the transition state of m-chloroperbenzoic acid (m-CPBA) epoxidation of acyclic allylic alcohols and its synthetic implications*, *Tetrahedron Lett.* 1983, 24, 5419; (b) Khan, F. A.; Satapathy, R.; Dash, J.; Savitha, G. *A Rapid and Stereoselective Route to the Trans-Hydrindane Ring System*, *J. Org. Chem.* 2004, 69, 5295.
- [6] (a) Detsi, A.; Koufaki, M.; Calogeropoulou, T. *Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]acetic Acid*, *J. Org. Chem.* 2002, 67, 4608; (e) Yu, D. D.; Forman, B. M. *Simple and Efficient Production of (Z)-4-Hydroxytamoxifen, a Potent Estrogen Receptor Modulator*, *J. Org. Chem.* 2003, 68, 9489.
- [7] Hu, S.; Zhang, Z.; Song, J.; Zhou, Y.; Han, B. *Efficient conversion of glucose into 5-hydroxymethylfurfural catalyzed by a common Lewis acid SnCl₄ in an ionic liquid*, *Green Chem.* 2009, 11, 1746.
- [8] Guo, Q.; Miyaji, T.; Hara, R.; Shen, B.; Takahashi, T. *Group 5 and group 6 metal halides as very efficient catalysts for acylative cleavage of ethers*, *Tetrahedron* 2002, 58, 7327.

- [9] McMurry, J. E.; Krepski, L. R. *Synthesis of unsymmetrical olefins by titanium (0) induced mixed carbonyl coupling. Some comments on the mechanism of the pinacol reaction*, J. Org. Chem. 1976, 41, 3929.
- [10] Robert J.; Rawson, I.; Harrison, T. *Procedure for the methylenation of olefins to cyclopropanes*, J. Org. Chem. 1970, 35, 2057.
- [11] Dams, R.; Malinowski, M.; Westdorp, I.; Geisy, H. I. *On the mechanism of the titanium-induced reductive coupling of ketones to olefins*, J. Org. Chem. 1982, 47, 248.
- [12] (a) Khan, F. A.; Saeed, A. *Synthesis of Reported and Revised Structures of Amathamide D and Synthesis of Convolutamine F, H and Lutamide A, C*, J. Org. Chem. 2012, 77, 2389; (b) Gupta, A.; Dwiwedi, A.; Keshari, G.; Sharma, R.; Balapure, A. K.; Singh, M. M.; Ray, S. *Rapid synthesis of 4-benzylidene and 4-[bis-(4-methoxyphenyl)-methylene-2-substituted phenyl-benzopyrans as potential selective estrogen receptor modulators (SERMs) using McMurry coupling reaction*, Bioorg. Med. Chem. Lett. 2006, 16, 6006; (c) Vivaina, S.; Titas, F.; Jenny, A.; Bochet, C. G. *Geometry determination of tetrasubstituted stilbenes by proton NMR spectroscopy*, Tetrahedron Lett. 2005, 46, 3793.
- [13] (a) Ahmed, N.; Pathe, G. K.; Venkata, B. B.; *Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn(IV)Cl₄ catalyst*, Tetrahedron Lett. 2014, 55, 3683; (b) Ahmed, N.; Van Lier, J. E.; *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 5407; (c) Ahmed, N.; Van Lier, J. E.; *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 2725; (d) Ahmed, N.; Konduru, N. K.; *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177; (e) Konduru, N. K.; Ahmed, N.; *Regioselective opening of chalcone epoxides with nitrogen heterocycles using indium(III) chloride as an efficient catalyst*, Synth. Commun. 2013, 43, 2008.
- [14] Dutta, K. A.; Konwar, D. *A new method for reductive coupling of carbonyl compounds to olefins*, Tetrahedron Lett. 2000, 41, 6227.

- [15] Gerard, A.; Potter, G. A.; McCague, R. *Highly stereoselective access to an (E)-vinyl bromide from an aryl ketone leads to short syntheses of (Z)-tamoxifen and important substituted derivatives*, J. Org. Chem. 1990, 55, 6184.

Part-B: Design, Synthesis of McMurry cross-coupled indanophen, analogs of Tamoxifen by novel SnCl₄-Zn reagent and Anti-Proliferative Evaluation of Flavone-Estradiol adduct and Indanone based Ligands against Breast Cancer Cell Line

5.1. INTRODUCTION

Breast cancer remains a major cause of death for women in the western world (2-10 times higher than for oriental women) with the global incidence estimated at 1.15 million in 2002.[1] It is the second leading cause of cancer related deaths. More than 18000 women are diagnosed with breast cancer each year. Although breast cancer mainly affects women, data shows that men can also be affected as well; each year more than 1000 men are diagnosed with breast cancer.[2] Approximately 80% of breast cancer cases occurs in post-menopausal women whose ovarian estrogen production has ceased with remaining estrogens originating in extra-glandular tissues. Estrogen is a hormone that promotes the growth of breast cancer cells. As an antiestrogen drug, Tamoxifen was designed to slow and stop the growth of the cancer cells that are constantly being produced in every breast cancer patient. Estrogen receptors α and β (ER α AND ER β) are transcription Factors that bind to specific hormone response elements located near their target genes and regulate their expression in a ligand-dependent manner . Genistein and other flavonoids are phytoestrogens, i.e. they function as selective estrogen receptor modulators (SERMs).[3] It is hypothesized that these flavonoids modulate the endogenous activities of estrogen receptors to slow down or prevent the developments of breast and ovarian cancers.[4] The estrogen mimetic effects of dietary compounds are currently being explored to prevent the symptoms associated to estrogen deficiency in women during menopause.[5,6] The molecular basis of flavonoids estrogenicity is particularly difficult to elucidate, principally because of the 17 β - estradiol (E2) mechanism of action which occurs via multiple pathways upon E2 binding to estrogen receptor α and β (ER α and ER β) The estrogen receptor complex can dimerize and interact directly with the DNA at the estrogen response element (ERE), or in the activated protein pathway (AP1), the monomer can interact with two proteins (c-Jun and c-Fos proto-oncogenes) to form a complex that binds to DNA.[7]

Many naturally occurring steroid hormones [8] and non-steroidal [9] derivatives are recognized by steroid hormone receptors (SHRs) either as agonists or antagonists depending on their interaction with the SHR. Both agonists or antagonists are used for the treatment of hormone-dependent breast cancers (HDBCSs).[10,11] Acquired resistance to TAM or other

selective ER modulator (SERMs) is unique in that the growth of resistant tumours is dependent on SERMs.[12,13] Acquired TAM resistance during the treatment of metastatic breast cancer occurs within one or two years. Prolong adjuvant treatment with endocrine therapy markedly reduces the likelihood of breast cancer recurrence. Five years of tamoxifen, for example, reduces the risk of recurrence by 41% [14] However, the regimen duration and the various side effects combined with the prophylactic, and hence delayed, efficacy are likely to decrease adherence. Indeed, despite the efficacy of endocrine therapy, nonadherence and premature discontinuation by up to 30% of women have been reported.[15-17] The clinical application of the laboratory strategy of long-term adjuvant antihormone therapy for the treatment of breast cancer has significantly improved breast cancer survival.[18] Selection of patients whose tumours express the oestrogen receptor (ER) are more likely to respond to long-term adjuvant tamoxifen (TAM).[19] or aromatase inhibitors (AIs)[20] than those without ER. The evolution of acquired resistance to TAM treatment was discovered using MCF-7 tumours transplanted in athymic mice to mimic years of adjuvant treatment in patients.[21] The activity of TAM in the breasts has been illuminated by recent developments in the complex endocrinology of breast cancer.[22] A second estrogen receptor, ER β , was discovered in 1996.[23] Tumors which had been classified as ER-negative due to the lack of ER α have been shown to contain ER β , which may be important in the proliferation of tamoxifen resistant tumors, although the role of this receptor is still poorly understood.[24]

Tamoxifen (TAM) and its congeners are widely used as a supplementary therapy to control cancers of the breast that test positive for the oestradiol receptor [25](ER). This series of molecules has a number of advantages in increasing the survival rate of patients, especially because they are relatively well tolerated over time. However, in the long run patients develop resistance to treatment with TAM. And in fact the development of certain tumours of the breast is eventually stimulated by TAM Research efforts aimed at finding new and effective anti-estrogens, without the disadvantage of TAM of clearly of great interest today, with this goal in mind, the company ICI has modified the 7 alpha position oestradiol, [26] Rousel-Uclaf, [27] (RU) has concentrated on 11beta position.

In the carbon- carbon bonds formation, the McMurry reaction plays an important role to obtain homo and cross-coupled alkenes from aliphatic and aromatic aldehydes and ketones in the presence of *in situ* generated low valent titanium (LVT) reagents at reflux temperature.[28]

However, the reaction gave a moderate yield due to homo and cross-coupled products formation. To enhance the yield of cross-coupled products under mild reaction conditions, different reagents are explored for the McMurry reaction. For example, magnesium-mercury couple, $\text{NbCl}_5/\text{NaAlH}_4$, [29] zinc-copper couple, [30] LiAlH_4 , [31] dicyclopentadienyl titanium dichloride, [32] trimethyl aluminium. [33] Although, these procedures have drawbacks like costly reagents, low yield, longer reaction time and/or less functional group tolerance. In recent years, tin tetrahalides (SnX_4 , $\text{X}=\text{Cl}$, Br) have been widely used as Lewis acids in numerous organic syntheses. [34] In many cases, these metal halides have been reported as efficient catalysts and easy to handle as compare to other metal halides such as TiX_4 , AlX_3 , ZnX_2 and ZrX_4 . [35]

Generally, metal alloy is used as reductive deoxygenating agent in the organic synthesis for coupling reactions. For example, zinc alloy is prepared by mixing of zinc and SnCl_4 in 2:1 ratio following the Rieck method. [36] where metals like Zn involves reduction of an oxidized metal species by enhancing the reactivity of zinc at the surface of the alloy. The reductive deoxygenating reagents may also be generated in situ by reaction of two equivalent of zinc dust with one equivalent metal chloride under refluxing temperature in ether or hydrocarbon solvents. In the case of McMurry reaction reagent Ti (IV) reduced to Ti (II) with reducing agent Zn in THF, which generate a complex $\text{TiCl}_4\text{-Zn}(\text{THF})_2$ in situ. [37,38] which is responsible for the coupling of aldehyde or ketone to pinacolate, followed by removal of TiO_2 gave olefins. [39] Likewise, it might be taking place in $\text{SnCl}_4\text{-Zn}$ and THF to form a complex $\text{SnCl}_4\text{-Zn}(\text{THF})_2$ for the coupling of aldehydes or ketones. Initially Sn(IV) converted into Sn(II) by reduction of tin halide with Zn, Sn(II) converted carbonyl oxygen to pinacolate, followed by removal of SnO_2 gave olefins.

Therefore, in continuation of our interest to develop new methods in the organic synthesis and the acid catalysis reactions. [40] Herein, we report a novel and efficient reagent, $\text{SnCl}_4\text{-Zn}$ system for a selective cross McMurry coupling between various indanone derivative and propiophenone derivative was achieved. We now disclosed a novel one- step synthetic strategy for tamoxifen analog using selective cross McMurry coupling between two aromatic ketone in good yield within 4-4.5 h at reflux temperature.

5.2. OBJECTIVE

Breast cancer is a second most common cancer and second leading cause of death for women. In the western world (2-10 times higher than for oriental women) with the global incidence estimated at 1.15 million in 2002. Breast cancer is always caused by genetic abnormality. About 90% of breast cancers are due to genetic abnormalities and 5-10 % of cancers are due to abnormality inherited from mother or father. Hence our intention to synthesize the drug used for the treatment of breast cancer and we have synthesized some indanophen analog of Tamoxifen by novel SnCl₄-Zn reagent and Flavone-Estradiol which shows Anti-Proliferative activity against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines (MCF-7 & MDA-MB-231).


5.3. RESULTS AND DISCUSSION

Initially, we performed the McMurry coupling of indanone **1r** with propiophenone **2r**, used in 1:1.5 ratio and varying the equivalents of SnCl₄-Zn (prepared in 1:2 ratio). We obtained the cross-coupled product **3rr** in 41% and 50% yields in 4h using 1 and 2 equivalent of SnCl₄-Zn respectively (Table1, entries 1 & 2). When SnCl₄-Zn was used in 3 equivalents, the yield was serendipitously improved up to 65% in 4h (Table1, entry 3). Further, increase in SnCl₄-Zn equivalent decreased the yields of the cross-coupled product **3rr** and increased the homo-coupled products (Table 1, entries 4 & 5). Similarly, we optimized the reaction condition by reaction of **1r** with **2s**. We observed that the cross-coupled product **3rs** gave 43-60 % yield. When SnCl₄-Zn was used in 1, 2, 3.5 & 4 (Table1, entries 6, 7, 9 & 10). The yield was serendipitously improved up to 70% in 4h when we used 3 equivalents, (Table1, entry 8).

We optimized the reaction time, by using optimized condition of table 1, we checked the progress of reaction from 1h-3h to get only 15 to 55 % of conversion at reflux temperature (Table 2, entries 1-3). Further increasing time from 3h to 4h gave a very good yield up to 65 % (Table 2, entry 4). And further increase in time from 4 to 5h decreased in product yield to 45 % (Table 2, entry 5). We also determined the formation of E and Z isomers in the cross-coupled product where E-isomer and Z- isomer were found as major and minor products respectively. Due to the closed R_f -values of Z- isomers with byproducts, we were unable to separate the Z- isomers by the column chromatography. However, the yields of Z- isomers were confirmed by GC analysis which is ranging between 2-5%.

Here, the optimal condition for cross McMurry couplings of substituted indanone **1r** with propiophenone **2r-2s** employed 3 equivalent of SnCl₄-Zn with a 1:1.5 mol ratio of **1r** to **2r-2s** to give **3rr-3rs** in very good yield in 4h.


Table 1. Optimized condition for cross-coupling reaction by using different equivalent of SnCl₄-Zn.



Entry	Ketones ^a	SnCl ₄ -Zn	Time(h)	Yield(%) ^b
1	1r+2r	SnCl ₄ -Zn (1 equiv.)	4	3rr (41)
2	1r+2r	SnCl ₄ -Zn (2 equiv.)	4	3rr (50)
3	1r+2r	SnCl ₄ -Zn (3 equiv.)	4	3rr (65)
4	1r+2r	SnCl ₄ -Zn (3.5 equiv.)	4	3rr (59)
5	1r+2r	SnCl ₄ -Zn (4 equiv.)	4	3rr (55)
6	1r+2s	SnCl ₄ -Zn (1 equiv.)	4	3rs (43)
7	1r+2s	SnCl ₄ -Zn (2 equiv.)	4	3rs (52)
8	1r+2s	SnCl ₄ -Zn (3 equiv.)	4	3rs (70)
9	1r+2s	SnCl ₄ -Zn (3.5 equiv.)	4	3rs (60)
10	1r+2s	SnCl ₄ -Zn (4 equiv.)	4	3rs (50)

^aThe mole ratios of 1r to 2r,2s were 1:1.5, ^bYield of isolated product

Table 2. Optimized condition for cross-coupling reaction by varying reaction time.




Entry	SnCl ₄ -Zn	Time (h)	Yield (%) ^a
1	SnCl ₄ -Zn (3 equiv.)	1	15
2	SnCl ₄ -Zn (3 equiv.)	2	40

3	SnCl ₄ -Zn (3 equiv.)	3	55
4	SnCl ₄ -Zn (3equiv.)	4	65
5	SnCl ₄ -Zn (3 equiv.)	5	45

^aIsolated yield of cross-product

Under optimal reaction conditions, the efficiency of different McMurry reagents was compared (Table 3). Aluminium and Indium complexes gave poor products yield (15 %) at reflux in 14 h (Table 3, entries 1, 2). However, the titanium complex (TiCl₄-Zn-THF) gave the yield (55 %) at reflux temperature in 6 h (Table 3, entry 3), while the tin complex (SnCl₄-Zn-THF) gave the optimal yield (70%) at reflux temperature within 4 h (Table 3, entry 4).

Table 3. Comparison of McMurry reagents and solvents in McMurry cross- coupling of Indanone and propiophenone.



Entry	McMurry reagents	Time (h)	Yield (%) ^a
1	AlCl ₃ -Zn (3 equiv.)	14	15
2	InCl ₃ -Zn (3 equiv.)	14	15
3	TiCl ₄ -Zn (3 equiv.)	6	55
4	SnCl ₄ -Zn (3 equiv.)	4	70

^a Isolated yield of cross-product at 64-66 °C.

5.3.1. Synthesis of Tamoxifen Analogs by Cross -McMurry coupling reaction between indanone derivatives and propiophenone derivatives.


To examine the scope and generality of the cross mcmurry coupling reaction we examine the reaction of substituted indanone **12a-12u** with substituted propiophenone **13b-13e** (table 4) under optimized reaction condition describe in entry **4 & 9** of table 1, pleasingly all of these reaction proceeded as anticipated to give the corresponding cross mcmurry coupled **3ab-3au** tamoxifen analog as well as homo coupled product **2aa-2tt** and **4bb-4uu**, but the cross mcmurry product **3ab-3au** with **52- 74%** yields dominant over homo-coupled products **2aa-2tt** and **4bb-4uu**, with **8-15%** yields. (Table 4)

Table 3 reveals that the reaction of substrate **12a-12e** with 1-(4-(2-(dimethylamino)ethoxy)phenyl)propan-1-one in molar ratio 1:1.5 respectively, by using 6 equivalent of low valent titanium and 12 equivalent of Zn was heated at reflux in THF under nitrogen atmosphere, the reaction takes 6h to completion to yield dominant cross-coupling product **3ab-3af** with 55-66% yields along with minor homo-coupled products **2aa-2ee** and **4bb-4ff** with 8-12% yields.

Similarly, the reaction of substrate **12f-12j** with 1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propan-1-one under same reaction condition as above to gave dominant cross-coupling product **3ag-3ak** with 52-59% yields along with minor homo-coupled products **2ff-2ll** and **4gg-4kk** with 8-14% yields, also the reaction of **12k-12o** with 4-hydroxy propiophenone to gave **3al-3ap** with 67-72% yields along with minor homo-coupled products **2mm-2qq** and **4ll-4pp** with 8-14% and reaction of **12p-12t** with propiophenone to gave **3aq-3au** with 65-74% yields along with minor homo-coupled products **2nn-2tt** and **4mm-4uu** with 8-14% yields respectively (Table 4). we observed that the reaction of **12k** to **12t** with unsubstituted propiophenone gave good yield and reaction completed in a short time as compared to reaction of **12a-12j** with 1-(4-(2-(dimethylamino)ethoxy)phenyl)propan-1-one and 1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propan-1-one.

The synthesized compounds were confirmed on the basis of their spectral data. In ^1H NMR spectra, the characteristic doublet signal for $-\text{CH}-\text{CH}-$ from indanone appeared for tamoxifen analog **3ab-3au** in the range of δ 4.12- 5.12 ppm, whereas for compound **12a-12t** in the range of δ 5.33- 5.20, also the characteristic quartet and triplet signal of $-\text{CH}_2\text{CH}_3$ appeared in between δ 0.90- 2.30 ppm, indicates the coupling of two molecule took place and products were formed. The structures of all the compounds were further confirmed by HRMS, ESI/MS and IR analysis.

The geometrical isomer is easily ascertained by the ^1H NMR spectra. In the more mobile Z-isomer, indanone ring proton is significantly up field (0.3 ppm) relative to the corresponding resonance in the E-isomer.[17] We observed that for E-isomer nmr signal for characteristic quartet and triplet signal of $-\text{CH}_2\text{CH}_3$ appeared downfield at 2.25 (q, $J = 7.0, 2.5$ Hz, 2H CH_3CH_2), 1.19 (t, $J = 7$ Hz, 3H CH_3CH_2) than the minor Z-isomer 2.00 (q, $J = 7.0, 2.5$ Hz, 2H CH_3CH_2), 0.80 (t, $J = 7$ Hz, 3H CH_3CH_2), also for $-\text{OCH}_2$ at 4.14-4.10 δ indicates the formation of E-isomer as the major product.

Table 4. Synthesis of Tamoxifen Analogs by Cross -McMurry coupling reaction between indanone derivatives and propiophenone derivatives.

Entry	Indanone ^a		Propiophenone ^a	Ti (Eq.)	Time (h)	Yield (%) ^b		
	R ₁	R ₂	R			2aa-2tt	3ab-3au ^c	4bb-4uu
1	H	H		3	6	10	3ab (66)	9
2	F	H		3	6	12	3ac (60)	8
3	H	F		3	6	8	3ad (64)	12
4	F	F		3	8	12	3ae (58)	9
5	H	Cl		3	8	12	3af (55)	8
6	H	H		3	9	12	3ag (58)	9
7	F	H		3	9	12	3ah (59)	9
8	H	F		3	9	10	3ai (58)	8
9	F	F		3	11	14	3aj (55)	9
10	H	Cl		3	11	14	3ak (52)	9
11	H	H	OH	3	4	12	3al (70)	9


12	F	H	OH	3	4	8	3am (72)	8
13	H	F	OH	3	4	14	3an (70)	10
14	F	F	OH	3	5	10	3ao (68)	8
15	H	Cl	OH	3	5	10	3ap (67)	9
16	H	H	H	3	3	14	3aq (72)	12
17	F	H	H	3	3	9	3ar (74)	10
18	H	F	H	3	3	12	3as (70)	9
19	F	F	H	3	4	8	3at (68)	8
20	H	Cl	H	3	4	9	3au (65)	10

^aThe mole ratio of **12a-12s** and propiophenone derivative **13b-13e** were 1:1.5. ^bIsolated yield. ^cE-isomer was confirmed by using H^1 NMR.







5.3.2. Synthesis of E and Z Tamoxifen analogs of indanone.

In table 5 compounds **4ab-4ag** and **5ab-5ag** were synthesized as a mixture of E and Z isomers which can be separated by using column chromatography and by comparing their spectral values in the literature. We observed that the E isomer is the major isomer with 52-55% yields and Z isomer is the minor product with 8-10% yields in 5 h, using $SnCl_4$: Zn (1:2 equiv.) in indanone and propiophenone (1: 1.5 equiv.). The 1H NMR chemical shift (δ) 1.0-1.3 ppm for $-CH_3$ and 2.0-2.3 ppm for $-CH_2$ indicated the **E** isomer of products **4ab-4ag** and δ 0.6-0.7 ppm for $-CH_3$ and 1.6-1.9 ppm for $-CH_2$ gave the **Z** isomer for products **5ab-5ag**. Similarly, ^{13}C NMR chemical shift (δ)13-15 ppm for $-CH_3$ and 27-28 ppm for $-CH_2$ indicated the **E** isomer for products **4ab-4ag** and δ 10-12 ppm for $-CH_3$ and 23-25 ppm for $-CH_2$ gave the **Z** isomer in **5ab-5ag**. Similarly, products **3ab-3au** was characterized as E-isomer. The NMR chemical shift (δ) values of $-CH_2CH_3$ in products **3ab-3ao** is matches with the **4ab-4ac** (E-isomer) and not with **5ab-5ac** (Z-isomer). We were unable to isolate the Z-isomer due to close R_f values with other byproducts. However, the yields of Z-isomers were confirmed by GC analysis which is ranging between 2-5%.

Table 5. Synthesis of E and Z-Tamoxifen analogs of indanone.



Entry	Indanone	E-Analog	Z-Analog	Time (h)
1				5
2				5
3				5
4				5


5		 <p>4af yield- 55%</p>	 <p>5af yield-8%</p>	5
6		 <p>4ag yield- 52%</p>	 <p>5ag yield-10%</p>	5

Mole ratio of indanone and propiophenone (1:1.5) and SnCl₄-Zn (1:2)


5.3.3. Synthesis of Flavone-Estradiols adduct

Scheme 1 and scheme 2 to shows that the Flavones-estradiol were synthesized by stille coupling between tin Estradiol derivatives with flavones derivatives in presence of palladium catalyst and 3 crystals of 2,6-dirtetbutyl-4-methyl phenol in toluene at 100-110 °C to gave products **6ab** to **6ag** in good yield up to 70% and reaction takes 2 days for completion.

Scheme 1. Synthesis of Flavone-Estradiols adduct by coupling at alpha to the carbonyl



Scheme 2. Synthesis of flavone-Estradiols adduct by coupling at benzene ring



5.3.4. Pharmacology

Anticancer evaluation


The antiproliferative activities of all synthesized conjugate were determined against the human cervical cancer cell line HeLa and estrogen-responsive breast cancer cell lines MCF-7, as well as the estrogen-independent breast cancer cell line MDA-MB-231, using the MTT assay and the corresponding inhibitory concentration 50% (IC_{50} s) value are enlisted in **Table 6**. As evident from **Table 6** and **Figure 1**, For a preliminary SAR evaluation, the series of synthesized compounds (3ab to 3ao) was first evaluated against HeLa and MCF-7 & MDA-MB-231 to investigate the effect of halogen, hydroxyl substituent on indanone moiety and side chain 2-methoxy-N,N-dimethylethanamine and 1-(2-methoxyethyl)piperidine on propiophenone moiety. The IC_{50} (half maximal inhibitory concentration) values of these compounds were determine as a measure of their respective cytotoxicity and are tabulated in Table 6. The compounds **3ac**, **3ad**, **3ae**, **3ao** having $R_1, R_2 =$ fluoro substituent and the R= 2-methoxy-N,N-dimethylethanamine and hydroxyl group shows high activity as standard drug doxorubicin against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines (MCF-7 & MDA-MB-231).











Among this series the compound **3ab** with $R_1, R_2 = \text{H}$ and R= 2-methoxy-N, N-dimethylethanamine shows weak activity comparable to standard drug but by introducing the fluoro substituent on indanone moiety and 2-methoxy-N, N-dimethylethanamine on propiophenone moiety in compounds 3ac, showed the highest antiproliferative potency with IC_{50} values of $02.56 \pm 0.028\mu\text{M}$, $03.62 \pm 0.219\mu\text{M}$ & $02.94 \pm 0.084\mu\text{M}$ against HELA, MCF-7

& MDA-MB-231 cell line, respectively than the drug doxorubicin. Similarly in compounds **3ad** & **3ae** showed equally antiproliferative activity to standard drug having IC_{50} values of $02.56 \pm 0.028 \mu\text{m}$, $03.57 \pm 0.014\mu\text{m}$, $03.62 \pm 0.219\mu\text{m}$, $3.26 \pm 0.120\mu\text{m}$ and $02.94 \pm 0.084\mu\text{m}$, $03.05 \pm 0.215\mu\text{m}$ respectively. In compounds **3af** having chloro substituent and 2-methoxy-N,N-dimethylethanamine side chain showed comparable antiproliferative potency to drug doxorubicin with IC_{50} values $06.65 \pm 0.197\mu\text{m}$, $08.81 \pm 0.176\mu\text{m}$, $07.48 \pm 0.283\mu\text{m}$ against HELA, MCF-7 & MDA-MB-231 respectively. Also the conjugate **3ao** with $R=OH$ and $R_1, R_2 = F$ showed most antiproliferative potency having IC_{50} values $02.88 \pm 0.021\mu\text{m}$, $02.24 \pm 0.176\mu\text{m}$, **$02.13 \pm 0.134 \mu\text{m}$** respectively.

By introducing the chain from $R = 2\text{-methoxy-n, n-dimethylethanamine}$ to $R = 1\text{-(2-methoxyethyl) piperidine}$ in compounds **3ag-3ak** seemed to have comparable activity displayed IC_{50s} in the range $4.09\text{-}13.05\mu\text{m}$, $8.05\text{-}14.28\mu\text{m}$, $5.68\text{-}12.08\mu\text{m}$ against HELA, MCF-7 and MDA-MB-231 respectively. If we change $R=OH$ then the compounds **3al-3ap** shows moderate activity displayed IC_{50s} in the range $5.05\text{-}10.75\mu\text{m}$ against HELA, $6.47\text{-}9.72\mu\text{m}$ against MCF-7 and $5.64\text{-}8.94\mu\text{m}$ against MDA-MB-231; by replacing $R = H$ in compounds **3aq-3au** shows weak activity comparable to standard drug displayed IC_{50s} in the range $9.95\text{-}27.65\mu\text{m}$ against HELA, $13.06\text{-}26.60\mu\text{m}$ against MCF-7 and $8.46\text{-}24.00\mu\text{m}$ against MDA-MB-231. from **Table 6** it reveals that the compounds **3ao** most potent with $r=OH$ among all the synthesized compounds displayed IC_{50s} $2.88\mu\text{m}$ against HELA, $2.24\mu\text{m}$ against MCF-7 and $2.13\mu\text{m}$ and **3ac-3ae** shows equally potent as that of standard drug doxorubicin displayed IC_{50s} in the range $2.56\text{-}3.81\mu\text{m}$ against HELA, $2.87\text{-}3.62\mu\text{m}$ against MCF-7 and $2.94\text{-}3.26 \mu\text{m}$ against MDA-MB-231.


Table 6. Showing anti-proliferative data (IC_{50} Values in μM) of all the synthesized tamoxifen analog drugs and standard drug against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines (MCF-7& MDA-MB-231).



Entry	DRUG	R ₁	R ₂	R	HeLa	MCF-7	MDA-MB-231
1	3ab	H	H		23.55 ± 0.070	27.80 ± 1.272	25.43 ± 0.985
2	3ac	F	H		02.56 ± 0.028	03.62 ± 0.219	02.94 ± 0.084
3	3ad	H	F		03.57 ± 0.014	03.26 ± 0.120	03.05 ± 0.215
4	3ae	F	F		03.81 ± 0.049	02.87 ± 0.127	03.26 ± 0.321
5	3af	H	Cl		06.65 ± 0.197	08.81 ± 0.176	07.48 ± 0.283
6	3ag	H	H		04.09 ± 0.431	11.40 ± 0.332	10.85 ± 0.535
7	3ah	F	H		08.69 ± 0.233	14.28 ± 0.296	12.08 ± 0.372
8	3ai	H	F		13.05 ± 0.070	09.78 ± 0.431	09.12 ± 0.288
9	3aj	F	F		06.44 ± 0.395	06.95 ± 0.342	05.68 ± 0.431
10	3ak	H	Cl		09.35 ± 0.827	08.05 ± 0.521	09.85 ± 0.635
11	3al	H	H	OH	05.31 ± 0.134	06.47 ± 0.134	06.38 ± 0.512
12	3am	F	H	OH	05.05 ± 0.007	07.09 ± 0.339	05.64 ± 0.186
13	3an	H	F	OH	10.70 ± 0.141	07.53 ± 0.509	08.94 ± 0.543
14	3ao	F	F	OH	02.88 ± 0.021	02.24 ± 0.176	02.13 ± 0.134
15	3ap	H	Cl	OH	10.75 ± 0.212	09.72 ± 0.360	08.46 ± 0.482
16	3aq	H	H	H	11.50 ± 0.141	13.03 ± 0.381	12.73 ± 0.736

17	3ar	F	H	H	12.80 ± 0.141	11.32 ± 0.346	12.16 ± 0.538
18	3as	H	F	H	27.65 ± 0.355	23.82 ± 0.459	20.63 ± 0.689
19	3at	F	F	H	26.50 ± 0.420	26.60 ± 0.989	24.00 ± 1.290
20	3au	H	Cl	H	09.95 ± 0.205	19.12 ± 0.459	15.39 ± 0.984
	Doxoru bicin*				02.33 ± 0.035	02.51 ± 0.183	02.18 ± 0.127

Figure 1. In vitro anti- cancer activity of a compounds 3ab-3au against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines (MCF-7& MDA-MB-231)




As evident from **Table 7** and **Figure 2**, the antiproliferative activities of Flavone-Estradiol adduct **6ab** to **6ag** were determined against the human cervical cancer cell line HeLa and estrogen-responsive breast cancer cell lines MCF-7, as well as the estrogen-independent breast cancer cell line MDA-MB-231. In Flavone-Estradiol adduct **6ad**, the coupling reaction took place at 2-position of flavones with 4'-methoxy substituent on the flavones moiety, showed greater antiproliferative activity than the standard drug doxorubicin having IC₅₀ Values 02.42 ± 0.226µM, 02.93 ± 0.137µM, 02.56 ± 0.322µM against MCF-7, MDA-MB-231 and HeLa, respectively. Also compound **6ab** with 3', 4' 5' - trimethoxy substituent on flavone was equally potent as that of doxorubicin with IC₅₀ 02.85 ± 0.165µM, 03.64 ± 0.276µM, 02.17 ± 0.183µM against MCF-7, MDA-MB-231 & HeLa resp. and the compound **6ae** and **6ag** were moderately active with IC₅₀ in between 07.27 ± 0.815µM to 08.42 ± 0.563µM, rest of the compounds **6ac** and **6af** shows poor activity having IC₅₀ more than 10.28 ± 0.736µM.

Table 7. Showing anti-proliferative data (IC₅₀s Values in μM) of all the synthesized Flavone-Estradiol adduct and standard drug against Human Breast cancer cell lines (MCF-7& MDA-MB-231) and Human Cervical cancer cell line (HeLa).

S. No.	Compounds code	MCF-7	MDA-MB-231	HeLa
1	6ab	02.85 \pm 0.165	03.64 \pm 0.276	02.17 \pm 0.183
2	6ac	17.38 \pm 1.212	20.52 \pm 1.388	22.44 \pm 1.436
3	6ad	02.42 \pm 0.226	02.93 \pm 0.137	02.56 \pm 0.322
4	6ae	07.72 \pm 0.628	08.42 \pm 0.563	07.27 \pm 0.815
5	6af	14.15 \pm 0.825	13.54 \pm 1.023	11.62 \pm 0.794
6	6ag	09.61 \pm 1.019	10.28 \pm 0.736	07.40 \pm 0.655
	Doxorubicin*	02.70 \pm 0.185	03.14 \pm 0.126	02.25 \pm 0.095

Figure 2. In vitro anti- cancer activity of a compounds 6ab-6ag against Human cervical cancer cell line (HeLa) and Human Breast cancer cell lines (MCF-7& MDA-MB-231).



5.4. CONCLUSION

In conclusion, we have developed a facile one-step synthetic strategy for tamoxifen analog. It involves selective cross McMurry coupling between a substituted indanone and substituted propiophenone. These compounds were screened for their anti proliferative activity against human cancer cell line. (Hela, MCF-7 & MDA-MB-231). The compounds 3ac, 3ad, 3ae, 3ao with an optimal combination of side chain at Para position of propiophenone and fluoro substituent on indanone moiety displayed the best activity among the test compounds having IC₅₀ = 2.13 - 3.81 μM of 3ac, 3ad, 3ae & 3ao and rest of the compounds also shows

comparable activity to the standard drug doxorubicin having $IC_{50} < 28\mu\text{m}$. The flavones-Estradiol adduct 6ab and 6ad shows excellent activity having IC_{50} Values in μM 02.85 ± 0.165 & 02.42 ± 0.226 and 03.64 ± 0.276 , 02.93 ± 0.137 against Human Breast cancer cell lines (MCF-7& MDA-MB-231) and 02.17 ± 0.183 , 02.56 ± 0.322 against Human cervical cancer cell line (HeLa) respectively and rest of the compounds also shows moderate activity to the standard drug doxorubicin having $IC_{50} < 10\mu\text{m}$.


5.5. EXPERIMENTAL DETAILS

5.5.1. General procedure for the synthesis of tamoxifen analog 3ab-3au/4ab-4ac & 5ab-5ac:


Under N_2 atmosphere, a three neck flask equipped with magnetic stirrer was charged with Zn-powder (1.5gm, 12 mmol) and 50 mL THF solvent. The mixture was cooled at 0°C and SnCl_4 (2.3mL, 6 mmol) was added drop wise at 0°C . The suspension was warmed to room temperature and stirred for 15 min and then heated at $64-66^\circ\text{C}$ for 1.5 h. The solution of solution of indanone derivative **1a-1t** and propiophenone derivative **2b-2e** (1:1.5 molar ratio, 2 mmol) dissolved in THF (30 mL) was added slowly at same temperature. TLC monitoring, the reaction mixture was stirred at same temperature until the carbonyl compound was consumed in the reaction. Then, the reaction mixture was cooled and quenched with 10% aqueous NaHCO_3 solution and extracted in EtOAc. The organic layer was washed with brine solution, dried with anhydrous Na_2SO_4 and concentrated in *vacuo*. The crude material was purified by column chromatography to give the desired products **3ab-3au/4ab-4ac & 5ab-5ac** in 52-72% % yields.

General procedure for the synthesis of Flavone-Estradiol adducts analog 6ab-6ag: Under N_2 - atmosphere, a four necked flask equipped with magnetic stirrer was charged with 0.11 mmol tin derivative and 0.1 mmol flavones derivative and three crystals of 2,6-ditert butyl-4-methylphenol dissolve in dry toluene (2 ml), flushed the reaction mixture for 10 min under nitrogen atmosphere. Added 6 mg of palladium catalyst again flush with N_2 gas for 5 min. Then, the reaction mixture was stirred for 2 days at $100-110^\circ\text{C}$. After completion of reaction, the solvent was evaporated under reduced pressure and washed with hexane to remove excess tin derivative. The reaction mixture was purified using silica gel column chromatography in 20:80 ethyl acetate/hexane to obtain flavones-estradiol adduct with 60-70% yields.

5.5.2 Spectral data of indanofen derivatives




(E)-1-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-3-phenyl-2,3-dihydro-1H-inden-2-ol (3ab): Light yellow semi solid; Yield: 66 %; **IR** ν_{\max} (**KBr**, cm^{-1}): 3452 (OH str), 2963 (aromatic C-H str), 1599 (aromatic, C=C str), 1451, 1419, 1262, 1021, 933, 868, 799 and 704; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz) δ (**ppm**): 7.92 (d, $J = 8$ Hz, 2H), 7.83 (d, $J = 7.5$ Hz, 2H), 7.60 (d, $J = 7$ Hz, 1H), 7.49-7.45 (m, 2H), 7.41 (dd, $J = 7.5, 2.5$ Hz, 2H), 7.27-7.25 (m, 2H), 6.92 (d, $J = 7.5$ Hz, 2H) 4.73 (d, $J = 3.5$ Hz, 1H), 4.62 (d, $J = 3.5$ Hz, 1H), 4.15 (t, $J = 1.5$ Hz, 2H), 2.90 (s, 6H), 2.61 (t, $J = 1.5$ Hz, 2H), 2.25 (q, $J = 8.0, 2.0$ Hz, 2H), 1.18 (t, $J = 7$ Hz, 3H) 3.60 (s, br, D_2O exchangeable, 1 H); **$^{13}\text{C-NMR}$** (CDCl_3 , 125 MHz) δ (**ppm**): 160.25, 157.05, 137.76, 132.57, 132.42, 131.77, 130.65, 130.49, 130.33, 129.65, 128.97, 128.68, 128.66, 127.05, 116.56, 116.32, 114.65, 71.65, 67.73, 61.35, 52.65, 48.35, 28.27, 14.03; **MS (EI, 70eV):** $m/z = 413$ [M^+ , $\text{C}_{28}\text{H}_{31}\text{NO}_2$]; **HRMS (ES-TOF) calcd** for $\text{C}_{28}\text{H}_{31}\text{NO}_2$ 413.2355, found 413.2354.



(E)-1-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-5-fluoro-3-phenyl-2,3-dihydro-1H-inden-2-ol (3ac): Light yellow semi solid; Yield: 60 %; **IR** ν_{\max} (**KBr**, cm^{-1}): 3408 (OH str), 2917 (aromatic C-H str), 1589 (aromatic, C=C str), 1489, 1415, 1288, 1177, 1091, 1014, 929 and 701; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz) δ (**ppm**): 7.88 (t, $J = 8$ Hz, 2H), 7.85 (t, $J = 8$ Hz, 2H), 7.55-7.49 (m, 5H), 7.41-7.39 (m, 1H), 6.86 (t, $J = 7.5$ Hz, 2H), 4.58 (d, $J = 4.0$ Hz, 1H), 4.41 (d, $J = 4.5$ Hz, 1H), 4.15 (t, $J = 2.0$ Hz, 2H), 2.90 (s, 6H), 2.62 (t, $J = 2.0$ Hz, 2H), 2.25 (q, $J = 7.0, 2.5$ Hz, 2H) 1.18 (t, $J = 7.0$ Hz, 3H), 3.42 (s, br, D_2O exchangeable, 1H); **^{13}C** (CDCl_3 , 125 MHz) δ (**ppm**): 159.68, 158.55, 157.11, 137.93, 132.55, 132.49, 131.65, 130.97, 130.77, 130.68, 129.65, 128.49, 128.47, 128.05, 127.66, 116.05, 114.11, 71.75, 67.72, 61.55, 52.11, 47.32, 26.05, 12.98; **MS (EI, 70eV):** m/z (%) = 431 [M^+ , $\text{C}_{28}\text{H}_{30}\text{FNO}_2$]; **HRMS (ES-TOF) calcd** for $\text{C}_{28}\text{H}_{30}\text{FNO}_2$ 431.2261, found 431.2259


(E)-1-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-2-ol (3ad): Light yellow semi solid; Yield: 64 %; **IR** ν_{\max} (**KBr**, cm^{-1}): 3391 (OH str), 2951 (aromatic C-H str), 1577 (aromatic, C=C str), 1468, 1401, 1271, 1152, 1084, 1002, 910 and 725; **$^1\text{H-NMR}$** (CDCl_3 , 500 MHz) δ (**ppm**): 7.87 (t, $J = 7.5$ Hz, 2H), 7.85 (t, $J = 7.5$ Hz, 2H), 7.55-7.49 (m, 5H), 7.41-7.39 (m, 1H), 6.86 (t, $J = 7.5$ Hz, 2H), 4.58 (d, $J = 4.0$ Hz, 1H), 4.41 (d, $J = 4.0$ Hz, 1H), 4.14 (d, $J = 3.5$ Hz, 1H), 2.90 (s, 6H), 2.62 (t, J

= 2.5, 2H), 2.25(q, $J = 7.0, 2.5$ Hz, 2H), 1.18 (t, $J = 8.0$, Hz, 3H), 3.40 (s, br, D₂O



exchangeable, 1 H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 159.54, 158.66, 137.95, 132.55, 132.49, 131.65, 130.49, 130.47, 130.05, 129.65, 128.97, 128.77, 128.68, 127.66, 116.03, 114.05, 71.73, 67.72, 61.05, 52.32, 47.11, 26.05, 12.95; MS (EI, 70eV): m/z (%) = 431[M⁺, C₂₈H₃₀FNO₂]; HRMS (ES-TOF) calcd for C₂₈H₃₀FNO₂ 431.2261, found 431.2259


(E)-1-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-5-fluoro-3-(4-fluorophenyl)-2,3-dihydro-1H-inden-2-ol (3ae): Light brown semi solid;



Yield: 58 %; IR ν_{\max} (KBr, cm⁻¹): 3426 (OH str), 2923 (aromatic C-H str), 1591 (aromatic, C=C str), 1417, 1395, 1282, 1170, 1092; ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 7.98 (t, $J = 8.5$ Hz, 2H), 7.79-7.76 (m, 2H), 7.70 (dd, $J = 7.5, 1.5$ Hz, 2H), 7.47 (dd, $J = 8.5, 2.0$ Hz, 1H), 7.25-7.36 (m, 2 H), 6.86 (dd, $J = 8.0, 3.0$ Hz, 2H), 4.52 (d, $J = 3.0$, Hz, 1H), 4.44 (d, $J = 3.0$ Hz, 1H), 4.15 (t, $J = 2.0$ Hz, 2H), 2.98 (s, 6H), 2.72 (t, $J = 2.0$ Hz, 2H), 2.25 (q, $J = 7.0, 2.5$ Hz, 2H), 1.19 (t, $J = 7$ Hz, 3H), 3.52 (s, br, D₂O exchangeable, 1 H);

¹³C- (CDCl₃, 125 MHz) δ (ppm): 161.27, 160.55, 159.47, 158.77, 138.76, 138.54, 130.68, 130.49, 130.05, 129.65, 128.97, 128.65, 127.66, 117.97, 117.66, 114.76, 70.72, 66.73, 61.35, 52.32, 48.05, 26.95, 13.32; MS (EI, 70eV): m/z = 449 [M⁺, C₂₈H₂₉F₂NO₂];


HRMS (ES-TOF) calcd for C₂₈H₂₉F₂NO₂ 449.2166, found 449.2168




(E)-1-(4-chlorophenyl)-3-(1-(4-(2-(dimethylamino)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (3af): Light brown semi solid; Yield:

55 %; IR ν_{\max} (KBr, cm⁻¹): 3449 (OH str), 2950 (aromatic C-H str), 1582 (aromatic, C=C str), 1389, 1275, 1059, 854, 723 (C-Cl, str); ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 8.08 (dd, $J = 7.0, 2.0$ Hz, 1H), 7.94 (d, $J = 8.5$ Hz, 1H), 7.83 (d, $J = 8.5$, Hz, 1H), 7.53 (d, $J = 8.5$ Hz, 2H), 7.47(d, $J = 8.5$ Hz, 1 H), 7.27 (t, $J = 7.0$ Hz, 2H), 7.16 (d, $J = 8.5$ Hz, 1H), 6.89 (dd, $J = 8.0, 2.5$ Hz, 2H), 4.67 (d, $J = 3.0$ Hz, 1H), 4.32 (d, $J = 3.0$ Hz, 1H), 3.94 (d, $J = 2.5$ Hz, 2H), 3.00 (s, 6H), 2.81(t, $J = 3.0$ Hz, 2H), 2.26 (q, $J = 8.0, 3.0$ Hz, 2H), 1.08 (t, $J = 8.0$ Hz, 3H), 3.41 (s, br, D₂O exchangeable, 1 H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 159.55, 157.27, 137.76, 132.54, 132.47, 131.77, 130.65, 130.49, 130.05, 129.65, 128.97, 128.68, 128.66, 127.03, 117.95, 115.76, 71.72, 67.73, 61.35, 52.32, 48.97,

28.95, 14.05; **MS (EI, 70eV):** m/z (%) = 447[M^+ , $C_{28}H_{30}ClNO_2$], 449[M^{+2}]; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}ClNO_2$ 447.1965, found 447.1967.




(E)-1-phenyl-3-(1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (3ag): Light yellow semi solid; Yield: 58 %; **IR ν_{max} (KBr, cm^{-1}):** 3420 (OH str), 2959, 2869 (aromatic C-H str), 1583 (aromatic, C=C str), 1253, 1063, 835; **1H -NMR ($CDCl_3$, 500 MHz) δ (ppm):** 7.91(d, J = 8.0 Hz, 2H), 7.83 (d, J = 8.5 Hz, 2H), 7.59 (t, J = 8.5 Hz, 1H), 7.48-7.45 (m, 2H), 7.42-7.39 (m, 2H), 7.27-7.25 (m, 2H), 6.91 (d, J = 8.0 Hz, 2H), 5.27 (d, J = 2.0 Hz, 1H), 5.12 (d, J = 2.0 Hz, 1H), 4.14 (t, J = 2.5 Hz, 2H), 2.92 (m, 2H), 2.76 (t, J = 6.0 Hz, 2H), 2.49 (s, 4H), 1.59 (q, J = 7.5, 3.0 Hz, 2H), 1.44 (t, J = 6.0 Hz, 2H), 1.18 (t, J = 8.0 Hz, 3H), 3.85 (s, br, D_2O exchangeable, 1 H), **^{13}C - ($CDCl_3$, 125 MHz) δ (ppm):** 158.27, 153.65, 137.77, 132.54, 132.47, 131.77, 130.65, 130.49, 130.05, 129.65, 128.97, 128.68, 128.66, 127.03, 118.95, 117.66, 117.05, 115.65, 76.16, 74.32, 63.73, 58.79, 56.95, 28.15, 26.97, 25.04, 13.05; **MS (EI, 70eV):** m/z = 453[M^+ , $C_{31}H_{35}NO_2$]; **HRMS (ES-TOF) calcd** for $C_{32}H_{35}NO_2$ 453.2668, found 453.2666.



(E)-5-fluoro-3-phenyl-1-(1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (3ah): Light brown semi solid; Yield: 59 %; **IR ν_{max} (KBr, cm^{-1}):** 3415 (OH str), 2931, 2873 (aromatic C-H str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **1H -NMR ($CDCl_3$, 500 MHz) δ (ppm):** 7.88-7.84 (m, 4H), 7.55-7.49 (m, 4H), 7.42-7.26 (m, 2H), 6.87 (t, J = 7.5 Hz, 2H), 4.68 (d, J = 3.5 Hz, 1H), 4.51 (d, J = 3.0 Hz, 1H), 3.83 (d, J = 3.0 Hz, 2H), 3.84-3.80 (m, 2H), 2.77 (t, J = 4.0 Hz, 2H), 2.39-2.36 (m, 4H), 1.49 (q, J = 7.5, 1.5 Hz, 2H), 1.14 (t, J = 6 Hz, 4H), 0.97 (t, J = 7.5 Hz, 3H), 3.83(s, br, D_2O exchangeable, 1H), **^{13}C - ($CDCl_3$, 125 MHz) δ (ppm):** 161.15, 157.78, 153.62, 137.47, 132.74, 132.57, 131.65, 130.79, 130.45, 130.05, 129.79, 128.93, 128.68, 128.66, 127.05, 117.00, 116.65, 116.08, 76.32, 74.16, 64.75, 58.93, 56.70, 27.79, 26.95, 25.43, 14.55; **MS (EI, 70eV):** m/z (%) = 471[M^+ , $C_{31}H_{34}FNO_2$]; **HRMS (ES-TOF) calcd** for $C_{31}H_{34}FNO_2$ 471.2574, found 471.2571.


(E)-1-(4-fluorophenyl)-3-(1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (3ai): Light yellow semi solid; Yield: 58 %; **IR ν_{max} (KBr, cm^{-1}):** 3429 (OH str), 2951, 2880 (aromatic C-H str), 1607 (aromatic, C=C str), 1271, 1107, 843, 729; **1H -NMR ($CDCl_3$, 500 MHz) δ (ppm):** 7.89-7.85 (m, 4H), 7.56-7.50 (m, 4H), 7.41-7.39 (m, 2H), 6.87

(t, $J = 7.5$ Hz, 2H), 4.67 (d, $J = 3.5$ Hz, 1H), 4.50 (d, $J = 4.0$ Hz, 1H), 3.74 (t, $J = 6.5$ Hz, 2H), 3.85-3.80 (m, 2H), 2.76 (t, $J = 6.0$ Hz, 2H), 2.40-2.39 (m, 4H), 1.48 (q, $J = 8.0$, 2.5 Hz, 2H), 1.14 (t, $J = 6.0$ Hz, 4H), 0.97 (t, $J = 7.5$ Hz, 3H), 3.45 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 161.15, 157.62, 153.78, 137.47, 132.74, 132.57, 131.65, 130.93, 130.68, 130.66, 129.79, 128.45, 128.16, 127.05, 117.00, 116.65, 116.05, 76.32, 74.08, 64.75, 58.93, 56.70, 27.87, 26.95, 25.79, 14.43; MS (EI, 70eV): m/z (%) = 471[M⁺, C₃₁H₃₄FNO₂]; HRMS (ES-TOF) calcd for C₃₁H₃₄FNO₂ 471.2574, found 471.2571.




(E)-5-fluoro-3-(4-fluorophenyl)-1-(1-(4-(2-(piperidin-1-yl)ethoxy) phenyl) propylidene)-2,3-dihydro-1H-inden-2-ol (3aj): Light yellow semi solid; Yield:

55%; IR ν_{\max} (KBr, cm⁻¹): 3382 (OH str), 2992, 2886 (aromatic C-H str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 8.05 (d, $J = 8.5$ Hz, 2H), 7.94 (d, $J = 8.5$ Hz, 1H), 7.83 (d, $J = 8.5$ Hz, 1H), 7.53 (d, $J = 8.5$ Hz, 2H), 7.47 (d, $J = 8.5$ Hz, 2H), 7.28 (t, $J = 8.5$ Hz, 2H), 7.16 (d, $J = 8.5$ Hz, 1H), 6.94 (d, $J = 8.5$ Hz, 2H), 4.98 (d, $J = 3.5$ Hz, 1H), 4.71 (d, $J = 4.0$ Hz, 1H), 3.94 (t, $J = 6.0$ Hz, 1H), 3.04-3.00 (m, 2H), 2.96 (t, $J = 6.0$ Hz, 2H), 2.49-2.48 (m, 2H), 1.69 (q, $J = 1.0, 7.5$ Hz, 4H), 1.44 (t, $J = 8.5$ Hz, 3H), 4.42 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 161.25, 160.57, 159.44, 158.76, 138.77, 138.57, 130.68, 130.49, 130.25, 129.65, 128.97, 128.65, 127.66, 117.97, 117.67, 114.76, 73.32, 70.72, 66.73, 61.35, 51.32, 30.09, 27.15, 26.09, 13.05; MS (EI, 70eV): m/z (%) = 489[M⁺, C₃₁H₃₃F₂NO₂]; HRMS (ES-TOF) calcd for C₃₁H₃₃F₂NO₂ 489.2479, found 489.2477.




(E)-1-(4-chlorophenyl)-3-(1-(4-(2-(piperidin-1-yl)ethoxy)phenyl)propylidene)-2,3-dihydro-

1H-inden-2-ol (3ak): Light yellow semi solid; Yield: 52 %; IR ν_{\max} (KBr, cm⁻¹): 3440 (OH str), 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1125 (C-O-C, str), 1091, 771 (C-Cl, str); ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 7.92 (d, $J = 7.0$ Hz, 2H), 7.83 (d, $J = 7.5$ Hz, 2H), 7.59 (d, $J = 7.0$ Hz, 1H), 7.48-7.45 (m, 1H), 7.41 (dd, $J = 7.0, 2.5$ Hz, 1H), 7.27-7.25 (m, 2H), 6.91 (d, $J = 7.5$ Hz, 1H), 5.27 (d, $J = 2.0$ Hz, 1H), 5.12 (d, $J = 3.0$ Hz, 1H), 4.14 (t, $J = 3.0$ Hz, 2H), 2.94-2.90 (m, 2H), 2.77 (t, $J = 6.0$ Hz, 2H), 2.49-2.47 (m, 4H),




1.59 (q, $J = 7.0, 2.0$ Hz, 2H), 1.44 (t, $J = 6.0$ Hz, 4H), 1.19 (t, $J = 7.0$ Hz, 3H), 3.70 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 157.78, 153.62, 137.74, 132.57, 132.47,

131.79, 130.65, 130.45, 130.05, 129.63, 128.79, 128.68, 128.66, 127.05, 118.96, 117.65, 117.05, 115.66, 76.13, 74.32, 64.73, 58.90, 56.75, 27.95, 26.79, 25.45, 14.35; **MS (EI, 70eV):** m/z (%) = 487[M⁺, C₃₁H₃₄ClNO₂], 489[M²⁺]; **HRMS (ES-TOF) calcd** for C₂₄H₂₀F₂O 487.2278, found 487.2276.




(E)-1-(1-(4-hydroxyphenyl) propylidene)-3-phenyl-2,3-dihydro-1H-inden-2-ol (3al): Light brown semi solid; Yield: 70%; **IR** ν_{\max} (KBr, cm⁻¹): 3429 (OH str), 2951, 2880 (aromatic C-H str), 1607 (aromatic, C=C str), 1271, 1107, 843, 729; **¹H-NMR (CDCl₃, 500 MHz) δ (ppm):** 8.11(dd, J = 8.5, 2.0 Hz, 2H), 7.94 (d, J = 8.5 Hz, 1H), 7.83 (d, J = 8.5 Hz, 1H), 7.53 (d, J = 8.5 Hz, 1H), 7.47(d, J = 8.5 Hz, 1H), 7.27 (t, J = 8.0 Hz, 2H), 7.16 (d, J = 8.5 Hz, 2H), 6.88 (dd, J = 8.0, 2.0 Hz, 2H), 4.67 (d, J = 4.0 Hz, 1H), 4.20 (d, J = 4.0 Hz, 1H), 2.19 (q, J = 2.0, 8.0 Hz, 2H), 1.10 (t, J = 8.0 Hz, 3H), 3.68 (s, br, D₂O exchangeable, 1H); 1.56 (s, br, D₂O exchangeable, 1H); **¹³C-** (CDCl₃, 125 MHz) δ (ppm): 159.60, 155.65, 142.65, 141.32, 138.52, 131.66, 130.97, 130.68, 129.97, 129.58, 128.68, 127.97, 126.68, 121.97, 121.68, 116.66, 115.32, 71.08, 51.68, 26.12, 13.03; **MS (EI, 70eV):** m/z (%) = 342[M⁺, C₂₄H₂₂O₂]; **HRMS (ES-TOF) calcd** for C₂₄H₂₂O₂ 342.1620 [M+H]⁺, found 342.1617.



(E)-5-fluoro-1-(1-(4-hydroxyphenyl)propylidene)-3-phenyl-2,3-dihydro-1H-inden-2-ol (3am): Light brown semi solid; Yield: 72%; **IR** ν_{\max} (KBr, cm⁻¹): 3415 (OH str), 2931, 2873 (aromatic C-H str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **¹H-NMR (CDCl₃, 500 MHz) δ (ppm):** 7.99-7.86 (m, 2H), 7.79-7.76 (m, 2H), 7.71 (dd, J = 1.5, 8.0 Hz, 2H), 7.49-7.44 (m, 2H), 7.34(dd, J = 2.0, 8.0 Hz, 2H), 6.88 (dd, J = 2.0, 7.0 Hz, 2H), 4.49 (t, J = 3.0 Hz, 1H), 4.46 (d, J = 3.0 Hz, 1H), 2.29 (q, J = 2.0, 8.0 Hz, 2H), 1.28 (t, J = 8.0 Hz, 3H), 6.17 (s, br, D₂O exchangeable, 1H), 3.70 (s, br, D₂O exchangeable, 1H); **¹³C-** (CDCl₃, 125 MHz) δ (ppm): 165.58, 158.32, 142.54, 141.47, 138.35, 130.97, 130.66, 129.97, 129.68, 128.97, 127.97, 126.95, 116.66, 115.05, 113.65, 73.05, 52.12, 28.03, 14.03; **MS (EI, 70eV):** m/z = 360[M⁺, C₂₄H₂₁FO₂]; **HRMS (ES-TOF) calcd** for C₂₄H₂₁FO₂ 360.1526, found 360.1529.

(E)-1-(4-fluorophenyl)-3-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (3an): Light yellow semi solid; Yield: 70%; **IR** ν_{\max} (KBr, cm⁻¹): 3382 (OH str), 2992, 2886 (aromatic C-H str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; **¹H-NMR (CDCl₃, 500 MHz) δ (ppm):** 7.88-7.84 (m, 4H), 7.55-7.50 (m, 4H), 7.42-7.39 (m, 2H), 6.87 (t, J = 8.0 Hz,

2H), 4.88 (d, $J = 3.5$ Hz, 1H), 4.61 (d, $J = 3.5$ Hz, 1H), 2.38 (q, $J = 2.0, 7.5$ Hz, 2H), 1.37 (t, $J = 7.0$ Hz, 3H), 3.65 (s, br, D₂O exchangeable, 1H), 1.62 (s, br, D₂O exchangeable, 1H), ¹³C- (CDCl₃, 125 MHz) δ (ppm): 162.32, 156.54, 142.47, 141.58, 138.65, 130.97, 130.68, 129.97, 129.68, 128.68, 127.96, 126.67, 116.65, 115.05, 113.66, 71.12, 55.08, 26.35, 14.35; MS (EI, 70eV): m/z (%) = 360[M⁺, C₂₄H₂₁FO₂]; HRMS (ES-TOF) calcd for C₂₄H₂₁FO₂ 360.1526, found 360.1528.



(E)-5-fluoro-3-(4-fluorophenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-

inden-2-ol (3ao): Light brown semi solid; Yield: 68%; IR ν_{\max} (KBr, cm⁻¹):


3405 (OH str), 2922, 2875 (aromatic C-H str), 1595 (aromatic, C=C str), 1266, 1089, 858, 731; ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 8.00-7.85 (m, 2H), 7.80-7.77 (m, 2H), 7.76-7.69 (m, 2H), 7.47 (dd, $J = 2.0, 8.0$ Hz, 1H), 7.36 (dd, $J = 2.0, 7.0$ Hz, 2H), 6.89 (dd, $J = 2.0, 8.0$ Hz, 2H), 4.50 (d, $J = 4.0$ Hz, 1H), 4.46 (d, $J = 3.5$ Hz, 1H), 2.29 (q, $J = 2.0, 8.0$ Hz, 2H), 1.28 (t, $J = 8.0$ Hz, 3


H), 6.10 (s, br, D₂O exchangeable, 1H), 1.72 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 163.58, 158.32, 142.65, 141.47, 138.54, 130.97, 130.68, 129.97, 129.68, 128.97, 127.68, 126.66, 116.65, 115.05, 113.66, 73.05, 52.12, 28.35, 14.59; MS (EI, 70eV): m/z (%) = 378[M⁺, C₂₄H₂₀F₂O₂]; HRMS (ES-TOF) calcd for C₂₄H₂₀F₂O₂ 378.1431, found 378.1434.

(E)-1-(4-chlorophenyl)-3-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol


(3ap): Light brown semi solid; Yield: 67%; IR ν_{\max} (KBr, cm⁻¹): 3440 (OH str), 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1091, 771 (C-Cl, str); ¹H-NMR (CDCl₃, 500 MHz) δ (ppm): 8.09 (dd, $J = 2.0, 7.5$ Hz, 2H), 7.94 (d, $J = 8.5$ Hz, 1H), 7.83 (d, $J = 8.5$ Hz, 1H), 7.53 (d, $J = 8.5$ Hz, 2H), 7.47 (d, $J = 8.5$ Hz, 1H), 7.27 (t, $J = 8.5$ Hz, 1H), 7.16 (d, $J = 8.5$ Hz, 1H), 6.89 (dd, $J = 2.0, 8.0$ Hz, 1H), 4.68 (d, $J = 3.5$ Hz, 1H), 4.21 (d, $J = 4.5$ Hz, 1H),

2.19(q, $J = 2.0, 7.0$ Hz, 2H), 1.19 (t, $J = 8.0$ Hz, 3H), 3.67 (s, br, D₂O exchangeable, 1H), 1.65 (s, br, D₂O exchangeable, 1H); ¹³C- (CDCl₃, 125 MHz) δ (ppm): 163.35, 142.68, 141.52, 138.75, 131.52, 130.97, 130.68, 129.98, 129.65, 128.68, 127.78, 126.36, 116.62, 115.35, 113.66, 70.13, 51.12, 26.66, 51.68, 15.68; MS (EI, 70eV): m/z (%) = 376[M⁺, C₂₄H₂₁ClO₂], 378[M²⁺]; HRMS (ES-TOF) calcd for C₂₄H₂₁ClO₂ 376.1230, found 376.1233.




**(E)-1-phenyl-3-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (3aq):**


Light brown semi solid; Yield: 72%; IR ν_{\max} (KBr, cm^{-1}): 3425 (OH str), 2935, 2877 (aromatic C-H str), 1585 (aromatic, C=C str), 1266, 1088, 862, 733; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.91-7.66 (m, 4H), 7.6-7.54 (m, 1H), 7.54-7.50 (m, 4H), 7.37-7.34 (m, 2H), 7.33-7.32 (m, 1H), 7.31-23 (m, 2H), 4.72 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 2.31 (q, $J = 1.0, 7.5$ Hz, 2H), 1.17 (t, $J = 7.0$ Hz, 3H), 3.30 (s, br, D_2O exchangeable, 1H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 157.60, 142.65, 141.32, 138.58, 131.52, 130.97, 130.68, 129.97, 129.68, 128.68, 127.78, 126.35, 121.97, 121.68, 116.66, 115.32, 71.12, 51.03, 26.66, 13.68; MS (EI, 70eV): m/z (%) = 326[M^+ , $\text{C}_{24}\text{H}_{22}\text{O}$]; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{22}\text{O}$ 326.1671, found 326.1673.

(E)-5-fluoro-3-phenyl-1-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (3ar):


Light yellow semi solid; Yield: 74%; IR ν_{\max} (KBr, cm^{-1}): 3449 (OH str), 2950 (aromatic C-H str), 1682 (C=O str), 1582 (aromatic, C=C str), 1389, 1275, 1059, 854; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.87-7.85 (m, 4H), 7.55-7.49 (m, 4H), 7.41-7.39 (m, 2H), 6.87 (t, $J = 7.5$ Hz, 2H), 4.58 (d, $J = 3.5$ Hz, 1H), 4.31 (d, $J = 4.0$ Hz, 1H), 2.37 (q, $J = 2.5, 7.5$ Hz, 2H), 1.38 (t, $J = 7.5$ Hz, 3H), 1.88 (s, br, D_2O exchangeable, 1H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 160.54, 156.47, 142.32, 141.58, 138.65, 130.97, 130.68, 129.97, 129.68, 128.66, 127.97, 126.68, 116.06, 115.05, 113.65, 71.12, 51.08, 26.35, 13.95; MS (EI, 70eV): m/z (%) = 344[M^+ , $\text{C}_{24}\text{H}_{21}\text{FO}$]; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{F}_2\text{O}$ 344.1576, found 344.1574

(E)-1-(4-fluorophenyl)-3-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (3as):


Light yellow semi solid; Yield: 70 %; IR ν_{\max} (KBr, cm^{-1}): 3439 (OH str), 2922 (aromatic C-H str), 1670 (C=O str), 1594 (aromatic, C=C str), 1491, 1399, 1296, 1095; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.88-7.85 (m, 4H), 7.56-7.50 (m, 4H), 7.42-7.39 (m, 2H), 6.87 (t, $J = 7.0$ Hz, 2H), 4.88 (d, $J = 3.5$ Hz, 1H), 4.60 (d, $J = 3.5$ Hz, 1H), 2.38 (q, $J = 2, 7.5$ Hz, 2H), 1.38 (t, $J = 6.5$ Hz, 3H), 1.70 (s, br, D_2O exchangeable, 1 H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 160.52, 156.44, 142.32, 141.58, 138.65, 130.97, 130.68, 129.78, 129.68, 128.68, 127.97, 126.68, 116.66, 115.05, 113.65, 71.08, 51.12, 26.35, 13.66; MS (EI, 70eV): m/z (%) = 344[M^+ , $\text{C}_{24}\text{H}_{21}\text{FO}$]; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{F}_2\text{O}$ 344.1576, found 344.1574.

(E)-5-fluoro-3-(4-fluorophenyl)-1-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (3at):

Light yellow semi solid; Yield: 68 %; IR ν_{\max} (KBr, cm^{-1}): 3466 (OH str), 2920 (aromatic C-H str), 1593 (aromatic, C=C str), 1398, 1281, 1095, 843; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.99-7.86 (m, 2H), 7.80-7.76 (m, 2H), 7.71 (dd, $J = 2.5, 8.5$ Hz, 2H), 7.47 (dd, $J = 2, 7.5$ Hz, 2H), 7.37-7.34 (m, 2H), 6.89 (dd, $J = 2.5, 7.5$ Hz, 2H), 4.50 (d, $J = 4.5$ Hz, 1H), 4.46 (d, $J = 4.5$ Hz, 1H), 2.29 (q, $J = 2, 8$ Hz, 2H), 1.28(t, $J = 8$ Hz, 3H), 3.52 (s, br, D_2O exchangeable, 1 H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 164.58, 160.32, 142.54, 141.47, 138.65, 130.97, 130.68, 129.97, 129.68, 128.66, 127.97, 126.95, 116.66, 115.05, 113.65, 73.12, 52.05, 28.35, 14.95; MS (EI, 70eV): m/z (%) = 362 [M^+ , $\text{C}_{24}\text{H}_{20}\text{F}_2\text{O}$]; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{20}\text{F}_2\text{O}$ 362.1482, found 362.1482.


(E)-1-(4-chlorophenyl)-3-(1-phenylpropylidene)-2,3-dihydro-1H-inden-2-ol (3au):

Light brown semi solid; Yield: 65 %; IR ν_{\max} (KBr, cm^{-1}): 3426 (OH str), 2923 (aromatic C-H str), 1591 (aromatic, C=C str), 1417, 1395, 1282, 1170, 1092, 757 (C-Cl, str); $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 8.08 (dd, $J = 2, 8$ Hz, 2H), 7.94 (d, $J = 7.5$ Hz, 1H), 7.83 (d, $J = 7.5$ Hz, 1H), 7.53 (d, $J = 7.5$ Hz, 2H), 7.47 (d, $J = 8.0$ Hz, 1H), 7.27(t, $J = 8.0$ Hz, 2H), 7.16 (d, $J = 8.0$ Hz, 1H), 6.87 (dd, $J = 2.0, 7.5$ Hz, 2H), 4.68 (d, $J = 3.5$ Hz, 1H), 4.21 (d, $J = 3.5$ Hz, 1H), 2.19 (q, $J = 2, 8$ Hz, 2H), 1.10 (t, $J = 8.5$ Hz, 3H), 1.60 (s, br, D_2O exchangeable, 1H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 156.60, 142.32, 141.58, 138.65, 131.52, 130.97, 130.68, 129.97, 129.68, 128.68, 127.7, 126.35, 116.66, 115.32, 113.65, 71.03, 51.12, 26.68, 13.66; MS (EI, 70eV): m/z = 360 [M^+ , $\text{C}_{24}\text{H}_{21}\text{ClO}$], 362 [M^{+2}]; HRMS (ES-TOF) calcd for $\text{C}_{24}\text{H}_{21}\text{ClO}$ 360.1281, found 360.1283.


(E)-5-bromo-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (4ab):

Yellow semi solid; Yield: 55%; IR ν_{\max} (KBr, cm^{-1}): 3453 (OH str), 2957 (aromatic C-H str), 1587 (aromatic, C=C str), 1385, 1274, 1064, 851; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.88 (dd, $J = 8.0, 2.5$ Hz, 2H), 7.81 (d, $J = 8.5$ Hz, 1H), 7.69-7.59 (m, 4H), 7.35-7.32 (m, 1H), 6.95(d, $J = 9$ Hz, 3 H), 5.34 (s, 1H), 4.87 (d, $J = 2.0$ Hz, 1H), 4.48 (d, $J = 2.0$ Hz, 1H), 4.26 (t, $J = 2.5$ Hz, 2H), 3.52 (s, 1H), 2.74 (s, 6H), 2.58 (t, $J = 2.5$ Hz, 2H), 2.12 (q, $J = 7.5, 1.5$ Hz, 2H), 1.04 (t, $J = 7.0$ Hz, 3H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 163.14, 161.127, 159.41, 157.88, 156.62, 140.112, 139.53,

136.28, 133.63, 131.54, 130.78, 129.62, 129.30, 124.37, 123.13, 116.12, 115.11, 73.13, 68.13, 62.15, 52.12, 47.45, 27.45, 14.10; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}BrNO_3$ 507.1409, found 507.1407.




(E)-5-chloro-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (4ac): Yellow semi solid; Yield: 52%; **IR** ν_{\max} (**KBr**, cm^{-1}): 3408 (OH str), 2917 (aromatic C-H str), 1589 (aromatic, C=C str), 1489, 1415, 1288, 1177, 1091, 1014, 929 and 701; **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 7.88 (t, $J = 8$ Hz, 2H), 7.85 (t, $J = 8$ Hz, 2H), 7.88 - 7.81 (m, 3H), 7.79 - 7.61 (m, 4H), 7.59 - 7.32 (m, 1H), 6.94 (d, $J = 8.0$ Hz, 3H), 5.34 (s, 1H), 4.87 (d, $J = 2.0$ Hz, 1H), 4.48 (d, $J = 2.0$ Hz, 1H), 4.26 (t, $J = 2.5$ Hz, 2H), 3.52 (s, 1H), 2.74 (s, 6H), 2.58 (t, $J = 2.5$ Hz, 2H), 2.12 (q, $J = 7.5, 1.5$ Hz, 1H), 1.04 (t, $J = 7.0$ Hz, 3H); **^{13}C -** ($CDCl_3$, 125 MHz) δ (ppm): 160.07, 159.62, 144.00, 143.57, 137.30, 136.65, 133.00, 130.92, 129.62, 129.29, 128.66, 128.07, 122.30, 117.13, 116.93, 73.13, 66.26, 61.16, 51.79, 46.79, 31.19, 14.92; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}ClNO_3$ 463.1914, found 463.1915.



(E)-3-(4-(2-(dimethylamino)ethoxy)phenyl)-5-fluoro-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (4ad): Light yellow semi solid; Yield: 52%; **IR** ν_{\max} (**KBr**, cm^{-1}): 3393 (OH str), 2953 (aromatic C-H str), 1575 (aromatic, C=C str), 1464, 1403, 1275, 1152, 1081, 1002, 911 and 725; **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 7.91 - 7.64 (m, 3H), 7.63 - 7.51 (m, 3H), 7.37 - 7.33 (m, 2H), 7.32 - 7.21 (m, 3H), 5.75 (s, 1H), 4.79 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 4.07 (d, $J = 2.5$ Hz, 2H), 3.6 (s, 1H), 3.12 (s, 6H), 2.50 (t, $J = 2.5$ Hz, 2H), 2.32 (q, $J = 8.5, 1.5$ Hz, 2H), 1.17 (t, $J = 7.0$ Hz, 3H); **^{13}C -** ($CDCl_3$, 125 MHz) δ (ppm): 163.14, 161.12, 159.41, 157.87, 156.62, 140.11, 139.52, 136.27, 133.62, 131.54, 130.77, 129.62, 129.30, 124.36, 123.12, 116.12, 115.10, 73.13, 68.12, 62.14, 52.81, 47.45, 27.45, 14.10; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}FNO_3$ 447.2210, found 447.2209.

(E)-5-bromo-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (4ae): Yellow semi solid; Yield: 55%; **IR** ν_{\max} (**KBr**, cm^{-1}): 3359 (OH str), 2957 (aromatic C-H str), 1572 (aromatic, C=C str), 1458, 1412, 1278, 1156, 1088, 1013, 915 and 732; **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 8.03 (d, $J = 8.0$ Hz, 3H), 7.82 (d, $J = 7.0$ Hz, 2H), 7.76 (dd, $J = 2.0, 7.0$ Hz, 4H), 7.49 (d, $J = 9.0$ Hz, 1H), 7.12 (t, $J = 7.5$ Hz,


3H), 5.56 (s, 1H), 4.75 (d, $J = 2.0$ Hz, 1H), 4.36 (d, $J = 2.0$ Hz, 1H), 4.14 (t, $J = 2.5$ Hz, 2H),



3.75 (s, 1H), 3.05(t, $J = 2.5$, 2H), 2.65(t, $J = 3.0$ Hz, 4H), 2.33 (q, $J = 1.5$, 9.0 Hz, 2H), 1.64-1.61 (m, 2 H), 1.51 (t, , $J = 2.5$ Hz, 2H), 1.02 (t, , $J = 8.0$ Hz, 3H); ^{13}C - (CDCl_3 , 125 MHz) δ (ppm): 161.13, 157.13, 156.41, 142.62, 140.10, 139.54, 136.27, 133.63, 131.54, 130.78, 129.62, 129.30, 122.37, 122.13, 116.19, 115.19, 73.13, 69.15, 58.10, 57.45, 52.81, 29.17,

25.14, 23.10, 12.56; HRMS (ES-TOF) calcd for $\text{C}_{31}\text{H}_{34}\text{BrNO}_3$ 547.1722, found 547.1724.


(E)-5-chloro-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (4af): Brown semi solid; Yield: 55%; IR ν_{max}



(KBr, cm^{-1}): 3419 (OH str), 2933, 2879 (aromatic C-H str), 1598 (aromatic, C=C str), 1262, 1083, 862, 739; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 7.96 (t, $J = 9.0$ Hz, 2H), 7.55-7.47 (m, 4H), 7.45-7.39 (m, 3H), 6.99-6.97 (m, 2H), 5.77 (s, 1H), 4.64 (d, $J = 2.0$ Hz, 1H), 4.21 (d, $J = 2.0$ Hz, 1H),


4.04 (t, $J = 2.5$ Hz, 2H), 3.75 (s, 1 H), 2.95 (t, $J = 2.5$ Hz, 2H), 2.58 (t, $J = 2.5$ Hz, 4H), 2.35 (q, $J = 7.0$, 1.5 Hz, 2H), 1.48 (t, $J = 2.5$ Hz, 4H), 1.01 (t, $J = 7.5$ Hz, 3H); ^{13}C - (CDCl_3 , 125 MHz) δ (ppm): 160.12, 158.41, 144.87, 144.62, 140.10, 139.54, 136.27, 133.63, 131.54, 130.78, 129.62, 124.37, 124.13, 117.69, 117.19, 73.15, 69.13, 58.10, 57.45, 52.81, 27.17, 25.14, 23.10, 13.13; HRMS (ES-TOF) calcd for $\text{C}_{31}\text{H}_{34}\text{ClNO}_3$ 503.2227, found 503.2227.

(E)-5-fluoro-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (4ag): Yellow semi solid;




Yield: 52%; IR ν_{max} (KBr, cm^{-1}): 3438 (OH str), 2953, 2882 (aromatic C-H str), 1609 (aromatic, C=C str), 1271, 1107, 846, 729; ^1H -NMR (CDCl_3 , 500 MHz) δ (ppm): 8.02 (d, $J = 8.0$ Hz, 2H), 7.77 (t, $J = 7.0$ Hz, 2H), 7.61 (t, $J = 7.0$ Hz, 3H), 7.48 (d, $J = 8.0$ Hz, 1H), 7.13 (t, $J = 8.0$ Hz, 3H), 5.55 (s,

1H), 4.74 (d, $J = 2.0$ Hz, 1H), 4.36 (d, $J = 2.0$ Hz, 1H), 4.14 (t, $J = 2.5$ Hz, 2H), 3.75 (s, 1H), 3.048 (t, $J = 2.5$ Hz, 2H), 2.65 (t, $J = 2.5$ Hz, 4H), 2.33 (q, $J = 2.5$, 7.5 Hz, 2H), 1.65 – 1.61 (m, 2H), 1.51 (t, $J = 2.5$ Hz, 4H), 1.02 (t, $J = 8.0$ Hz, 3H); ^{13}C - (CDCl_3 , 125 MHz) δ (ppm): 161.12, 157.12, 156.41, 142.62, 140.10, 139.54, 136.27, 133.63, 131.54, 130.78, 129.62, 129.30, 122.37, 122.13, 116.19, 115.19, 73.13, 69.15, 58.10, 57.45, 52.81, 27.17, 25.14, 23.10, 12.55; HRMS (ES-TOF) calcd for $\text{C}_{31}\text{H}_{34}\text{FNO}_3$ 487.2523, found 487.2524.




(Z)-5-bromo-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (5ab): Brown semi solid; Yield: 8%; IR ν_{\max} (KBr, cm^{-1}): 3415 (OH str), 2934, 2875 (aromatic C-H str), 1599 (aromatic, C=C str), 1267, 1085, 865, 635; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.89-7.69 (m, 4H), 7.55-7.48 (m, 2H), 6.97-6.81(m, 5H), 4.69 (d, $J = 2.5$ Hz, 2H), 4.28 (d, $J = 2.5$ Hz, 2H), 4.27 (t, $J = 2.5$ Hz, 2H), 2.93 (s, 6H), 2.87 (t, $J = 2.5$ Hz, 2H), 1.78 (q, $J = 8.0, 2.5$ Hz, 2H), 0.67 (t, $J = 7$ Hz, 3H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 163.14, 161.22, 159.42, 157.87, 156.62, 140.12, 139.53, 136.27, 133.63, 132.54, 130.77, 129.62, 129.30, 124.37, 123.13, 116.12, 115.10, 71.14, 66.13, 60.13, 50.17, 46.45, 25.45, 12.20; HRMS (ES-TOF) calcd for $\text{C}_{28}\text{H}_{30}\text{BrNO}_3$ 507.1409, found 507.1407.




(Z)-5-chloro-3-(4-(2-(dimethylamino)ethoxy)phenyl)-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (5ac): Brown semi solid; Yield: 10%; IR ν_{\max} (KBr, cm^{-1}): 3451 (OH str), 2955 (aromatic C-H str), 1584 (aromatic, C=C str), 1387, 1275, 1062, 855, 725 (C-Cl, str); $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.90 -7.85 (m, 2H), 7.54 – 7.59 (m, 2H), 7.10 – 7.03 (m, 3H), 7.00- 6.93 (m, 4H), 5.52 (s, 1H), 4.52 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 4.06 (t, $J = 2.5$ Hz, 2H), 3.50 (s, 1H), 2.86 (s, 6H), 2.63 (t, $J = 2.5$ Hz, 2 H), 1.67 (q, $J = 1.5, 7.5$ Hz, 2H), 0.67 (t, $J = 6.5$ Hz, 3H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 160.12, 159.62, 159.29, 144.01, 143.62, 137.12, 136.65, 133.09, 130.92, 129.87, 129.29, 128.66, 128.07, 122.30, 117.29, 116.93, 72.33, 65.26, 61.17, 51.76, 45.69, 26.31, 11.92; HRMS (ES-TOF) calcd for $\text{C}_{28}\text{H}_{30}\text{ClNO}_3$ 463.1914, found 463.1912.

(Z)-3-(4-(2-(dimethylamino)ethoxy)phenyl)-5-fluoro-1-(1-(4-hydroxyphenyl)propylidene)-2,3-dihydro-1H-inden-2-ol (5ad): Brown semi solid; Yield: 9%; IR ν_{\max} (KBr, cm^{-1}): 3382 (OH str), 2992, 2886 (aromatic C-H str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; $^1\text{H-NMR}$ (CDCl_3 , 500 MHz) δ (ppm): 7.91 – 7.71 (m, 4H), 7.70-7.42 (m, 4H), 6.96 (t, $J = 8.5$ Hz, 1H), 6.86 (t, $J = 8.5$ Hz, 2H), 5.29 (s, 1H), 4.50 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 4.03 (t, $J = 2.5$ Hz, 2H), 3.39 (s, 1H), 2.78 (s, 6H), 2.66 (t, $J = 2.5$ Hz, 2H), 1.78 (q, $J = 2.5, 6.0$ Hz, 2H), 0.68 (t, $J = 6.5$ Hz, 3H); $^{13}\text{C-}$ (CDCl_3 , 125 MHz) δ (ppm): 163.14, 161.12, 159.41, 157.87, 156.62, 140.11, 139.52, 136.27, 133.62, 131.54,




130.77, 129.62, 129.30, 124.36, 123.12, 116.17, 115.10, 71.13, 66.12, 60.13, 50.17, 46.45, 25.45, 12.10; **HRMS (ES-TOF) calcd** for $C_{28}H_{30}FNO_3$ 447.2210, found 447.2209..




(Z)-5-bromo-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (5ae): Light yellow semi solid; Yield:10 %; **IR** v_{max} (**KBr**, cm^{-1}): 3444 (OH str), 2922 (aromatic C-H str), 1595 (aromatic, C=C str), 1418, 1328, 1235, 1129(C-O-C, str), 1091; **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 7.91-7.86 (m, 3H), 7.71-

7.51 (m, 1H), 7.49-7.26 (t, $J = 8.0$ Hz, 4H), 7.12-6.85 (m, 4H), 5.59(s, 1H), 4.59 (d, $J = 2.0$ Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 2.98 (t, $J = 2.5$ Hz, 2H), 2.87(t, $J = 2.5$ Hz, 4H), 4.02 (t, $J = 2.5$ Hz, 2H), 1.87 (q, $J = 1.5, 8.0$ Hz, 2H), 1.34 (t, $J = 2.5$ Hz, 2H), 1.26 (t, $J = 2.5$ Hz, 4H), 0.78 (t, $J = 7.0$ Hz, 3H)); **^{13}C -** ($CDCl_3$, 125 MHz) δ (ppm): 161.124, 157.13, 156.41, 142.63, 140.10, 139.54, 136.27, 133.63, 131.54, 130.77, 129.62, 129.30, 122.36, 122.12, 116.19, 115.19, 73.11, 69.15, 58.48, 57.55, 52.81, 25.25, 23.14, 21.30, 10.77; **HRMS (ES-TOF) calcd** for $C_{31}H_{34}BrNO_3$ 547.1722, found 547.1724.



(Z)-5-chloro-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (5af): Light yellow semi solid; Yield: 8%; **IR** v_{max} (**KBr**, cm^{-1}): 3431 (OH str), 2951, 2880 (aromatic C-H str), 1608 (aromatic, C=C str), 1271, 1109, 843, 729; **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 7.87 (t, $J = 8.0$ Hz, 3H), 7.52-7.11 (m, 3H),


7.01-6.92 (m, 5H), 5.61 (s, 1H), 4.67 (d, $J = 2.0$ Hz, 1H), 4.23 (d, $J = 2.0$ Hz, 1H), 4.11 (t, $J = 2.5$ Hz, 2H), 2.67-2.52 (m, 6 H), 1.86 (q, $J = 8.5, 1.5$ Hz, 2H), 1.49-1.25 (m, 6H), 0.68 (t, $J = 7.0$ Hz, 3H); **^{13}C -** ($CDCl_3$, 125 MHz) δ (ppm): 160.12, 158.41, 144.87, 144.67, 140.10, 139.54, 136.22, 133.62, 131.50, 130.77, 129.64, 129.32, 124.36, 123.12, 117.69, 117.10, 73.19, 69.13, 58.10, 57.44, 52.85, 25.67, 23.83, 21.14, 11.10; **HRMS (ES-TOF) calcd** for $C_{31}H_{34}ClNO_3$ 503.2227, found 503.2228.




(Z)-5-fluoro-1-(1-(4-hydroxyphenyl)propylidene)-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-2,3-dihydro-1H-inden-2-ol (5ag): Light yellow semi solid; Yield: 10%; **IR** v_{max} (**KBr**, cm^{-1}): 3440 (OH str), 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1408, 1338, 1231, 1125(C-O-C, str), 1091, 650 (C-F, str); **1H -NMR** ($CDCl_3$, 500 MHz) δ (ppm): 7.91-7.18 (m, 3H),

7.70-7.42 (m, 4H), 6.96 (t, $J = 8$ Hz, 1H), 6.86 (t, $J = 8.0$ Hz, 3H), 5.59 (s, 1H), 4.59 (d, $J = 2$

Hz, 1H), 4.18 (d, $J = 2.0$ Hz, 1H), 4.03 (t, $J = 2.5$ Hz, 3H), 3.45 (s, 1H), 2.98 (t, $J = 2.5$ Hz, 2H), 2.87 (t, $J = 2.5$ Hz, 4H), 1.87 (q, $J = 8.0, 1.0$ Hz, 2H), 1.34 (t, $J = 2.5$ Hz, 4H), 1.26 (t, $J = 2.5$ Hz, 4H), 0.78 (t, $J = 7.0$ Hz, 3H); ^{13}C - (CDCl_3 , 125 MHz) δ (ppm): 161.12, 157.13, 156.41, 142.62, 140.10, 139.54, 136.27, 133.62, 131.55, 130.77, 129.62, 129.30, 122.36, 122.12, 116.19, 115.19, 73.10, 69.14, 58.45, 57.55, 52.81, 25.25, 23.14, 21.30, 10.77; **HRMS (ES-TOF) calcd** for $\text{C}_{31}\text{H}_{34}\text{FNO}_3$ 487.2523, found 487.2525.



(E)-6-(2-(3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl)vinyl)-2-(4-methoxyphenyl)-4H-chromen-4-one (6ac): Cream color solid, yield: 70%, ^1H NMR(CDCl_3 , 500 MHz): 8.26 (s, 1H), 7.87 (d, $J = 7$ Hz, 2H), 7.70 (d, $J = 8.5$ Hz, 1H), 7.50 (d, $J = 8.5$ Hz, 2H), 7.08 (d, $J = 8.5$ Hz, 1H), 7.01 (d, $J = 8.5$ Hz, 2H), 6.76 (s, 1H), 6.69-6.59 (m, 3H), 3.88 (s, 3H), 3.70 (s, br, D_2O exchangeable, 1H, OH), 2.83-2.80 (m, 2H), 2.24-1.54 (m, 13H), 1.01 (s, 3H); **HRMS (ES-TOF) calcd** for $\text{C}_{36}\text{H}_{36}\text{NaO}_5$ ($\text{M} + \text{Na}$) 571.2460, found 571.2481.



(E)-3-(2-(3,17-dihydroxy-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-17-yl)vinyl)-2-(4-methoxyphenyl)-4H-chromen-4-one (6ad): Cream color solid, yield: 65%, ^1H NMR(CDCl_3 , 500 MHz): 8.26 (s, 1H), 7.87 (d, $J = 7$ Hz, 2H), 7.70 (d, $J = 8.5$ Hz, 1H), 7.50 (d, $J = 8.5$ Hz, 2H), 7.08 (d, $J = 8.5$ Hz, 1H), 7.01 (d, $J = 8.5$ Hz, 2H), 6.76 (s, 1H), 6.69-6.59 (m, 3H), 3.88 (s, 3H), 3.70 (s, br, D_2O exchangeable, 1H, OH), 2.83-2.80 (m, 2H), 2.24-1.54 (m, 13H), 1.01 (s, 3H). **IR ν_{max} (KBr, cm^{-1}):** 3650, 3501, 1682, 1400, 1215, 1034; **HRMS (ES-TOF) calcd** for $\text{C}_{36}\text{H}_{36}\text{NaO}_5$ ($\text{M} + \text{Na}$) 571.2460, found 571.2481.

5.6. REFERENCES

- [1] (a) Ferlay, J.; Bray, F.; Pisani, P.; Parkin, D. M. *IARC Cancer base No.5 version 2.0* IARC Press, Lyon. 2004; (b) Maggiolini, M.; Bonfiglio, D.; Marsico, S.; Panno, M. L.; Cenni, B.; Picard, D. *Estrogen receptor α mediates the proliferative but not the cytotoxic dose-dependent effects of two major phytoestrogens on human breast cancer cells*, *Mol. Pharmacol.* 2001, 60, 595.
- [2] Corey, E. J.; Czako, B.; Laszlo, K. *Molecules and medicine*. New Jersey: John Wiley & Sons, Inc. 2007.

- [3] (a) Kuiper, G. G.; Lemmen, J. G.; Carrlsson, B.; Carton, J. C.; Safe, S. H.; Vander Saag, P. T.; Gustafsson, I. A. *Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β* , *Endocrinology*. 1998, 139, 4252; (b) Irfan, I.; Sawangjaroen, N.; Bhat, A. R.; Azam, A. *New Dioxazole Derivatives: Synthesis and Effects on the Growth of Entamoeba histolytica and Giardia intestinalis*, *Eur. J. Med. Chem.* 2010, 45, 1648.
- [4] Limer, J. L.; Speirs, V. *Phyto-oestrogens and breast cancer chemoprevention*, *Breast Cancer Res.* 2004, 6, 119.
- [5] Fitzpatrick, L. A. *Alternatives to estrogen*, *Med. Clin. North Am.* 2003, 87, 1091.
- [6] Duffy, C.; Perez, K.; Partridge, A. *Implications of phytoestrogen intake for breast cancer*, *Cancer J. Clin.* 2007, 57, 260.
- [7] Ascenzi, P.; Bocedi, A.; Marino, M. *Structure-function relationship of estrogen receptor α and β : impact on human health*, *Mol. Aspects Med.* 2006, 27, 299.
- [8] (a) Mitrasinovic, P. M. *Advances in the Structure-based Design of the Influenza A Neuraminidase Inhibitors*, *Current. Drug. Targets.* 2010, 11, 315; (b) Descoteaux, C.; Provencher-Mandeville, J.; Mathieu, I.; Perron, V.; Mandal, S. K.; Asselin, E.; Berube, G. *Synthesis of 17β -estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines*, *Bioorg. Med. Chem. Lett.* 2003, 13, 3927.
- [9] (a) Angelis, M. D.; Stossi, F.; Waibel, M.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A. *Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites*, *Bioorg. Med. Chem.* 2005, 13, 6529; (b) Kilikli, A. A.; Dengiz, C.; Zcan, S.; Balci, M. *Synthesis of Indolin-2-one, Isoindolin-1-one and Indole Derivatives from Homophthalic Acid*, *Synthesis* 2011, 22, 3697.
- [10] Gottardis, M. M.; Jordan, V. C. *Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration*, *Cancer Res.* 1988, 48, 5183.
- [11] Yao, K.; Lee, E. S.; Bentreme, D. J. *Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice*, *Clin. Cancer Res.* 2000, 6, 2028.
- [12] Ingle, J. N.; Ahmann, D. J.; Green, S. J.; Engl, N. *Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer*, *J. Med.* 1981, 304, 16.

- [13] (a) Abid, M.; Bhat, A. R.; Athar, F.; Azam, A. *Synthesis, Spectral Studies and Antiamoebic Activity of New 1-N-substituted Thiocarbamoyl-3-phenyl-2-pyrazolines*, Eur. J. Med. Chem. 2009, 44, 417; (b) Bhat, A. R.; Athar, F.; Azam, A. *Bispyrazolines: Synthesis, Characterization and Antiamoebic Activity as Inhibitors of growth of Entamoeba Histolytica*, Eur. J. Med. Chem. 2009, 44, 426; (c) Iqbal, P. F.; Bhat, A. R.; Azam, A. *Antiamoebic coumarins from the root bark of Adina cordifolia and their new thiosemicarbazone derivatives*, Eur. J. Med. Chem. 2009, 44, 2252.
- [14] Fink, A. K.; Gurwitz, J.; Rakowski, W.; Guadagnoli, E.; Silliman, R. A. *Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor--positive breast cancer*, J. Clin. Oncol. 2004, 22, 3309.
- [15] T. L. Lash, M. P. Fox, J. L. Westrup, A. K. Fink, R. A. Silliman, *Adherence to tamoxifen over the five-year course*, Breast Cancer Res. Treat. 2006, 99, 215.
- [16] (a) Mitrasinovic, P. M. *Advances in boron-based supramolecular architecture*, Current. Org. Synthe. 2012, 9, 233; (b) Mitrasinovic, P. M. *Epidermal growth factor receptors: a functional perspective*, Current Radiopharmaceuticals 2012, 5, 29; (c) Vu, A. T.; Cohn, S. T.; Manas, E. S.; Harris, H. A.; Mewshaw, R. E. *Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites*, Bioorg. Med. Chem. 2005, 13, 6529.
- [17] Jordan, V. C. *Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer*, Endocr. Relat. Cancer 2014, 21, 235.
- [18] Davies, C.; Godwin, J.; Gray, R. *Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomized trials*, Lancet. 2011, 378, 771.
- [19] Vu, A. T.; Cohn, S. T.; Manas, E. S.; Harris, H. A.; Mewshaw, R. E. *ER β ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives*, Bioorg. Med. Chem. Lett. 2005, 15, 4520.
- [20] Gottardis, M. M.; Jordan, V. C. *Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration*, Cancer Res. 1988, 48, 5183.
- [21] (a) Srinivas, K. K.; Simon, A. W.; John, T. I.; Samuel, R. D.; Khan, S. R. *Modulating Paclitaxel Bioavailability for Targeting Prostate Cancer*, Bioorg & Med. Chem. 2007, 15,

- 4973; (b) Srinivas, K. K.; Maria, A.; Manuel, H.; Sujata, B. V.; Khan, S. R. *Design, Synthesis and Biological Evaluation of Novel Riccardiphenol Analogs*, Bioorg & Med. Chem. 2005, 13, 2873; (c) Gottardis, M. M.; Jordan, V. C. *Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration*, Cancer Res. 1988, 48, 5183.
- [22] (a) Jordan, V. C. *Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 1. Receptor Interactions*, J. Med. Chem. 2003, 46, 883; (b) Jordan, V. C. *Antiestrogens and Selective Estrogen Receptor Modulators as Multifunctional Medicines. 2. Clinical Considerations and New Agents*, J. Med. Chem. 2003, 46, 1081.
- [23] (a) Quraishi, M. A.; Thakur, V. R. *Synthesis and biological activity of some new 6-thiophene-7H-indeno [2, 1-c] quinolines*. Ind. Chem. Soci. 1989, 66, 815; (b) Quraishi, M. A.; Thakur, V. R.; Dhawan, S. N. *Synthesis of 6-(4-chlorophenyl)-7H-indeno[2,1-c]quinolines and their biological activity*, Ind. J. Med. Chem. 1989, 28, 891; (c) Jordan, V. C. *Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. receptor interactions*, J. Med. Chem. 2003, 46, 883; (d) Jordan, V. C. *Antiestrogens and selective estrogen receptor modulators as multifunctional medicines, Clinical Considerations and New Agents*, J. Med. Chem. 2003, 46, 1081.
- [24] (a) Kuiper, G. G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J. A. *Cloning of a novel estrogen receptor expressed in rat prostate and ovary*, Proc. Natl. Acad. Sci. U.S.A 1996, 93, 5925; (b) Mosselman, S.; Polman, J.; Dijkema, R. *ER β : identification and characterization of a novel human estrogen receptor*, FEBS Let. 1996, 392, 49; (c) Jada, S. R.; Hamzah, A. S.; Lajis, N. H.; Saad, M. S.; Malcolm F. G.; Stevens, J. *Stanslas, "Semisynthesis and cytotoxic activities of andrographolide analogues"*, Journal of Enzyme Inhibition and Medicinal Chemistry 2006, 21, 145.
- [25] (a) Modzelewska, C. P., Achanta, G.; Davidson, N. E.; Huang, P.; Khan, S. R. *Anticancer activities of novel chalcone and bis-chalcone derivatives*, Bioorg & Med. Chem. 2006, 14, 3491; (b) De Cremoux, P.; Tran-Perennou, C.; Elie, C.; Boudou, E.; Barbaroux, C. *Biochem. Quantitation of estradiol receptors alpha and beta and progesterone receptors in human breast tumors by real-time reverse transcription-polymerase chain reaction. Correlation with protein assays*, Pharmacol. 2002, 64, 507; (c) Najim, N.; Bathich, Y.; Zain, M. M.;

- Hamzah, A. S.; Shaameri, Z. *Evaluation of the bioactivity of novel spiroisoxazoline type compounds against normal and cancer cell lines*, *Molecules* 2010, 15, 9340.
- [26] Banerjee, M.; Emonnd, J.; Lindeman, S. V.; Rathore, R. *Practical synthesis of unsymmetrical tetraarylethylenes and their application for the preparation of [triphenylethylene-spacer-triphenylethylene] Triads*, *J. Org. Chem.* 2007, 72, 8054.
- [27] Lalit, N.; Goswami, M. E.; Dobhal, M. P.; Zhang, M.; Missert, J. R.; Masayuki, S.; Kadish, K. M.; Pandey, R. *Remarkable Features of the McMurry Reaction Conditions in Dimerization of Formyl- and 2-Formylvinylpurpurinimides. Electrochemistry of Monomeric Ni(II) Purpurinimide and the Corresponding Dyads*, *J. Org. Chem.* 2009, 74, 568.
- [28] (a) McMurry, J. E. *Carbonyl-coupling reactions using low-valent titanium*, *Chem. Rev.* 1989, 89, 1513-1524; (b) McMurry, J. E.; Felming, M. P. *New method for the reductive coupling of carbonyls to olefins. Synthesis of β -carotene*, *J. Am. Chem. Soc.* 1974, 96, 4708.
- [29] Corey, E. J.; Danheiser, C. S. *New reagents for the intermolecular and intramolecular pinacolic coupling of ketones and aldehydes*, *J. Org. Chem.* 1976, 41, 258.
- [30] Ghiringelli, D. *A synthesis of (S,S)-(+)-grahamimycin A1*, *Tetrahedron Lett.* 1983, 24, 287-290.
- [31] Sato, F.; Urabe, H. In *Titanium and Zirconium in Organic Synthesis*; Marek, I., Ed.; Wiley-VCH: Weinheim, Germany 2002; pp 319.
- [32] Gauthier, S.; Mailhot, J.; Labrie, F. *New Highly Stereoselective Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-4-Hydroxytoremifene via McMurry Reaction*, *J. Org. Chem.* 1996, 61, 3890.
- [33] Yu, D. D.; Forman, B. M. *Simple and efficient production of (Z)-4-Hydroxytamoxifen, a potent estrogen receptor modulator*, *J. Org. Chem.* 2003, 68, 9489.
- [34] Khan, S. R. *Preparation of boronic chalcone derivatives as anticancer Agents*, *PCT Int. Appl.* (2003), WO 2003106384 A2 20031224.
- [35] Guo, Q.; Miyaji, T.; Hara, R.; Shen, B.; Takahashi, T. *Group 5 and group 6 metal halides as very efficient catalysts for acylative cleavage of ethers*, *Tetrahedron* 2002, 58, 7327.

- [36] McMurry, J. E.; Krepski, L. R. *Synthesis of unsymmetrical olefins by titanium (0) induced mixed carbonyl coupling. Some comments on the mechanism of the pinacol reaction*, J. Org. Chem. 1976, 41, 3929.
- [37] Robert J.; Rawson, I.; Harrison, T. *Procedure for the methylenation of olefins to cyclopropanes*, J. Org. Chem. 1970, 35, 2057.
- [38] Dams, R.; Malinowski, M.; Westdorp, I.; Geisy, H. I. *On the mechanism of the titanium-induced reductive coupling of ketones to olefins*, J. Org. Chem. 1982, 47, 248.
- [39] (a) Rao, M. L. N.; Dhanorkar, R. J.; "Threefold and chemoselective couplings of triarylbismuth with benzylic chlorides and iodides using palladium catalysis", RSC Adv. 2014, 4, 13134; (b) Rao, M. L. N.; Dhanorkar, R. J.; "Pd-catalyzed chemoselective threefold cross-coupling of triarylbismuth with benzylic bromides", RSC Adv. 2013, 3, 6794; (c) Dams, R.; Malinowski, M.; Westdorp, I.; Geisy, H. I. *On the mechanism of the titanium-induced reductive coupling of ketones to olefins*, J. Org. Chem. 1982, 47, 248.
- [40] Detsi, A.; Koufaki, M.; Calogeropoulou, T. *Synthesis of (Z)-4-Hydroxytamoxifen and (Z)-2-[4-[1-(p-Hydroxyphenyl)-2-phenyl-1-butenyl]phenoxy]acetic Acid*, J. Org. Chem. 2002, 67, 4608.
- [41] (a) Ahmed, N.; Pathe, G. K.; Venkata, B. B.; *Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn(IV)Cl₄ catalyst*, Tetrahedron Lett. 2014, 55, 3683; (b) Ahmed, N.; Van Lier, J. E.; *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 5407; (c) Ahmed, N.; Van Lier, J. E.; *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 2725; (d) Ahmed, N.; Konduru, N. K.; *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177.

CHAPTER-4

SeO₂ in water: A mild and efficient promoter for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of carbonyl carbons

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, *RSC Advances*
2015, 5, 59114-59119.

SeO₂ in water: A mild and efficient promoter for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of carbonyl carbons

6.1. INTRODUCTION

Protection and deprotection of the functional groups is the most frequent used strategies in the multi-steps organic syntheses. In particular, the protection and the deprotection of hydroxyl and phenolic groups is extremely important because of its presence of a number of compounds of natural products, biological and synthetic compounds such as carbohydrates, macrolides, peptides, steroids, nucleotides and polyethers.[1] The protection of hydroxyl groups with 3,4-dihydro-2H-pyran (DHP) is the most common method because of the stability of the product, 2-tetrahydropyranyl ethers (THPEs) in the strong basic conditions such as Grignard reagents, organolithium, metal hydrides, catalytic hydrogenation, alkylating and acylating conditions.[2] Similarly, methoxymethyl chloride (MOMCl) and acetyl chloride/acetic anhydride (CH₃COCl/Ac₂O) reagents are used for the hydroxyl and phenolic groups protection.[3]

Deprotection of these groups (Acetyl, THP and MOM ethers) therefore required efficient methods to avoid the product decomposition and/or loss of other functional groups in the molecules. Several catalytic methods have been explored for the selective deacetylation of alcohols and phenols under acidic and basic conditions. For example, the deprotection of acetates such as NaOMe,[4a] micelles,[4b] Zn-MeOH,[4c] Cyclodextrins,[4d] enzymes,[4e] metallo-enzyme,[4f] metal complexes,[4g] and antibodies,[4h] montmorillonite k-10,[4i] I₂,[4j] NaBO₃,[4k] and HCOONH₄-SiO₂,[4l] for the detetrahydropyranlation include protic acids,[5a-d] Lewis acids like BF₃-etherate,[5e] LiBr,[5f] LiBF₄,[5g] LiOTf,[5h] LiClO₄,[5i] Sc(OTf)₃,[5j] In(OTf)₃,[5k] I₂,[5l] InCl₃,[5m] ZrCl₄,[5n] CuCl₂,[5o] NH₄Cl,[5p] graphite,[5q] clay materials,[5r] silica-supported sulfuric acid,[5s] electrogenerated acids,[5t] bis(trimethylsilyl)sulphate,[5u] Distannoxane,[5v] triphenylphosphine dibromide,[5w] DDQ,[5x] and heteropoly acids.[5y] Similarly, for the demethoxymethylation include HCl,[6a] BBr₃,[6b] pyridinium *p*-toluene sulphonate under strong acidic condition,[6c] ZnBr₂ and TiCl₄ in aprotic solvents,[6d] Me₂BBr[6e] and (i-PrS)₂BBr.[6f] Most of these methods have one or other drawbacks such as long reaction time, low yields, reflux at high temperature and tedious workup procedures.[7] Hence, there is still scope to develop mild and efficient methods in the deacetylation, detetrahydropyranlation and demethoxymethylation of hydroxyl of alcoholic and phenolic groups.

In the alpha carbonyl carbon (active methyl and methylene) oxidation to dicarbonyl molecule, various reagents and reaction conditions have been explored that include ammonium chlorochromate,[8a] I₂,[8b] CrO₃-NH₄Cl,[8c] HBr,[8d] MeSSMe-CuCl₂-CuO,[8e] Cu(OAc)₂.H₂O,[8f] P-Me-sulphonic acid,[8g] SeO₂-DMSO,[8h] KI+O₂-t-BuNH₂. [8i] However, SeO₂ is not reported for one-pot deprotection and alpha carbonyl carbons oxidation in eco-friendly environment. In continuation of our interest [9] to develop new methods for the organic synthesis, herein, we report an efficient green protocol of deprotection of acetyl, tetrahydropyranyl and methoxymethyl ethers and sequel oxidation of alpha carbonyl carbons to dicarbonyl group using SeO₂ in water as a novel reagent.

6.2. OBJECTIVE


Protection and deprotection is a most common conversion in multi step organic synthesis. The MOM, THP ethers and esters of hydroxyl group is a very frequently used strategy. These methods are attractive because they are easy to deprotect and stable enough in basic media and reaction involving acylating agent like Grignard, lithium alkyl. As a part of ongoing research program to developed the methods for the deprotection, our goal is to developed cheap, inexpensive, green protocol for the deprotection of hydroxyl group and we observed that the SeO₂-water system provided an efficient one-pot green protocol for the deprotection of Acetyl, THP and MOM ethers in alcohols and phenols and sequel oxidation of alpha carbonyl carbons to dicarbonyl compound at 80 °C within 30-60 min.

6.3. RESULTS AND DISSCUSSION

6.3.1. Optimization reaction conditions by using different oxidizing agents

We screened different oxidizing agents in water for the deprotection and sequel oxidation, where CrO₃, DDQ and PCC in H₂O failed to give the product (**Table 1, entries 1, 3 & 6**), OsO₄ and MnO₂ gave a poor yield (5-10%) at 80 °C after 6h (**Table 1, entry 2 & 7**),while, substrate:SeO₂ (1:3 ratio) in 1ml H₂O gave the optimal yield (85-95%) in the one-pot deacetylation, detetrahydropyranylation and sequel oxidation of alpha carbonyl carbons to dicarbonyl group at 80 °C within 1h (**Table 1, entry 5**). When, we used substrate:SeO₂ (1:1ratio) in 1ml H₂O gave only deprotection product in 95 % yields in 1h-3h (**Table 1, entry 4**). The novel method also used for the one-pot demethoxymethylation and sequel oxidation of alpha carbon but gave moderate product yields (40%) at 80 °C in 1h. Therefore, substrate:SeO₂ (1:3 ratio) in 1ml H₂O was selected as an optimized condition.

Table 1. Optimization of deprotection conditions for Ac, THP and MOM groups and sequel oxidation of alpha carbonyl carbon




Entry	Substrate.:Reagent (equiv.)	Time (h)	Yield ^a (%) (deacetylation)	Yield ^b (%) (detetrahydropyranylation)
1	Sub.:CrO ₃ (1:1)	24 h	No reaction	No reaction
2	Sub.:OsO ₄ (1:1)	6 h	8	5
3	Sub.:DDQ(1:1)	24 h	No reaction	No reaction
4	Sub.:SeO ₂ (1:1)	1h-3h	Only deprotection	Only deprotection
5	Sub.:SeO ₂ (1:3)	1 h	95	94
6	Sub.:PCC(1:1)	6 h	No reaction	No reaction
7	Sub.:MnO ₂ (1:1)	6h	10	10

6.3.2. Solvent effect

In the case of low soluble or insoluble compounds, even under optimized conditions, the reaction gave moderate yield (35%). Therefore, 3-4 drops of organic solvents (THF, dioxane, DMF, DEE, ethanol, methanol, CHCl₃ and DMSO) were used to improve the solubility, in which THF and dioxane gave maximum 60% and 94% yields respectively (**Table 2, entries 1-10**). However, the SeO₂ in organic solvents without H₂O failed to give the product (**Table 2, entry 2**).

Table 2. Solvents effects in deprotection of Ac, THP and MOM groups and sequel oxidation of alpha carbons.



Entry	H ₂ O(1ml):Solvents	Yield ^a	Yield ^b
-------	--------------------------------	--------------------	--------------------


	(3-4 drops)	(%)	(%)
1	H ₂ O	30	35
2	Organic solvents*	0	0
3	H ₂ O:THF	65	60
4	H ₂ O:Dioxane	95	94
5	H ₂ O:DMF	50	40
6	H ₂ O:DEE	25	20
7	H ₂ O:Ethanol	0	0
8	H ₂ O:methanol	0	0
9	H ₂ O:CHCl ₃	0	0
10	H ₂ O:DMSO	50	40





















[a] Yields of deacetylation, [b] Yields of detetrahydropyranylation, *DMSO, Dioxane, THF, DMF



















6.3.3. Examples of the deprotection of acetyl, THP and MOM ethers

Only deacetylation, detetrahydropyranylation and demethoxymethylation products were afforded using substrate:SeO₂ (1:1ratio) in 1ml H₂O at 80 °C (Table 3, entries 1-10). In the case of entry **11- 24** of chalcone, dihydrochalcone, epoxide only acetyl, THP and MOM removal were observed without sequel oxidation of alpha carbonyl carbon due to used of substrate:SeO₂ (1:1 ratio) in H₂O system. The products were confirmed on the basis of their spectral data (supporting information). For example, product **15q**, the ¹H-NMR spectra showed the characteristic two triplet peak at δ 2.80 & 2.73 ppm, *J*= 6.0 - 6.5 Hz for -CH₂-CH₂- protons and broad peak at δ 5.45 ppm for hydroxyl group. IR value at 3425 cm⁻¹ for -OH groups indicates only deprotection without oxidation of alpha carbonyl carbon. In ¹³CNMR spectra, the characteristic peak at δ 199.12 ppm for one -CO- groups and peak at 45.81 & 30.17 of -CH₂-CH₂- groups indicates only deprotection.

Table 3. Examples of deprotection of Ac, THP and MOM groups in alcohols and phenols.



Entry	ROAc/THP/MOM	ROH	Time (min)	Yield ^a (%)	Yield ^b (%)	Yield ^c (%)
1		 15a	30	92	89	40
2		 15b	30	92	88	40
3		 15c	60	--	--	--
4		 15d	30	95	85	35
5		 15e	30	94	90	32
6		 15f	30	95	92	35
7		 15g	30	90	93	40
8		 15h	30	94	92	35
9		 15i	30	93	95	40
10		 15j	30	95	95	32

11			30	96	95	35
12			30	97	96	40
13			30	93	94	32
14			30	90	85	30
15			30	92	85	30
16			30	90	87	35
17			30	93	95	38
18			30	96	94	40
19			30	94	94	35

20			30	92	90	32
21			30	95	90	35
22			30	94	95	35
23			30	95	96	40
24			30	90	96	35

Yields (**15a-15x**) from [a] ROAc, [b] ROTHP and [c] ROMOM respectively.

6.3.4. Examples of the deprotection of acetyl, THP and MOM ethers and sequel oxidation of alpha carbonyl carbon

Under optimized reaction conditions using substrate:SeO₂,1:3 ratio, the reaction gave the deprotection and sequel oxidation of methylene carbon alpha carbonyl carbon to carbonyl groups in excellent yield (85-95%) for the deacetylation, detetrahydropyranylation and moderate yield 30-40% for demethoxymethylation (Table 4, entries 3-10) within 30-60 min at 80 °C. Interestingly, acetyl and THP removal and sequel oxidation of methylene carbon alpha carbonyl carbon to carbonyl groups were observed in the protected hydroxyl acetophenone and dihydrochalcones to give the corresponding hydroxy dicarbonyl derivatives **16e-16j** in excellent yield (85-95%).


We used excess of substrate:SeO₂, in 1:4, 1:5 & 1:6 ratios, also altering the reaction time from 60-120 minutes to checked for the oxidation of another alpha carbon, but no further oxidation was observed, (Table 4, entries 11), also under optimized condition we took





dicarbonyl compounds for further alpha carbon oxidation, but no change was observed. (Table 4, entries 12)



















The reagent is also useful for the deprotection of methoxymethyl ether (MOM) of phenolic compounds like, chalcone and chalcone epoxides but the yield of the product was moderate 30-40% (Table 4, entries 3-12). In demethoxymethylation we performed reaction for 1h-3h, but no further conversion were observed, reaction gave only 30-40 % product, and remaining starting material was recovered by column chromatography.

The products were characterized on the basis of their spectral analysis ^1H - and ^{13}C -NMR, GC-MS (supporting information). For example, product **16e**, the ^1H -NMR spectra showed the characteristic singlet peak at δ 3.99 ppm for $-\text{CH}_2$ and disappear the characteristic two triplet peak at δ 2.80 and 2.72 ppm ($J = 5.5 - 6.5$ Hz) of $-\text{CH}_2-\text{CH}_2-$ and broad peak at δ 5.19 ppm for hydroxyl group, indicates oxidation of alpha carbonyl carbon. In ^{13}C -NMR spectra, the characteristic peak at δ 197.12 and 191.10 ppm for two carbonyl ($-\text{CO}-\text{CO}-$) groups and peak at δ 50.89 ppm for $-\text{CH}_2$ confirms the oxidation of alpha carbonyl carbon, this confirmation also support by the disappearance of peak at 46.35 and 30.51 ppm of $-\text{CH}_2-\text{CH}_2-$ groups in dihydrochalcone. IR value at 3415 cm^{-1} for $-\text{OH}$ groups, 1705 and 1715 cm^{-1} for dicarbonyl indicates the deprotection and sequel oxidation of alpha carbonyl carbon. The structures of all other compounds were further confirmed by GCMS (supporting information).

Table 4. Deprotection of Ac, THP and MOM groups and sequel oxidation of alpha carbonyl carbon.



Entry	Active methylene compounds	Dicarbonyl	Time (min)	Yield ^a (%)	Yield ^b (%)	Yield ^c (%)
1		 16a	60	92	95	32
2		 16b	60	90	88	32


3			60	93	95	40
4			30	94	94	35
5			60	91	85	40
6			60	93	88	40
7			60	90	87	30
8			60	95	85	35
9			60	94	82	35
10			60	95	80	30
11 ^d			>120	-	-	-

12 ^e			>60	-	-	-
-----------------	--	--	-----	---	---	---

^aYields of deacetylation, ^bYields of detetrahydropyranylation, ^cYields of demethoxymethylation, Used substrate:SeO₂, in 1:4, 1:5 & 1:6 ratios, also altering the reaction time but no further oxidation was observed, ^eUnder optimized condition we took dicarbonyl compounds for further alpha carbon oxidation, but no change was observed.

6.4. PLAUSIBLE MECHANISM

A plausible mechanism was proposed (Scheme 1). First, selenium dioxide and water reacts to form the selenous acid *in situ* which reacted with tetrahydropyranyl dihydrochalcone **I** to make complex **II**. Selenous acid ligated with oxygen of tetrahydropyranyl dihydrochalcone **II**, followed by removal of DHP via intramolecular abstraction of proton with seloxide ion to give compound **III**. Further, complex **III** undergoes keto-enol tautomerization to get compound **IV**. The key step is the beta-ketoseleninic acid **V** formation by the attack of selenous acid electrophile on enol **IV** of dihydrochalcone and Pummerer like [10] reaction to obtained compound **VI**. Then, hydrolysis gave the deprotected alpha-diketone **VII** of THP dihydrochalcone.



Scheme 1. Propose mechanism for the deprotection of THP Ethers and oxidation of active methylene in SeO₂: Water.

6.5. CONCLUSION


In conclusion, we have developed an efficient one-pot green protocol for the deprotection of alcoholic and phenolic acetyl, tetrahydropyranyl and methoxymethyl ethers and sequel oxidation of active alpha carbonyl carbons to dicarbonyl group using substrate: SeO₂ (1:3 ratio) in H₂O. The reaction gave excellent yield (85-95%) for acetyl and THP ethers and moderate yield (30-40%) at 80 °C within 30-60 min. However, using substrate: SeO₂ (1:1 ratio) in H₂O, selectively afforded only deprotection of alcoholic and phenolic acetyl, tetrahydropyranyl and methoxymethyl ethers. This methodology has advantages such as versatility of reagent, short reaction time, high yields, inexpensive reagents, environment friendly green protocol and easy workup procedures.

6.6. EXPERIMENTAL DETAILS


6.6.1. General Procedure for Deprotection of Acetyl esters, Tetrahydropyranyl and methoxymethyl ethers of Alcohol and Phenol: SeO₂ (1 mmol) was added to a stirred solution of Esters and ethers (1 mmol) in a water (1ml) and 3-4 drops of dioxane, suspension obtained, applied heating to 80 °C. After TLC monitoring, the resulting reaction mixture was poured in cold water and extracted with EtOAc. The organic layer was washed with brine, dried with anhyd.Na₂SO₄, and concentrated in *vacuo* to give the corresponding product which was purified by silica gel column chromatography with hexane- EtOAc eluent to obtain the products **15a to 15x** (table 3) in excellent yield 85-95% and 30-40% for deacetylation, detetrahydropyranylation and demethoxymethylation respectively. Similarly,

General Procedure for Deprotection of Acetyl esters, Tetrahydropyranyl ethers and methoxymethyl ethers of Alcohols and Phenols and sequel oxidation of alpha carbonyl carbon: SeO₂ (3 mmol) was added to a stirred solution of Esters and ethers (1mmol) in a water (1ml) and 3 to 4 drops of dioxane, suspension obtained, applied heating to 80 °C, gave products **16a to 16j** (table 4) in excellent yield 85-95% and 30-40% for deacetylation, detetrahydropyranylation and demethoxymethylation followed by sequel oxidation of alpha carbonyl carbon respectively.


6.6.2. Characterization data for selected synthesized compounds.




Cyclohexanol (15a): ¹H NMR (CDCl₃, 500 MHz) δ ppm: 3.75 (s, 1H), 3.08-3.04 (m, 1H), 2.32 (t, *J* = 6 Hz, 1H), 1.64-1.61 (m, 4H), 1.51 (t, *J* = 6 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm: 69.148, 36.270, 25.144, 23.100; GC-MS (*m/z*): 100 [M⁺, C₆H₁₂O].




Phenylmethanol (15b): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.46-7.41 (m, 2H), 7.37 (d, $J = 8$ Hz, 1H), 7.15 (d, $J = 7.5$ Hz, 2H) 4.79 (s, 1H), $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 142.62, 131.54, 130.71, 129.62, 69.13; **GC-MS (m/z):** 108 [M^+ , $\text{C}_7\text{H}_8\text{O}$].




1-(3-hydroxyphenyl)ethanone (15e): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.53-7.51 (m, 2H), 7.35 (t, $J = 10$ Hz, 1H), 7.12-7.09 (m, 1H) 6.10 (s, 1H), $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 130.02, 121.23, 120.87, 114.75, 26.89; **GC-MS (m/z):** 136 [M^+ , $\text{C}_8\text{H}_8\text{O}_2$].




4-bromophenol (15f): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.44 (d, $J = 9$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H), 5.31 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 157.12, 133.61, 122.37, 115.19; **GC-MS (m/z):** 172 [M^+], 174 [$\text{m}+2$] for $\text{C}_6\text{H}_5\text{BrO}$.




Phenol (15g): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.30-7.26 (m, 2H), 6.98 (dd, $J = 9, 1$ Hz, 2H), 6.90-6.88 (m, 2H), 6.11 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 155.51, 129.85, 120.91, 115.51; **GC-MS (m/z):** 94 [M^+] for $\text{C}_6\text{H}_6\text{O}$.




4-Hydroxy benzaldehyde (15h): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 9.86 (s, 1H), 7.84-7.81 (m, 2H), 6.98 (t, $J = 7$ Hz, 2H), 6.25 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 191.34, 161.60, 132.61, 129.94, 116.08; **GC-MS (m/z):** 122 [M^+] for $\text{C}_7\text{H}_6\text{O}_2$.



2-Hydroxy benzaldehyde (15i): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 11.01 (s, 1H), 9.88 (t, $J = 4.5$ Hz, 1H), .52 (dd, $J = 8.5$ Hz, 2H), 6.98 (t, $J = 10$ Hz, 2H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 194.36, 162.15, 136.27, 131.54, 122.37, 122.13, 117.69; **GC-MS (m/z):** 124 [M^+] for $\text{C}_7\text{H}_8\text{O}_2$.




2-Naphthol (15j): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.76 (t, $J = 8$ Hz, 2H), 7.68 (d, $J = 10$ Hz, 1H), 7.44 (d, $J = 9$ Hz, 1H), 7.34 (d, $J = 9$ Hz, 1H), 7.10-7.15 (m, 2H), 5.02 (s, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 153.36, 134.65, 129.98, 129.03, 127.87, 126.65, 126.46, 123.75, 117.80, 109.58; **GC-MS (m/z):** 144 [M^+] for $\text{C}_{10}\text{H}_8\text{O}$.




(E)-1-(4-fluorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (15k): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 8.02 (d, $J = 8.5$ Hz, 2H), 7.74 (d, $J = 15.5$ Hz, 1H), 7.57 (d, $J = 8.5$ Hz, 2H), 7.51 (d, $J = 16$ Hz, 1H), 7.39 (t, $J = 8.5$


Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H), 6.24 (s, 1H, br, D₂O exchangeable); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 187.50, 164.68, 162.67, 141.94, 132.02, 131.52, 131.45, 129.53, 122.46, 116.42, 116.25. IR ν_{\max} (KBr, cm⁻¹): 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; GC-MS (m/z): 242 [M⁺, C₁₅H₁₁FO₂].




(E)-1-(4-chlorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (15l): ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.02 (d, $J = 9$ Hz, 2H), 7.76 (d, $J = 15.5$ Hz, 1H), 7.64-7.61 (m, 2H), 7.46 (d, $J = 15.5$ Hz, 1H), 7.14-7.09 (m, 4H), 5.54 (s, 1H, br, D₂O exchangeable); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 187.24, 162.41, 141.68, 131.76, 131.26, 131.19, 129.27, 122.20, 116.16, 115.99; IR ν_{\max} (KBr, cm⁻¹): 3408 (OH str), 2928, 2876 (aromatic C-H str), 1684 (C=O str), 1598 (aromatic, C=C str), 1268, 1085, 864, 735; GC-MS (m/z): 258 [M⁺, C₁₅H₁₁ClO₂].



(E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (16c): ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.01 (t, $J = 8.5$ Hz, 2H), 7.73 (d, $J = 15.5$ Hz, 1H), 7.55-7.44 (m, 3H), 7.47 (d, $J = 15.5$ Hz, 1H), 6.95 (d, $J = 7.5$ Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 186.98, 162.15, 141.42, 131.51, 131.00, 130.93, 129.02, 121.95, 115.91, 115.74, 115.31; IR ν_{\max} (KBr, cm⁻¹): 3410 (OH str), 2926, 2875 (aromatic C-H str), 1686 (C=O str), 1599 (aromatic, C=C str), 1265, 1078, 862, 730; GC-MS (m/z): 302 [M⁺, C₁₅H₁₁BrO₂], 304 [M+2,].




1-(4-fluorophenyl)-3-(4-hydroxyphenyl)propan-1-one (16d): ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.01 (d, $J = 9$ Hz, 2H), 7.75 (d, $J = 8$ Hz, 1H), 7.63 (dd, $J = 8, 3$ Hz, 2H), 7.45 (d, $J = 8.5$ Hz, 1H), 7.14-7.09 (m, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 200.12, 165.89, 157.59, 133.27, 131.65, 131.57, 130.77, 117.41, 116.20, 47.15, 30.49; IR ν_{\max} (KBr, cm⁻¹): 3419 (OH str), 2933, 2875 (aromatic C-H str), 1684 (C=O str), 1587 (aromatic, C=C str), 1266, 1087, 865, 739; GC-MS (m/z): 244 [M⁺, C₁₅H₁₃FO₂].




1-(4-chlorophenyl)-3-(4-hydroxyphenyl)propan-1-one (15o): ¹H NMR (CDCl₃, 500 MHz) δ ppm 7.73 (d, $J = 9$ Hz, 1H), 7.57 (d, $J = 8$ Hz, 2H), 7.52 (d, $J = 8, 3$ Hz, 1H), 7.39 (d, $J = 8.5$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H), 5.54 (s, 1H), 2.80 (t, $J = 6.0$ Hz, 2H), 2.73 (t, $J = 7.0$ Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 201.14, 157.88, 139.58, 136.23, 133.63, 131.54, 130.78, 129.62, 116.12, 115.10,

46.46, 31.17; **IR** ν_{\max} (**KBr**, cm^{-1}): 3406 (OH str), 2930, 2877 (aromatic C-H str), 1685 (C=O str), 1598 (aromatic, C=C str), 1269, 1087, 865, 733; **GC-MS** (**m/z**): 260 [M^+ , $\text{C}_{15}\text{H}_{13}\text{ClO}_2$].




1-(4-bromophenyl)-3-(4-hydroxyphenyl)propan-1-one (15p): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.02 (d, $J = 7.5$ Hz, 2H), 7.74 (d, $J = 7.5$ Hz, 1H), 7.57 (d, $J = 8.5$ Hz, 2H), 7.51 (d, $J = 8.0$ Hz, 2H), 7.39 (d, $J = 8.5$ Hz, 2H), 5.45 (s, 1H), 2.80 (t, $J = 6.5$ Hz, 2H), 2.73 (t, $J = 6.0$ Hz,

2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 199.12, 157.13, 136.27, 133.63, 131.54, 130.78, 129.62, 129.30, 115.19, 45.81, 30.17; **IR** ν_{\max} (**KBr**, cm^{-1}): 3425 (OH str), 2928, 2885 (aromatic C-H str), 1687 (C=O str), 1599 (aromatic, C=C str), 1265, 1079, 862, 725; **GC-MS** (**m/z**): 304, 306 [M^+ , $\text{C}_{15}\text{H}_{13}\text{BrO}_2$].




(E)-3-(4-fluorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (15q): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.00 (d, $J = 8.0$ Hz, 2H), 7.76 (d, $J = 15.5$ Hz, 1H), 7.62 (dd, $J = 6, 13.5$ Hz, 2H), 7.46 (d, $J = 14.5$ Hz, 1H),

7.10 (t, $J = 8.5$ Hz, 2H), 6.95 (d, $J = 8.0$ Hz, 2H), 6.24 (s, 1H, br, D_2O exchangeable); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 187.50, 164.68, 162.67, 141.94, 132.02, 131.52, 131.45, 129.53, 122.46, 116.42, 116.25; **IR** ν_{\max} (**KBr**, cm^{-1}): 3419 (OH str), 2935, 2877 (aromatic C-H str), 1684 (C=O str), 1599 (aromatic, C=C str), 1268, 1087, 866, 731; **GC-MS** (**m/z**): 243 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_2$].




(E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (15r): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.87 (d, $J = 8.5$ Hz, 2H), 7.54 (dd, $J = 8.5, 5$ Hz, 2H), 7.05 (d, $J = 8.5$ Hz, 2H), 6.95 (d, $J = 8.5$ Hz, 2H), 6.42

(s, 1H, br, D_2O exchangeable); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 187.20, 162.37, 141.64, 131.72, 131.22, 131.15, 129.23, 122.16, 116.12, 115.95; **IR** ν_{\max} (**KBr**, cm^{-1}): 3411 (OH str), 2930, 2881 (aromatic C-H str), 1688 (C=O str), 1594 (aromatic, C=C str), 1270, 1089, 868, 729; **GC-MS** (**m/z**): 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_2$].




(E)-3-(4-bromophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (15s): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.00 (d, $J = 8.5$ Hz, 2H), 7.77 (d, $J = 15.5$ Hz, 1H), 7.63 (t, $J = 8$ Hz, 2H), 7.46 (d, $J = 15.5$ Hz, 1H), 7.09 (t, $J = 8.5$ Hz, 2H), 6.94 (d, $J = 8$ Hz, 2H), 6.24 (s, 1H); ^{13}C NMR (CDCl_3 , 125

MHz) δ ppm 186.88, 162.05, 141.32, 131.41, 130.90, 130.83, 128.92, 121.85, 115.81, 115.64, 115.21; **IR ν_{\max} (KBr, cm^{-1}):** 3409 (OH str), 2929, 2873 (aromatic C-H str), 1688 (C=O str), 1591 (aromatic, C=C str), 1259, 1075, 865, 733; **GC-MS (m/z):** 302, 304 [M^+ , $\text{C}_{15}\text{H}_{11}\text{BrO}_2$].




3-(4-fluorophenyl)-1-(4-hydroxyphenyl)propan-1-one(15t): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.88 (d, $J = 8.5$ Hz, 2H), 7.55 (dd, $J = 8.5$, 5 Hz, 2H), 7.06 (t, $J = 8.5$ Hz, 2H), 6.96 (d, $J = 9.0$ Hz, 2H), 5.90 (s, 1H), 2.80 (t, $J = 5.0$ Hz, 2H), 2.72 (t, $J = 5.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 199.68, 166.54, 156.47, 132.65, 130.97, 130.68, 129.97, 128.66, 116.66, 115.05, 46.35, 30.51; **IR ν_{\max} (KBr, cm^{-1}):** 3421 (OH str), 2937, 2879 (aromatic C-H str), 1686 (C=O str), 1587 (aromatic, C=C str), 1262, 1089, 870, 727; **GC-MS (m/z):** 244 [M^+ , $\text{C}_{15}\text{H}_{13}\text{FO}_2$].




(3-(4-fluorophenyl)oxiran-2-yl)(4-hydroxyphenyl)methanone (15u): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.02(d, $J = 8.5$ Hz, 2H), 7.73 (dd, $J = 8.0$ Hz, 1H), 7.57 (t, $J = 8.5$ Hz, 2H), 7.52 (d, $J = 8.0$ Hz, 1H), 7.39 (d, $J = 8.5$ Hz, 2H), 5.62 (s, 1H), 4.22 (d, $J = 2.0$ Hz, 1H), 4.17 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 197.32, 156.54, 138.65, 130.97, 130.68, 129.97, 129.68, 128.68, 127.96, 126.67, 116.65, 71.12, 59.35; **IR ν_{\max} (KBr, cm^{-1}):** 3421 (OH str), 2937, 2879 (aromatic C-H str), 1686 (C=O str), 1596 (aromatic, C=C str), 1267, 1088, 867, 733; **GC-MS (m/z):** 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_3$].

(4-fluorophenyl)(3-(4-hydroxyphenyl)oxiran-2-yl)methanone (15v): ^1H NMR (CDCl_3 , 500




MHz) δ ppm 8.01(d, $J = 8.5$ Hz, 2H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.31 (t, $J = 8.0$ Hz, 2H), 7.13 (d, $J = 8.5$ Hz, 1H), 5.59 (s, 1H), 4.42 (d, $J = 1.5$ Hz, 1H), 4.26 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 197.41, 167.14, 157.88, 131.54, 130.78, 129.62, 124.36, 116.12, 115.10, 72.13, 58.10; **IR ν_{\max} (KBr, cm^{-1}):** 3417 (OH str), 2939, 2881 (aromatic C-H str), 1687 (C=O str), 1589 (aromatic, C=C str), 1263, 1091, 871, 729; **GC-MS (m/z):** 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_3$].




(4-chlorophenyl)(3-(4-hydroxyphenyl)oxiran-2-yl)methanone (15w): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.87 (d, $J = 8.5$ Hz, 2H), 7.54 (dd, $J = 8.5$, 5 Hz, 1H), 7.06 (t, $J = 8.5$ Hz, 2H), 6.96 (d, $J = 9.0$ Hz, 1H), 5.65 (s, 1H), 4.30 (d, $J = 1.5$ Hz, 1H), 4.23 (d, $J = 2.0$ Hz, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 198.20, 157.12, 139.53, 133.63, 131.54, 130.78, 129.62, 124.42, 115.10, 71.46, 59.17; **IR**

ν_{\max} (KBr, cm^{-1}): 3411 (OH str), 2930, 2881 (aromatic C-H str), 1688 (C=O str), 1594 (aromatic, C=C str), 1270, 1089, 868, 729; GC-MS (m/z): 274 [M^+ , $C_{15}H_{11}ClO_3$].




(4-bromophenyl)(3-(4-hydroxyphenyl)oxiran-2-yl)methanone (15x):

$^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 8.01(d, $J = 9.0$ Hz, 2H), 7.75 (d, $J = 8.0$ Hz, 1H), 7.63 (dd, $J = 8.5$, 5 Hz, 2H), 7.45 (d, $J = 9.5$ Hz, 1H), 7.13 (d, $J = 9.0$ Hz, 2H), 5.40 (s, 1H), 4.39 (d, $J = 2.5$ Hz, 1H), 4.28 (d, $J = 2.5$ Hz, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 198.01, 159.07, 133.01, 130.92, 129.62, 129.29, 128.66, 128.07, 117.13, 73.13, 60.17; IR ν_{\max} (KBr, cm^{-1}): 3411 (OH str), 2933, 2879 (aromatic C-H str), 1689 (C=O str), 1595 (aromatic, C=C str), 1275, 1079, 869, 725; GC-MS (m/z): 318, 320 [M^+ , $C_{15}H_{11}BrO_3$].



2-(4-hydroxyphenyl)-2-oxoacetaldehyde (16c): $^1\text{H NMR}$ (CDCl_3 , 500 MHz)


δ ppm 9.50(s, 1H), 7.88-7.86 (m, 2H), 6.89-6.87 (m, 2H), 5.58 (s, 1H, br, D_2O exchangeable); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 190.69, 187.73, 163.98, 132.91, 130.67, 116.55; GC-MS (m/z): 150 [M^+ for $C_8H_6O_3$].



1-(4-hydroxyphenyl)propane-1,2-dione (16d): $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ


ppm 7.93-7.90 (m, 2H), 6.92-6.89 (m, 2H), 6.55 (s, 1H), 2.18 (s, 3H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 197.85, 192.83, 164.85, 131.44, 124.80, 117.22, 23.05; GC-MS (m/z): 164 [M^+ , $C_9H_8O_3$].

3-(4-fluorophenyl)-1-(4-hydroxyphenyl)propane-1,2-dione (16e): $^1\text{H NMR}$ (CDCl_3 , 500



MHz) δ ppm 7.73(d, $J = 9.0$ Hz, 1H), 7.57 (d, $J = 7.5$ Hz, 2H), 7.53 (d, $J = 9.0$ Hz, 1H), 7.38 (d, $J = 8.5$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H), 5.19 (s,


1H), 3.99 (s, 2H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 197.12, 191.10, 166.42, 163.17, 131.54, 130.71, 129.62, 129.30, 122.38, 117.19, 116.11, 50.89; GC-MS (m/z): ; IR ν_{\max} (KBr, cm^{-1}): 3415 (OH str), 2935, 2879 (aromatic C-H str), 1685 (C=O str), 1593 (aromatic, C=C str), 1268, 1087, 865, 731; GC-MS (m/z): 258 [M^+ , $C_{15}H_{11}FO_3$].




3-(4-chlorophenyl)-1-(4-hydroxyphenyl)propane-1,2-dione(16f): ^1H

NMR (CDCl_3 , 500 MHz) δ ppm 8.02 (d, $J = 8.5$ Hz, 2H), 7.73 (d, $J = 9.0$ Hz, 1H), 7.57 (d, $J = 8.5$ Hz, 2H), 7.50 (d, $J = 8.0$ Hz, 1H), 7.38 (d, $J = 8.5$ Hz, 2H), 5.45 (s, 1H), 3.79 (s, 2H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 197.41, 190.12, 157.13, 140.10, 133.63, 131.54, 130.78, 129.62, 129.30, 116.19, 50.81; IR ν_{\max} (KBr,


cm^{-1}): 3407 (OH str), 2933, 2875 (aromatic C-H str), 1689 (C=O str), 1594 (aromatic, C=C str), 1270, 1090, 870, 729; **GC-MS (m/z)**: 274 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_3$].




3-(4-bromophenyl)-1-(4-hydroxyphenyl)propane-1,2-dione (16g): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.86 (d, $J = 8.5$ Hz, 2H), 7.54-7.52 (m, 2H), 7.05 (d, $J = 9.0$ Hz, 2H), 6.95 (d, $J = 8.5$ Hz, 2H), 6.42 (s, 1H), 3.85 (s, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 196.62, 191.12, 157.29, 133.01, 130.92, 129.87, 129.29, 128.66, 128.07, 116.93, 51.77; **IR ν_{max} (KBr, cm^{-1})**: 3425 (OH str), 2928, 2885 (aromatic C-H str), 1687 (C=O str), 1599 (aromatic, C=C str), 1265, 1079, 862, 725; **GC-MS (m/z)**: 318, 320 [M^+ , $\text{C}_{15}\text{H}_{11}\text{BrO}_3$].



1-(4-fluorophenyl)-3-(4-hydroxyphenyl)propane-1,2-dione (16h): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 78.03-7.99 (m, 2H), 7.58 (d, $J = 7.5$ Hz, 2H), 7.53-7.50 (m, 3H), 7.33 (t, $J = 8.5$ Hz, 1H), 7.13 (d, $J = 8.5$ Hz, 2H), 5.31 (s, 1H), 2.79 (s, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 197.65, 190.05, 168.52, 156.60, 130.68, 129.97, 128.68, 127.78, 116.66, 115.32, 51.12; **IR ν_{max} (KBr, cm^{-1})**: 3417 (OH str), 2935, 2871 (aromatic C-H str), 1679 (C=O str), 1581 (aromatic, C=C str), 1267, 1088, 867, 741; **GC-MS (m/z)**: 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_3$].



1-(4-chlorophenyl)-3-(4-hydroxyphenyl)propane-1,2-dione (16i): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.97-7.94 (m, 3H), 7.55-7.43 (m, 3H), 7.47 (t, $J = 9.0$ Hz, 1H), 6.98 (dd, $J = 8.5, 2.0$ Hz, 1H), 5.31 (s, 1H), 2.73 (s, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 197.27, 191.55, 157.77, 131.68, 130.49, 130.05, 129.65, 128.97, 128.65, 127.66, 117.54, 48.52; **IR ν_{max} (KBr, cm^{-1})**: 3401 (OH str), 2931, 2885 (aromatic C-H str), 1688 (C=O str), 1594 (aromatic, C=C str), 1275, 1091, 867, 729; **GC-MS (m/z)**: 274 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_3$].



1-(4-bromophenyl)-3-(4-hydroxyphenyl)propane-1,2-dione (16j): ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.88-7.79 (m, 3H), 7.57 (d, $J = 7.5$ Hz, 1H), 7.64-7.59 (m, 3H), 7.33 (t, $J = 8.5$ Hz, 1H), 6.94 (d, $J = 8.5$ Hz, 3H), 5.34 (s, 1H), 2.71 (s, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 196.68, 190.25, 157.05, 141.35, 131.77, 130.65, 130.49, 129.65, 128.97, 116.56, 49.85; **IR ν_{max} (KBr, cm^{-1})**: 3405 (OH str), 2930, 2871 (aromatic C-H str), 1675 (C=O str), 1591 (aromatic, C=C str), 1259, 1071, 865, 733; **GC-MS (m/z)**: 318, 320 [M^+ , $\text{C}_{15}\text{H}_{11}\text{BrO}_3$].

6.7. REFERENCES

- [1] (a) Amaranth, V.; Broom, A. D. *Chemical synthesis of oligonucleotides*, Chem. Rev., 1977, 77, 183; (b) Robertson, D. N. *Adducts of tert-alcohols containing an ethynyl group with dihydropyran. Potentially useful intermediates*, J. Org. Chem. 1960, 25, 931.
- [2] Hajipour, A. R.; Kargosha, M.; Ruoho, A. E.; *Tetrahydropyranylation of alcohols under solvent-free conditions*, Synth. Commun. 2009, 39, 1084.
- [3] (a) Green, T. W.; Wuts, P. G. M. *Organic Synthesis*, 3rd ed.; John Wiley: New York, 1999, 306; (b) Caine, D.; Deutsch, H. J. *Stereospecific total synthesis of gibberellic acid. A key tricyclic intermediate*, J. Am. Chem. Soc. 1978, 100, 8031; (c) Isobe, M.; Iio, H.; Kawai, T.; Goto, T. *Total synthesis of (S)-12-hydroxy-5,8,14-cis,-10-trans-eicosatetraenoic acid (Samuelsson's HETE)*, J. Am. Chem. Soc. 1978, 100, 1942; (c) Belal, M.; Das, D. K.; Khan, A. T. *Synthesis of Pyrido[2,3-c]coumarin Derivatives by an Intramolecular Povarov Reaction*, Synthesis 2015, 47, 1109.
- [4] (a) Otera, J. *Transesterification*, Chem. Rev. 1993, 93, 1449; (b) Kunitake, T.; Okahata, Y.; Sakamoto, T.; *Multifunctional hydrolytic catalyses. 8. Remarkable acceleration of the hydrolysis of p-nitrophenyl acetate by micellar bifunctional catalysts*, J. Am. Chem. Soc. 1976, 98, 7799; (c) Gonzalez, A. G.; Jorge, Z. D.; Dorta, H. L.; Rodriguez, F. L. *Deacylation of aromatic acetates. A new method of selective protection of the hydroxyl function*, Tetrahedron Lett. 1981, 22, 335; (d) Tee, V. S.; Mazza, C.; Zano-Hemmer, R. L.; Giorgi, I. B. *Ester Cleavage by Cyclodextrins in Aqueous Dimethyl Sulfoxide Mixtures. Substrate Binding versus Transition State Binding*, J. Org. Chem. 1994, 59, 7602; (e) Parmer, V. S.; Prasad, A. K.; Sharma, N. K.; Bisht, K. S.; Pati, H. N.; Taneja, P. *Regioselective enzyme-catalyzed deacetylation of benzyl phenyl ketone peracetates in organic solvents*, Bioorg. Med. Chem. Lett. 1993, 3, 585; (f) Crampton, M. R.; Holt, K. E.; Perey, J. M. *NaOAc-Mediated Selective Deprotection of Aromatic Acetates and Its Application in the Synthesis of Natural Products*, J. Chem. Soc. 1990, 2, 1701; (g) Boisselier, V. L.; Postel, M.; Dunach, E. *Bi(III) as new catalyst for the selective hydrolysis of esters*, Tetrahedron Lett. 1997, 38, 2981; (h) Guo, J.; Huang, W.; Scanlan, T. S. *Facile and selective deprotection of aryl acetates using sodium perborate under mild and neutral conditions*, J. Am. Chem. Soc. 1994, 116, 8062; (i) Bandgar, B. P.; Uppalla, L. S.; Sagar, A. D.; Sadavarte, V. S. *A mild procedure for rapid and selective deprotection of aryl acetates using natural kaolinitic clay as a reusable catalyst*, Tetrahedron Lett. 2001, 42, 1163; (j)

- Das, B.; Banerjee, J.; Ramo, R.; Pal, R.; Ravindranath, N.; Ramesh, C. *Studies on Novel Synthetic Methodologies. Part 29. Efficient, selective deprotection of aromatic acetates catalyzed by Amberlyst-15 or iodine*, Tetrahedron Lett. 2003, 44, 5465;(k) Bandgar, B. P.; Uppalla, L. S.; Patil, V. S. *An efficient catalyst for one-pot protection of hydroxyl group*, New J. Chem. 2003, 5, 68; (l) Ramesh, C.; Mahender, G.; Ravindranath, N.; Das, B. *A convenient, rapid, highly selective and eco-friendly method for deprotection of aryl acetates using silica gel supported ammonium formate under microwave irradiation*, Green Chem. 2003, 5, 68.
- [5] a) Tamami, B.; Parvanak, K. *Chemoselective tetrahydropyranylation of alcohols and phenols using polystyrene supported aluminum chloride as a catalyst*, Tetrahedron Lett. 2004, 45, 715; (b) Namboodiri, V. V.; Varma, R. S. *Solvent-free tetrahydropyranylation (THP) of alcohols and phenols and their regeneration by catalytic aluminum chloride hexahydrate*, Tetrahedron Lett. 2002, 43, 1143; (c) Babu, B. S.; Balasubramanian, K. *Mild and efficient tetrahydropyranylation of alcohols - catalysis by lithium perchlorate in diethyl ether*, Tetrahedron Lett. 1998, 39, 9287; (d) Reddy, P. N.; Sunil, B. K.; Kumar, P. S.; Srinivasulu, N. Y.; Reddy, T.; Rajitha, B. *Origins of the journal Khimiya Geterotsiklicheskikh soedinenii*, Chemistry of Heterocyclic Compounds 2005, 41, 11;(e) Khan, F. A.; Upadhyay, K. S. *An efficient Synthesis of a Cyclopentannulated Pyrrolidine Derivative*, Synthesis 2011, 15, 2423; (f) Diaz, R. R.; Melgarejo, C. R.; Plaza, M. T.; Cubero, I. I. *A Novel, Mild, and Practical Regeneration of Alcohols from their Allylic Ethers by NBS/H₂O*, J. Org. Chem. 1994, 59, 7928; (g) Narender, M.; Reddy, M. S.; Rao, K. R. *Electro-Deprotection—Electrochemical Removal of Protecting Groups*, Synthesis 2004, 30, 1741; (h) Wiles, C.; Watts, P.; Haswell, S. *Pyridinium p-toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranylation of alcohols*, Tetrahedron Lett. 2005, 61, 5209; (i) Karimi, B.; Maleski, J. *Lithium triflate (LiOTf) catalyzed efficient and chemoselective tetrahydropyranylation of alcohols and phenols under mild and neutral reaction conditions*, Tetrahedron Lett. 2002, 43, 5353;(j) Mineno, T. *A fast and practical approach to tetrahydropyranylation and depyranylation of alcohols using indium triflate*, Tetrahedron Lett. 2002, 43, 7975;(k) Ranu, B. C.; Saha, M. *A Simple, Efficient, and Selective Method for Tetrahydropyranylation of Alcohols on a Solid Phase of Alumina Impregnated with Zinc Chloride*, J. Org. Chem. 1994, 59, 8269;(l) Haraldsson, G. G.;

Baldwin, J. E. *A selective cleavage of aromatic benzyl ethers located ortho to a carbonyl group by magnesium bromide*, Tetrahedron 1997, 53, 215; (m) Tanemura, K.; Haraguchi, T.; Suzuki, T. *2,3-Dichloro-5,6-dicyano-p-benzoquinone as a mild and efficient catalyst for the tetrahydropyranylation of alcohols*, Bull. Chem. Soc. Jpn. 1992, 65, 304; (n) Kumar, H. M. S.; Reddy, B. V. S.; Reddy, E. J.; Yadav, J. S. *Hydroxyl group deprotection reactions with Pd(OH)₂/C: a convenient alternative to hydrogenolysis of benzyl ethers and acid hydrolysis of ketals*, Chem. Lett. 1999, 28, 857; (o) Yadav, J. S.; Srinivas, D.; Reddy, G. S. *A mild and versatile method for the tetrahydropyranylation of alcohols and their detetrahydropyranylation*, Synth. Commun. 1998, 28, 1399; (p) Molnarand, A. T. B. *Mild and efficient tetrahydropyranylation and deprotection of alcohols catalyzed by heteropoly acids*, Tetrahedron Lett. 1996, 37, 8597; (q) Akiyama, T.; Shima, H.; Ozaki, S.; β -(Trimethylsilyl)ethoxymethyl chloride. *A new reagent for the protection of the hydroxyl group*, Synlett 1992, 22, 415 ; (r) Srikrishna, A. R.; Sattigeri, J. A.; Vijaykumar, D. *A new, convenient reductive procedure for the deprotection of 4-methoxybenzyl (MPM) ethers to alcohols*, J. Org. Chem. 1995, 60, 5961; (s) Matthew, K. K.; Waymouth, R. M. *Solvent-free tetrahydropyranylation (THP) of alcohols and phenols and their regeneration by catalytic aluminum chloride hexahydrate*, Organometalics 2010, 29, 6051; (t) Akai, S.; Tanaka, R.; Hoshi, H.; Sato, K. I. *Selective Deprotection Method of N-Phenylcarbamoyl Group*, J. Org. Chem. 2013, 78, 8802; (u) Syam, S.; Abdelvhab, S. I.; Mamary, M. A.; Syam, M. *Molecule, β -(Trimethylsilyl)ethoxymethyl chloride. A new reagent for the protection of the hydroxyl group* 2012, 17, 6179; (v) Sabhita, G.; Yadav, J. S.; Rajkumar, M.; Babu, R. *A Highly Efficient, Mild, and Selective Cleavage of β -Methoxyethoxymethyl (MEM) Ethers by Cerium(III) Chloride in Acetonitrile*, Org. Lett. 2001, 3, 1149; (w) Rigby, J. H.; Wilson, J. Z.; *Removal of methoxyethoxymethyl ethers with trimethylsilyl chloride-sodium iodide*, Tetrahedron Lett. 1984, 25, 1429; (x) William, D. R.; Sakdarat, S. *Opportunities for selective removal of methoxyethoxymethyl (MEM) ethers*, Tetrahedron Lett. 1983, 24, 3965; (y) Han, J. H.; Kwon, Y. E.; Sohn, J. H.; Ryu, D. H. *A facile method for the rapid and selective deprotection of methoxymethyl (MOM) ethers*, Tetrahedron 2010, 66, 1673.

- [6] (a) Ali, H.; Van Lier, J. E. *ChemInform Abstract: An Easy Route for the Synthesis of Pyrazine-2,3-dicarbonitrile 5,6-Bis-substituted Derivatives Using a Palladium Catalyst*, Tetrahedron Letters 2012, 53, 4824; (b) Isobe, M.; Iio, H.; Kawai, T.; Goto, T. *Total*

- synthesis of (S)-12-hydroxy-5,8,14-cis,-10-trans-eicosatetraenoic acid (Samuelsson's HETE)*, J. Am. Chem. Soc. 1978, 100, 1942; (c) Ergun, M.; Dengiz, C.; Ozer, M. S.; Sahin, E.; Balci, M. *Synthesis of thio- and furan-fused heterocycles: fuopyranone, fuopyrrolone, and thienopyrrolone derivatives*, Tetrahedron 2014, 70, 5993; (d) Miyashita, M.; Yoshikoshi, A.; Grieco, P. A. *Pyridinium p-toluenesulfonate. A mild and efficient catalyst for the tetrahydropyranylation of alcohols*, J. Org. Chem. 1977, 42, 3772; (e) Schelhaas, M.; Waldmann, H. *Protecting group strategies in organic synthesis*, Angew. Chem., Int. Ed. 1996, 35, 2056; (f) Salomon, C. J.; Mata, E. G.; Mascaretti, O. A. *Recent developments in chemical deprotection of ester functional groups*, Tetrahedron 1993, 49, 3691.
- [7] (a) Liu, L.; Chen, M.; Cai, K.; *Montmorillonite Clay Catalysis XI¹: Protection and Deprotection of Hydroxyl Group by Formation and Cleavage of Trimethylsilyl Ethers Catalysed by Montmorillonite K-10*, Chinese Chemical Letters 1992, 8, 585; (b) Mahato, K.; Ray B.; Prasanta; Khan, A. T. *L-proline-catalysed unusual product formation from the reaction of 4-hydroxydithiocoumarin and aldehydes through a pseudo-three-component reaction*, Synlett 2014, 25, 2438.
- [8] (a) Li, H.; Xue, W.; Wu, A. *Palladium-catalyzed cross-coupling reactions of carboxylic anhydrides with organozinc reagents*, Tetrahedron 2014, 31, 4645; (b) Liu, L.; Chen, M.; Cai, K. *Selective oxidation of active carbon-hydrogen bonds with ammonium chloride-chromic anhydride complex*, Gaodeng Xuexiao Huaxue Xuebao 1993, 6, 809; (c) Pandey, S.; Kar, J. R.; Azam, A.; Pandey, S.; Chawla, H. M. *Competitive Self and Induced Aggregation of Calix[4]arene Ethers and Their Interaction with Pinacyanol Chloride and Methylene Blue in Nonaqueous Media*, J. Solu. Chem. 2010, 39, 107; (d) Lokhande, P. D.; Waghmare, S. R.; Gaikwad, H.; Hankare, P. P. *Organic Chemistry Including Medicinal Chemistry* 2013, 2, 300; (e) Mikol, G. J.; Russell, G. A. *Phenylglyoxal*, Organic Syntheses 1968, 48, 109; (f) Zhu, Y.; Cai, Q.; Gao, Q.; Jia, F.; Liu, M.; Gao, M.; Wu, A. *Target-oriented synthesis: miscellaneous synthetic routes to access 1,4-enediones through the coupling of 1,3-dicarbonyl compounds with multiform substrates*, Tetrahedron 2013, 31, 6392; (g) Zhou, Q.; Yuan, X.; Xiao, Y.; Dong, L.; Chen, Y. *Aminocatalytic asymmetric Diels-Alder reaction of phosphorus dienophiles and 2,4-dienals*, Tetrahedron 2013, 48, 10369; (h) Zhang, Z.; Su, J.; Zha, Z.; Wang, Z. *Electrochemical synthesis of the aryl α -keto esters from acetophenones mediated by*

- KI, European Journal Chemistry 2013, 52, 17711; (i) Jerussi R. A. 'Selective organic transformation' Vol. 1, B. S. Thyagarajan, Ed. Wiley-Interscience, New York, N. Y. pp 304.
- [9] (a) Ahmed, N.; Pathe, G. K.; Venkata, B. B. *Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn(IV)Cl₄ catalyst*, Tetrahedron Lett. 2014, 55, 3683; (b) Ahmed, N.; Van Lier, J. E. *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 5407; (c) Ahmed, N.; Van Lier, J. E. *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 2725; (d) Ahmed, N.; Konduru, N. K. *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177; (e) Konduru, N. K.; Ahmed, N. *Regioselective opening of chalcone epoxides with nitrogen heterocycles using indium(III) chloride as an efficient catalyst*, Synth. Commun. 2013, 43, 2008.
- [10] (a) Pummerer, R. *Phenylsulphoxyacetic Acid. II*, Chem. Ber. 1910, 43, 1401; (b) Russel, G. A.; Mikol, G. J. in 'Mechanism in molecular migration' vol, 1, B. S. Thyagarajan, ed., interscience, New York, N. Y. 1968, pp 157; (c) Corey, E. J.; Schaefer, J. P. *The mechanism of oxidation of ketones by selenium dioxide*, J. Am. Chem. Soc. 1960, 82, 918.

CHAPTER- 5

Part-A: Mild and efficient reductive deoxygenation of epoxides to olefins with SnCl₂/NaI as a novel reagent

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, Synthesis **2015, Ahead of print.**

Part-B: Efficient and green protocol for the eliminative deoxygenation of aliphatic and aromatic epoxides to olefin with polyphosphoric acid as a novel catalyst

Gulab Khushalrao Pathe^a and Naseem Ahmed*^a, Helvetica Chimica Acta **2015, Under Review.**

Part A: Mild and efficient reductive deoxygenation of epoxides to olefins with SnCl₂/NaI as a novel reagent**7.1. INTRODUCTION**

Epoxidation of organic compounds is well-known in organic and pharmaceutical syntheses to obtain a number of oxygen-containing intermediates.[1] In contrast, the reverse reaction (reductive deoxygenation) of epoxide to alkene is little-known with NaOH/n-BuNBr,[2] [Fe₄S₄(SC₆H₅)₄]²⁻,[3] CpTiCl₂/Mg,[4] PPh₃,[5] Na/Hg[6] and NaBH₄. [7] However, these catalysts have some drawbacks such as low activity, low atom efficiency, tedious work up and moisture sensitive reaction conditions.

The SnCl₂ is used as a non-toxic, inexpensive and mild Lewis acid catalyst in diverse organic synthesis. It was mainly used for the functional groups reduction such as nitrile and nitro groups and as a catalyst in ring cyclization reactions to yield heterocycles: benzoxazoles, quinoxalines, benzimidazoles and allylation of carbonyl compounds.[8] It was also used as a Lewis acid catalyst for the C-C bond formation, Sonn-Muller reaction, Stephen reduction,[9] polymerization of L-lactide and trans-esterification reactions. Recent deoxygenation reactions of epoxides to olefins was reported using Co(salane)₂/NaHg,[10] (EtO)₂P(O)TeNa,[11] LiI/Amberlyst-15,[12] LReO₃/PPh₃,[13] MoO(Et₂dtc)₂[14] reagents but these methods have drawbacks like less functional group tolerance, less versatility, low yields, long reaction time and tedious workup. Therefore, the development of simple and efficient reductive deoxygenation methods is of high interest.

In continuation of our interest in Lewis acid/base catalysis [15] and the importance of inexpensive, easily available, and stable catalysts in epoxide ring opening. Herein, we report a facile and eco-friendly protocol in the reductive deoxygenation of aliphatic and aromatic epoxides to olefins in the presence of SnCl₂/NaI combination as a highly efficient catalyst to afford alkenes in excellent yields (96%) within 2-10 min. at reflux in ethanol.

7.2. OBJECTIVE

Deoxygenation of epoxide into alkene is well-known in organic synthesis and pharmaceutical industry. Several methods have been applied for this conversion but these methods have a drawback like tedious work-up, moisture sensitive reaction etc. In our continuous efforts to obtain a facile and environment-friendly protocol in the reductive deoxygenation of aliphatic and aromatic epoxides to olefins. A highly efficient green protocol


was reported for the eliminative deoxygenation of organic epoxides to olefins using SnCl_2/NaI as a novel reagent. The reaction gave an excellent yield (85-96%) at reflux in ethanol within 2-10 mins without affecting other functional groups.

7.3. RESULTS AND DISCUSSION

7.3.1. Optimization reaction conditions for deoxygenation of styrene epoxide by SnCl_2/NaI

We optimized the deoxygenation reaction conditions in the reaction of styrene oxide (1equiv.) with novel SnCl_2/NaI reagent by varying molar ratios and different solvents (Table1). The product was obtained in excellent yield (96%) in ethanol at reflux using SnCl_2 (2 equiv.) and NaI (3 equiv.) within 5 min (Table1, entry 5). When, we increased or decreased molar ratios of SnCl_2/NaI reagent and solvents, the reaction gave lower yields (Table 1).

Table1. Optimization of deoxygenation reaction in styrene oxide with SnCl_2/NaI .





Entry	NaI(eq.)	SnCl_2 (eq.)	Solvent	Time (min)	Temp	Yields (%) ^a
1	3	2	DMF	5	Reflux	25
2	3	2	THF	5	Reflux	10
3	1	2	Ethanol	5	Reflux	50
4	2	2	Ethanol	5	Reflux	60
5	3	2	Ethanol	5	Reflux	96
6	4	2	Ethanol	5	Reflux	70
7	3	2	NMP	5	Reflux	20
8	3	2	DMSO	5	Reflux	20

^aYields of isolated products

7.3.2. Comparison of the SnCl_2/NaI reagent and recent reported methods of deoxygenation of epoxides to corresponding olefins


Our method is expanded to overcome the drawbacks of the previous reported methods. In order to show the advantages of the method, we have compared with other methods in the deoxygenation of epoxides to the corresponding olefins (Table 2).

Table 2. Comparison of the SnCl₂/NaI reagent and recent reported methods of deoxygenation of epoxides to corresponding olefins

























Sub.	SnCl ₂ /NaI min.[yields%]	Co(salane) ₂ / NaHg h[yields%]	(EtO) ₂ P(O) TeNa h[yields%]	LiI/Ambe- rlyst 15 h[yields%]	LReO ₃ / PPh ₃ h[yields%]	MoO (Et ₂ dtc) ₂ h[yields%]
	2-5 [95]	6 [95]	42 [88]	-	-	36 [92]
	2-5 [95]	1 [95]	-	3[85]	2 [32]	-

7.3.3. Examples of the deoxygenation of aliphatic and aromatic epoxides by SnCl₂/NaI

Under optimal condition, SnCl₂/NaI reagent was explored for various aliphatic and aromatic epoxides (Table 3). As depicted in table 3, the SnCl₂/NaI reagent surprisingly gave the products **17a -17l** in excellent yield (85-96%) (Table 3, entries 1-12) within 2-5 minutes at reflux temperature. Various aromatic epoxides (Table 3, entries 1-3 & 9-11), alicyclic (Table 3, entry 4, 6 & 12) and aliphatic (Table 3, entries 5,7 & 8) were transformed to alkenes in excellent yield. The carbonyl, nitro, hydroxyl, esters and ketones groups in the deoxygenation of alicyclic epoxides (Table 3, entries 4 & 12) and ether linkage in the aromatic and aliphatic epoxides (Table 3, entries 8 & 9) remained unaffected during the reaction. Our method is also highly stereospecific in nature. For example, deoxygenation of cis-stilbene oxide gave cis-stilbene and trans-stilbene oxide to trans-stilbene (Table 3, entry 10 & 11) and the chemoselectivity between epoxide ring and hydroxyl group (Table 3, entry 12). All products were characterized by comparing their physical and chemical properties with authentic samples.[16]

Table 3. Deoxygenation of aliphatic and aromatic epoxide by SnCl₂/NaI

Entry	Epoxides	Product	Time (min) ^a	Yield (%) ^a
-------	----------	---------	-------------------------	------------------------


1		 17a	2	96*
2		 17b	4	92
3		 17c	5	90
4		 17d	5	88
5		 17e	2	85
6		 17f	3	85
7		 17g	2	88
8		 17h	3	86
9		 17i	5	90
10		 17j	5	85
11		 17k	2	95
12		 17l	3	88

^aYields of Isolated products, all these product are characterized by comparing their physical and chemical properties with authentic samples [16]. *Volatile compounds isolated by fractional distillation (supporting information)

7.3.4. Examples of the deoxygenation of chalcone epoxide by SnCl₂/NaI

Under optimal condition, we have converted various chalcone epoxides to chalcone **18a-18q** with novel reagent SnCl₂/NaI in excellent yields (92-96%) within 5 minutes at reflux temperature in ethanol without affecting carbonyl, hydroxyl and halogen groups (Scheme 1). For example, product **18h**, the ¹H-NMR spectra showed two characteristic doublet peaks at δ 4.25 & 4.06 ppm (*J* = 1.5-2 Hz) of the corresponding epoxide (-CHOCH-) disappeared and two protons peak of -CH=CH- appeared downfield in aromatic proton region between δ 6.5-8.0 ppm. ¹³C-NMR spectra, the disappearance of characteristic peak at δ 61.03 & 58.81 ppm of (-CHOCH-) groups and that two protons peaks appeared in downfield region at δ 122.41 & 116.20 ppm and carbonyl peak somewhat shifted downfield compared to corresponding epoxide, indicated deoxygenation of chalcone epoxide to chalcone. These compounds were further characterised by IR and GC-MS.



Scheme 1. Deoxygenation of chalcone epoxide by SnCl₂/NaI



7.3.5. Examples of the deoxygenation of styrene epoxide by SnCl₂/NaI

In Scheme 2, we performed deoxygenation of various nitro styrene epoxides with novel reagent SnCl₂/NaI in ethanol to afford products **19a-19j** in excellent yields 85-93% within 5-7 minutes at reflux temperature (Scheme 2). The products were characterized on the basis of their spectral analysis. For example, product **19b**, ¹H-NMR spectra showed absence of two characteristic doublet peaks at δ 5.41 & 3.87 ppm of –CHOCH-N- (J = 2.5 Hz) and appearance of –CH=CH-N in aromatic region. Similarly, ¹³C-NMR spectra, the absence of two characteristic peaks at δ 100.18 & 89.26 ppm of –COC-N- carbon nitrostyrene epoxide, indicated deoxygenation of nitrostyrene epoxide to nitrostyrene. These compounds were further characterised by IR and GC-MS.



Scheme 2. Deoxygenation of nitro styrene epoxide by SnCl₂/NaI.



7.3.6. Examples of the deoxygenation of nitrochromene epoxide by SnCl₂/NaI


We also carried out deoxygenation of hindered chromene epoxides with novel reagent SnCl₂/NaI in ethanol (Scheme 3). It gave deoxygenation products **20a -20j** in excellent yield (85-90%) within 5-10 minutes at reflux temperature. Spectral analysis for example, compound **20b**, ¹H-NMR spectra showed the characteristic singlet peak at δ 6.86 ppm of –CH=CH-N- and absence of peak at δ 3.82 ppm of nitrochromene epoxide indicated deoxygenation product. Similarly, in ¹³C-NMR spectra, the characteristic peaks at δ 60.67 & 116.94 ppm of –C=C-N- carbon indicated the deoxygenation to nitrochromene. These compounds were further characterised by IR and GC-MS.

Scheme 3. Deoxygenation of nitrochromene epoxide by SnCl₂/NaI



7.4. Plausible mechanism for the deoxygenation epoxide to olefin by SnCl_2/NaI .

In the deoxygenation reactions consistently brown color was observed due to the generation of molecular iodine, by taking into account this observation, we gave the plausible reaction mechanism, where a nucleophile attack of oxygen lone pair electrons of epoxide on tin dichloride liberates the chloride ion followed by epoxide ring opening by iodide ion and removal of the molecular iodine to give the corresponding olefins (Scheme 4).



Scheme 4. Plausible mechanism for the deoxygenation epoxide to olefin by SnCl_2/NaI .

7.5. CONCLUSION

In conclusion, we have reported SnCl_2/NaI in ethanol as an efficient reagent during eliminative deoxygenation reaction for epoxides to olefins in excellent yield (85-96%) within 2-10 mins. This method has advantages as inexpensive reagent, high yield, short reaction time, eco-friendly, green reaction and high functional group tolerance.

7.6. EXPERIMENTAL DETAILS

Organic solvents were dried by standard methods; the reagents (chemicals) were purchased from commercial sources, and used without further purification. All reactions were monitored by TLC using precoated silica gel aluminum plates. Visualization of TLC plates was accomplished with an UV lamp. Column chromatography was performed using silica gel 60–120 mesh size (RANKEM Limited) with EtOAc–hexanes as eluent. Melting points were recorded on Perfit apparatus and are uncorrected. All products were characterized by NMR, IR and MS spectra. ^1H and ^{13}C NMR spectra were recorded in deuterated chloroform (CDCl_3) on a 500 MHz and 125 MHz spectrometer (Bruker), respectively. Chemical shifts were reported in parts per million (ppm, δ) downfield from tetramethylsilane. Proton coupling patterns are described as singlet (s), doublet (d), triplet (t), quartet (q), multiplet (m), and broad (br).

7.6.1. General procedure for the synthesis of chromene epoxides (39-49): Aqueous NaOH (5M, 10 ml) was added drop wise to a stirred solution of chromines (18 mmol) in aq. THF (30 ml, H_2O : THF, 1:2 ratio) and further stirred for 10 min. Then, H_2O_2 (15 ml, 30% wt.%) was added drop wise and further stirred for 2 days at room temperature. TLC monitoring, the reaction mixture was poured in water. The resulting precipitate was filtered, washed with water and dried under reduced pressure. The product was recrystallized in EtOH or silica gel column chromatography in petroleum ether: CH_2Cl_2 (8:2) as eluent gave chromine epoxide (39-49) in 60-70% yields.

General procedure for Deoxygenation of aliphatic and aromatic epoxide, chalcone epoxide, nitro styrene epoxide and nitrochromene epoxide by novel SnCl_2/NaI reagent:

To a solution epoxide (1mmol) and NaI (3mmol) in absolute alcohol (5ml), SnCl_2 (2mmol) was added in a several portions. The mixture was stirred at reflux temperature and the progress of reaction was monitored by TLC. within 2-10 min the reaction mixture is poured in ice-water, precipitation obtained, stirred for 10 min and filtered the solid, dried to obtained pure products **17a-17l/ 18a-18q/19a-19j and 20a- 20j** with 85-96% yield. *2-(2-chlorophenyl)-3-nitro-2H-chromene (20c)*: Yellow solid; Yield: 243 mg (85%); melting point-90-92°C; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.15(s, 1H), 7.48 (dd, $J = 1\text{Hz}, 9.5\text{Hz}$, 1H), 7.34(dd, $J = 2\text{Hz}, 8\text{Hz}$, 1H), 7.32-7.27 (m, 2H), 7.192 (dd, $J = 2\text{Hz}, 8\text{Hz}$, 1H), 7.07 (s, 1H), 7.0 (dt, $J=1\text{Hz}$, 1H), 6.82 (d, $J=8\text{Hz}$, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 153.61, 146.74, 144.99, 139.94, 134.77, 129.92, 128.99, 128.72, 128.59, 127.21, 122.34, 121.94, 116.91, 114.47, 79.59.

IR (ν_{\max} , cm^{-1}): 3069, 2923, 1644, 1511, 1327, 1107; GCMS (m/z) 287 [M^+ , $\text{C}_{15}\text{H}_{10}\text{ClNO}_3$] 289, 287, 270, 257, 241, 205, 176, 146 (100%), 89, 76, 63.

Note: Examples are same for the both sections therefore experimental section given in Part: B for all spectral data of synthesized compounds.

7.7. REFERENCES

- [1] (a) Madesclaire, M. *Reduction of sulfoxides to thioesters*, *Tetrahedron* 1988, 44, 6537; (b) Abad, A.; Concepcion, P.; Corma, A.; Garcia, H. *A collaborative effect between gold and a support induces the selective oxidation of alcohols*, *Angew. Chem. Int. Ed.* 2005, 44, 4066; (c) Hayashi, T.; Tanaka, K.; Haruta, M. *Selective vapor-phase epoxidation of propylene over Au/TiO₂ catalysts in the presence of oxygen and hydrogen*, *J. Catal.* 1998, 178, 566; (d) Zhang, X.; Shi, H.; Xu, B. Q. *Catalysis by gold: Isolated surface Au³⁺ ions are active sites for selective hydrogenation of 1,3-butadiene over Au/ZrO₂ catalysts*, *Angew. Chem., Int. Ed.* 2005, 44, 7132; (e) Girard, P.; Namy, J. L.; Kagan, H. B. *Mild preparation of samarium iodide and ytterbium iodide and their use as reducing or coupling agents*, *J. Am. Chem. Soc.* 1980, 102, 2693; (f) Concellon, J. M.; Bardales, E. *Synthesis of (E)- α,β -Unsaturated Esters with Total or High Diastereoselectivity from α,β -Epoxyester*, *Org. Lett.* 2002, 4, 189; (g) Martin, M. G.; Ganem, B. *Epoxides as alkene protecting groups. A mild and efficient deoxygenation*, *Tetrahedron Lett.* 1984, 25, 251; (h) Davis, R. E. *Cyclic sulfides. III. Reaction of some ethylene sulfides with triphenylphosphine and with triethyl phosphite*, *J. Org. Chem.* 1958, 23, 1767; (i) Singh, A. K.; Quraishi, M. A. *The Effect of Some Bis-thiadiazole Derivatives on the Corrosion of Mild Steel in Hydrochloric acid*, *Corrosion Science* 2010, 52, 1373; (j) Ansari, K. R.; Quraishi, M. A. *Isatin derivatives as a non-toxic corrosion inhibitor for mild steel in 20% H₂SO₄*, *Corrosion Science* 2015, 95, 62; (k) Aalbersberg, W. G. L.; Vollhardt, K. P. C. *J. Am. Chem. Soc.* 1977, 99, 2792; (l) Shoppee, C. W.; Sternhell, S.; Taylor, W. C. *Some metabolites of *Cylindrocarpon radicum*: the structure of radicum (monorden)*, *Aust. J. Chem.* 1966, 19, 1265; (m) Mahesh, M.; Murphy, J. A.; Wassel, H. P. *Novel Deoxygenation Reaction of Epoxides by Indium*, *J. Org. Chem.* 2005, 70, 4118; (n) Firouzabadi, H.; Iranpoor, N.; Jafapour, M. *Rapid, highly efficient and stereoselective deoxygenation of epoxides by ZrCl₄/NaI*, *Tetrahedron Lett.* 2005, 46, 4107.

- [2] (a) Silverman, R. B. *Model studies for a molecular mechanism of action of oral anticoagulants*, J. Am. Chem. Soc. 1981, 103, 3910; (b) Preusch, P. C.; Suttie, J. W. *A chemical model for the mechanism of vitamin K epoxide reductase*, J. Org. Chem. 1983, 48, 3301.
- [3] Itoh, T.; Nagano, T.; Sato, M.; Hirobe, M. *Deoxygenation of oxirane compounds to olefins by iron complex $[Fe_4S_4(SC_6H_5)_4]^{2-}$ in the presence of sodium borohydride*, Tetrahedron Lett. 1989, 30, 6387.
- [4] Marples, B. A.; Muxworthy, J. P.; Baggaley, K. H. *Oxidative cleavage of benzyl ethers using dimethyldioxirane*, Synlett 1992, 22, 646.
- [5] Rao, M. L. N.; Giri, S. *Pd-Catalyzed Threefold Arylation of Baylis–Hillman Bromides and Acetates with Triarylbismuth Reagents*, E. J. Org. Chem. 2012, 24, 4580.
- [6] Yamada, N.; Mizuochi, M.; Morita, H. *Thermolysis of β -hydroxysulfides bearing several heteroaromatics*, Tetrahedron 2007, 63, 3408.
- [7] Kai, K.; Takeuchi, J.; Kataoka, T.; Yokoyama, M.; Watanabe, N. *Structure-activity relationship study of flowering-inducer FN against Lemna paucicostata*, Tetrahedron 2008, 64, 6760.
- [8] Wang, Z.; *Comprehensive Organic Name Reaction and Reagents*; John Wiley & Sons, 2010, 2659.
- [9] (a) Kundu, A.; Prabhakar, S.; Vairamani, M.; Roy, S. *A novel Copper(II)/Tin(II) reagent for aqueous carbonyl allylation: In situ diagnostics of reactive organometallics in water*, Organometallics 1997, 16, 4796; (b) Mahato, K.; Bagdi, P. R.; Khan, A. T. *$Yb(OTf)_3$ catalysed regioselective synthesis of unusual di- and tri- substituted 3,4-dihydrothiochromeno[3,2-e][1,3]thiazin-5(2H)-one derivatives through a pseudo four-component hetero-Diels-Alder reaction*, RSC Advances 2015, 5, 48104.
- [10] Isobe, H.; Branchaud, B. P.; *Epoxide deoxygenation mediated by salen complexes*, Tetrahedron Lett. 1999, 40, 8747.
- [11] Clive, D. L.J.; Menchen, S. M. *Alkali Metal O,O-diethyl phosphorotelluroates, a reagent class for deoxygenation of epoxides, especially terminal epoxides*, J. Org. Chem. 1980, 45, 2347.
- [12] Righi, G.; Bovicelli, P.; Sperandio, A.; *An easy deoxygenation of conjugated epoxides*, Tetrahedron 2000, 56, 1733.

- [13] Gable, K. P.; Brown, E. C. *Tantalum-mediated cleavage of an N:N bond in an organic diazene (azoarene) to produce an imidometal (M:NR) complex: an η^2 -diazene complex is not an intermediate*, *Organometallics* 2000, 19, 944.
- [14] Moloy, K. G. *Oxygen atom transfer reactions. Epoxide deoxygenation by bis (diethyldithiocarbamato)oxomolybdenum*, *Inorg. Chem.* 1988, 27, 677.
- [15] (a) Ahmed, N.; van Lier, J. E. *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, *Tetrahedron Lett.* 2007, 48, 13; (b) Ahmed, N.; van Lier, J. E. *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, *Tetrahedron Lett.* 2006, 47, 5345; (c) Ahmed, N.; Konduru, N. K. *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2, 6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, *Beilstein J. Org. Chem.* 2012, 8, 177.
- [16] (a) Iranpoor, N.; Firouzabadi, H.; Jamalian, A. *Silphos [PCl₃-n(SiO₂)_n]: a heterogeneous phosphine reagent for the conversion of epoxides to β -bromo formates or alkenes*, *Tetrahedron* 2006, 62, 1823; (b) Choi, K. H.; Choi, K.; Kim, J. H.; Yoon, C. M.; Yoo, B. W. *Mild and efficient deoxygenation of epoxides with bis(cyclopentadienyl)titanium(IV) dichloride-indium system*, *Bull. Korean Chem. Soc.* 2005, 26, 1495.

Part-B: Efficient and green protocol for the eliminative deoxygenation of aliphatic and aromatic epoxides to olefin with polyphosphoric acid as a novel catalyst

8.1. INTRODUCTION

Epoxidation of organic compounds is well-known in organic and pharmaceutical syntheses to obtain a number of oxygen-containing intermediates.[1] In contrast, the reverse reaction (reductive deoxygenation) of epoxides to alkenes is little-known with NaOH/n-BuNBr,[2] $[\text{Fe}_4\text{S}_4(\text{SC}_6\text{H}_5)_4]^{2-}$, [3] CpTiCl₂/Mg,[4] PPh₃, [5] indium- metal, Na/Hg [6] and NaBH₄. [7] However, these catalysts have some drawbacks such as low activity, low atom-economy, tedious work up and moisture sensitive reaction conditions.

Polyphosphoric acid (PPA) has been used extensively in organic syntheses.[8] for example, in acylation, alkylation, cyclization, acid catalyzed reactions like dehydration, rearrangements and synthesis of polymer and N-containing heterocycles.[9-11] Epoxides are being potential precursors for a variety of molecules, recently, some methods for deoxygenation of epoxides to olefins were studied using LiI/Amberlyst-15,[12] LReO₃/PPh₃, [13] Co(salane)₂/Na-Hg, [14] (EtO)₂P(O)-TeNa, [15] MoO(Et₂dte)₂ [16] but these reagents have drawbacks as less tolerance of functional groups, low yields, long reaction time and tedious workup with moisture sensitive reaction conditions. Therefore, the development of simple and efficient catalytic deoxygenation methods is of high interest.

In continuation of our interest in Lewis acid/base catalysis [17] and the importance of inexpensive, easily available, and stable catalysts in epoxide ring opening. Herein, we report a facile and eco-friendly protocol in the eliminative deoxygenation of aliphatic and aromatic epoxides to olefins in the presence of PPA (30 mol% loading) as a highly efficient catalyst to afford alkenes in excellent yields (85-96%) within 5-15 min. at 50 °C under neat condition.

8.2. OBJECTIVE

Deoxygenation of epoxide into alkene is well-known in organic synthesis and pharmaceutical industry. Several methods have been applied for this conversion but these methods have a drawback like tedious work-up, moisture sensitive reaction etc. In our continuous efforts to obtain a facile and environment-friendly protocol in the eliminative deoxygenation of aliphatic and aromatic epoxides to olefins, herein, we demonstrate that phosphoric acid act as a highly efficient catalyst in 30 mol % loading to afford the alkenes in


excellent yields (85-96%) within 5-15 min. at 50 °C. This methodology is very good alternative to the known methods of deoxygenation of epoxides.

8.3. RESULTS AND DISCUSSION

8.3.1. Optimization reaction conditions for deoxygenation of styrene epoxide by PPA

We optimized the deoxygenation reaction conditions in the reaction of styrene oxide (1 equiv.) with PPA by varying mol% and solvents (**Table 1**). The product was obtained in excellent yield (95%) at 50 °C using PPA (30 mol%) within 5-10 min under neat condition (**Table 1, entry 6**). However, further increase or decrease in mol% of PPA and use of other organic solvents, gave lower yields (**Table 1**).

Table 1. Optimized condition for the deoxygenation of styrene oxide by polyphosphoric acid




Entry	Mol % of PPA	Solvent	Time (min)	Temp (°C)	Yields ^a (%)
1	30	DMF	15	Reflux	15
2	30	ACN	15	Reflux	20
2	30	Ethanol	15	Reflux	30
4	10	-	15	50	20
5	20	-	15	50	50
6	30	-	5-10	50	95
7	40	-	10	50	85
8	30	NMP	15	Reflux	15
9	30	DMSO	10	Reflux	15



^aYield of isolated product

8.3.2. Comparison of polyphosphoric acid system with earlier methods

In order to show the advantages of our method, we have also compared the existing methods in the case of eliminative deoxygenation of epoxides to olefins (**Table 2**).

Table 2. Comparison of the green PPA system with formerly reported systems for deoxygenation of epoxides to alkenes




























Substrate	30 mol % PPA min.[yields%]	LiI/ Amberlyst 15 h[yields%]	LReO ₃ / PPh ₃ h[yields%]	Co(salane) ₂ / NaHg h[yields%]	(EtO) ₂ P(O)- TeNa h [yields%]	Mo (Et ₂ dtc) ₂ h[yields%]
	< 10 [96]	-	-	6 [95]	42 [88]	36 [92]
	< 10 [96]	3[85]	2 [32]	1 [95]	-	-
With or without Solvent	Without Solvent	With Solvent	With Solvent	With Solvent	With Solvent	With Solvent

8.3.3. Examples of the deoxygenation of aliphatic and aromatic epoxide by PPA

Under optimal conditions, PPA catalyst was explored for various aliphatic and aromatic epoxides (**Table 3**) to afford alkenes **21a-21l** in excellent yields 85-96% at 50 °C under neat condition (**Table 3, entries 1-12**) within 5-10 minutes. Like, aromatic (**Table 3, entries 1-3 & 9-11**), alicyclic (**Table 3, entry 4, 6 & 12**), aliphatic (**Table 3, entries 5,7 & 8**) epoxides were transformed to alkenes in excellent yields. The carbonyl, nitro, hydroxyl, esters and ketone groups in the deoxygenation of alicyclic epoxides (**Table 3, entries 4 & 12**) and ether linkage in the aromatic and aliphatic epoxides (**Table 3, entries 8 & 9**) remained unaffected during the reaction. Our method is also highly stereospecific in nature. For example, deoxygenation of Z-stilbene oxide gave Z-stilbene and E-stilbene oxide to E-stilbene (**Table 3, entry 10 & 11**) and the chemoselectivity between epoxide ring and hydroxyl group (**Table 3, entry 12**). All products were characterized by comparing with their physical and chemical properties of authentic samples. [18]

Table 3. Deoxygenation of aliphatic and aromatic epoxide by polyphosphoric acid




Entry	Epoxides	Product	Time (min)	Yield (%) ^a
1		 21a	5	95
2		 21b	5	92
3		 21c	5	90
4		 21d	5	88
5		 21e	6	93
6		 21f	5	88
7		 21g	5	85
8		 21h	6	85
9		 21i	6	88
10		 21j	10	86
11		 21k	5	96
12		 21l	5	95

^a Yields of Isolated product, all these product are characterized by comparing their physical and chemical properties with authentic samples.[18]

8.3.4. Examples of the deoxygenation of chalcone epoxide by PPA

Under optimal condition, we have converted various chalcone epoxides to chalcone **22a-22q** with novel PPA catalyst in excellent yield (90-95%) within 5-10 minutes at 50 °C (Scheme 1). As depicted in Scheme 1, PPA has transformed various chalcone epoxides into corresponding chalcones in excellent yield without affecting carbonyl, hydroxyl and halogen groups (Scheme 1). The products were characterized on the basis of their spectral analysis ¹H- and ¹³C-NMR, GC-MS (see, supporting information). For example, product **22h**, the ¹H-NMR spectra showed two characteristic doublet peaks at δ 4.25 & 4.06 ppm ($J = 1.5-2$ Hz) of corresponding epoxide (-CHOCH-) disappeared and two protons peak of -CH=CH- appeared downfield in aromatic proton region between δ 6.5-8.0 ppm. ¹³C-NMR spectra, the disappearance of characteristic peaks at δ 61.03 & 58.81 ppm of (-CHOCH-) groups and the two protons peak appeared in downfield region at δ 122.41 & 116.20 ppm and carbonyl peak somewhat shifted downfield compared to the corresponding epoxide, indicated deoxygenation of chalcone epoxide to chalcone. These compounds were further characterised by IR and GC-MS.


Scheme 1. Deoxygenation of chalcone epoxide by polyphosphoric acid



8.3.5. Examples of the deoxygenation of styrene epoxide by PPA

We also performed deoxygenation of various nitro styrene epoxides with PPA catalyst at 50 °C under neat condition to afford products **23a-23j** in excellent yields 85-92 % within 5-10 min. (Scheme 2). The products were characterized on the basis of their spectroscopic analysis. For example, product **23b**, ¹H-NMR spectra showed absence of two characteristic doublet peaks at δ 5.41 & 3.87 ppm of –CHOCH-N- ($J = 2.5$ Hz) and appearance of –CH=CH-N in aromatic region. Similarly, ¹³C-NMR spectra, the absence of two characteristic peaks at δ 100.18 & 89.26 ppm of –COC-N- carbon nitrostyrene epoxide indicated deoxygenation of nitrostyrene epoxide to nitrostyrene. These compounds were further characterised by IR and GC-MS.



Scheme 2. Deoxygenation of nitro styrene epoxide by polyphosphoric acid



8.3.6. Examples of the deoxygenation of styrene epoxide by PPA

We also carried out deoxygenation of hindered chromene epoxides with catalyst PPA (Scheme 3). It gave deoxygenation products **24a -24j** in excellent yield (85-90%) within 10-15 minutes at 50 °C under neat condition. Spectral analysis for example, compound **24b**, ¹H-NMR spectra showed the characteristic singlet peak at δ 6.86 ppm of –CH=CH-N- and absence of peak at δ 3.82 ppm of nitrochromene epoxide indicated the deoxygenation product. Similarly, in ¹³C-NMR spectra, the characteristic peaks at δ 60.67 & 116.94 ppm of –C=C-N- carbon indicated the deoxygenation to nitrochromene. These compounds were further characterised by IR and GC-MS.


Scheme 3. Deoxygenation of nitrochromene epoxide by polyphosphoric acid



8.4. MECHANISM

In scheme 4, we suggested a plausible reaction mechanism as S_N2 nucleophilic attack of oxygen lone pair of epoxide on phosphorous of PPA (like Wittig and Horner- Wadsworth-Emmons reactions) followed by the reaction like [2+2] chelotropic pericyclic reaction gave the corresponding alkenes with removal of meta-phosphoric acid [19] (Scheme 4).

Scheme 4. Plausible mechanism for the deoxygenation of epoxides to alkenes



8.5. CONCLUSION


In conclusion, we have reported polyphosphoric acid as an efficient catalyst in the eliminative deoxygenation reaction for epoxides to give olefins in excellent yield (85-96%) under neat condition. This method has advantages as inexpensive reagent, high yield, short reaction time, eco-friendly and green reaction.

8.6. EXPERIMENTAL DETAILS

8.6.1. General procedure for the synthesis of chromene epoxides (39-49): Aqueous NaOH (5M, 10 ml) was added drop wise to a stirred solution of chromines (18 mmol) in aq. THF (30 ml, H₂O: THF, 1:2 ratio) and further stirred for 10 min. Then, H₂O₂ (15 ml, 30% wt.%) was added drop wise and further stirred for 2 days at room temperature. TLC monitoring, the reaction mixture was poured in water. The resulting precipitate was filtered, washed with water and dried under reduced pressure. The product was recrystallized in EtOH or silica gel column chromatography in petroleum ether: CH₂Cl₂ (8:2) as eluent gave chromene epoxide (39-49) in 60-70% yields.

General procedure for the Deoxygenation of aliphatic and aromatic epoxide, chalcone epoxide, nitro styrene epoxide and nitrochromene epoxide by novel Catalyst polyphosphoric acid: The PPA (30 mol%) was added to a epoxide (1mmole) and the mixture was heated under neat condition for 15 min at 50 °C, and the progress of reaction was monitored by TLC. After 15 min the reaction mixture was poured in ice-water, precipitation obtained, stirred for 10 min and filtered the solid, dried to gave pure products **21a-21l/ 22a-22q/23a-23j and 24a- 24j** with 85-96% yield. 2-(2-cholorophenyl)-3-nitro-2H-chromene (3d): Yellow solid; Yield: 258 mg (90%); melting point-90-92 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.15(s, 1H), 7.48 (dd, *J* = 1Hz, 9.5Hz, 1H), 7.34(dd, *J*= 2Hz, 8Hz, 1H), 7.32-7.27 (m, 2H), 7.192 (dd, *J* = 2Hz, 8Hz, 1H), 7.07 (s, 1H), 7.0 (dt, *J*=1Hz, 1H), 6.82 (d, *J*=8Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 153.61, 146.74, 144.99, 139.94, 134.77, 129.92, 128.99, 128.72, 128.59, 127.21, 122.34, 121.94, 116.91, 114.47, 79.59; I R (ν_{max}, cm⁻¹): 3069, 2923, 1644, 1511, 1327, 1107; GCMS (m/z) 287 [M⁺. C₁₅H₁₀ ClNO₃] 289, 287, 270, 257, 241, 205, 176, 146 (100%), 89, 76, 63.


8.6.2. Characterization data for selected synthesized compounds




2-phenyloxirane (1): Colorless oily liquid; Yield: 115 mg (96%); boiling point-145 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 7.34-7.24 (m, 5H), 3.83 (t, *J* = 4.0 Hz, 1H), 3.12 (t, *J* = 5.0 Hz, 1H), 2.77 (dd, *J* = 7.0, 3.5 Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 137.68, 128.61, 128.29, 125.59, 52.48, 51.35; IR ν_{max} (KBr, cm⁻¹): 2994, 2888 (aromatic C-H str), 1622 (aromatic, C=C str), 1263, 1096, 860, 745; GC-MS (m/z): 120 [M⁺, C₈H₈O].

(3-(4-chlorophenyl)oxiran-2-yl)(phenyl)methanone (20): White solid; Yield: 247 mg (96%); melting point-155 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.01 (d, *J* = 8.5, 1.5 Hz, 2H), 7.62


(d, $J = 7.5$ Hz, 1H), 7.49 (t, $J = 8.5$ Hz, 2H), 7.37 (t, $J = 7.0$ Hz, 2H), 7.30 (dd, $J = 8.5, 2.5$ Hz, 2H), 4.25 (d, $J = 1.5$ Hz, 2H), 4.06 (d, $J = 1.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 192.83, 135.44, 134.23, 134.11, 129.13, 129.04, 128.45, 127.22, 61.03, 58.81; IR ν_{max} (KBr, cm^{-1}): 2933, 2877 (aromatic C-H str), 1598 (aromatic, C=C str), 1266, 1085, 866, 731; GC-MS (m/z): 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_2$].



2-(4-chlorophenyl)-3-nitrooxirane (31): Yellow oily liquid; Yield: 189 mg, (95%); boiling point-150-152 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.44 (d, $J = 8.5$ Hz, 2H), 7.26 (d, $J = 8.5$ Hz, 2H), 5.41 (s, 1H), 3.87 (s, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 136.00, 132.98, 128.93, 127.36, 100.18, 89.26; IR (ν_{max} , cm^{-1}): 3118, 3057, 1516, 1339; GCMS (m/z): 199 [M^+ , $\text{C}_8\text{H}_6\text{ClNO}_3$].




2-(4-chlorophenyl)-1a-nitro-2,7b-dihydro-1aH-oxireno[2,3-c]chromene (41): Brown oily liquid; Yield: 196 mg (65%); boiling point-160-163 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.36 (dd, $J = 7.0, 2.0$ Hz, 2H), 7.21 (t, $J = 7.5$ Hz, 1H), 7.11-6.97 (m, 3H), 6.94 (dd, $J = 6.5, 2.0$ Hz, 1H), 5.29 (s, 1H), 3.82 (s, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 153.61, 134.77, 129.92, 128.99, 128.72, 128.59, 127.21, 122.34, 121.94, 116.91, 111.47, 89.87, 60.67; IR (ν_{max} , cm^{-1}): 3070, 2925, 1642, 1513, 1329, 1108; GCMS (m/z): 303 [M^+ , $\text{C}_{15}\text{H}_{10}\text{ClNO}_4$].




styrene (21a): Colorless oily liquid; Yield: 99 mg (95%); boiling point-145 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.43-7.41 (m, 2H), 7.35-7.31 (m, 2H), 7.27-7.24 (m, 1H), 7.15-7.13 (m, 1H), 6.73 (m, 1H), 5.78 (d, $J = 1.5$, 1H), 5.26 (d, $J = 1.5$, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 137.63, 136.95, 128.61, 127.89, 126.29, 125.58, 113.91; IR (ν_{max} , cm^{-1}): 3106, 2908, 2839, 1498, 1309; GCMS (m/z): 104 [M^+ , C_8H_8].




(E)-chalcone (22a): Yellow solid; Yield: 192 mg (94%); melting point-55-57 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 8.5$ Hz, 2H), 7.38 (d, $J = 8.5$ Hz, 4H), 7.30 (d, $J = 8.5$ Hz, 4H), 7.12 (d, $J = 8.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 190.70, 144.98, 138.28, 134.96, 132.91, 130.67, 129.07, 128.73, 128.61, 128.56, 122.15; IR ν_{max} (KBr, cm^{-1}): 2935, 2877 (aromatic C-H str), 1585 (aromatic, C=C str), 1266, 1088, 862, 733; GC-MS (m/z): 208 [M^+ , $\text{C}_{15}\text{H}_{12}\text{O}$].




(E)-1,3-bis(4-fluorophenyl)prop-2-en-1-one (22b): Yellow solid; Yield: 224mg (92%); melting point-56-58 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.01 (d, $J = 8.5$ Hz, 2H), 7.73 (d, $J = 8.5$ Hz, 1H), 7.58-7.49 (m, 2H), 7.39




(d, $J = 8.5$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 190.47, 165.40, 162.90, 143.65, 138.18, 132.98, 130.50, 130.41, 128.75, 128.57, 128.20, 121.82, 116.35, 116.13; ; IR ν_{max} (KBr, cm^{-1}): 2922, 2875 (aromatic C-H str), 1595 (aromatic, C=C str), 1266, 1089, 858, 731; GC-MS (m/z): 244 [M^+ , $\text{C}_{15}\text{H}_{10}\text{F}_2\text{O}$].




(E)-1,3-bis(4-chlorophenyl)prop-2-en-1-one (22c): Yellow solid; Yield: 255 mg (92%); melting point-56-57 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.01 (d, $J = 8.5$ Hz, 2H), 7.77-7.61 (m, 3H), 7.46 (d, $J = 8.5$ Hz, 1H), 7.14-7.09 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 188.66, 142.59, 136.27, 133.66, 131.56, 130.77, 129.60, 129.29, 122.41, 118.60, 118.19; IR ν_{max} (KBr, cm^{-1}): 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1091, 771 (C-Cl, str); GC-MS (m/z): 276 [M^+ , $\text{C}_{15}\text{H}_{10}\text{Cl}_2\text{O}$], 278 [M^{+2}]



(E)-1,3-bis(4-bromophenyl)prop-2-en-1-one (22d): Yellow solid; Yield: 334mg (90%); melting point-55-59 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.00 (d, $J = 9.0$ Hz, 2H), 7.75-7.61 (m, 3H), 7.45 (d, $J = 9.0$ Hz, 1H), 7.14-7.08 (m, 4H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 190.69, 144.98, 138.29, 134.96, 132.91, 130.67, 129.07, 128.74, 128.61, 128.56, 122.16; IR ν_{max} (KBr, cm^{-1}): 2992, 2886 (aromatic C-H str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; GC-MS (m/z): 364 [M^+ , $\text{C}_{15}\text{H}_{10}\text{Br}_2\text{O}$], 366 [M^{+2}].




(E)-3-(4-chlorophenyl)-1-(4-fluorophenyl)prop-2-en-1-one (22e): Yellow solid; Yield: 239 mg (92%); melting point-58-59 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.01 (d, $J = 7.5$ Hz, 2H), 7.74 (d, $J = 15.5$ Hz, 1H), 7.57 (d, $J = 8.5$ Hz, 2H), 7.51 (d, $J = 16.0$ Hz, 2H), 7.38 (d, $J = 8.5$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 188.69, 161.14, 142.67, 134.07, 132.24, 131.54, 130.78, 130.44, 129.82, 124.64, 122.49, 116.20; IR ν_{max} (KBr, cm^{-1}): 2931, 2873 (aromatic C-H str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; GC-MS (m/z): 260 [M^+ , $\text{C}_{15}\text{H}_{10}\text{ClFO}$].




(E)-1-(4-bromophenyl)-3-(4-fluorophenyl)prop-2-en-1-one (22f): Yellow solid; Yield: 285mg (94%); melting point-60-62 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.02 (d, $J = 8.5$ Hz, 2H), 7.93-7.75 (m, 1H), 7.74 (d, $J = 15.5$ Hz, 2H), 7.57 (d, $J = 8.5$ Hz, 1H), 7.39-7.30 (m, 2H), 6.98 (d, $J = 8.5$ Hz, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 190.70, 160.07, 144.98, 138.28, 134.96, 132.91, 130.67, 129.07,


128.73, 128.61, 122.16; **IR v_{max} (KBr, cm⁻¹):** 2951, 2880 (aromatic C-H str), 1607 (aromatic, C=C str), 1271, 1107, 843, 729; **GC-MS (m/z):** 304 [M⁺, C₁₅H₁₀BrFO], 306 [M⁺²].




(E)-3-(4-fluorophenyl)-1-phenylprop-2-en-1-one (22g): Yellow solid; Yield: 214mg (95%); melting point-60-62 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 8.01 (d, *J* = 7.0 Hz, 2H), 7.72 (d, *J* = 15.5 Hz, 1H), 7.55-7.49 (m, 5H), 7.26 (d, *J* = 7.0 Hz, 1H), 6.98 (d, *J* = 7.0 Hz, 2H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 188.66, 161.13, 142.59, 136.27, 133.65, 131.56, 130.76, 129.60, 129.29, 122.40, 116.20; **IR v_{max} (KBr, cm⁻¹):** 2920 (aromatic C-H str), 1592 (aromatic, C=C str), 1406, 1336, 1233, 1125(C-O-C, str), 1091, 771 (C-Cl, str); **GC-MS (m/z):** 226[M⁺, C₁₅H₁₁FO].




(E)-3-(4-chlorophenyl)-1-phenylprop-2-en-1-one (22h): Yellow solid; Yield: 229 mg (95%); melting point-56-57 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 8.01 (d, *J* = 9.0 Hz, 2H), 7.78-7.56 (m, 4H), 7.53-7.51 (m, 3H), 7.48-7.26 (m, 2H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 188.66, 142.59, 136.27, 133.65, 131.57, 130.77, 129.60, 129.29, 122.41, 116.20; **IR v_{max} (KBr, cm⁻¹):** 2992, 2886 (aromatic C-H str), 1620 (aromatic, C=C str), 1262, 1095, 860, 743; **GC-MS (m/z):** 242 [M⁺, C₁₅H₁₁ClO].




(E)-3-(4-bromophenyl)-1-phenylprop-2-en-1-one (22i): Yellow solid; Yield: 265 mg (93%); melting point-55-57 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 8.02 (t, *J* = 8 Hz, 2H), 7.72 (d, *J* = 8 Hz, 2H), 7.56-7.50 (m, 3H), 7.27 (d, *J* = 7.5 Hz, 1H), 6.99 (d, *J* = 7 Hz, 2H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 190.00, 143.45, 138.09, 133.45, 133.05, 129.69, 129.35, 128.77, 128.59, 122.52, 120.35; **IR v_{max} (KBr, cm⁻¹):** 2951, 2880 (aromatic C-H str), 1607 (aromatic, C=C str), 1271, 1107, 843, 729; **GC-MS (m/z):** 286[M⁺, C₁₅H₁₁BrO], 288 [M⁺²].




(E)-1-(4-fluorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (22j): Yellow solid; Yield: 243 mg (95%); melting point-59-61 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 8.01 (d, *J* = 8.5 Hz, 2H), 7.74 (d, *J* = 15.5 Hz, 1H), 7.58-7.49 (m, 3H), 7.38 (d, *J* = 8.5 Hz, 2H), 6.98 (d, *J* = 8.5 Hz, 2H), 3.88 (m, 3H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 190.47, 165.40, 162.90, 143.65, 138.18, 132.98, 131.18, 130.50, 130.41, 128.75, 128.57, 128.20, 121.82, 116.35, 116.33, 55.47; **IR v_{max} (KBr, cm⁻¹):** 2931, 2873 (aromatic C-H str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **GC-MS (m/z):** 256[M⁺, C₁₆H₁₃FO₂].

**(E)-1-(4-chlorophenyl)-3-(4-methoxyphenyl)prop-2-en-1-one (22k):**


Yellow solid; Yield: 255mg (94%); melting point-58-60 °C; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 8.02 (d, $J = 9.0$ Hz, 2H), 7.73 (d, $J = 9$ Hz, 1H) 7.57 (d, $J = 8.5$ Hz, 3H), 7.50 (d, $J = 8.5$ Hz, 2H), 6.98 (d, $J = 8.5$ Hz, 2H), 3.83 (s, 3H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 189.52, 161.94, 145.41, 137.29, 131.95, 130.46, 130.06, 127.72, 127.45, 119.15, 114.55, 55.55; IR ν_{max} (KBr, cm^{-1}): 2950 (aromatic C-H str), 1582 (aromatic, C=C str), 1389, 1275, 1059, 854, 723 (C-Cl, str); GC-MS (m/z): 272 [M^+ , $\text{C}_{16}\text{H}_{13}\text{ClO}_2$].

**(E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (22l):**

Yellow solid; Yield: 222 mg (92%); melting point-60-62 °C; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 8.001 (d, $J = 8$ Hz, 2H), 7.775 (d, $J = 15.5$ Hz, 1H), 7.633 (t, 2H), 7.471 (d, $J = 16$ Hz, 1H), 7.11 (t, $J = 8.5$ Hz, 2H), 6.95 (d, $J = 8.5$ Hz, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 187.50, 164.68, 162.67, 141.94, 132.02, 131.52, 131.45, 129.53, 122.46, 116.42, 116.25; IR ν_{max} (KBr, cm^{-1}): 3426 (OH str), 2923 (aromatic C-H str), 1591 (aromatic, C=C str), 1417, 1395, 1282, 1170, 1092; GC-MS (m/z): 242 [M^+ , $\text{C}_{15}\text{H}_{11}\text{FO}_3$].


**(E)-1-(4-chlorophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (22m):**

Yellow solid; Yield: 239 mg (93%); melting point-58-62 °C; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.992 (d, $J = 8.5$ Hz, 2H), 7.766 (d, $J = 15.5$ Hz, 1H), 7.636- 7.583 (m, 2H), 7.462 (d, $J = 15.5$ Hz, 1H), 7.102 (t, $J = 8.5$ Hz, 2H), 6.946 (d, $J = 8.5$ Hz, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 187.24, 162.41, 141.68, 131.76, 131.26, 131.19, 129.27, 122.20, 116.16, 115.99; IR ν_{max} (KBr, cm^{-1}): 3452 (OH str), 2963 (aromatic C-H str), 1599 (aromatic, C=C str), 1451, 1419, 1262, 1021, 933, 868, 799 and 704; GC-MS (m/z): 258 [M^+ , $\text{C}_{15}\text{H}_{11}\text{ClO}_3$].

**(E)-1-(4-bromophenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one (22n):**


Yellow solid; Yield: 286mg (95%); melting point-60-63 °C; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 7.992 (d, $J = 8.5$ Hz, 2H), 7.767 (d, $J = 15.5$ Hz, 1H), 7.625 (m, 2H), 7.462 (d, $J = 15.5$ Hz, 1H), 7.102 (t, $J = 8.5$ Hz, 2H), 6.946 (d, $J = 8.5$ Hz, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 186.98, 162.15, 141.42, 131.51, 131.00, 130.93, 129.02, 121.95, 115.91, 115.74, 115.31; IR ν_{max} (KBr, cm^{-1}): 3408 (OH str), 2917

(aromatic C-H str), 1589 (aromatic, C=C str), 1489, 1415, 1288, 1177, 1091, 1014, 929 and 701; **GC-MS (m/z):** 302[M⁺, C₁₅H₁₁BrO₂], 304 [M⁺²].




(E)-3-(4-fluorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (22o):

Yellow solid; Yield: 222 mg (92%); melting point-60-62 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 7.99(d, J = 8.5 Hz, 2H), 7.77(d, J = 15.5 Hz, 1H), 7.62(dd, J = 6, 13.5 Hz, 2H), 7.46(d, J = 15.5 Hz, 1H), 7.10(t, J = 8 Hz, 2H), 6.95(d, J = 8.5 Hz, 2H), 6.24(s, 1H, br, D₂O exchangeable); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 187.50, 164.68, 162.67, 141.94, 132.02, 131.52, 131.45, 129.53, 122.46, 116.42, 116.25; **IR vmax (KBr, cm⁻¹):** 3415 (OH str), 2931, 2873 (aromatic C-H str), 1681 (C=O str), 1597 (aromatic, C=C str), 1263, 1081, 860, 737; **GC-MS (m/z):** 242 [M⁺, C₁₅H₁₁FO₂].




(E)-3-(4-chlorophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (22p):

Yellow solid; Yield: 245 mg (95%); melting point-61-64 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 7.99(d, J = 8.5 Hz, 2H), 7.76(d, J = 15.5 Hz, 1H), 7.63-7.61(m, 2H), 7.45(d, J = 16 Hz, 1H), 7.10(t, J = 8.5 Hz, 2H), 6.94(d, J = 8.5 Hz, 2H), 6.2(s, 1H, br, D₂O exchangeable); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 187.20, 162.37, 141.64, 131.72, 131.22, 131.15, 129.23, 122.16, 116.12, 115.95; **IR vmax (KBr, cm⁻¹):** 3408 (OH str), 2928, 2876 (aromatic C-H str), 1684 (C=O str), 1598 (aromatic, C=C str), 1268, 1085, 864, 735; **GC-MS (m/z):** 258 [M⁺, C₁₅H₁₁ClO₂].



(E)-3-(4-bromophenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one (22q):


Yellow solid; Yield: 289 mg (90%); melting point-61-63 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 7.99(d, J = 8 Hz, 2H), 7.77(d, J = 15.5 Hz, 1H), 7.63(t, J = 8 Hz, 2H), 7.46(d, J = 15.5 Hz, 1H), 7.10(t, J = 8.5 Hz, 2H), 6.95(d, J = 8 Hz, 2H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 186.88, 162.05, 141.32, 131.41, 130.90, 130.83, 128.92, 121.85, 115.81, 115.21; **IR vmax (KBr, cm⁻¹):** 3410 (OH str), 2926, 2875 (aromatic C-H str), 1686 (C=O str), 1599 (aromatic, C=C str), 1265, 1078, 862, 730; **GC-MS (m/z):** 302 [M⁺, C₁₅H₁₁BrO₂], 304 [M⁺²].




(E)-1-(2-nitrovinyl) benzene (23a): Yellow Solid; Yield: 135 mg (91%);

melting point - 55-57 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.02(d, J = 14 Hz, 1H), 7.59(d, J = 14 Hz, 1H), 7.57-7.53(m, 2H), 7.52-7.48(m, 1H), 7.32-


7.43 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 139.54, 136.27, 131.54, 130.77, 129.62, 124.36; IR (ν_{max} , cm^{-1}): 3106, 3042, 1508, 1341. GCMS (m/z): 149 [M^+ . $\text{C}_8\text{H}_7\text{NO}_2$] 150, 149(100%), 148, 132, 125, 104, 92, 74, 60.




(E)-1-chloro-4-(2-nitrovinyl) benzene (23b): Yellow solid; Yield: 170 mg (90%); melting point-115-116 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 13.5$ Hz, 1H), 7.58 (d, $J = 13.5\text{Hz}$, 1H), 7.52-7.51(m, 2H), 7.47-7.45(m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 137.30, 136.65, 133.00, 130.92, 129.62, 129.29; IR(ν_{max} , cm^{-1}): 3099, 3025, 1590, 1398; GCMS (m/z): 183 [M^+ . $\text{C}_8\text{H}_6\text{ClNO}_2$] 185, 183, 149, 148, 136, 125, 102(100%), 74, 73.




(E)-1-chloro-2-(2-nitrovinyl) benzene (23c): Brown solid; Yield: 168 mg (92%); melting point-40-42 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.96 (d, $J = 13.6$ Hz, 1H), 7.51 (d, $J = 13.6\text{Hz}$, 1H), 7.47-7.45 (m, 2H), 6.91-6.89 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 139.52, 136.27, 133.62, 131.54, 130.77, 129.62, 129.30, 124.36; IR (ν_{max} , cm^{-1}): 3116, 3056, 1516, 1338; GCMS (m/z): 183 [M^+ . $\text{C}_8\text{H}_6\text{ClNO}_2$] 185, 183, 149, 148, 136, 125, 102(100%), 74, 73.



(E)-1-bromo-4-(2-nitrovinyl) benzene (23d): Light yellow solid; Yield: 204 mg (90%); melting point-148-150 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.94 (d, $J = 14$ Hz, 1H), 7.60-7.58 (m, 2H), 7.57(d, $J = 14$ Hz), 7.42-7.40 (m, 2H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 139.54, 136.27, 133.61, 131.54, 130.71, 129.62, 122.37; IR (ν_{max} , cm^{-1}): 3102, 3052, 1507, 1331; GCMS (m/z): 227 [M^+ . $\text{C}_8\text{H}_6\text{ClNO}_2$] 227, 229, 226, 228, 180, 182(100%), 178, 175.




(E)-1-methyl-4-(2-nitrovinyl) benzene (23e): Yellow solid; Yield: 146 mg (90%); melting point-100-102 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.99 (d, $J = 13.5\text{Hz}$, 1H), 7.57(d, $J = 13.5\text{Hz}$, 1H), 7.45-7.43 (m, 2H), 7.26-7.25 (m, 2H), 2.41(s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 140.10, 139.54, 136.27, 133.62, 131.54, 130.77, 129.62, 23.10; IR (ν_{max} , cm^{-1}): 3110, 3056, 2916, 1496, 1336; GCMS (m/z): 163 [M^+ . $\text{C}_9\text{H}_9\text{NO}_2$] 168, 163, 146, 114, 102, 80 (100%).




(E)-1-methoxy-4-(2-nitrovinyl) benzene (23f) : Yellow solid; Yield: 155 mg (87%); melting-point-86-88 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.97 (d, $J = 13.5\text{Hz}$, 1H), 7.57(d, $J = 13.5$ Hz, 1H), 7.38-7.35 (m, 1H), 7.15-7.13 (m, 1H.), 7.05-7.03(m, 2H), 3.853 (s, 3H) ; ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 157.12, 139.54,


136.27, 130.77, 122.36, 115.19, 57.45; **IR (vmax, cm⁻¹):** 3104, 2904, 2838, 1495, 1307; **GCMS (m/z):** 179 [M⁺.C₉H₉NO₃] 179, 132, 118, 103, 89(100%).




(E)-1,2-dimethoxy-4-(2-nitrovinyl)benzene (23g): Yellow solid; Yield: 183 mg (88%); melting point-138-140 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 7.96 (d, *J* = 13.5Hz, 1H), 7.53(d, *J* = 13.5Hz, 1H), 7.18-7.16 (m, 1H), 7.00-6.91 (m, 2H), 3.947 (s, 3H), 3.901(s, 3H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 149.87, 149.10, 138.54, 135.27, 122.36, 121.12, 115.89, 115.06, 57.87; **IR (vmax, cm⁻¹):** 3128, 2958, 2923, 1500, 1334; **GCMS (m/z):** 209[M⁺.C₁₀H₁₁NO₄] 209, 163, 162,147, 119, 77(100%).




(E)-1,2,3-trimethoxy-5-(2-nitrovinyl)benzene (23h): Yellow Solid; Yield: 207 mg (87%); melting point-115-116 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 7.93 (d, *J* = 13.6Hz, 1H), 7.53(d, *J* = 13.6Hz, 1H), 6.75(s, 2H), 3.91(s, 3H), 3.90(s, 6H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 155.12, 143.62, 137.12, 136.65,129.87, 106.00, 61.17, 55.76; **IR (vmax, cm⁻¹):** 3104, 2935, 2832, 1503, 1323; **GCMS (m/z):** 239 [M⁺.C₁₁H₁₃NO₅] 239, 191, 176, 149, 120, 63, (100%), 53.



(E)-4-(2-nitrovinyl) phenol (23i): Yellow solid; Yield: 148 mg (90%); melting point-162-164 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 7.96 (d, *J* = 13.6Hz, 1H), 7.51 (d, *J* = 13.6Hz, 1H), 7.47-7.45(m, 2H), 6.91-6.89 (m, 2H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 157.87, 140.11, 139.52, 130.77, 123.12, 115.10; **IR (vmax, cm⁻¹):** 3370, 3108, 1483, 1339; **GCMS (m/z):** 165 [M⁺.C₈H₇NO₃] 166, 165, 148, 118(100%), 91, 65.




(E)-1-nitro-3-(2-nitrovinyl) benzene (23j): Light Brown solid; Yield: 178 mg, (92%); melting point-120-122 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 7.96 (d, *J* = 13.7Hz, 1H), 7.56 (d, *J* = 13.7 Hz, 1H), 7.50-7.48 (m, 2H), 7.44-7.43 (m, 2H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 148.13, 140.10, 139.54, 136.27, 133.61, 130.71, 122.35, 122.12; **IR (vmax, cm⁻¹):** 3100, 2832, 1522, 1349; **GCMS (m/z):** 194 [M⁺.C₈H₆N₂O₄] 194, 147, 108, 102 (100%), 89, 76, 63.




3-nitro-2-phenyl-2H-chromene (24a): Yellow solid; Yield: 222 mg (88%); melting point-98-100 °C; **¹H NMR (CDCl₃, 500 MHz) δ ppm** 8.05 (s, 1H), 7.38-7.36 (m, 2H), 7.33-7.30 (m, 5H), 7.01-6.98 (m, 1H), 6.87-6.85 (m, 1H), 6.58 (s, 1H); **¹³C NMR (CDCl₃, 125 MHz) δ ppm** 153.61, 146.47, 141.96, 141.35, 134.47, 130.03, 129.03, 128.85, 127.34, 127.12, 122.96, 122.60, 117.43, 107.37, 79.79; **IR (vmax, cm⁻¹):**


¹): 3071, 1646, 1507, 1328, 1215; **GCMS (m/z):** 253 [M⁺. C₁₅H₁₁NO₃] 253, 236, 207, 178(100%), 152, 89, 77, 63.




2-(4-chlorophenyl)-3-nitro-2H-chromene (24b): Yellow solid; Yield: 252 mg (88%); melting point-150 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.05 (s, 1H), 7.35-7.27 (m, 6H), 6.99 (t, *J* = 7.5 Hz, 1H), 6.86(d, *J* = 8Hz, 1H), 6.57 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 156.96, 147.43, 145.11, 139.90, 128.84, 128.80, 127.33, 126.58, 122.91, 122.55, 117.43, 115.91, 79.47; **IR (ν_{max}, cm⁻¹):** 3076, 2923, 1639, 1495, 1323, 1214; **GCMS (m/z):** 287 [M⁺. C₁₅H₁₀ ClNO₃] 287, 270, 257, 241(100%), 205, 178, 89, 77, 63.



2-(2-chlorophenyl)-3-nitro-2H-chromene (24c): Yellow solid; Yield: 258 mg (90%); melting point-90-92 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.15(s, 1H), 7.48 (dd, *J* = 1Hz, 9.5Hz, 1H), 7.34(dd, *J* = 2Hz, 8Hz, 1H), 7.32-7.27 (m, 2H), 7.192 (dd, *J* = 2Hz, 8Hz, 1H), 7.07 (s, 1H), 7.0 (dt, *J*=1Hz, 1H), 6.82 (d, *J*=8Hz, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 153.61, 146.74, 144.99, 139.94, 134.77, 129.92, 128.99, 128.72, 128.59, 127.21, 122.34, 121.94, 116.91, 114.47, 79.59; **IR (ν_{max}, cm⁻¹):** 3069, 2923, 1644, 1511, 1327, 1107; **GCMS (m/z):** 287 [M⁺. C₁₅H₁₀ ClNO₃] 289, 287, 270, 257, 241, 205, 176, 146 (100%), 89, 76, 63.




2-(4-bromophenyl)-3-nitro-2H-chromene (24d): Yellow solid; Yield: 291 mg (88%); melting point-162 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.23 (s, 1H), 8.19 (d, *J* = 8.5Hz, 1H), 8.13 (s, 1H), 7.71(d, *J* = 8Hz, 1H), 7.52(t, *J* = 8 Hz, 1H), 7.36 (t, *J* = 7.5 Hz), 7.05 (t, *J* = 7.5Hz), 6.90 (d, *J* = 8.5Hz, 1H), 6.66 (s, 1H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 153.36, 146.74, 144.02, 141.16, 133.48, 132.27, 128.94, 128.72, 127.36, 124.24, 123.16, 122.48, 117.41, 79.11; **IR (ν_{max}, cm⁻¹):** 3078, 2923, 1639, 1496, 1323, 1065; **GCMS (m/z):** 331 [M⁺. C₁₅H₁₀ Br NO₃] 333, 331, 287, 285, 205 (100%), 176, 146, 89, 76, 63.



3-nitro-2-p-tolyl-2H-chromene (24e): Yellow solid; Yield: 226 mg (85%); meltingpoint-136-138 °C; ¹H NMR (CDCl₃, 500 MHz) δ ppm 8.04 (s, 1H), 7.32-7.28 (m, 2H), 7.25-7.24 (m, 2H), 7.11(d, *J* = 8 Hz), 6.98 (dt, *J* = 1Hz, 1H), 6.84 (dd, *J* = 1Hz, 7.5Hz), 6.54 (s, 1H), 2.304 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz) δ ppm 153.68, 148.83, 145.95, 140.06, 131.42, 129.70, 128.80, 127.32, 127.05, 122.86, 122.59,

117.42, 79.71; **IR** (ν_{\max} , cm^{-1}): 3078, 2924, 1646, 1506, 1321, 1114; **GCMS** (m/z): 267 [M^+ . $\text{C}_{16}\text{H}_{13}\text{NO}_3$] 267, 250, 237, 221(100%), 178, 146, 91, 77, 65.


2-(4-methoxyphenyl)-3-nitro-2H-chromene (24f): Yellow solid; Yield: 240 mg (85%); melting point-158-160 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 8.03 (s, 1H), 7.31 (d, $J = 7.5\text{Hz}$, 2H), 7.30-7.28 (s, 2H), 7.02-6.96 (m, 1H), 6.85-6.80 (m, 3H), 6.52 (s, 1H), 3.75 (s, 3H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm



160.78, 153.74, 146.82, 143.94, 128.81, 128.55, 127.34, 126.41, 122.87,

122.62, 117.43, 114.42, 107.42, 79.54; **IR** (ν_{\max} , cm^{-1}): 2945, 1645, 1507, 1326, 1179;

GCMS (m/z): 283 [M^+ . $\text{C}_{16}\text{H}_{13}\text{NO}_4$] 283, 266, 253, 237, (100%), 222, 194, 165, 91, 89, 69.



2-(3,4-dimethoxyphenyl)-3-nitro-2H-chromene (24g): Yellow solid; Yield: 269 mg (86%); melting point-86-88 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm


8.05 (s, 1H), 7.33-7.29 (m, 2H), 7.01-6.98 (m, 1H), 6.92 (d, $J = 2.05\text{ Hz}$, 1H), 6.87-6.84 (m, 2H), 6.74 (d, $J = 8.5\text{Hz}$), 6.51 (s, 1H), 3.82 (s, 6H); ^{13}C NMR (CDCl_3 , 125

MHz) δ ppm 153.67, 150.27, 149.31, 144.79, 141.99, 128.84, 127.35, 126.69, 122.95, 122.61,

119.97, 117.47, 111.20, 109.78, 107.35, 79.77; **IR** (ν_{\max} , cm^{-1}): 2931, 1645, 1517, 1334,

1145; **GCMS** (m/z): 313 [M^+ . $\text{C}_{17}\text{H}_{15}\text{NO}_5$] 314, 313, 267 (100%), 251, 223, 177, 122, 91, 77,

63.




3-nitro-2-(3,4,5-trimethoxyphenyl)-2H-chromene (24h): Yellow solid; Yield: 291 mg (85%); melting point-130-132 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500

MHz) δ ppm 8.05 (s, 1H), 7.34 (t, $J = 7.5\text{Hz}$, 1H), 7.01 (t, $J = 7.5\text{Hz}$, 1H), 6.89 (d, $J = 8\text{ Hz}$, 1H), 6.56 (s, 2H), 6.51 (s, 1H), 3.79 (s, 6H), 3.75 (s, 3H); ^{13}C NMR (CDCl_3 ,

125 MHz) δ ppm 153.59, 147.49, 145.59, 139.13, 129.75, 128.87, 127.33, 123.05, 122.55,

117.46, 107.20, 104.11, 79.93; **IR** (ν_{\max} , cm^{-1}): 2941, 2832, 1576, 1507, 1329, 1128; **GCMS**

(m/z): 343 [M^+ . $\text{C}_{18}\text{H}_{17}\text{NO}_6$] 344, 343, 313, 297, 207 (100%), 191, 168, 91, 77, 63.




4-(3-nitro-2H-chromene-2-yl) phenol (24i): Yellow solid; Yield: 242 mg (90%); melting point-144-146 $^{\circ}\text{C}$; ^1H NMR (CDCl_3 , 500 MHz) δ ppm 7.66

(s, 1H), 7.64 (s, 1H), 7.60-7.57 (m, 2H), 7.34-7.32 (m, 2H), 7.29-7.26 (m, 2H), 7.11-7.09 (m, 2H), 6.90-6.87 (m, 1H); ^{13}C NMR (CDCl_3 , 125 MHz) δ ppm 153.38,

147.18, 144.74, 142.09, 136.00, 132.98, 129.31, 128.93, 128.46, 127.36, 123.14, 122.49,

117.40, 79.06; **IR** (ν_{\max} , cm^{-1}): 3069, 2954, 1650, 1515, 1391, 1187; **GCMS** (m/z): 269 [M^+ .

$\text{C}_{15}\text{H}_{11}\text{NO}_4$] 269, 252, 236, 223(100%), 165, 131, 89, 77, 65.



3-nitro-2-(3-nitrophenyl)-2H-chromene (24j): Yellow solid; Yield: 268 mg (90%); melting point-160-162 °C; $^1\text{H NMR}$ (CDCl_3 , 500 MHz) δ ppm 8.42-8.41 (m, 1H), 8.35-8.33 (m, 1H), 8.31 (s, 1H), 8.21 (dd, $J = 1\text{Hz}, 8\text{Hz}$, 1H), 8.06-8.03 (m, 1H), 8.42-8.41(m, 1H), 7.88(d, $J = 8\text{Hz}, 1\text{Hz}$, 1H), 7.77 (d, $J = 8\text{Hz}$, 1H), 7.70-7.66 (m, 2H), 7.61 (t, $J = 8\text{Hz}$), 6.90-6.87 (m, 1H); $^{13}\text{C NMR}$ (CDCl_3 , 125 MHz) δ ppm 153.00, 148.59, 144.68, 142.16, 136.67, 133.14, 130.15, 129.12, 127.40, 124.89, 123.49, 122.34, 122.13, 117.44, 78.56; **IR** ($\text{vmax}, \text{cm}^{-1}$): 3074, 1649, 1520, 1395, 1070. **GCMS** (m/z) 298 [M^+ . $\text{C}_{15}\text{H}_{10}\text{N}_2\text{O}_5$] 299, 298, 283, 252, 205(100%), 176, 130, 102, 76, 63.

8.7. References

- [1] (a) Madesclaire, M. *Reduction of sulfoxides to thioethers*, Tetrahedron 1988, 44, 6537; (b) Abad, A.; Concepcion, P.; Corma, A.; Garcia, H. *A collaborative effect between gold and a support induces the selective oxidation of alcohols*, Angew. Chem. Int. Ed. 2005, 44, 4066; (c) Hayashi, T.; Tanaka, K.; Haruta, M. *Selective vapor-phase epoxidation of propylene over Au/TiO₂ catalysts in the presence of oxygen and hydrogen*, J. Catal. 1998, 178, 566; (d) Zhang, X.; Shi, H.; Xu, B.Q. *Catalysis by gold: Isolated surface Au³⁺ ions are active sites for selective hydrogenation of 1,3-butadiene over Au/ZrO₂ catalysts*, Angew. Chem., Int. Ed. 2005, 44, 7132; (e) Girard, P.; Namy, J. L.; Kagan, H.B. *Mild preparation of samarium iodide and ytterbium iodide and their use as reducing or coupling agents*, J. Am. Chem. Soc. 1980, 102, 2693; (f) Concellon, J. M.; Bardales, E. *Synthesis of (E)- α,β -unsaturated esters with total or high diastereoselectivity from α,β -Epoxyester*, Org. Lett. 2002, 4, 189; (g) Martin, M. G.; Ganem, B. *Epoxides as alkene protecting groups. A mild and efficient deoxygenation*, Tetrahedron Lett. 1984, 25, 251; (h) Davis, R.E. *Cyclic sulfides. III. Reaction of some ethylene sulfides with triphenylphosphine and with triethyl phosphite*, J. Org. Chem. 1958, 23, 1767; (i) Neureiter, N. P.; Bordwell, F. G. J. Am. Chem. Soc. 1959, 81, 578; (j) Snyder, H. R.; Stewart, J. M.; Ziegler, J. B. J. Am. Chem. Soc. 1947, 69, 2672; (k) Aalbersberg, W. G. L.; Vollhardt, K. P. C. J. Am. Chem. Soc. 1977, 99, 2792; (l) Iranpoor, N.; Kazemi, F. *Cerium(IV) catalysis. Efficient conversion of epoxides to thiiranes*, Synthesis. 1996, 821; (m) Shoppee, C. W.; Sternhell, S.; Taylor, W. C. *Aust. Some metabolites of *Cylindrocarpon raditicola*: the structure of raditicola (monorden)*, J. Chem. 1966, 19, 1265; (n) Mahesh, M, Murphy, J. A.; Wassel, H, P. *Novel Deoxygenation Reaction of Epoxides by Indium*, J. Org. Chem. 2005, 70, 4118; (o) Firouzabadi, H.;

- Iranpoor, N.; Jafapour, M. *Rapid, highly efficient and stereoselective deoxygenation of epoxides by $ZrCl_4/NaI$* , Tetrahedron Lett. 2005, 46, 4107.
- [2] Silverman, R. B. *Model studies for a molecular mechanism of action of oral anticoagulants*, J. Am. Chem. Soc. 1981, 103, 3910.
- [3] Itoh, T.; Nagano, T.; Sato, M.; Hirobe, M. *Deoxygenation of oxirane compounds to olefins by iron complex $[Fe_4S_4(SC_6H_5)_4]^{2-}$ in the presence of sodium borohydride*, Tetrahedron Lett. 1989, 30, 6387.
- [4] Marples, B. A.; Muxworthy, J. P.; Baggaley, K. H. *Oxidative cleavage of benzyl ethers using dimethyldioxirane*, Synlett 1992, 22, 646.
- [5] Csuk, R.; Dorr, P.; *Convenient oxidative debenzylation using dimethyldioxirane*, Tetrahedron 1994, 50, 9983.
- [6] Yamada, N.; Mizuochi, M.; Morita, H. *Thermolysis of β -hydroxysulfides bearing several heteroaromatics*, Tetrahedron 2007, 63, 3408.
- [7] Kai, K.; Takeuchi, J.; Kataoka, T.; Yokoyama, M.; Watanabe, N. *Structure-activity relationship study of flowering-inducer FN against *Lemna paucicostata**, Tetrahedron 2008, 64, 6760.
- [8] Masson, J-F, *Brief Review of the Chemistry of Polyphosphoric Acid (PPA) and Bitumen*, Energy & Fuels, 2008, 22, 2637.
- [9] Preusch, P. C.; Suttie, J.W. *A chemical model for the mechanism of vitamin K epoxide reductase*, J. Org. Chem. 1983, 48, 3301.
- [10] Bradsher, C. K.; Beavers, D. J.; *Aromatic cyclodehydration. XXXII. Loss of the isopropyl group on cyclodehydration*, J. Am. Chem. Soc. 1956, 78, 3193.
- [11] Popp, F. D.; McEwen, W. E.; *Polyphosphoric acid as a reagent in organic chemistry*, Chem. Rev. 1958, 58, 321.
- [12] Righi, G.; Bovicelli, P.; Sperandio, A.; *An easy deoxygenation of conjugated epoxides*, Tetrahedron 2000, 56, 1733.
- [13] Gable, K. P.; Brown, E. C. *Efficient Catalytic Deoxygenation of Epoxides Using $[Tris(3,5-dimethylpyrazolyl)hydridoborato]rhenium$ Oxides*, Organometallics 2000, 19, 944.
- [14] Isobe, H.; Branchaud, B. P.; *Epoxide deoxygenation mediated by salen complexes*, Tetrahedron Lett. 1999, 40, 8747.

- [15] Clive, D. L. J.; Menchen, S. M. *Alkali Metal O,O-diethyl phosphorotelluroates, a reagent class for deoxygenation of epoxides, especially terminal epoxides*, J. Org. Chem. 1980, 45, 2347.
- [16] Moloy, K. G. *Phosphine basicities as determined by enthalpies of protonation*, Inorg. Chem. 1988, 27, 677.
- [17] (a) Ahmed, N.; van Lier, J. E. *TaBr₅-catalyzed Biginelli reaction: one-pot synthesis of 3,4-dihydropyrimidin-2-(1H)-ones/thiones under solvent-free conditions*, Tetrahedron Lett. 2007, 48, 13; (b) Ahmed, N.; van Lier, J. E. *Silica gel supported TaBr₅: new catalyst for the facile and rapid cyclization of 2'-aminochalcones to the corresponding 2-aryl-2,3-dihydroquinolin-4(1H)-ones under solvent-free conditions*, Tetrahedron Lett. 2006, 47, 5345 (c) Ahmed, N.; Konduru, N. K. *Efficient, highly diastereoselective MS 4 Å-promoted one-pot, three-component synthesis of 2,6-disubstituted-4-tosyloxytetrahydropyrans via Prins cyclization*, Beilstein J. Org. Chem. 2012, 8, 177.
- [18] (a) Rao, M. L. N.; Deepak, N.; Jadhav, D. N.; Dasgupta, P. *"Pd-Catalyzed Tandem Chemoselective Synthesis of 2-Arylbenzofurans using Threefold Arylating Triarylbismuth Reagents"*, Eur. J. Org. Chem., 2013,4, 781; (b) Rao, M. L. N.; Giri, S. *"Pd-catalyzed threefold arylations of mono, di and tetra-bromo-quinones using triarylbismuth reagents"* RSC Adv. 2012, 2, 12739; (c) Iranpoor, N.; Firouzabadi, H.; Jamalian, A. *Silphos [PCL₃-n(SiO₂)_n]: a heterogeneous phosphine reagent for the conversion of epoxides to β-bromo formates or alkenes*, Tetrahedron 2006, 62, 1823; (d) Choi, K. H.; Choi, K.; Kim, J. H.; Yoon, C. M.; Yoo, B. W. *Mild and efficient deoxygenation of epoxides with bis(cyclopentadienyl)titanium(IV) dichloride-indium system*, Bull. Korean Chem. Soc. 2005, 26, 1495.
- [19] (a) Gable, K. P.; Brown, E. C. *Rhenium-catalyzed epoxide deoxygenation: Scope and limitations*, Synlett 2003, 14, 2243; (b) Patra, A.; Bandyopadhyay, M.; Mal, D. *Mo(CO)₆-promoted facile deoxygenation of α,β-epoxy ketones and α,β-epoxy esters*, Tetrahedron Lett. 2003, 44, 2355; (c) Antonioletti, R.; Bovicelli, P.; Fazzolari, E.; Righi, G. *Stereo- and regiocontrolled transformations of vinyloxiranes with metal halides*, Tetrahedron Lett. 2000, 41, 9315.



NMR SPECTRA'S

1




Figure S-1: ^1H NMR Spectrum of compound **1n**




Figure S-2: ¹³C NMR Spectrum of compound 1n




Figure S-3: ^1H NMR Spectrum of compound **1o**




Figure S-4: ^{13}C NMR Spectrum of compound 1o

gkp-ind-oh-br

7.874
7.856
7.548
7.538
7.531
7.520
7.255
7.071
7.054
7.037
6.958
6.940

5.303
5.293
5.289
5.221
5.217

4.206
4.191



```
Current Data Parameters
NAME: gkp-19-INDANONE
EXPNO: 1
PROCNO: 1

F2 - Acquisition Parameters
Date_ 20120417
Time 13.50
INSTRUM spect
PROBHD 5 mm CPIC 1H-
PULPROG zgpg30
TD 65536
SOLVENT CDCl3
NS 2
DS 2
SWH 10330.570 Hz
FIDRES 0.121623 Hz
AQ 3.1710267 sec
RG 40.2
DM 65.000 sec
DE 4.50 usec
TE 300.2 K
SI 1.0000000 sec
TD 1

----- CHANNEL f1 -----
NUC1 13
P1 9.00 usec
PL 0.00 dB
PL1W 0.1830000 MHz
SFO1 500.136050 MHz

F2 - Processing parameters
SI 32768
SF 500.1360123 MHz
WDW EM
SSB 0
GB 0.30 Hz
PC 1.00
```




Figure S-5: ¹H NMR Spectrum of compound 1p





Figure S-7: ^1H NMR Spectrum of compound 1q



```

Current Data Parameters
NAME      GKP-IND-F-OH
EXPNO    1
PROCNO   1
F2 - Acquisition Parameters
Date_    2011106
Time     11:49
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
TD        65536
SOLVENT  CDCl3
NS        2
DS        4
SWH       30000.000 Hz
F2 - F1    0.00000000 sec
AQ         1.00000000 sec
RG         10930
SW         16.400 sec
DE         6.50 sec
TE         300.2 K
D1         2.00000000 sec
D11        0.03000000 sec
TAD        1
===== CHANNEL f1 =====
NUC1       13C
P1         0.80 sec
PC1        1.50 dB
PC1M       68.44607511
SFO1       125.7678443 MHz
===== CHANNEL f2 =====
CH2REG2   waltz16
NUC2       1H
PC2        2.00 sec
PC2M       16.00 dB
PC2M2      14.9724056 dB
PC2M3      7.13934498 dB
PC2M4      0.23737326 dB
SFO2       500.1360993 MHz
F2 - Processing parameters
SI         32768
SF         125.7577933 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40

```

Figure S-8: ^{13}C NMR Spectrum of compound 1q

gkp-ind-cl-oh





Figure S-9: ¹H NMR Spectrum of compound 1r




```

===== CHANNEL F1 =====
NAME: GKP-IND-CL-OH
PROCNO: 1
F2 - ACQUISITION PARAMETERS
TIME: 011119
INSTRUM: spect
PULPROG: zgpg30
PROBHD: 5 mm PABBO QNP
PULPROG2: zgpg30
TD: 65536
SOLVENT: CDCl3
AQ: 372
RG: 300
ORIG: 30031022 Hz
FIDRES: 0.418222 Hz
AQ: 1.0012410 sec
RG: 10.000
AQ: 16.470 usec
RG: 16.700 usec
TD: 65536
SOL: CDCl3
D1: 2.00000000 sec
D11: 0.00000000 sec
D12:
===== CHANNEL F2 =====
NAME:
PROCNO:
F2:
P1: 3.00 usec
P1L: 64.44619218 W
P1FL: 125.7574613 MHz
===== CHANNEL F3 =====
NAME:
PROCNO:
F3:
P1: 80.00 usec
P1L: 14.00000000 W
P1FL: 14.97244800 M
P1FLM: 0.21977428 W
P1FLM: 0.21977428 W
D1: 0.00000000 sec
F2 - PROCESSING PARAMETERS
SI:
SF: 125.7574613 MHz
WDW: EM
SSB: 0
LB: 1.00 Hz
GB:
PC: 1.40

```

Figure S-10: ¹³C NMR Spectrum of compound 1r

gkp-ind-br-oh



```
Current Data Parameters
NAME: gkp-ind-br-oh
PROCNO: 1
F1 - Acquisition Parameters
Date_: 201904
Time: 13:45
INSTRUM: spect
PROBHD: 5 mm QNP1H
PULPROG: zgpg30
AQ: 0.121
RG: 655
AQ: 0.121
SFO: 500.136
SF: 500.136
FIDRES: 0.119000 Hz
AQ: 0.121
SFO: 500.136
SF: 500.136
FIDRES: 0.119000 Hz
===== CHANNEL f1 =====
NUC1: 1
P1: 12.00
PL1: 0.00
PL12: 0.00
PL13: 0.00
PL14: 0.00
PL15: 0.00
===== CHANNEL f2 =====
NUC2: 13
P2: 0.00
PL2: 0.00
PL22: 0.00
PL23: 0.00
PL24: 0.00
PL25: 0.00
===== CHANNEL f3 =====
NUC3: 15
P3: 0.00
PL3: 0.00
PL32: 0.00
PL33: 0.00
PL34: 0.00
PL35: 0.00
===== CHANNEL f4 =====
NUC4: 1
P4: 0.00
PL4: 0.00
PL42: 0.00
PL43: 0.00
PL44: 0.00
PL45: 0.00
```

Figure S-11: ¹H NMR Spectrum of compound 1s




Figure S-13: ¹H NMR Spectrum of compound 3c




Figure S-14: ^{13}C NMR Spectrum of compound 3c




Figure S-15: ¹H NMR Spectrum of compound 4c

BVS-1-61 SN C13




Figure S-16: ¹³C NMR Spectrum of compound 4c

BVS-1-133 SN

8.148
8.136
8.133
8.000
7.996
7.992
7.961
7.946
7.944
7.875
7.861
7.859
7.715
7.700
7.685
7.617
7.601
7.588
7.571
7.555
7.539
7.473
7.457
7.441
7.267
5.579
5.571
5.340
5.332
5.326

3.824
3.811



```
===== CHANNEL f1 =====  
NAME BVS-1-133-SN-1  
EXPNO 1  
PROCNO 1  
F2 - Acquisition Parameters  
Date_ 20110725  
Time 15.14  
INSTRUM spect  
PROBHD 5 mm PABBO-60  
PULPROG zgpg30  
TD 65536  
SOLVENT CDCl3  
NS 16  
DS 4  
SWH 10330.572 Hz  
FIDRES 0.157632 Hz  
AQ 3.172647 sec  
RG 68  
SQ 44  
DM 48.400 usec  
DE 6.00 usec  
TE 300.2 K  
SI 1.0000000 sec  
TD0 1  
  
===== CHANNEL f2 =====  
NUC1 13  
P1 16.00 usec  
PL1 0.00 dB  
SFO1 101.2532 MHz  
F2 - Processing parameters  
SI 320.130768 MHz  
SF 500.130768 MHz  
WDW EM  
SSB 0  
LB 0.30 Hz  
GB 0  
PC 1.00
```





Figure S-17: ¹H NMR Spectrum of compound 4e

BVS-1-133 SN C13




Figure S-18: ¹³C NMR Spectrum of compound 4e

BVS-2-150



```
Current Data Parameters
NAME      BVS-2-150
EXPNO    2
PROCNO   1

F2 - Acquisition Parameters
Date_    20110615
Time     15.41
INSTRUM  av500
PROBHD   5 mm PATXI 1H/
PULPROG  zg30
TD        65536
SOLVENT  CDCl3
NS        14
DS        4
SFO      10330.572 Hz
FIDRES   0.157632 Hz
AQ        3.170407 sec
RG        71.8
SM        48.400 usec
SE        6.00 usec
TE        296.2 K
D1        1.0000000 sec
TD0       1

===== CHANNEL f1 =====
NUC1      1H
P1        7.70 usec
PL1       2.00 dB
SFO1      500.1330885 MHz

F2 - Processing parameters
SI        32768
SF        500.1300141 MHz
WDW       0
SSB       0
LA        0.70 Hz
GB        0
PC        1.00
```




Figure S-19: ¹H NMR Spectrum of compound 4p

BVS-2-150SN C13




Figure S-20: ¹³C NMR Spectrum of compound 4p

BVS-2-151-4




Figure S-21: ^1H NMR Spectrum of compound 4q

BVS-2-151 C13




Figure S-22: ^{13}C NMR Spectrum of compound 4q

BVS-2-185 H1




Figure S-23: ¹H NMR Spectrum of compound 4s

BVS-2-185 C13




Figure S-24: ¹³C NMR Spectrum of compound 4s

BVS-2-152 SN H1




Figure S-25: ¹H NMR Spectrum of compound 4t

BVS-2-152 SN C13




Figure S-26: ¹³C NMR Spectrum of compound 4t

BVS-2-153 H1




Figure S-27: ¹H NMR Spectrum of compound 4v

BVS-2-153 C13 SN




Figure S-28: ¹³C NMR Spectrum of compound 4v

BVS-2-219




Figure S-29: ¹H NMR Spectrum of compound 6a

BVS-2-225




Figure S-30: ¹H NMR Spectrum of compound 6a

BRUKER

===== CHANNEL f1 =====
NUC1 13C
P1 14.90 u
PUL 2.00 u
SFO1 500.1330885 M
F2 - Processing parameter
SI 32788
SF 500.1300152 M
WDW EM
SSB 0
LB 0.30 H
GB 0
PC 1.00

BVS-2-224




Figure S-31: ¹H NMR Spectrum of compound 6c




Figure S-32: ^1H NMR Spectrum of compound 6c



===== CHANNEL f1 =====
NUC1 13C
P1 0.01000000
PL1 0.00000000
SFO1 125.7619444 MHz

===== CHANNEL f2 =====
NUC2 1H
P2 0.01000000
PL2 0.00000000
PL12 19.44000000
SFO2 500.1370000 MHz

SI - Processing parameters
SI 125.7619444 MHz
SF 500.1370000 MHz
AQ 0.00000000
RG 32768
WDW EM
SS 0
LB 3.00 Hz
GB 0
PC 3.00

GKP-3C13

141.76
138.77
128.97
128.65
127.66
120.09

77.76
77.65
77.42

19.65





Figure S-33: ¹³C NMR Spectrum of compound 2ad

GKP-4C13

162.68

133.58

130.68


127.35

115.78

77.92

77.66

77.51



```
Current Data Parameters
NAME      GKP-4C13
EXPNO    3
PROCNO   1

F2 - Acquisition Parameters
Date_    010310
Time     09.05
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       168
DS       2
SWH      35030.029 Hz
FIDRES   0.48222 Hz
AQ       1.0912410 sec
RG       812
SM       16.800 usec
SE       0.000 usec
TE       297.0 K
DQ       2.0000000 sec
d11      0.0000000 sec
DELTA    1.8000000 sec
TD0      1

===== CHANNEL f1 =====
NUC1      13C
P1        9.80 usec
PL1       1.00 dB
SFO1      125.7702640 MHz

===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2      1H
P2        80.00 usec
PL2       2.00 dB
PL12      19.00 dB
PL13      19.00 dB
SFO2      500.1320000 MHz

F2 - Processing parameters
SI        32768
SF        125.7617800 MHz
WDW       EM
SSB       0
GB        0
PC        1.00
```





Figure S-35: ^{13}C NMR Spectrum of compound 9c

GP-4a



BRUKER





Figure S-36: ¹H NMR Spectrum of compound 9c




Figure S-37: ^{13}C NMR Spectrum of compound 11ab

GP-103




Figure S-38: ¹H NMR Spectrum of compound 12ab

GP-103C13

144.35
143.27
137.95
132.55
132.49
131.65
130.49
130.47
130.05
129.65
128.97
128.77
128.68

77.68
77.65
77.35
67.72
61.05

27.05

12.95



```

Current Data Parameters
NAME      GP-103C13
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20141017
Time     9.29
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       108
DS       2
SWH       30030.029 Hz
FIDRES    0.458222 Hz
AQ       1.0912410 sec
RG       81
DM       16.600 usec
DE       6.50 usec
TE       297.2 K
D1       2.0000000 sec
d11      0.0000000 sec
DELTA    1.8000000 sec
TD0      1

===== CHANNEL f1 =====
NUC1      13C
P1       19.00 usec
PL1      1.00 dB
SFO1     125.7678400 MHz

===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2      1H
PCPD2    90.00 usec
PL2      1.00 dB
PL12     16.60 dB
PL13     23.60 dB
SFO2     500.1320000 MHz

F2 - Processing parameters
SI       32768
SF       125.7678400 MHz
GB       0
WDW      EM
SSB      0
LB       1.00 Hz
GB2      0
PC       1.40
    
```





Figure S-39: ¹³C NMR Spectrum of compound 12ab




Figure S-40: ^1H NMR Spectrum of compound 12ac

GP-104C13



```
Current Data Parameters
NAME      GP-104C13
EXPNO    10
PROCNO   1
F2 - Acquisition Parameters
Date_    20140101
Time     9:29
INSTRUM  mv500
PROBHD   5 mm PABBO WB-
PULPROG  zgpg30
DS       40026
SOLVENT  CDCl3
NS       128
DS       30030.029 Hz
FIDRES   0.458222 Hz
AQ       1.5913112 sec
RG       812
SWH       16.050 MHz
SB       6.50 MHz
FE       297.3 F
SI       2.0000000 sec
SFO      0.0300000 MHz
DELTA    1.8999999 sec
TD       1
===== CHANNEL f1 =====
NUC1      13C
P1        9.00 usec
PL1       1.00 dB
SFO1      125.7603640 MHz
===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2      1H
PCPD2     80.00 usec
PL2       2.00 dB
PL12      16.40 dB
PL13      23.40 dB
SFO2      500.1320000 MHz
F2 - Processing parameters
SI       32768
WDW       125.7677890 MHz
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
```

156.27
141.54
137.76
132.54
132.47
131.77
130.65
130.49
130.05
129.65
128.97
128.68
128.66
127.03
100.06
77.68
77.65
77.49
67.82
64.13
60.33
54.52
28.95
14.05





Figure S-41: ^{13}C NMR Spectrum of compound 12ac




Figure S-42: ^1H NMR Spectrum of compound 12ad

GP-105-C13

143.45
143.05
134.31
129.74
129.52
128.65
127.93
127.69
127.65
126.76
125.75
125.48
125.18
124.07

77.89
77.47
77.19
68.56
62.95

28.01
21.54
13.47



```
===== CHANNEL 01 =====
NUC1: 13C
P1: 1.00 uS
PC: 0.00 dB
SFO1: 125.762800 MHz

===== CHANNEL 02 =====
NUC2: 1H
P2: 1.00 uS
PC2: 0.00 dB
SFO2: 500.136000 MHz

===== CHANNEL 03 =====
NUC3: 1H
P3: 1.00 uS
PC3: 0.00 dB
SFO3: 500.136000 MHz

===== CHANNEL 04 =====
NUC4: 1H
P4: 1.00 uS
PC4: 0.00 dB
SFO4: 500.136000 MHz

===== CHANNEL 05 =====
NUC5: 1H
P5: 1.00 uS
PC5: 0.00 dB
SFO5: 500.136000 MHz

===== CHANNEL 06 =====
NUC6: 1H
P6: 1.00 uS
PC6: 0.00 dB
SFO6: 500.136000 MHz

===== CHANNEL 07 =====
NUC7: 1H
P7: 1.00 uS
PC7: 0.00 dB
SFO7: 500.136000 MHz

===== CHANNEL 08 =====
NUC8: 1H
P8: 1.00 uS
PC8: 0.00 dB
SFO8: 500.136000 MHz

===== CHANNEL 09 =====
NUC9: 1H
P9: 1.00 uS
PC9: 0.00 dB
SFO9: 500.136000 MHz

===== CHANNEL 10 =====
NUC10: 1H
P10: 1.00 uS
PC10: 0.00 dB
SFO10: 500.136000 MHz

===== CHANNEL 11 =====
NUC11: 1H
P11: 1.00 uS
PC11: 0.00 dB
SFO11: 500.136000 MHz

===== CHANNEL 12 =====
NUC12: 1H
P12: 1.00 uS
PC12: 0.00 dB
SFO12: 500.136000 MHz

===== CHANNEL 13 =====
NUC13: 1H
P13: 1.00 uS
PC13: 0.00 dB
SFO13: 500.136000 MHz

===== CHANNEL 14 =====
NUC14: 1H
P14: 1.00 uS
PC14: 0.00 dB
SFO14: 500.136000 MHz

===== CHANNEL 15 =====
NUC15: 1H
P15: 1.00 uS
PC15: 0.00 dB
SFO15: 500.136000 MHz

===== CHANNEL 16 =====
NUC16: 1H
P16: 1.00 uS
PC16: 0.00 dB
SFO16: 500.136000 MHz

===== CHANNEL 17 =====
NUC17: 1H
P17: 1.00 uS
PC17: 0.00 dB
SFO17: 500.136000 MHz

===== CHANNEL 18 =====
NUC18: 1H
P18: 1.00 uS
PC18: 0.00 dB
SFO18: 500.136000 MHz

===== CHANNEL 19 =====
NUC19: 1H
P19: 1.00 uS
PC19: 0.00 dB
SFO19: 500.136000 MHz

===== CHANNEL 20 =====
NUC20: 1H
P20: 1.00 uS
PC20: 0.00 dB
SFO20: 500.136000 MHz
```





Figure S-43: ¹³C NMR Spectrum of compound 12ad




Figure S-44: ^1H NMR Spectrum of compound 12ae

GP-106C13

146.05
145.79
144.93
137.47
132.74
132.57
131.65
130.93
130.68
130.66
129.79
128.79
128.45
128.16
127.05

77.79
77.35
77.16
68.78
64.05

27.87
21.15
19.35
14.43



```
Current Data Parameters
NAME      GP-106C13
EXPNO    1
PROCNO   1

F2 - Acquisition Parameters
Date_    20100101
Time     9.35
INSTRUM  av600
PROBHD   5 mm PABBO 60-
PULPROG  zgpg30
TD       65537
SOLVENT  CDCl3
NS       108
DS       2
SWH      20030.029 Hz
FIDRES   0.498222 Hz
AQ       1.0912410 sec
RG       412
SM       16.450 usec
DE       6.00 usec
TE       297.5 K
SI       2.0000000 sec
d11      0.0000000 sec
DELTA    1.8999999 sec
TDR      1

===== CHANNEL f1 =====
NUC1      13C
P1        9.00 usec
PL1       1.00 dB
SFO1     125.7703640 MHz

===== CHANNEL f2 =====
CPDPRG2   waltz16
NUC2      1H
PCPD2     80.00 usec
PL2       2.00 dB
PL12      16.00 dB
PL13      20.00 dB
SFO2     500.1320000 MHz

F2 - Processing parameters
SI        32768
SF        125.7677990 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
```





Figure S-45: ¹³C NMR Spectrum of compound 12ae




Figure S-46: ^1H NMR Spectrum of compound 12af

GP-107C13

142.65
141.32
138.52
131.66
130.97
130.68
129.97
129.58
128.68
127.97
126.68
121.97
121.68
116.66
115.32
77.92
77.78
77.66
77.12
70.68
64.08
26.12
13.03



```
Current Data Parameters
NAME: GP-107 C13
EXPNO: 10
PROCNO: 0

F2 - Acquisition Parameters
Date_: 20140106
Time: 9.10
INSTRUM: av500
PROBHD: 5 mm PABBO QNP
PULPROG: zgpg30
TD: 65536
SOLVENT: CDCl3
NS: 150
DS: 2
SWH: 50070.029 Hz
FIDRES: 0.458222 Hz
AQ: 1.091212 sec
RG: 812
SW: 14.650 usec
DE: 6.00 usec
TE: 297.2 K
D1: 2.0000000 sec
d11: 0.0000000 sec
DELTA: 1.8999999 sec
TD0: 1

===== CHANNEL f1 =====
NUC1: 13C
P1: 9.00 usec
PL1: 1.00 dB
SFO1: 125.7603600 MHz

===== CHANNEL f2 =====
CPDPRG2: waltz16
NUC2: 1H
PCPD2: 80.00 usec
PL2: 2.00 dB
PL12: 16.40 dB
PL13: 20.40 dB
SFO2: 500.1320000 MHz

F2 - Processing parameters
SI: 32768
SF: 125.7577890 MHz
WDW: EM
SSB: 0
LB: 1.00 Hz
GB: 0
PC: 1.40
```





Figure S-47: ¹³C NMR Spectrum of compound 12af




Figure S-48: ^1H NMR Spectrum of compound 12ag

GP-108-C13



```
Current Data Parameters
NAME      GP-108C13a
EXPNO     1
PROCNO    1

F2 - Acquisition Parameters
Date_     20140103
Time      9
INSTRUM   spect
PROBHD    5 mm PABBO SP-
PULPROG   zgpg30
ID        65236
SOLVENT   CDCl3
NS        108
DS        2
SWH       50030.029 Hz
FIDRES    0.458222 Hz
AQ        1.0912410 sec
RG        812
DM        16.650 usec
DE        6.50 usec
TE        297.0 K
D1        2.0000000 sec
d11       0.0300000 sec
DELTA     1.8300000 sec
TD        1

===== CHANNEL f1 =====
NUC1      13C
P1        9.00 usec
PL1       1.00 dB
SFO1      125.767840 MHz

===== CHANNEL f2 =====
CPDPRG2   waltz16
NUC2      1H
PCPD2     80.00 usec
PL2       2.00 dB
PL12      16.40 dB
PL13      20.40 dB
SFO2      500.132000 MHz

F2 - Processing parameters
SI        32768
SF        125.7677890 MHz
WDW       EM
SSB       0
LB        1.00 Hz
GB        0
PC        1.40
```

142.51
141.28
138.58
131.52
130.97
130.68
129.97
129.68
128.68
127.78
126.35
121.97
121.68

77.97
77.92
77.66
68.03
66.51

26.68
13.66





Figure S-49: ¹³C NMR Spectrum of compound 12ag




Figure S-50: ^1H NMR Spectrum of compound 12ah




Figure S-51: ^{13}C NMR Spectrum of compound 12ah




Figure S-52: ¹H NMR Spectrum of compound 12ai



```
Current Data Parameters
NAME      GP-110C13
EXPNO    3
PROCNO   9

F2 - Acquisition Parameters
Date_    20181130
Time     9.11
INSTRUM  av500
PROBHD   5 mm PABBO QNP
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       128
DS       4
SWH      50530.029 Hz
FIDRES   0.458232 Hz
AQ       1.291111 sec
RG       312
SW       16.652 usec
DE       6.00 usec
TE       297.5 K
SI       2.0000000 sec
SFO1     0.0300000 MHz
DELTA    1.8999999 sec
TSD      1

===== CHANNEL F1 =====
NUC1      13C
P1        9.80 usec
PL1       1.00 dB
SFO1     125.7703646 MHz

===== CHANNEL F2 =====
CPDPRG2  waltz16
NUC2      1H
PCPD2    80.00 usec
PL2       2.00 dB
PL12     16.40 dB
PL13     20.40 dB
SFO2     500.1320000 MHz

F2 - Processing parameters
SI       32768
SF       125.7677890 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
```

GP-110C13

160.55
142.32
141.65
138.58
130.97
130.66
129.97
129.68
128.68
127.97
126.68
125.65
116.66
115.08
77.96
77.95
77.62
67.67
64.15
27.35
13.08





Figure S-53: ¹³C NMR Spectrum of compound 12ai





Figure S-54: ¹H NMR Spectrum of compound 3ab

GP-62-C13






Figure S-56: ^1H NMR Spectrum of compound 3ac

GP-60-C13



```
Current Data Parameters
NAME      GP-60-C13
EXPNO    10
PROCNO   1

F2 - Acquisition Parameters
Date_    20160229
Time     9:07
INSTRUM  spect
PROBHD   5 mm PABBO BB-
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       108
DS       2
SWH      30530.029 Hz
FIDRES   0.488222 Hz
AQ       1.0912410 sec
RG        812
DM       16.650 usec
DE       6.00 usec
TE       297.0 K
D1       2.0000000 sec
d11      0.0300000 sec
DELTA    1.8999999 sec
TDS      1

===== CHANNEL F1 =====
NUC1      13C
P1        9.80 usec
PL1       1.00 dB
SFO1     125.7678940 MHz

===== CHANNEL F2 =====
CPDPRG2  waltz16
NUC2      1H
PCPD2     80.00 usec
PL2       2.00 dB
PL12     14.00 dB
PL13     20.00 dB
SFO2     500.1320000 MHz

F2 - Processing parameters
SI        32768
SF       125.7678940 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
```





Figure S-57: ¹³C NMR Spectrum of compound 3ac




Figure S-58: ^1H NMR Spectrum of compound 3ad

GP-52-C13




Figure S-59: ¹³C NMR Spectrum of compound 3ad




Figure S-60: ¹H NMR Spectrum of compound 3ag

GP-77 C13






Figure S-61: ¹³C NMR Spectrum of compound 3ag



1H NMR (400 MHz, CDCl3) δ 7.887 (d, 1H), 7.871 (d, 1H), 7.870 (d, 1H), 7.860 (d, 1H), 7.856 (d, 1H), 7.846 (d, 1H), 7.554 (d, 1H), 7.549 (d, 1H), 7.540 (d, 1H), 7.536 (d, 1H), 7.532 (d, 1H), 7.527 (d, 1H), 7.524 (d, 1H), 7.519 (d, 1H), 7.516 (d, 1H), 7.506 (d, 1H), 7.503 (d, 1H), 7.498 (d, 1H), 7.415 (d, 1H), 7.412 (d, 1H), 7.400 (d, 1H), 7.398 (d, 1H), 7.393 (d, 1H), 7.260 (d, 1H), 6.887 (d, 1H), 6.872 (d, 1H), 6.870 (d, 1H), 4.681 (d, 1H), 4.674 (d, 1H), 4.512 (d, 1H), 4.504 (d, 1H), 3.754 (d, 1H), 3.748 (d, 1H), 3.729 (d, 1H), 3.847 (d, 1H), 3.833 (d, 1H), 3.824 (d, 1H), 3.818 (d, 1H), 3.803 (d, 1H), 2.780 (d, 1H), 2.772 (d, 1H), 2.756 (d, 1H), 2.392 (d, 1H), 1.501 (d, 1H), 1.498 (d, 1H), 1.484 (d, 1H), 1.467 (d, 1H), 1.151 (d, 1H), 1.139 (d, 1H), 1.129 (d, 1H), 0.987 (d, 1H), 0.972 (d, 1H), 0.967 (d, 1H).

Figure S-62: ^1H NMR Spectrum of compound 3ah

GP-73-C13



```
Current Data Parameters
NAME      GP-73C13
EXPNO    10
PROCNO   1

F2 - Acquisition Parameters
Date_    20140502
Time     9.11
INSTRUM  av500
PROBHD   5 mm PABBO 5B-
PULPROG  zgpg30
TD       65536
SOLVENT  CDCl3
NS       198
DS       2
SWH      30096.029 Hz
FIDRES   0.458222 Hz
AQ       1.0912410 sec
RG       812
DM       16.650 usec
DE       6.00 usec
TE       297.0 K
D1       2.0000000 sec
d11      0.0300000 sec
DELTA    1.8999999 sec
TD0      1

===== CHANNEL f1 =====
NUC1     13C
P1       9.80 usec
PL1      1.00 dB
SFO1     125.7703440 MHz

===== CHANNEL f2 =====
CPDPRG2  waltz16
NUC2     1H
PCPD2    80.00 usec
PL2      2.00 dB
PL3      16.40 dB
PL4      16.40 dB
SFO2     500.1320000 MHz

F2 - Processing parameters
SI       32768
SF       125.7577890 MHz
WDW      EM
SSB      0
LB       1.00 Hz
GB       0
PC       1.40
```

Figure S-63: ^{13}C NMR Spectrum of compound 3ah




Figure S-64: ¹H NMR Spectrum of compound 3ai

GP-74-C13

161.15
157.62
153.78
137.47
132.74
132.57
131.65
130.93
130.68
130.66
129.79
128.79
128.45
128.16
127.05
117.00
116.65
116.05

77.79
77.35
77.16
76.32
74.08
64.75
58.93
56.70

27.87
26.95
25.79
14.43



```
Current Data Parameters
NAME      GP-74C13
EXPNO    10
PROCNO   1
F2 - Acquisition Parameters
Date_    20160501
Time     9.11
INSTRUM  av500
PROBHD   5 mm PABBO 5M-
PULPROG  zgpg30
TD        65536
SOLVENT  CDCl3
NS        182
DS        2
SWH       35030.029 Hz
FIDRES    0.488212 Hz
AQ         1.0912415 sec
RG         612
DE         16.400 umsec
TE         4.00 umsec
TDI        297.0 Hz
d11        2.0000000 sec
DELTA     0.0300000 sec
1.8999999 sec
TD0        1
----- CHANNEL f1 -----
NUC1       13C
P1         4.100 umsec
PL1        1.00 dB
SFO1       125.767890 MHz
----- CHANNEL f2 -----
CPDPRG2   waltz16
NUC2
PCPD2     80.00 umsec
PL2        2.00 dB
PL12       16.40 dB
PL13       20.40 dB
SFO2       500.1326500 MHz
F2 - Processing parameters
SI         32768
SF         125.767890 MHz
WDW        EM
SSB        0
LB         1.00 Hz
GB         0
PC         1.40
```





Figure S-65: ¹³C NMR Spectrum of compound 3ai




Figure S-66: ^1H NMR Spectrum of compound 3an

GP-75-C-13




Figure S-67: ¹³C NMR Spectrum of compound 3an




Figure S-68: ¹H NMR Spectrum of compound 3as

GP-91-C13




Figure S-69: ^{13}C NMR Spectrum of compound 3as




Figure S-70: ¹H NMR Spectrum of compound 4ab




Figure S-71: ¹³C NMR Spectrum of compound 4ab





Figure S-72: ^1H NMR Spectrum of compound 4ac






Figure S-74: ¹H NMR Spectrum of compound 4ae





Figure S-75: ^{13}C NMR Spectrum of compound 4ae






Figure S-77: ^{13}C NMR Spectrum of compound 4af




Figure S-78: ¹H NMR Spectrum of compound 4ag




Figure S-79: ^{13}C NMR Spectrum of compound 4ag




Figure S-80: ¹H NMR Spectrum of compound 5ab




Figure S-81: ^{13}C NMR Spectrum of compound 5ab

GP-5ac





Figure S-82: ¹H NMR Spectrum of compound 5ac






Figure S-84: ^1H NMR Spectrum of compound 5ad




Figure S-85: ^{13}C NMR Spectrum of compound 5ad





Figure S-86: ^1H NMR Spectrum of compound 5ae







Figure S-88: ^1H NMR Spectrum of compound 5af






Figure S-90: ^1H NMR Spectrum of compound 5ag





Figure S-91: ^{13}C NMR Spectrum of compound 5ag



```

Current Data Parameters
NAME:          16e-1
EXPNO:        1
PROCNO:       1
F2 - Acquisition Parameters
Date_         20111111
Time         16.28
INSTRUM:      spect
PROBHD:       5 mm PABBO
PULPROG:      zg30
TD:           65536
SOLVENT:      CDCl3
AQ:           14
RG:           1024
FIDRES:       0.170250 Hz
AQ:           3.1720407 sec
RG:           1024
AQ:           16.5000000 sec
RG:           4.1000000 sec
RG:           0.0200000 sec
RG:           1.00000000 sec
RG:           1
===== CHANNEL f1 =====
NUC1:          1H
P1:           14.000000 sec
PL1:          0.000000 dB
SFO1:         500.136099 MHz
=====
F2 - Processing parameters
SI:           32768
SF:           500.136099 MHz
WDW:          EM
SSB:          0
LB:           0.30 Hz
GB:           0
PC:           1.00
  
```

Figure S-92: ¹H NMR Spectrum of compound 16e




Figure S-93: ^{13}C NMR Spectrum of compound 16e




Figure S-94: ¹H NMR Spectrum of compound 16f




Figure S-95: ^{13}C NMR Spectrum of compound 16f




Figure S-96: ¹H NMR Spectrum of compound 16g




Figure S-97: ^{13}C NMR Spectrum of compound 16g





Figure S-98: ^1H NMR Spectrum of compound 16h



```

Current Data Parameters
NAME: GP-92-C13
EXPNO: 10
PROCNO: 1

F2 - Acquisition Parameters
Date_: 20140503
Time: 9.10
INSTRUM: spect
PROBHD: 5 mm PABBO
PULPROG: zgpg30
TD: 65536
SOLVENT: CDCl3
NS: 108
DS: 2
SWH: 20570.029 Hz
FIDRES: 0.458212 Hz
AQ: 3.0912410 sec
RG: 812
SQ: 16.600 usec
DE: 6.00 usec
TE: 297.0 F
D1: 2.0000000 sec
d11: 0.0300000 sec
DELTA: 1.8999999 sec
TD0: 1

===== CHANNEL f1 =====
NUC1: 13C
P1: 9.00 usec
PL1: 1.00 dB
SFO1: 125.7703640 MHz

===== CHANNEL f2 =====
CPDPRG2: waltz16
NUC2: 1H
PCPD2: 80.00 usec
PL2: 2.00 dB
PL12: 16.40 dB
PL13: 20.40 dB
SFO2: 500.1370950 MHz

F2 - Processing parameters
SI: 32768
SF: 125.7577290 MHz
WDW: EM
SSB: 0
LB: 1.00 Hz
GB: 0
CB: 1.40
  
```

Figure S-99: ¹³C NMR Spectrum of compound 16h




Figure S-100: ^1H NMR Spectrum of compound 16i






Figure S-101: ¹³C NMR Spectrum of compound 16i



GP-62-C13



```
Current Data Parameters
NAME: GP-62-C13
EXPNO: 1
PROCNO: 1

F2 - Acquisition Parameters
Date_ 2018081
Time 9:19
INSTRUM spect
PROBHD 5 mm PABBO MM-
PULPROG zgpg30
TD 65536
SFO 400.13
SOLVENT CDCl3
NS 2048
DS 4
SWH 30636.000 Hz
FIDRES 0.468222 Hz
AQ 1.091210 sec
RG 312
DM 16.450 sec
DE 6.00 sec
TE 300.2
SI 2.0000000 sec
S1 0.0300000 sec
DELTA 1.8999999 sec
TD0 1

===== CHANNEL f1 =====
NUC1 13C
P1 9.80 usec
PL1 0.00 dB
SFO1 125.767860 MHz

===== CHANNEL f2 =====
CPDPRG2 waltz16
NUC2 1H
P2 89.00 usec
PL2 2.00 dB
PL12 16.40 dB
PL13 16.40 dB
SFO2 500.130000 MHz

F2 - Processing parameters
SI 32768
SF 125.767860 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40
```

Figure S-103: ^{13}C NMR Spectrum of compound 16j




Figure S-104: ¹H NMR Spectrum of compound 23a




Figure S-105: ^{13}C NMR Spectrum of compound 23a




Figure S-107: ¹³C NMR Spectrum of compound 23b




Figure S-108: ^1H NMR Spectrum of compound 23c




Figure S-109: ^{13}C NMR Spectrum of compound 23c




Figure S-110: ¹H NMR Spectrum of compound 23d




Figure S-111: ¹³C NMR Spectrum of compound 23d




Figure S-112: ^1H NMR Spectrum of compound 23e




Figure S-113: ^{13}C NMR Spectrum of compound 23e




Figure S-114: ¹H NMR Spectrum of compound 23f




Figure S-115: ^{13}C NMR Spectrum of compound 23f




Figure S-116: ¹H NMR Spectrum of compound 23g




Figure S-117: ^{13}C NMR Spectrum of compound 23g




Figure S-118: ^1H NMR Spectrum of compound 23h




Figure S-119: ¹³C NMR Spectrum of compound 23h




Figure S-120: ¹H NMR Spectrum of compound 23i




Figure S-121: ¹³C NMR Spectrum of compound 23i




Figure S-122: ¹H NMR Spectrum of compound 23j




Figure S-123: ¹³C NMR Spectrum of compound 23j




Figure S-124: ¹H NMR Spectrum of compound 24a




Figure S-126: ¹H NMR Spectrum of compound 24b




Figure S-127: ¹³C NMR Spectrum of compound 24b




Figure S-129: ¹³C NMR Spectrum of compound 24c




Figure S-130: ^1H NMR Spectrum of compound 24d




Figure S-131: ¹³C NMR Spectrum of compound 24d




Figure S-132: ¹H NMR Spectrum of compound 24e




Figure S-133: ¹³C NMR Spectrum of compound 24e




Figure S-135: ^{13}C NMR Spectrum of compound 24f




Figure S-136: ^1H NMR Spectrum of compound 24g




Figure S-137: ¹³C NMR Spectrum of compound 24g




Figure S-138: ¹H NMR Spectrum of compound 24h




Figure S-139: ^{13}C NMR Spectrum of compound 24h




Figure S-140: ^1H NMR Spectrum of compound 24i




Figure S-141: ¹³C NMR Spectrum of compound 24i




Figure S-142: ^1H NMR Spectrum of compound 24j





Figure S-143: ¹³C NMR Spectrum of compound 24j

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample info:

Sample ID	: BVS-2-221 RACEMIC	Amount	: 0
Sample	: BVS-2-221 RACEMIC	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Bhrinivasivenkat.b\BVS-2-221 RACEMIC)


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	54.080	10830.192	109.358	49.6	61.5	1.51
2	59.300	11013.546	88.494	50.4	38.5	2.49
	Total	21843.738	177.853	100.0	100.0	

Chromatogram of **5a** (racemic).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID : BVS-2-221 chairal-1 Amount : 0
Sample : BVS-2-221 chairal-1 ISTD Amount : 0
Inj. Volume [ml] : 0 Dilution : 1



Result Table (Uncal - F:\Shrinivas\venkat.b\BVS-2-221 chairal-1)


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	54.710	2269.937	26.611	13.0	19.6	1.29
2	58.747	15224.951	109.040	87.0	80.4	2.00
	Total	17494.889	135.651	100.0	100.0	

Chromatogram of **5a** (asymmetric).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID	: BVS-2-214 Racemic	Amount	: 0
Sample	: BVS-2-214 Racemic	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Shrinivas\venkat.b\BVS-2-214 Racemic)


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	26.920	2576.361	42.957	50.0	57.5	0.94
2	35.363	2580.839	31.704	50.0	42.5	1.27
	Total	5157.201	74.661	100.0	100.0	

Chromatogram of **6a** (racemic).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID	: BVS-2-214 CHAIRAL-1	Amount	: 0
Sample	: BVS-2-214 CHAIRAL-1	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Shrinivas\venkat.b\BVS-2-214 CHAIRAL-1-12-11)


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	27.987	615.855	9.368	13.9	17.0	0.98
2	36.900	3829.838	45.782	86.1	83.0	1.31
	Total	4445.692	55.150	100.0	100.0	

Chromatogram of **6a** (asymmetric).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID : BVS-2- 221 (RACEMIC EPOXIDE SINGLE BROMO) Amount : 0
Sample : BVS-2- 221 (RACEMIC EPOXIDE SINGLE BROMO) ISTD Amount : 0
Inj. Volume [ml] : 0 Dilution : 1



Result Table (Uncal - F:\Shrinivas\venkat.b\BVS-2- 221 (RACEMIC EPOXIDE SINGLE BROMO))


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	20.493	11127.669	178.922	49.9	50.3	1.06
2	22.127	11182.367	176.941	50.1	49.7	1.03
Total		22310.036	355.863	100.0	100.0	

Chromatogram of **5b** (racemic).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID	: BVS-2-221 (EPOXIDE BROMO-1)\17.04.12.	Amount	: 0
Sample	: BVS-2-221 (EPOXIDE BROMO-1)\17.04.12.	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Shrinivas\venkat.b\17.04.12\BVS-2-221 (EPOXIDE BROMO-1)\17.04.12.)


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	21.270	3345.229	89.675	11.2	14.5	0.59
2	22.450	26653.670	527.569	88.8	85.5	0.76
	Total	29998.898	617.244	100.0	100.0	

Chromatogram of **5b** (asymmetric).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID	: BVS-2-225 (RACEMIC SINGLEBROMO -2)	Amount	: 0
Sample	: BVS-2-225 (RACEMIC SINGLEBROMO -2)	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Shrinivas\venkat.b\17.04.12\BVS-2-225 (RACEMIC SINGLEBROMO -2))


	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	40.147	8771.229	59.125	50.1	51.0	2.46
2	56.433	8744.352	56.862	49.9	49.0	2.46
	Total	17515.581	115.988	100.0	100.0	

Chromatogram of 6b (racemic).

DEPT. OF CHEMISTRY
IIT ROORKEE

Sample Info:

Sample ID	: BVS-2-225 (ASSYMME SINGLEBROMO)	Amount	: 0
Sample	: BVS-2-225 (ASSYMME SINGLEBROMO)	ISTD Amount	: 0
Inj. Volume [ml]	: 0	Dilution	: 1



Result Table (Uncal - F:\Shrinivasvenkat.b\17.04.12\BVS-2-225 (ASSYMME SINGLEBROMO))

	Reten. Time [min]	Area [mV.s]	Height [mV]	Area [%]	Height [%]	W05 [min]
1	38.887	15400.980	96.525	12.5	15.1	2.55
2	53.167	107678.977	543.640	87.5	84.9	3.10
	Total	123079.957	640.165	100.0	100.0	

Chromatogram of **6b** (asymmetric).

LIST OF PUBLICATIONS

1. Naseem Ahmed, Gulab Khushalrao Pathe and B. Venkata Babu “Highly efficient deprotection of phenolic tetrahydropyranyl and methoxymethyl ethers and sequel cyclization to indanones using Sn(IV)Cl₄ catalyst” *Tetrahedron Letters* **2014**, 55, 3683 – 3687.
2. Naseem Ahmed, Gulab Khushalrao Pathe and B. Venkata Babu “SnCl₄ or TiCl₄: Highly efficient catalysts for deprotection of phenolic THP and MOM ethers and sequel one-pot Asymmetric synthesis of 3-aryl-2-hydroxy-2,3-dihydroindan-1-one from chalcone epoxides” *RSC Advance*, **2015**, Ahead of print.
3. Gulab Khushalrao Pathe and Naseem Ahmed” SnCl₄: Zn- A novel reductive system for deoxygenative coupling of aliphatic, aromatic, chalcone epoxide and indanone carbonyl compounds to olefins” *Tetrahedron Letters* **2015**, 56, 1555-1561.
4. Gulab Khushalrao Pathe, Naveen Konduru, Iram Parveen and Naseem Ahmed” Design, Synthesis of McMurry cross-coupled indanophen analogs of Tamoxifen by novel SnCl₄-Zn reagent and Anti-Proliferative Evaluation of Flavone-Estradiol adduct and Indanone based Ligands against Breast Cancer Cell Line, *European Journal of Medicinal Chemistry*, **2015**, Under Review
5. Gulab Khushalrao Pathe and Naseem Ahmed “SeO₂-water: an efficient catalyst for deprotection of acetyl, methoxymethyl and tetrahydropyranyl ethers and sequel oxidation of carbonyl carbons” *RSC Advance*, **2015**, Ahead of print.
6. Gulab Khushalrao Pathe and Naseem Ahmed “Mild and efficient reductive deoxygenation of epoxides to olefins with SnCl₂/NaI as a novel reagen” *Synthesis*, **2015**, Ahead of print.
7. Gulab Khushalrao Pathe and Naseem Ahmed “Solvent free green protocol for the eliminative deoxygenation of aliphatic and aromatic epoxides, to olefin by novel, efficient polyphosphoric acid as catalyst” *Helvetica chemical acta*, **2015**, Under Review.